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Interferon, the Cell Cycle and Herpesvirus 
H. Costa, S. Correia, R. Nascimento and R.M.E. Parkhouse 
Instituto Gulbenkian de Ciência 
Portugal 
1. Introduction 
Herpesviruses are a large group of successful, and widely distributed, double-stranded 
DNA viruses of serious medical and veterinary importance. Although they infect many 
different animal species, they are host specific at the individual species level. On the other 
hand, they share a common life style, first with an acute infection in epithelial cells which is 
followed by the establishment of persistence in neurons (α-herpesvirus), monocytes (β-
herpesvirus), or B lymphocytes (γ-herpesvirus). The varied pathology of these different 
groups of herpesvirus is typically associated with reactivation of a persistent infection and 
the subsequent production of virus. Thus, the immune system faces three distinct 
challenges: how to control the acute phase, the persistent virus, and the consequences of 
reactivation. For this reason, control of herpesvirus infection calls on the many functional 
arms of both the innate and adaptive immune systems, which in turn have exerted the 
selection pressure that has driven the evolution of many strategies of immune evasion. This 
chapter will focus on herpesviruses host evasion genes manipulating cell cycle progression 
and interferon.  
All members of order Herpesvirales have a biphasic infection cycle consisting of replicative 
(lytic) and latent phases. During the lytic cycle and viral reactivation, most of the viral genes 
are expressed in a cascade manner and large numbers of infectious virus particles are 
released. Latency, on the other hand, is characterized by limited gene expression, lack of 
virion production and, in the case of γ-herpesviruses, is associated with immortalization and 
transformation of infected cells. Virus survival at each phase depends on evasion of the host 
immune response. Thus, the escape from immune detection in the early phases of infection 
may be almost as important as in the latent phase (Vider-Shalit et al., 2007). The typical 
herpesvirus life cycle is a challenge for the development of a global antiviral therapy or 
protective vaccines. Although all herpesviruses present a similar lytic phase and are able to 
establish latency in a specific set of cells, the cell types in which they remain latent, and thus 
have evolved virus host cell evasion molecular mechanisms, differ widely from one virus to 
another (Pellet & Roizman, 2007). One promising approach is to explore new viral targets, 
particularly viral proteins involved in host immune evasion.  An effective herpesvirus 
vaccine would therefore be a genetically targeted mutant with one or more non-
immunogenic host evasion genes deleted, and with appropriate investigation of the 
pathogenesis to ensure safety. 
Bioinformatic analysis of putative homologues showed that 39 conserved herpesvirus protein 
families and 20 single proteins had significant sequence similarity to human gene products, 
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with 54% of them being involved in host-virus interaction, particularly control of apoptosis 
and immune response (Holzerlandt et al., 2002). There are, however, evasion proteins encoded 
by genes without sequence homology to cellular genes. In these cases, the viral protein 
function can only be accessed by functional assays or sophisticated structural assays, such as x-
ray crystallography (Cooray et al., 2007). Virus proteins without sequence homology with 
cellular genes can still be functional homologues of cellular proteins. One interesting example 
is the HSV-1 US3, a viral protein kinase, that has no sequence homology to the cellular kinase 
Akt, yet it is able to phosphorylate tuberous sclerosis complex 2 (TSC2) on S939 and T1462, the 
same sites targeted by cellular Akt to inhibit TSC activity and activate mTORC1 in uninfected 
cells. This strategy allows the virus to bypass the strict limits normally imposed on the cellular 
Akt, promoting mTORC1 activation even when Akt activity is low or undetectable, as may be 
the case in non-proliferating cells (Chuluunbaatar et al., 2010). 
Virus host evasion strategies conserved in all herpesviruses are likely to manipulate conserved 
cellular pathways that are regulated by all herpesviruses. Others, on the other hand, may be 
restricted to one subfamily or species, with a function related to a more restricted specific 
aspect of the virus life cycle, particularly during latency. While the latter can be explored for 
the development of a specific herpesvirus therapy, functional studies of herpesvirus 
homologous protein families are advantageous for a global herpesvirus treatment. 
Herpesviruses have evolved a wide repertoire of host evasion genes that impact on many 
components of the immune response, such as antigen presentation, autophagy, and 
apoptosis, which have been extensively reviewed and are not included in this chapter. Here, 
we focus on two virus proteins conserved in all herpesviruses, ORF36 and UL24. The first 
contains a conserved kinase domain with cellular homology, while UL24 is an unassigned 
gene with no cellular homolog. Their roles in manipulating interferon and the cell cycle 
have been the focus of our laboratory and will be described in detail. 
2. The immune response to viruses 
The immune system is an astoundingly resourceful defence system which has evolved to 
protect animals from external and internal threats, that is, invading pathogens and tissue 
damage, respectively. It is able to generate a number of different cells, secreted effector 
molecules and intracellular mechanisms that act independently and together. This wide 
variety of possible responses reflects the equally wide variety of extracellular and 
intracellular threats and life-styles. As a necessary correlate, the immune system must 
distinguish between pathogen molecules (“non self”) and its own cells and proteins (“self”), 
and also select and apply the most “appropriate” immune effector mechanism.  
Following the elimination of the pathogen, it is equally important to switch off the selected 
immune effector mechanisms. Failure at either the level of self-non-self discrimination, or 
appropriate regulation of immune responses, can lead to non-infectious diseases - for 
example, autoimmune and inflammatory diseases. As pathogens have evolved many 
mechanisms to manipulate the immune system, however, these provide “ready-made tools” 
for the development of novel therapeutic approaches; for example, viruses have evolved a 
variety of mechanisms to inhibit the inflammatory response. 
The immune response against virus infections can be divided into innate and adaptive 
defence components. The innate immune response is the first line of defence as it is always 
present and rapidly activated in a normal host upon exposure to the invading virus. Many 
viral infections are resolved by the innate immune system before intervention by the 
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adaptive immune system, which is the second-line of defence to be mobilized. This adaptive 
response comprises the antibody response and the lymphocyte cell-mediated response, 
usually called humoral and cell-mediated immune responses, respectively (Flint, 2004). A 
successful immune response to an infection must be appropriately selected and regulated, as 
inefficient or inappropriate regulation can fail to eliminate the invader and/or cause disease. 
Viruses, in particular, have evolved multiple strategies to down-regulate, or terminate, 
immune responses, and thus provide enormous potential as source of strategies for 
immunomodulation, as indicated above. 
This section will focus on virus manipulation of innate immunity, particularly the interferon 
system.  
2.1 Innate immunity 
Innate immunity is the most immediate line of response to pathogens, which needs to be 
potent and rapid, and functions to eliminate and prevent the spread of the pathogen prior to 
the subsequent action of the adaptive immune response. However, it must also be transient 
because its continued activity can damage the host. Importantly, innate immunity also 
shapes and regulates the subsequent adaptive immune response as a result of the combined 
influence of antigen presentation and the secreted cytokine/chemokine profile. Among 
these secreted effectors, interferon is absolutely essential for virus immunity. 
Viruses are recognised as foreign, and thus potentially dangerous, by a limited number of 
germline-encoded host pattern-recognition receptors (PRRs), which recognize viral 
pathogen-associated molecular patterns (PAMPs). As PAMPS are highly conserved 
structures, the corresponding PRRs are also conserved. Of particular interest for virus 
infection is the TLR3 molecule that interacts with double-stranded RNA of viral origin. 
There is, in addition, TLR7/8 and TLR9 which also localise to endosomes and recognise 
viral DNA. Cells also recognise viruses in their cytoplasm through the retinoic acid-
inducible gene I (RIG-I)-like helicases (RLHs), consisting of RIG-I and the melanoma 
differentiation-associated gene-5 (MDA5), that recognise viral RNA. Other sensors such as 
DAI or IFI16 detect viral DNA. These molecules initiate similar signalling transduction 
pathways which also results in the production of type I IFN and pro-inflammatory 
cytokines (Takeuchi & Akira, 2007). Pro-inflammatory cytokines can also be induced 
independently of IFN, by activation of the inflammasome which also has specific sensors 
localised both in endosomes and in the cytoplasm. 
2.2 The interferon system 
The interferons constitute three groups of cytokines (type I, II, and III) with overlapping, 
specific and redundant activities, and plays a major role in virus immunity. They are secreted 
by a variety of cell types as a result of disparate pathogen molecular signals, which in turn 
activate similarly overlapping, specific, and redundant intracellular signalling pathways. The 
complexity of the system has presumably evolved together with the co-evolution of virus 
mechanisms for its subversion. Thus, in order to discuss virus strategies for the manipulation 
of the interferon system, we must first describe its essentials in some detail. 
Interferons control a variety of biological functions, including modulation of the immune 
system, regulation of apoptosis, inhibition of proliferation, induction of differentiation, and 
inhibition of angiogenesis.  The importance of the interferon response against viral 
infections has been dramatised by demonstrating increased susceptibility to virus infection 
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of mice deficient for different components of the IFN system (Arnheiter et al., 1996; Chee et 
al., 2003; Haller et al., 1981; Hefti et al., 1999). 
2.2.1 Induction of IFN expression 
Four major families of PRRs with relevance for IFN have been identified: Toll-like receptors 
(TLRs), RIG-I-like receptors, NOD-like receptors, and C-type lectin receptors. Recently, 
several cytosolic nucleic acid sensors have also been found, such as DAI, AIM-2, RNA 
polymerase III and LRRFIP1. The PRRs detect pathogens invading from different routes 
through their differential localization in distinct subcellular compartments, such as the cell 
surface, endosome, and cytoplasm. Upon recognition of the pathogen, PRRs trigger major 
downstream signalling pathways, involving NF-κB, MAPK, and/or IRF3/7, to induce the 
production of inflammatory cytokines and/or type I interferons (IFNs), thereby leading to 
antimicrobial immune responses. 
2.2.2 Transcriptional control of IFN expression 
Although, as described above, there are different routes to initiate transcription of IFN type 
I, the downstream kinases and transcription factors are common to all. The induction of 
Type I IFN is primarily regulated at the level of transcription, with the IFN regulatory 
factors (IRFs) IRF-1, IRF-3, IRF-5 and IRF-7 and NF-кB having major roles   (Barnes et al., 
2001; Watanabe et al., 1991; Wathelet et al., 1998).  
Transcription of the IFN-β gene involves the formation of a large, multi-subunit complex 
called the “enhanceosome”. It comprises the promoter-specific transcription factors, 
associated structural elements, and basal transcriptional machinery to enhance gene 
expression. The promoter enhancer region is composed of four positive regulatory regions 
(PRDI-IV) (Hiscott et al., 2006). The PRDI and PRDIII sequences contain sites for binding of 
IRF-3 and IRF-7, the PRDII site binds NF-кB heterodimers, while PRDIV binds ATF-2 and c-
Jun heterodimers. Upon binding to the promoter region by the different activated 
transcription factors, and the high-mobility group (HMG) chromatin-associated protein 
HMGI(Y), the complete transcriptional machinery of the enhanceosome is formed by the 
additional recruitment of CBP/p300 (Honda et al., 2006).  
The induction of IFN-α expression is less well understood. Its promoter region contains 
binding sites for IRFs but lacks binding sites for NF-кB. Although the identity of the IRF 
member that stimulates IFN-α is uncertain, there is some evidence that IRF-7 is required for 
induction; for example, in fibroblast cells there is no primary induction of IFN-α gene, as 
IRF-7 gene expression is dependent on feedback induction by IFN-β. On the other hand, 
with regards to plasmocytoid DCs, which constitutively express IRF-7 and induce the 
expression of massive amounts of IFN type I, the induction of IFN-α is not dependent on the 
primary induction of IFN-β and its feedback loop (Lin et al., 2000; Marie et al., 1998). 
The induction of type II interferon secretion is restricted to a small group of cells, with NK 
cells and CD8 T cells being the main source of IFN-γ. However, other cell types, such as 
macrophages and DCs, have also been reported to produce type II IFN under specific 
conditions (Darwich et al., 2009). 
2.2.3 Signalling responses to IFN 
As secreted factors, type I IFNs regulate a range of immune responses through binding to 
the type I IFN receptor, composed of two subunits, IFN-α receptor 1 (IFNAR1) and IFNAR2. 
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Upon interferon binding, the two subunits of the receptor associate and facilitate the 
activation of Tyk2 and Jak1. The phosphorylation of the IFNAR1 by Tyk2 creates a docking 
site for STAT2 and its subsequent phosphorylation by Tyk2, while Jak1 phosphorylates 
STAT1 (Colamonici et al., 1994; Novick et al., 1994; Shuai et al., 1993). The activated STATs 
dissociate from the receptor forming a stable heterodimer and associate with p48 (also 
known as IRF-9), forming the ISGF3 multimeric complex that translocates to the nucleus and 
binds to IFN-stimulated response elements (ISRE) present in the promoter region of IFN-
stimulated genes (ISGs) (Mogensen et al., 1999; Stark et al., 1998). Until recently, the 
assembly of the ISGF3 complex was thought to be in the nucleus. However it has been 
recently shown that it is IFNAR2 that forms a docking site for p48 which, together with 
STAT1 and STAT2, then becomes acetylated (Tang et al., 2007). The transcriptional co-factor 
CREB-binding protein (CBP) is a mediator for these acetylation reactions, implying that 
acetylation plays a major role in the signal transduction pathway activated by the receptors 
(Tang et al., 2007).  
The Type II IFN receptor also consists of two subunits: the IFNGR1 that associates with Jak1, 
and the IFNGR2, which constitutively associates with Jak2. Binding of IFN-γ to the receptor 
leads to its dimerization, which brings Jak1 and Jak2 into close proximity, resulting in the 
activation of Jak2 and trans-phosphorylation of Jak1. Activated Jaks phosphorylate the C-
terminus of IFNGR1 which creates a pair of binding sites for STAT1, which are then 
phosphorylated and dissociate from the receptor. The STAT1 homodimer translocates to the 
nucleus and binds to unique elements of IFN-γ stimulated genes, the gamma-activation 
sequence (GAS), and stimulates transcription. Of note is the fact that type I IFN stimulation 
is also able to form STAT1-homodimers and leads to the induction of genes containing GAS 
elements in their promoter region (Bach et al., 1997; Stark et al., 1998). The Jak-Stat pathway 
plays an important role in the response to IFN and in mounting an effective and rapid anti-
viral response through the induction of ISGs. The subsequent decay of the response requires 
negative regulators of STAT signalling, which include cytoplasmic tyrosine phosphatases, 
nuclear and cytoplasmic regulators and truncated forms of STAT proteins.  
2.2.4 IFN-induced antiviral state 
One of the major functions of interferon is the induction of an anti-viral state in cells infected 
by viruses. The anti-viral state is characterized by the expression of genes that are induced 
by interferon in order to limit virus replication and subsequent spread to neighbouring cells. 
The interferon stimulated genes (ISGs) are crucial components of the interferon responses as 
they set up the antiviral, antiproliferative and immunoregulatory state in the host cells. The 
best-characterized IFN inducible components that have been already reviewed are the 
enzymes dsRNA-dependent protein kinase (PKR), 2’,5’-oligoadenylate synthetase (2’5’OAS), 
and Mx proteins (Garcia et al., 2006; Haller et al., 2007; Silverman, 2007). Other proteins that 
are induced and play important roles in the antiviral response are ISG15, ISG54 and ISG56, 
ISG20, PML, and TRIM.  
2.3 Viral evasion of interferon responses 
Whatever its lifestyle, a virus will always have appropriate and complementary strategies 
for evasion of host defences. The interferon system is a powerful and first line of defence 
against virus infections, and so it is not surprising that viruses have evolved multiple means 
of down-regulating IFN responses. These include inhibiting IFN production, inhibiting the 
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against virus infections, and so it is not surprising that viruses have evolved multiple means 
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Herpesviridae – A Look into This Unique Family of Viruses 
 
8 
IFN-mediated signalling pathways, and blocking the action of IFN-induced enzymes with 
antiviral activity. Even within one of these strategies, viruses have evolved multiple 
molecular mechanisms to achieve the same result. During the past few years, much has been 
learned about the molecular mechanisms used by viruses to manipulate and escape the host 
interferon response. The exact strategy exploited by a virus will presumably depend on the 
biology of the host-virus interaction, and will be a major factor that will influence the 
pathogenesis of that virus infection (Randall & Goodbourn, 2008). 
2.4 Herpesviruses evasion of the interferon system 
As herpesviruses are known to trigger the induction of type I IFN during the primary 
infection of a cell (Ankel et al., 1998; Boehme et al., 2004; Mossman et al., 2001), it is not 
surprising that an effective evasion of these initial type I IFN responses is essential for virus 
replication and establishment of latency.  
The modulation of interferon responses by herpesviruses is already an extensive area of 
research, with several proteins already been described to inhibit IFN signalling, 
antagonizing IFN-initiated gene transcription, and target IRF-3 and IRF-7 activation. The 
multiplicity of these genes reflects the importance of diminishing IFN responses for virus 
survival. Understanding their strategies of evasion might lead to the development of new 
treatments or prevention strategies for diseases associated with these viruses. 
The Kaposi’s Sarcoma Herpesvirus (KSHV) is one of the examples of a herpesvirus 
modulating interferon responses. During primary infection, a decreased transcription of 
type I IFN genes and subsequent binding to the receptors has been demonstrated (Naranatt 
et al., 2004).  One of the candidate genes responsible for this evasion strategy is ORF45, 
which is a major component of the KSHV viral tegument, thus delivered into the host cells 
at the most early stages of infection (Zhu et al., 2005; Zhu & Yuan, 2003).  In addition, ORF45 
has been found to inhibit the phosphorylation and nuclear translocation of IRF-7 (Zhu et al., 
2002). The combination of these two effects points to the ORF45 protein as a significant 
contributor in the antagonism of type I IFN in de novo KSHV infections. 
During lytic reactivation, several KSHV proteins are also involved in evasion of IFN 
responses. The ORF10 (RIF) inhibitory function is not at the level of IFN induction but rather 
at the IFN signalling pathway, by forming complexes with several critical factors of the 
signalling pathway such as the type I IFN receptor subunits, the janus kinases and STAT2 
(Bisson et al., 2009). The multiple targeting of components of this signalling pathway ensures 
that the ISGF3 complex is not formed and does not translocate into the nucleus thus 
inhibiting the transcription of ISGs. The ORF50 protein functions as a transcription factor 
and is essential for KSHV reactivation from latency (Sun et al., 1998). This viral protein 
targets IRF-7 for proteasomal degradation (Yu et al., 2005), and more recently has been 
shown to mediate degradation of TRIF also by targeting it for proteasomal degradation 
(Ahmad et al., 2011). The ORF K8 (K-bZIP) has been shown to inhibit IRF-3, but instead of 
direct interaction with the transcription factor, this viral protein binds efficiently to the 
PRDIII-I region of the IFN-β promoter, thus inhibiting the binding of the IRF-3-CBP/p300 
complex (Lefort et al., 2007). This strategy leads to inhibition of formation of a functional 
enhanceosome complex, thereby resulting in a defective transcription of IFN-β. 
There are several IRF member homologues in KSHV. For example, the protein encoded by 
ORF K9 was described as the first viral member of the family, vIRF-1 (Moore et al., 1996). The 
vIRF-1 protein interferes with the transactivation ability of both IRF-1 and IRF-3 by targeting a 
 
Interferon, the Cell Cycle and Herpesvirus 
 
9 
common transcriptional cofactor; CBP/p300 (Burysek et al., 1999; Lin et al., 2001). The vIRF2 is 
also an inhibitor of the expression of IFN inducible genes, which are regulated by IRF-1, IRF-3 
and ISGF3, but not by IRF-7 (Fuld et al., 2006). In addition, this viral protein also interacts with 
PKR and thereby prevents the antiviral effects mediated by PKR (Burysek & Pitha, 2001).  
The KSHV has also evolved multiple strategies to avoid host immune responses during 
latency, including antagonizing type I IFN signaling pathways. Examples of these are the 
expression of latent proteins such as LANA, which inhibits function of IRF-3 (Cloutier & 
Flamand, 2010) and vIRF-3, which binds to IRF-7 (Joo et al., 2007). 
In the case of HCMV infection, the mechanisms for subversion of interferon have been 
extensively studied. However, only a small number of genes have been identified as being 
responsible for modulation of the interferon response. The immediate-early proteins of 
HCMV are the obvious candidates, as they are the first genes being expressed, and indeed, 
the IE72 protein has been shown to play a role in inhibiting the antiviral state by binding to 
promyelocytic leukemia (PML) protein and disrupting PML-associated nuclear bodies (NBs) 
leading to the displacement of PML-NB associated proteins such as PML, Sp100 and Daxx 
(Ahn et al., 1998; Ahn & Hayward, 1997; Korioth et al., 1996; Wilkinson et al., 1998). In 
addition, IE72 also binds to Stat2, and to a lesser extent, to STAT1, thereby inhibiting the 
IFN signaling pathway (Huh et al., 2008; Paulus et al., 2006). The IE86 protein has been 
described as an inhibitor of IFN-β production by blocking NF-κB (Taylor & Bresnahan, 
2005). On the other hand, UL83 has been also shown to inhibit IFN-β production, but in this 
case by inhibiting IRF-3 phosphorylation and translocation into the nucleus (Abate et al., 
2004). HCMV also encode two PKR antagonists, proteins IRS1 and TRS1 (Cassady, 2005; 
Hakki & Geballe, 2005). Recently, an HCMV protein without known function, ORF94, was 
identified as an inhibitor of OAS expression during infection, therefore limiting the 
induction of OAS-mediated antiviral response (Tan et al., 2011). 
In order to replicate and persist, the HSV-1 virus, like the above described herpesviruses, also 
elicits innate immune responses just after virus entry - for example, through activation of IRF-3 
(Preston et al., 2001). Such evasion strategies include the expression of genes that target the 
IRF-3 signaling pathway, thereby inhibiting the production of IFN type I, and interfering with 
the signaling through the receptors and inhibiting the anti-viral state. Examples of such early 
expressed HSV-1 evasion genes include ICP0 and ICP27 which already had a described 
function, but were subsequently found to also inhibit IRF-3 accumulation in the nucleus 
(Eidson et al., 2002; Melroe et al., 2004), and to inhibit STAT1 phosphorylation and its 
subsequent translocation to the nucleus (Johnson & Knipe, 2010; Johnson et al., 2008), 
respectively. Another HSV-1 protein, ICP34.5, was identified as playing a role in the PKR 
signaling pathway due to its sequence homology with mouse MyD116 (He et al., 1998; He et al., 
1997). More recently, ICP34.5 has been found to form a complex with TBK1, thereby 
disrupting the interaction between TBK1 and IRF-3 (Verpooten et al., 2009). Finally, US11 and 
UL41 have been shown to: bind to PKR (Cassady et al., 1998), to block the activation of OAS 
(Sanchez & Mohr, 2007); and to mediate the degradation of cellular proteins such as ISGs 
(Kwong & Frenkel, 1989; Matis & Kudelova, 2001; Paladino & Mossman, 2009). 
2.5 The herpesviruses viral protein kinases family 
All of the α-, β- and γ-herpesviruses genomes contain several genes that are conserved 
between families. One of these is the protein kinase family, which includes ORF36 from 
KSHV, UL13 from HSV, BGLF4 from Epstein-Barr virus, and UL97 from HCMV. 
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
8 
IFN-mediated signalling pathways, and blocking the action of IFN-induced enzymes with 
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Conservation of these viral protein kinase domains among the herpesviruses suggests that 
they are indispensable for survival of herpesviruses. The HCMV UL97 protein was the first 
to be defined and described as a protein that phosphorylates the antiviral nucleoside 
analogue ganciclovir, and therefore, could be a useful tool in the understanding of the 
antiviral activity of new selective anti-HCMV compounds (Littler et al., 1992). Subsequently, 
other groups demonstrated that UL97 is an auto-phosphorylating serine-threonine kinase 
(He et al., 1997). Along with a conserved role, these individual kinases may have unique 
functions in the context of viral infection. For example, the inhibition of the activity of 
HCMV UL97 protein kinase by a number of compounds that exhibit a pronounced antiviral 
effect is not shared by other protein kinases, such as BGLF4, illustrating the fact that low 
homology between the members of this group complicates the design of compounds able to 
target all herpesviruses, and suggesting that structure-based inhibitor designed for each 
group of herpesviruses might be more effective. On the other hand, Cyclopropavir (CPV), 
with a mechanism of action similar to ganciclovir, is active against HCMV as well as both 28 
variants of HHV 6 and KSHV (James et al., 2011).  
The kinase domain containing KSHV ORF36 homologue was tested, and indeed, not only 
displayed an intrinsic protein kinase activity but was also autophosphorylated on a serine 
residue (Park et al., 2000). Several studies have demonstrated that these conserved 
herpesvirus protein kinases impact at multiple steps in the virus life cycle, such as 
regulation of viral and cellular genes, nuclear egress, virus maturation and replication, 
chromosome condensation, and tissue tropism (Asai et al., 2007; Gershburg & Pagano, 2008; 
Hamza et al., 2004; Izumiya et al., 2007; Kawaguchi & Kato, 2003; Michel & Mertens, 2004).  
The ORF36 proteins from KSHV, HSV (UL13), HCMV (UL97) and Epstein-Barr virus 
(BGLF4) localize predominantly in the nucleus of cells (Daikoku et al., 1997; Marschall et al., 
2005; Park et al., 2000), and are only expressed several hours post-infection, with an early-
late kinetics (Martinez-Guzman et al, 2003). However, due to the fact that they are present in 
the virion (Overton et al., 1992; Varnum et al., 2004; Zhu et al., 2005), they are released into 
the cytoplasm of host cells just after virus entry and play essential roles as innate host 
evasion proteins. Until recently, this conserved herpesviruses family of protein kinases did 
not have any assigned function. Further experiments, however, showed that the UL97 viral 
protein kinase was able to mimic cdc2 in infected cells by targeting the same 
phosphorylation site in eukaryotic elongation factor 1 delta (Kawaguchi et al., 2003). In 
addition, ORF36 from KSHV was showed to be involved in the activation of c-jun N-
terminal kinase (JNK) pathway (Hamza et al., 2004).  The ORF36 from MHV-68, a murine 
gamma-herpesvirus, was also found to phosphorylate histone H2AX during infection, 
suggesting that the virus actively initiates and benefits from the host DNA damage response 
(Tarakanova et al., 2007b), a function that is only shared by BGLF4 and not by the other 
homologues. Recently, phosphorylation of H2AX has been shown to correlate with gamma-
herpesviruses latency in vivo (Tarakanova et al., 2010a). 
More recently, however, ORF36 from the murine gamma-herpesvirus, MHV-68, has also 
been shown to suppress the host IFN mediated response by inhibiting the transcription 
factor IRF-3 (Hwang et al., 2009). This function, although not requiring the conserved kinase 
domain, is shared by the other homologues. The ORF36 protein binds directly to IRF-3, in a 
region that is required for CBP binding to IRF-3. In the signaling pathway that leads to the 
activation of IFN-β, both CBP and Pol II are recruited to the promoter region, and when 
ORF36 is expressed, this recruitment, mediated by activated IRF-3, is impaired  (Hwang et 
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al., 2009). The BGLF4 kinase was also shown to suppress the IRF-3 signaling pathway by 
inhibiting binding of IRF-3 to the IFN-β promoter (Wang et al., 2009). In addition, studies by 
others (Jong et al., 2010) have identified RNA helicase A (RHA) as an interacting partner of 
KSHV ORF36.  
The principle focus of our work is on KSHV, which, as described above, has evolved many 
genes for the inhibition of type I IFN responses. Multiplicity of these genes reflects the 
importance of inhibiting IFN responses for virus survival. Specifically, we have screened the 
non-homologous genes for an inhibitory impact on the IFN response using reporter assays 
detecting activation of the critical transcription factors in particular conserved non-
homologous herpesvirus genes, as they conservation suggests that their function must be 
important for virus survival and spreading. The ORF36 is indeed one such gene and, as 
already described, interacts directly with IRF-3 and inhibits IFN-β expression. When 
screened in ISRE and GAS reporter assays ORF36 inhibited both type I and type II IFN 
signaling cascades (Our unpublished results). The only other KSHV gene described so far to 
be interfering with the Jak-Stat signaling pathway is the IL-6 viral homologue, which play a 
role in the IL-6/STAT3 pathway. Our work raises the possibility that signaling through the 
type I and type II IFN receptors is inhibited by the ORF36 protein through a mechanism 
involving RHA and CBP. This is due to our observations that suggest that ORF36 does not 
impact directly on the STAT1 and STAT2 signaling transcription factors, but instead seems 
to be targeting a molecule downstream in the signaling cascade, perhaps one involved in the 
regulation/formation of the transcription complex at the promoter regions of both ISRE and 
GAS sequences, such as CBP or RHA.  
We have also demonstrated that ORF36 of KSHV inhibited the expression of genes 
controlled through ISRE and GAS sequences in their promoter regions upon stimulation 
with IFN-α and IFN-γ, respectively. This inhibition was dependent on the kinase domain of 
ORF36, as its mutation reverted its inhibitory activity in both type I and type II IFN 
responses. As the STAT transcription factors are key regulators in this signaling pathway, 
we decided to investigate if the expression of ORF36 was interfering with the activation and 
subsequent nuclear translocation of STAT 1 and STAT2 after treatment of cells with IFN-α 
and IFN-γ. Both STATs were expressed at equal levels, and phosphorylated at specific 
residues in cells expressing ORF36 when compared to empty transfected cells after IFN 
treatment. However, the expression of the ORF36 protein did not alter the localization of the 
STATs proteins before or after treatment of the cells with type I and type II IFN. Thus both 
STAT1 and STAT2 similarly translocated to the nucleus upon IFN treatment in cells with 
and without expression of ORF36. These results suggest that the ORF36 protein may play a 
role in the nucleus, although this will have to be confirmed.  
In conclusion, ORF36 is yet another multifunctional virus host evasion molecule which has 
impact at different stages of the virus replication cycle. Finally, a comprehensive 
understanding of herpesvirus mediated manipulation of interferon is far from complete, but 
will certainly provide a better understanding of the virus-host interactions, and a possible 
route to novel control strategies. 
3. The cell cycle and DNA damage  
3.1 Cell cycle progression 
The eukaryotic cell cycle is operationally divided into four phases: G1, S, G2, and M. 
Quiescent cells, which are metabolically active but not dividing, are in the G0 phase, outside 
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Conservation of these viral protein kinase domains among the herpesviruses suggests that 
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The eukaryotic cell cycle is operationally divided into four phases: G1, S, G2, and M. 
Quiescent cells, which are metabolically active but not dividing, are in the G0 phase, outside 
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the cell cycle.  The three DNA damage-induced cell cycle checkpoints, G1/S, intra-S, and 
G2/M, are critical points in the cell cycle that monitor the integrity of the genome, leading to 
repair or programmed cell death if DNA damage is detected. The DNA damage sensor 
molecules that activate the checkpoints and the signal transducer molecules, such as protein 
kinases and phosphatases, appear to be shared by the different checkpoints to varying 
degrees. The specificity of the checkpoint is due to the effector proteins, which inhibit phase 
transition (Sancar et al., 2004).  
The G1/S checkpoint prevents cells from entering the S phase in the presence of DNA 
damage by inhibiting the initiation of replication. In the case of double strand breaks, the 
kinase ATM initiates the checkpoint pathway by phosphorylation of Chk2, which, in turn, 
will phosphorylate Cdc25A, thereby causing its inactivation and consequent accumulation 
of the phosphorylated (inactive) form of Cdk2. If the DNA damage is caused by UV light, 
phosphorylation of Cdc25A is mediated by ATR-Chk1 proteins. In either case, this rapid 
response is followed by the p53-mediated maintenance of G1/S arrest. During this phase 
there is an ATM-mediated increase in the level of p53 due to an increase in protein stability, 
followed by posttranslational modifications, such as phosphorylation at amino acid residues 
15 and 20, which regulate p53 functions. A key target for transcriptional activation of p53 is 
the cyclin-dependent kinase inhibitor, p21. The p53-dependent increase in p21 expression 
inhibits cyclin E and cyclin A-associated Cdk2 activities preventing G1-to-S phase 
progression (Lukas et al., 2004; Sancar et al., 2004).     
The intra-S phase checkpoint is activated by damage encountered during the S phase or by 
unrepaired damage that escapes the G1/S checkpoint and leads to a block in replication. 
When double strand breaks are detected in S phase, the ATM-dependent pathway is 
activated leading to proteosome-mediated degradation of Cdc25A and consequently to the 
failure to maintain activation of cyclin-Cdk2 complexes and thus inhibition of DNA 
synthesis. A block of replication fork progression by intrinsic events or environmental 
insults, on the other hand, triggers an ATR-dependent pathway. In this latter case, members 
of the Rad family of checkpoint proteins function as DNA damage sensors and as scaffolds 
for the assembly of signaling complexes (Abraham, 2001).  
The G2/M checkpoint prevents cells from undergoing mitosis in the presence of DNA 
damage, which could lead to the propagation of unrepaired DNA to the next generation. 
Double mutations of ATR and ATM completely eliminate G2 arrest following DNA damage, 
suggesting that both kinases are key regulators of this checkpoint. Thus, depending on the 
type of DNA damage, the ATM-Chk2 and/or ATR-Chk1 pathway is activated to arrest the 
cell cycle in G2 phase (Sancar et al., 2004). Both pathways converge on the Cdc25C 
phosphatase. The Cdc2 catalityc subunit is inhibited by its phosphorylation at Thr14/Tyr15. 
Dephosphorylation of Cdc2 inhibitory sites by Cdc25C activates Cdc2-Cyclin B1 complex, 
allowing progression of cell cycle to mitosis. The activity of Cdc2 is also regulated by the 
availability of the cyclin B subunit. During S phase, cyclin B1 mRNA and protein begin to 
accumulate and their levels are maximal at G2/M. As cells pass through mitosis, cyclin B1 is 
ubiquitinated and degraded (Lou & Chen, 2005; Sancar et al., 2004). 
3.2 Herpesvirus modulation of the cell cycle  
Replication of DNA viruses in host cells triggers a variety of cellular signaling cascades that 
regulate cell cycle, including the DNA damage response. It is generally accepted that viruses 
modulate the cell cycle to promote a transition through G1-S phase and achieve the cellular 
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environment for productive virus replication (Sato & Tsurumi, 2010). The herpesviruses 
genome, in contrast to other small DNA viruses, encodes a viral DNA polymerase and 
accessory factors, so it is not essential to promote entry into S phase of the cell cycle to 
exploit cellular genes involved in DNA replication. The interaction between herpesviruses 
and cell cycle regulatory mechanisms is more complex as some viral factors elicit cell cycle 
arrest while others promote cell cycle progression. Thus, it seems that herpesviruses induce 
cell cycle arrest, but they are able to block it in the cell cycle phase which most favors viral 
replication, perhaps to avoid competition with cellular DNA replication (Flemington, 2001).  
Examples of cell cycle regulation by herpesviruses can be found in all three α-, β-, and γ-
herpesvirinae subfamilies.  
Herpes simplex virus type 1 (HSV-1) infection disrupts cell cycle progression in two 
different ways depending on the cell cycle phase. In quiescent cells, HSV-1 infection 
prevents G1 entry by inhibition of cyclin D/CDK4,6-specific and cyclin E/CDK2-specific 
phosphorylation of the retinoblastoma protein pRb. On the other hand, HSV-1 induces G1/S 
arrest in dividing cell cultures by inhibition of preexisting cyclin E/CDK2 and cyclin 
A/CDK2 activities (Ehmann et al., 2000; Song et al., 2000). The ability of HSV-1 to alter 
cellular environment in order to enhance viral replication has been related to the expression 
of immediate-early protein ICP0. Infection with a mutant virus in which ICP0 is the only IE 
protein expressed resulted in p53-independent cell cycle arrest in G1/S and G2/M phase. 
Although ICP27 also plays a key role in the activation of G1/S phase (Song et al., 2001), 
infection with different mutant viruses demonstrated that the mitotic block requires ICP0 
expression (Hobbs & DeLuca, 1999; Lomonte & Everett, 1999). 
Similar to HSV-1, several studies demonstrated that HCMV infection leads to drastic and 
temporally coordinated alterations in the expression of host cell regulatory proteins, such as 
cyclins, resulting in cell cycle arrest at more than one phase (Bresnahan et al., 1996; Dittmer 
& Mocarski, 1997; Jault et al., 1995; Lu & Shenk, 1996). The cell cycle arrest was independent 
of the cell cycle phase (G0, G1, and S) at the moment of infection with HCMV (Salvant et al., 
1998). The immediate-early proteins IE1/IE2 and UL69 have been described as being able to 
block cell cycle in G1, suggesting that they may have a role in HCMV manipulation of cell 
cycle progression (Castillo et al., 2005; Lu & Shenk, 1996; Wiebusch & Hagemeier, 1999). 
Infection with UV-irradiated HCMV virus resulted in G1 arrest when cells exit from G0, but 
it was unable to block the S phase entry in cycling cells, indicating that gene expression is 
required and excluding viral capsid proteins, such as UL69, function. Thus, it seems that 
under different conditions, these proteins may have a higher or lower impact on cell cycle 
regulation by HCMV (Wiebusch & Hagemeier, 1999).  
The γ-herpesvirus EBV lytic program promotes its own specific cell cycle-associated 
activities involved in the progression from G1 to S phase, while at the same time inhibiting 
cellular DNA synthesis. Although the levels of p53 and CDK inhibitors remain unchanged 
throughout the lytic infection, there is an increase in the amounts of cyclin E/A and the 
hyperphosphorylated form of pRb. The resultant “quasi” S-phase cellular environment is 
essential for the transcription of viral immediate-early and early genes, probably due to the 
availability of transcription factors, such as E2F-1 and Sp1, which are expressed during S 
phase (Kudoh et al., 2004; Kudoh et al., 2003).  The EBV gene which has a relevant role in cell 
cycle modulation is the immediate early transcription factor Zta, also known as ZEBRA or 
BZLF1. The Zta protein mediates the induction of three key cell cycle regulatory factors, p21, 
p27, and p53, resulting in G0/G1 cell cycle arrest in several epithelial cell lines (Cayrol & 
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Flemington, 1996). Interestingly, Zta mediates the induction of each one of these proteins, in 
part, through distinct pathways, a strategy which may have evolved to ensure that lytic 
replication occurs in a growth-arrested setting in different tissues in various states of 
differentiation (Rodriguez et al., 1999). This emphasizes a fundamental aspect of pathogen-
host evasion, the logical tailoring of the host evasion mechanism to the life style of the 
pathogen.   
Recent studies with HHV-6A, one of the less studied β-herpesviruses, demonstrated that 
infection of T cells with HHV-6A results in cell cycle arrest at the G2/M phase. In this case, 
G2 arrest may serve to block the clonal expansion and proliferation of HHV-6A specific T 
cells to maintain immune suppression and evade the antiviral immune response (Li et al., 
2011). The mechanism that regulates the block in cell cycle progression by HHV-6A involves 
the inactivation of the cdc2-cyclin B1 complex and the increased expression of p21 protein in 
a p53-dependent manner. Manipulation of the cell cycle was also described for HHV-6B 
(Øster et al., 2005) and HHV-6A infection in cord blood mononuclear cells (De Bolle et al., 
2004), but with different results, suggesting that the regulatory pathways and mechanisms 
induced by HHV-6 infection might be different according to the type of infected cells, once 
again correlating host evasion with host biology.  
The regulation of cell cycle by herpesviruses is closely related to activation of the DNA 
damage response, including double strand break repair pathways. Viral infection confronts 
the host cell with large amounts of exogenous genetic material that might be recognized as 
abnormal and damaged DNA and so precipitates the premature apoptosis of the virus 
infected cells (Weitzman et al., 2004). During replication, herpesvirus DNA is synthesized in 
a rolling-circle manner to produce head-to-tail concatemers that are subsequently cleaved 
into unit-length genomes. These too may be recognized as double strand breaks and trigger 
a DNA damage response (McVoy & Adler, 1994). Thus, in order to establish a productive 
infection, it is essential that viruses defend themselves from the host cell DNA damage 
response machinery. Paradoxically, recent reports indicate that such cellular responses may 
have a beneficial role in viral replication (Luo et al., 2011).  
Thus, during HSV-1 infection, RPA, RAD51, NBS1, and Ku86 components of the HR 
pathway are recruited to replication compartments, suggesting that homologous repair may 
play a role at the earliest stages of HSV-1 DNA replication. The phosphorylation of NBS1 
and RPA indicates, in addition, that HSV-1 infection may activate components of the DNA 
damage response. Although siRNA-mediated “knock down” studies indicated that ATM is 
not absolutely required for HSV DNA replication and infectious virus production (Shirata et 
al., 2005), another report has demonstrated that absence of specific DNA repair proteins, 
such as ATM or MRN complex, result in significant defects in viral replication, suggesting 
that a DNA damage response environment is beneficial for productive HSV-1 infection 
(Lilley et al., 2005). Consistent with the HSV-1 infection studies, the mechanism of cell cycle 
arrest by ICP0 requires ATM and Chk2 proteins, and results from the activation of ATM-
Chk2-Cdc25C DNA damage pathway (Li et al., 2008).  
The DNA damage response is also activated during HCMV replication, as indicated by the 
phosphorylation of ATM and H2AX and the downstream proteins Chk2 and p53. However, 
during HCMV infection, the localization of various checkpoint proteins, normally organized 
near the site of damage, is altered, inhibiting their normal function. Importantly, recent 
results indicate that the DNA damage response mediated by E2F1 transcription factor 
contributes to replication of HCMV (E et al., 2011).  
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The EBV BGLF4 kinase may be relevant for EBV-induced DNA damage, as it induces H2AX 
phosphorylation. This function, conserved in the MHV-68 homolog (ORF36), is dependent 
of the kinase domain and is enhanced by ATM (Tarakanova et al., 2007a). Recently, it has 
been demonstrated that ORF36 and H2AX have an important role in the establishment of 
MHV-68 latency, suggesting that γ-herpesviruses may exploit the components of DNA 
damage responses, not only during lytic replication, but also during latent infection in vivo 
(Tarakanova et al., 2010b). 
It is still not clear if virus-induced DNA damage involves the recognition of existing double 
strand breaks. Thus, it is possible that the trigger of herpesvirus-induced DNA damage 
response is not the recognition of viral DNA as double-strand breaks, or actual damage to 
DNA, but is the recruitment of DNA damage repair factors observed during viral infection.  
Understanding the interaction between the DNA damage response machinery and virus 
infections will not only provide insights into viral pathology and persistence, but also new 
ideas for the development of antiviral and anti-tumour drugs. Moreover, knowledge of 
virus–host interactions can elucidate the mechanisms of key cellular control processes and 
help in identifying as yet unrecognized signaling pathways. Thus, the study of virus host 
evasion mechanisms can provide new tools to study recognition and repair of damaged 
DNA by cellular machinery. 
3.3 The UL24 family: Multifunctional virus host evasion proteins 
The UL24 gene is located in the unique long segment of HSV-1 genome, overlapping the 
thymidine kinase gene (McGeoch et al., 1988). It is conserved not only in all three 
subfamilies of human herpesviruses, but also in other mammalian, avian, and reptilian 
herpesviruses, with exception of amphibians or fish, all of which have a distinct relationship 
to all subfamilies. Of the core herpesviruses genes, UL24 is the only one that remains 
unassigned to any functional category (Davison et al., 2002); its universal presence in 
herpesviruses and lack of homology with cellular genes suggests that UL24 gene family has 
a relevant role in the viral life cycle and/or host evasion mechanisms. The UL24 
homologues are generally expressed with late kinetics, although HSV-1 UL24 has a complex 
transcription pattern with leaky-late kinetics since its expression is not completely 
dependent on viral replication (Pearson & Coen, 2002).  The HSV-2 UL24 and HCMV UL76 
homologues, however, have unambiguously been identified as virion-associated proteins, 
and so they are found within the cell from the moment of infection (Hong-Yan et al., 2001; 
Wang et al., 2000). The alignment of the predicted amino acid sequences of UL24 
homologues reveals five regions of strong sequence similarity (Jacobson et al., 1989). 
Interestingly, a comparison of sequence profiles, enriched by predicted secondary structure, 
has identified UL24 as a novel PD-(D/E)XK endonuclease belonging to a large superfamily 
of restriction endonuclease-like fold proteins (Knizewski et al., 2006). To date, however, no 
nuclease activity has been reported for UL24 or any of its homologues.  
Deletion of the UL24 gene in HSV-1 resulted in a virus with significantly reduced plaque 
size and associated decreased viral yield, suggesting that the UL24 function, although not 
essential, is important for virus growth, at least in cell culture (Jacobson et al., 1998; Jacobson 
et al., 1989). Similar results were obtained for HSV-2 UL24 (Blakeney et al., 2005), VZV 
ORF35 (Ito et al., 2005), MHV-68 ORF20 (Nascimento & Parkhouse, 2007), and HCMV UL76 
from AD169 strain (Yu et al., 2003). Global functional analysis conducted using HCMV 
Towne complete genome, however, indicated that UL76 is an essential gene for viral 
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Flemington, 1996). Interestingly, Zta mediates the induction of each one of these proteins, in 
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The DNA damage response is also activated during HCMV replication, as indicated by the 
phosphorylation of ATM and H2AX and the downstream proteins Chk2 and p53. However, 
during HCMV infection, the localization of various checkpoint proteins, normally organized 
near the site of damage, is altered, inhibiting their normal function. Importantly, recent 
results indicate that the DNA damage response mediated by E2F1 transcription factor 
contributes to replication of HCMV (E et al., 2011).  
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ORF35 (Ito et al., 2005), MHV-68 ORF20 (Nascimento & Parkhouse, 2007), and HCMV UL76 
from AD169 strain (Yu et al., 2003). Global functional analysis conducted using HCMV 
Towne complete genome, however, indicated that UL76 is an essential gene for viral 
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replication (Dunn et al., 2003). Virus strains with substitution mutations in the endonuclease 
motif of UL24 exhibited titers in the mouse eye model that were 10-fold lower than the wild-
type virus and similar results were obtained in trigeminal ganglia. Furthermore, the 
percentage of virus reactivation was also significantly lower. These results are consistent 
with the endonuclease motif being important for the role of UL24 in vivo (Leiva-Torres et al., 
2010). Further deletion studies revealed that absence of UL24 from HSV-1, HSV-2 and VZV 
leads to a syncytial plaque phenotype, similar to that observed for other HSV-1 viral 
proteins, suggesting that UL24, like UL20 and gK, may have a role in viral egress (Blakeney 
et al., 2005; Ito et al., 2005; Pearson & Coen, 2002), although the possible involvement of UL24 
in assembly and egress of virus particles remains to be explored. 
During viral infection, UL24 homologues are detected predominantly in the nucleus, and 
transiently localize in the nucleoli (Hong-Yan et al., 2001; Nascimento & Parkhouse, 2007; 
Pearson & Coen, 2002; Wang et al., 2000). Indeed, infection with HSV-1 results in dramatic 
alterations to nuclear structure and organization, including the morphology of nucleoli 
(Besse & Puvion-Dutilleul, 1996). Moreover, in cells infected with HSV-1, in contrast to the 
large, prominent spots observed within the nucleus of mock-infected cells, nucleolin had a 
diffuse distribution throughout the nucleus. Significantly, cells infected with two 
independent UL24-deficient viruses, UL24XB and UL24XG, retained the prominent punctate 
foci of nucleolin revealed by staining, although not absolutely identical to the distribution 
seen in uninfected cells.  
Thus UL24 must contribute to the observed alteration of the nucleoli in HSV-1 infected cells 
(Lymberopoulos & Pearson, 2007), a conclusion reinforced by experiments demonstrating 
that expression of the N-terminal domain of UL24 alone is sufficient to induce the 
redistribution of nucleolin in the nucleus (Bertrand & Pearson, 2008). A similar impact of 
UL24 on nucleolar morphology was observed with B23, another abundant nucleolar protein, 
but not with fibrillarin, which also assumes a diffuse nuclear distribution as a consequence 
of HSV-1 infection, but in a UL24-independent manner (Callé et al., 2008; Lymberopoulos et 
al., 2011). Since UL24 is implicated in the redistribution of B23 and nucleolin, it is possible 
that it plays a role in nuclear egress through its effect on nucleoli, although how nucleolin 
affects HSV-1 nuclear egress is obscure. Finally, the fact that deletion of UL24 conserved 
homology domains, including the putative endonuclease motifs, resulted in loss of nucleolin  
and B23 dispersal activity, suggests that this function may be shared among all 
herpesviruses and must be relevant for the viral life cycle (Bertrand et al., 2010; Bertrand & 
Pearson, 2008; Lymberopoulos et al., 2011).  
The first results that demonstrated UL24 involvement with cell cycle manipulation were 
obtained for ORF20 protein, the UL24 homologue from MHV-68 (Nascimento & Parkhouse, 
2007). This virus is a particularly useful model for the study of herpesvirus in vivo. Similar to 
the human homologues, ORF20 is located in the nucleus and, when transiently expressed in 
human and murine cell lines, it induces cell cycle arrest at the G2/M phase, followed by 
apoptosis at later time points.  During the G2 phase, the cyclin B/Cdc2 complex is inactive 
as the Cdc2 protein is in the phosphorylated form.  Consistent with the observed G2 arrest, 
cells expressing MHV-68 ORF20 showed an increased phosphoryation of Cdc2 at the 
inhibitory site Tyr15 and a consequent inactivation of Cdc2-cyclin B complex was 
demonstrated (Nascimento & Parkhouse, 2007). As ORF20 belongs to UL24 gene family, the 
possibility that other homologues might have a role in cell cycle modulation was explored. 
In fact, the UL24 homologues from human herpesviruses representative of each subfamily 
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(HSV-1 UL24, HCMV UL76 and KSHV ORF20) also induced cell cycle arrest followed by 
apoptosis. Moreover, and as observed for MHV-68 ORF20, the UL24 homologues expression 
also resulted in Cdc2 phosphorylation at the Tyr-15 inactivation site and consequent 
inhibition of the mitotic cdc2-cyclin B complex (Nascimento et al., 2009).  
The precise mechanism of cell cycle arrest induced by UL24 homologues remains to be 
clarified. An interesting and possible explanation is the recent report that HCMV UL76 
induces chromosomal aberrations and DNA damage (Siew et al., 2009). Phosphorylation of 
ATM and γ-H2AX, accepted signals of DNA damage activation, were also observed for 
HSV-1 UL24 (our unpublished work), possibly revealing a conserved effect similar to the 
observed cell cycle arrest. It may be relevant that the number of cells with DNA damage 
breaks increased with increasing levels of the UL76 protein, a feature perhaps related to the 
putative endonuclease activity of the viral protein (Siew et al., 2009).  
Another example of this multi-functionality of virus host evasion proteins is the induction of 
the expression of interleukin-8 (IL-8) by the HCMV UL76 gene (our unpublished work). 
Thus the up-regulation of IL-8 observed in infections with HCMV (Murayama et al., 1997), 
HSV-1 (Li et al., 2006), KSHV (Lane et al., 2002), and EBV (Klein et al., 1996) is consistent with 
the properties of the conserved herpesvirus host evasion gene, UL24 gene family. The pro-
inflammatory chemokine IL-8 is a member of the CXC chemokine family that binds with 
high affinity to two chemokine receptors, CXCR1 and CXCR2 (Zlotnik & Yoshie, 2000) and 
is predominantly chemotactic for neutrophils. Following infection, HCMV spreads via the 
bloodstream to various organs. During this phase, infectious HCMV is detected in all major 
leukocyte populations, with neutrophils being the most frequent reservoirs of viral DNA.  
Although the virus may not replicate within them, neutrophils play an important role in the 
dissemination of HCMV throughout the body. Significantly, IL-8 expression is up-regulated 
in HCMV infected cells (Craigen et al., 1997), and its secretion has direct consequences as it 
increases the production of infectious virus (Murayama et al., 1994). Thus the stimulation of 
IL-8 expression appears to be a virus strategy evolved to enhance virus dissemination and 
survival, playing a key role in the pathogenesis of the infection. In summary, it is interesting 
that activation of DNA damage by UL76, a single viral gene, without cellular homology, yet 
conserved in all herpesviruses, has two very different activities, cell cycle manipulation and 
IL-8 induction, both very important for HCMV life cycle and host evasion. Whether these 
two activities are the consequence of two entirely different functional domains, or are in 
some way related, remains to be seen. 
To further understand the role of UL24 on viral pathogenesis in vivo, we constructed two 
independent ORF20 deletion mutant MHV-68 viruses. Since MHV-68 infects both outbred 
and inbred mice, MHV-68 is a useful model to study the lytic and latent phase of 
herpesvirus infection and consequent pathogenesis in vivo. After intranasal inoculation of 
mice, MHV-68 replicates in lung epithelial cells. This lytic phase of infection is resolved 
within 10-12 days in mice infected with wild-type virus. In contrast, in mice infected with 
the two independent mutants for ORF20, the virus titers in the lungs were still elevated after 
ten days post-infection, whereas it was almost undetectable, at the same time point in the 
mice infected with wild-type MHV-68 and revertant viruses. However, fifteen days after 
infection, the lytic phase in mice infected with ORF20 deficient viruses was resolved and the 
virus established latency in the spleen. The fundamental cause of the extended viraemia in 
mice infected with ORF20-mutant viruses remains to be elucidated. After the initial lytic 
virus replication in the lungs, MHV-68 establishes latency in B lymphocytes in the spleen. In 
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some way related, remains to be seen. 
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herpesvirus infection and consequent pathogenesis in vivo. After intranasal inoculation of 
mice, MHV-68 replicates in lung epithelial cells. This lytic phase of infection is resolved 
within 10-12 days in mice infected with wild-type virus. In contrast, in mice infected with 
the two independent mutants for ORF20, the virus titers in the lungs were still elevated after 
ten days post-infection, whereas it was almost undetectable, at the same time point in the 
mice infected with wild-type MHV-68 and revertant viruses. However, fifteen days after 
infection, the lytic phase in mice infected with ORF20 deficient viruses was resolved and the 
virus established latency in the spleen. The fundamental cause of the extended viraemia in 
mice infected with ORF20-mutant viruses remains to be elucidated. After the initial lytic 
virus replication in the lungs, MHV-68 establishes latency in B lymphocytes in the spleen. In 
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contrast to the extended acute phase of ORF20 mutant viruses, no major difference was 
found in the reactivation from latency of mutant virus compared to MHV-68 wild type 
infection (Nascimento et al., 2011).  
Other studies in vivo, using UL24 homologues from HSV-2 or VZV, also suggest a critical 
role for UL24 in viral pathogenesis. Intravaginal inoculation of BALB/c mice and Hartley 
guinea pigs with a UL24 deletion mutant of HSV-2 virus resulted in delayed disease 
kinetics and minimal disease progression, and the mutant virus was avirulent at higher 
doses compared to the parental virus (Blakeney et al., 2005). Deletion mutant VZV virus 
infection of skin and T cells xenografts in vivo also indicated that ORF35 is a determinant 
of VZV virulence (Ito et al., 2005). It would be important to analyze the ORF20 mutant 
MHV-68 pathogenesis in its natural host, the wood mice (members of the genus 
Apodemus) (Ehlers et al., 2007), as a recent comparative analysis revealed that MHV-68 
infection of BALB/c (M. musculus) and laboratory-bred wood mice are markedly different 
(Hughes et al., 2010).  
In conclusion, manipulation of the DNA damage response is a major target of herpesviruses, 
and one that in turn may determine a variety of significant outcomes to favor the virus, with 
cell cycle arrest and induction of IL-8 now identified.  
4. Conclusion 
Many virus genes that manipulate host defense mechanisms are recognized by their 
homology to cellular genes. Viruses, however, contain many genes without any homology 
or known function in the now vast sequences database. As all the structural proteins and 
most of the enzymes of herpesvirus are now known, it is likely that a considerable 
number of their non-assigned, non-homologous genes have evolved for host 
manipulation, thus offering opportunities for other novel strategies for control of virus 
infection, such as construction of a gene deletion, avirulent virus vaccines. Indeed, as we 
report here, the UL24 gene family, which is conserved in all herpesviruses, and has no 
cellular homologue, combines the dual function of inhibiting cell cycle progression and 
inducing IL-8 expression. 
Significantly, both UL24 and the kinase ORF36 are genes conserved in α-, β- and γ- 
herpesviruses, and both share the function of activating the DNA damage pathway. At the 
same time, both UL24 and ORF36 impact on innate immunity, the first inducing expression 
of IL-8, and the second inhibiting IFN responses. Thus UL24, like many other virus host 
evasion genes, is multifunctional, impacting on two cellular activities, the cell cycle and IL-8 
expression. Although at first site this particular combination of targets for one viral gene is 
not an obviously rational one, future studies may provide the logical mechanistic link for 
many more multifunctional virus host evasion genes.  
In conclusion, non-homologous virus genes may be an Aladdin’s cave of “ready-made 
tools” for the manipulation of cell biology and immune responses, and the multi-
functionality of virus host evasion genes may provide important tools to unravel the 
complex interactions underlying the regulation of intracellular signaling.  
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contrast to the extended acute phase of ORF20 mutant viruses, no major difference was 
found in the reactivation from latency of mutant virus compared to MHV-68 wild type 
infection (Nascimento et al., 2011).  
Other studies in vivo, using UL24 homologues from HSV-2 or VZV, also suggest a critical 
role for UL24 in viral pathogenesis. Intravaginal inoculation of BALB/c mice and Hartley 
guinea pigs with a UL24 deletion mutant of HSV-2 virus resulted in delayed disease 
kinetics and minimal disease progression, and the mutant virus was avirulent at higher 
doses compared to the parental virus (Blakeney et al., 2005). Deletion mutant VZV virus 
infection of skin and T cells xenografts in vivo also indicated that ORF35 is a determinant 
of VZV virulence (Ito et al., 2005). It would be important to analyze the ORF20 mutant 
MHV-68 pathogenesis in its natural host, the wood mice (members of the genus 
Apodemus) (Ehlers et al., 2007), as a recent comparative analysis revealed that MHV-68 
infection of BALB/c (M. musculus) and laboratory-bred wood mice are markedly different 
(Hughes et al., 2010).  
In conclusion, manipulation of the DNA damage response is a major target of herpesviruses, 
and one that in turn may determine a variety of significant outcomes to favor the virus, with 
cell cycle arrest and induction of IL-8 now identified.  
4. Conclusion 
Many virus genes that manipulate host defense mechanisms are recognized by their 
homology to cellular genes. Viruses, however, contain many genes without any homology 
or known function in the now vast sequences database. As all the structural proteins and 
most of the enzymes of herpesvirus are now known, it is likely that a considerable 
number of their non-assigned, non-homologous genes have evolved for host 
manipulation, thus offering opportunities for other novel strategies for control of virus 
infection, such as construction of a gene deletion, avirulent virus vaccines. Indeed, as we 
report here, the UL24 gene family, which is conserved in all herpesviruses, and has no 
cellular homologue, combines the dual function of inhibiting cell cycle progression and 
inducing IL-8 expression. 
Significantly, both UL24 and the kinase ORF36 are genes conserved in α-, β- and γ- 
herpesviruses, and both share the function of activating the DNA damage pathway. At the 
same time, both UL24 and ORF36 impact on innate immunity, the first inducing expression 
of IL-8, and the second inhibiting IFN responses. Thus UL24, like many other virus host 
evasion genes, is multifunctional, impacting on two cellular activities, the cell cycle and IL-8 
expression. Although at first site this particular combination of targets for one viral gene is 
not an obviously rational one, future studies may provide the logical mechanistic link for 
many more multifunctional virus host evasion genes.  
In conclusion, non-homologous virus genes may be an Aladdin’s cave of “ready-made 
tools” for the manipulation of cell biology and immune responses, and the multi-
functionality of virus host evasion genes may provide important tools to unravel the 
complex interactions underlying the regulation of intracellular signaling.  
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1. Introduction 
Herpesviridae is a large class of animal viruses. Herpes simplex virus type 1 (HSV-1) is a 
prototypic virus in this taxonomic group. HSV-1 belongs to the Alphaherpesviridae which are 
most frequently responsible for cold-sore lesions around the lips and mouth. HSV-1 is 
extensively studied not only as a causative agent of human disease but also as a general 
model system for the gene expression. In the lytic replication cycle of HSV-1, temporally 
ordered viral gene expression is typically observed, that is, immediate early, early and late 
gene (Boehmer & Lehman, 1997; Boehmer & Nimonkar, 2003) . This classification of viral 
gene is based on the expression timing from the start of the infection. The immediate early 
gene is expressed within 30 minutes from the infection. The expression of the immediate 
early gene is introduced by the cooperation between the host transcription factor and VP-16 
which is packed in the tegmentum of HSV-1 particle. The protein complex, composed of the 
host transcription factor and VP-16, binds to the immediate early gene promoter and then 
activates the immediate early gene expression (Wysocka & Herr, 2003). Immediate early 
genes encode the transcription factors. Under the control of the immediate early gene 
products, other viral genes are expressed (Weir, 2001; Yamamoto et al., 2006). 2~3 hours 
after infection, the early gene is expressed, delayed from the immediate early gene and 
proceeding to the late gene. Finally, the late gene expression has started after 8 hours after 
infection. Both the early and the late gene expression are regulated by the immediate early 
gene products such as ICP4 (Kim et al., 2002). The difference of the expression timing 
between the early and late gene is caused by the structural difference of the early and the 
late gene promoter as shown in Fig.1. 
In the early gene promoter, many binding sites to the immediate early gene products are 
tandemly repeated. On the other hand, the number of repeat binding sites in the late 
gene promoter is fewer than that in the early gene promoter. The binding affinity of the 
early gene promoter to the immediate early gene products is higher as compared with 
the late gene promoter. Therefore the expression of the early gene proceeds to that of the 
late gene. The mechanism regulating the temporally ordered viral gene expression of 
HSV-1 is clarified as mentioned above. But the function of this expression pattern is not 
clear yet. The functional meaning of the expression profile of the HSV-1 gene is 
theoretically studied (Nakabayashi & Sasaki, 2009). In this chapter, the function of the 
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1. Introduction 
Herpesviridae is a large class of animal viruses. Herpes simplex virus type 1 (HSV-1) is a 
prototypic virus in this taxonomic group. HSV-1 belongs to the Alphaherpesviridae which are 
most frequently responsible for cold-sore lesions around the lips and mouth. HSV-1 is 
extensively studied not only as a causative agent of human disease but also as a general 
model system for the gene expression. In the lytic replication cycle of HSV-1, temporally 
ordered viral gene expression is typically observed, that is, immediate early, early and late 
gene (Boehmer & Lehman, 1997; Boehmer & Nimonkar, 2003) . This classification of viral 
gene is based on the expression timing from the start of the infection. The immediate early 
gene is expressed within 30 minutes from the infection. The expression of the immediate 
early gene is introduced by the cooperation between the host transcription factor and VP-16 
which is packed in the tegmentum of HSV-1 particle. The protein complex, composed of the 
host transcription factor and VP-16, binds to the immediate early gene promoter and then 
activates the immediate early gene expression (Wysocka & Herr, 2003). Immediate early 
genes encode the transcription factors. Under the control of the immediate early gene 
products, other viral genes are expressed (Weir, 2001; Yamamoto et al., 2006). 2~3 hours 
after infection, the early gene is expressed, delayed from the immediate early gene and 
proceeding to the late gene. Finally, the late gene expression has started after 8 hours after 
infection. Both the early and the late gene expression are regulated by the immediate early 
gene products such as ICP4 (Kim et al., 2002). The difference of the expression timing 
between the early and late gene is caused by the structural difference of the early and the 
late gene promoter as shown in Fig.1. 
In the early gene promoter, many binding sites to the immediate early gene products are 
tandemly repeated. On the other hand, the number of repeat binding sites in the late 
gene promoter is fewer than that in the early gene promoter. The binding affinity of the 
early gene promoter to the immediate early gene products is higher as compared with 
the late gene promoter. Therefore the expression of the early gene proceeds to that of the 
late gene. The mechanism regulating the temporally ordered viral gene expression of 
HSV-1 is clarified as mentioned above. But the function of this expression pattern is not 
clear yet. The functional meaning of the expression profile of the HSV-1 gene is 
theoretically studied (Nakabayashi & Sasaki, 2009). In this chapter, the function of the 
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temporally ordered viral gene expression of HSV-1 is considered from the point of view 
of the efficiency of the replication of HSV-1. Further, evolution of the temporal 
expression profile of the viral gene is taken into consideration. From the genome 
structure of HSV-1, the evolutionary process of HSV-1 is estimated (Umene & Sakaoka, 
1999). Here, the evolution of HSV-1 is evaluated by the efficiency of the replication but 
not the genome structure. The regulatory system for the efficient replication of virus is 
developed through the evolutionary process. The HSV-1 genotype whose gene 
expression is optimally regulated to maximize the virion production is selected through 
the evolutionary process. It is considered that not only viral replication, but many 
biological systems, are optimized through the evolutionary process. It is shown that the 
optimality principle is valid and feasible to understand the mechanism of the biological 
system (Khanin et al., 2004; Tyurin & Khanin, 2005, 2006). It is confirmed how viral gene 
expression is temporally regulated to maximize the virion production by using the 
evolutionary simulation. The obtained expression pattern obtained from the 




Fig. 1. The structural difference between the early and the late gene promoter. The 
expression timing of the early and late gene is determined by the structure of their 
promoters. In the early gene promoter, binding sites for the transcription factor are 
tandemly repeated. The number of binding sites in the late gene promoter is fewer than that 
in the early gene promoter. 
2. Function of temporally ordered viral gene expression 
The preceding expression of the early gene is necessary for the efficient replication of HSV-1. 
Though the classification of viral gene is based on the expression timing after infection, the 
protein function of viral gene is clearly distinguished between the early and the late gene 
(Nishiyama, 2004). Early genes encode the enzymes contributing to the DNA replication, 
while late genes encode the structural proteins of the HSV-1 particle (Cann, 2000). It is 
theoretically shown that the preceding DNA replication to the assembly of virion is 
appropriate for the efficient replication of HSV-1. The replication process is schematically 
shown in Fig. 2.  
 


















Fig. 2. The intracellular replication cycle of HSV-1. The replication of HSV-1 has started 
when the genome DNA of HSV-1 invades into the cell. First, the immediate early gene is 
expressed within 30 min. after infection. Under the control of the immediate early gene, both 
the early and the late gene are expressed. Early and late gene products contribute to the 
genome DNA replication and virion assembly, respectively. Finally, the complete virion is 
newly produced. 
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Notations used in the model (1) are summarized in Table1.  
 
 Immediate Early Early Late 
mRNA [RNAI] [RNAE] [RNAL] 
Protein [Immediate] [Early] [Late] 
Transcription rate I E L 
mRNA degradation rate IRNA ERNA LRNA  
Translation rate I E L 
Protein degradation rate I E L 
Table 1. Notations used in the model (1). 
The time course of HSV-1 replication is calculated from this mathematical model (1). The 
dependence of the intracellular dynamics of virion on the expression rates of the early and 
the late gene respectively designated by E and L is investigated. As a result, when the 
expression ratio E/L exceeds a certain threshold, HSV-1 virion is continuously reproduced. 
On the other hand, when the ratio E/L is smaller than a certain threshold level, HSV-1 
replication is arrested. To understand this switching mechanism of the HSV-1 replication, 
model (1) is simplified for the theoretical analysis. 



































The diagram of the simplified model (2) is shown in Fig. 3. 
Time dependent solutions of [DNA], [Early] and [Late] are obtained as a function of 



























ξ ξ α ξ ξ ξD D


















Herpesviridae – A Look into This Unique Family of Viruses 
 
32









[DNA]  [DNA]  [RNA ]
[RNA ]  [Immediate]
[RNA ]  degradation
[Immediate]  degradation
[DNA]  [Immediate]  [DNA]  [Immediate]  [RNA ]
[RNA ]  [Early]



























[DNA]  [Early]  2[DNA]  [Early]
[DNA]  [Immediate]  [DNA]  [Immediate]  [RNA ]
[RNA ]  [Late]







































[DNA] [DNA][Early] [DNA][Late] [DNA]
[RNA ] [DNA] [RNA ]
[Immediate] [RNA ] [Immediate]
[RNA ] [DNA][Immediate] [RNA ]














































Optimal Gene Expression for Efficient Replication of Herpes Simplex Virus Type 1 (HSV-1) 
 
33 
Notations used in the model (1) are summarized in Table1.  
 
 Immediate Early Early Late 
mRNA [RNAI] [RNAE] [RNAL] 
Protein [Immediate] [Early] [Late] 
Transcription rate I E L 
mRNA degradation rate IRNA ERNA LRNA  
Translation rate I E L 
Protein degradation rate I E L 
Table 1. Notations used in the model (1). 
The time course of HSV-1 replication is calculated from this mathematical model (1). The 
dependence of the intracellular dynamics of virion on the expression rates of the early and 
the late gene respectively designated by E and L is investigated. As a result, when the 
expression ratio E/L exceeds a certain threshold, HSV-1 virion is continuously reproduced. 
On the other hand, when the ratio E/L is smaller than a certain threshold level, HSV-1 
replication is arrested. To understand this switching mechanism of the HSV-1 replication, 
model (1) is simplified for the theoretical analysis. 



































The diagram of the simplified model (2) is shown in Fig. 3. 
Time dependent solutions of [DNA], [Early] and [Late] are obtained as a function of 



























ξ ξ α ξ ξ ξD D























I I E E L L
I E L
RNA RNA RNA
γ β γ β γ βξ ,ξ ,ξ ,
δ δ δ
   . D0 is an initial condition for [DNA]. To 
investigate the trajectory of [DNA] as a function of [Immediate], the threshold for the 
continuous replication of HSV-1 without an arrest is analytically obtained as E/L>1/2 
from the simplified model (2) and (3). Here 1 and 2 indicate the reaction rate constant of 
genome DNA replication and the virion assembly, respectively. Therefore E1 and L2 
indicate the net genome DNA replication and virion assembly, respectively. This continuous 
replication of HSV-1 is caused by the effect of the positive feedback in the replication cycle. 
When the replication of genome DNA exceeds the virion assembly, the viral gene expression 
is further increased from the replicated viral DNA. Inversely, when the virion assembly 
exceeds the genome DNA replication, DNA of HSV-1 is consumed by the virion assembly. 
When all of the HSV-1 genome is consumed, HSV-1 replication is arrested because the 
template of the replication is absent. This result indicates that the temporally ordered viral 
gene expression, preceding expression of the early gene to the late gene, is necessary for the 












Fig. 3. The diagram of the simplified model (2). 
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3. Evolutionary process of HSV-1 gene expression 
In this section, the evolution of the regulatory mechanism of HSV-1 gene expression is 
considered. The temporal profile of HSV-1 gene expression is determined by the structure of 
the promoter region on the HSV-1 genome. The structure of the HSV-1 promoter is changed 
by the mutation. For example, binding site is newly produced or lost by the point mutation 
in the promoter region. In the previous section, it is shown that the replication of HSV-1 is 
critically affected by the expression pattern of the viral gene. If the expression rate of the 
early gene is affected by the mutation in the promoter region of the early gene, replication 
dynamics of this mutant is changed as compared with that of the wild type. It is considered 
that the mutant with large expression rate of early gene becomes advantageous because of 
the continuous and efficient replication. It is considered that the frequency of the mutant 
with large expression rate of the early gene increases through the evolutionary process 
because of the improvement of the efficiency of the replication. It is hypothesized that the 
temporally ordered expression pattern of viral genes autonomously evolves through such 
an evolutionary process to maximize the efficiency of the replication of HSV-1. This 
hypothesis is confirmed by the evolutionary simulation. 
3.1 Evolutionary simulation of the viral gene expression 
Here, the procedure of the evolutionary simulation is briefly explained. Many genotypes 
of HSV-1 with various expression rates of the early and late genes are generated by 
drawing the random number. The production of virion of genotype j until a certain 
waiting time for the virion release designated by v(j)() is calculated according to the 











. This process means that the frequency of HSV-1 genotype with 
gene expression rate increasing the virion production increases its frequency. Mutation is 
reproduced by adding the random number to the expression rate E(j) and L(j). These 
processes are iterated over and over. After sufficient iterations, HSV-1 genotype with 
optimum gene expression rate maximizing the virion production is selected. The 
procedure of the evolutionary simulation is summarized in Fig. 4. 
The initial condition of viral gene expression is set that the expression rate of the early gene 
is equal to that of the late gene. It is shown by the evolutionary simulation that HSV-1 
genotype with large E and small L is selected through the evolutionary process. The 
frequency of HSV-1 genotype with large E and small L increases. The mean values of E 
and L increase and decrease, respectively. This result indicates that the temporally ordered 
gene expression of HSV-1 autonomously evolves to maximize the replication. 
This result indicates that the preceding expression of the early gene to that of the late gene 
autonomously evolves from the initial condition when the expression rate of the early gene 
is equal to that of the late gene to maximize the efficiency of the virion production. If the 
new binding site to the transcription factor is newly created by the mutation in the early 
gene promoter, the mutant with large expression rate of the early gene becomes 
advantageous and increases its frequency. As a result, tandemly repeated binding sites 
observed in the early gene promoter are created. Inversely, a new binding site in the late 
gene prevents the efficient replication of HSV-1, because genome DNA of HSV-1 is 
consumed by the excessively expressed late gene product. HSV-1 replication stops because 
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of the absence of the template of the replication. The binding site in the late gene cannot 
increase. The structural difference between the early gene promoter and the late gene 


















Fig. 4. The procedure of the evolutionary simulation. 
 
Optimal Gene Expression for Efficient Replication of Herpes Simplex Virus Type 1 (HSV-1) 
 
37 
But the genotype of HSV-1 with large E and or small L is not always advantageous. There is a 
condition for the evolution of the temporally ordered HSV-1 gene expression. It is also shown 
by the evolutionary simulation that the long waiting time for the virion release is necessary to 
evolve the preceding expression of the early gene to that of the late gene. Waiting time 
designated by  is the period when HSV-1 replicates its copy in the infected cell until the newly 
produced virion is released from the infected cell. When waiting time for the virion release is 







Fig. 5. A sample path of the evolutionary simulation. The mean expression rate of the early 
(red), late (blue) and mean value of virion (black) of 1000 HSV-1 genotypes are plotted. The 
initial expression rate of the early gene is equal to that of the late gene. The HSV-1 genotype 
with large E increases its frequency as generation proceeds. The virion production rapidly 
increases when the expression ratio of the early gene to the late gene is larger than a certain 
threshold level. 
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Fig. 6. A sample path of the evolutionary simulation with small waiting time . HSV-1 
genotype with small E (red) and large L (blue) increases its frequency as generation 
proceeds. The virion production (black) slightly increases. Amount of virion remains at a 
small level as compared with the case when waiting time for the virion release is large. 
The virion production of HSV-1 genotype with large E and small L is delayed in the initial 
phase of the replication as compared with HSV-1 genotype with small E and large L. As a 
result, when waiting time for the virion release from the infected cell is small, HSV-1 
genotype with small E and large L becomes advantageous in spite of the fact that the 
replication of the HSV-1 genotype with small E and large L is arrested after sufficiently 
long time has passed after infection. Preceding expression of the early gene to that of the late 
gene cannot autonomously evolve. This result indicates that there is a trade-off between the 
initial speed and the final amount of virion production. When the expression of early gene 
becomes large, virion is continuously produced by the positive feedback in the replication 
cycle. But it takes much time to produce the virion. Inversely, when the late gene expression 
is large, virion is reproduced faster. But the replication cycle stops after sufficiently long 
time has passed because the positive feedback of the replication cannot function. To 
compare the virion production indicated by right-hand side axis in Fig. 5 and 6, the virion 
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production remains small when  is small. From the results of the evolutionary simulations, 
it is suggested that HSV-1 develops the efficient replication system with preceding 
expression of the early gene to that of the late gene under the condition that the waiting time 
for the virion release from the infected cell is large. 
4. Conclusion 
The function and the evolution of temporally ordered viral gene expression is investigated 
from the point of view of the efficiency of the replication. The preceding expression of the 
early gene to that of the late gene is advantageous for the continuous replication of HSV-1 
without an arrest. Continuous replication of HSV-1 is caused by the effect of the positive 
feedback in the replication cycle. When the expression ratio E/L exceeds a certain threshold 
level, the positive feedback can function. 
The expression timing of the viral genes is determined by the structure of their promoters. It 
is suggested by the evolutionary simulation that the tandemly repeated binding sites to the 
transcription factor in the early gene promoter autonomously evolves through the 
evolutionary process to maximize the virion production. As the promoter activity of the 
early gene increases, the efficiency of HSV-1 replication is improved. But large expression 
rate of the early gene is not always advantageous for the replication. The sufficiently long 
waiting time for the virion release is necessary to increase the frequency of HSV-1 genotype 
with large expression ratio of the early gene to the late gene. When waiting time for the 
virion release is small, the HSV-1 genotype with small E and large L that faster, but 
restrictedly, replicates its copy becomes advantageous. Preceding expression of the early 
gene to that of the late gene can evolve when the waiting time for the virion release is 
sufficiently long. 
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production remains small when  is small. From the results of the evolutionary simulations, 
it is suggested that HSV-1 develops the efficient replication system with preceding 
expression of the early gene to that of the late gene under the condition that the waiting time 
for the virion release from the infected cell is large. 
4. Conclusion 
The function and the evolution of temporally ordered viral gene expression is investigated 
from the point of view of the efficiency of the replication. The preceding expression of the 
early gene to that of the late gene is advantageous for the continuous replication of HSV-1 
without an arrest. Continuous replication of HSV-1 is caused by the effect of the positive 
feedback in the replication cycle. When the expression ratio E/L exceeds a certain threshold 
level, the positive feedback can function. 
The expression timing of the viral genes is determined by the structure of their promoters. It 
is suggested by the evolutionary simulation that the tandemly repeated binding sites to the 
transcription factor in the early gene promoter autonomously evolves through the 
evolutionary process to maximize the virion production. As the promoter activity of the 
early gene increases, the efficiency of HSV-1 replication is improved. But large expression 
rate of the early gene is not always advantageous for the replication. The sufficiently long 
waiting time for the virion release is necessary to increase the frequency of HSV-1 genotype 
with large expression ratio of the early gene to the late gene. When waiting time for the 
virion release is small, the HSV-1 genotype with small E and large L that faster, but 
restrictedly, replicates its copy becomes advantageous. Preceding expression of the early 
gene to that of the late gene can evolve when the waiting time for the virion release is 
sufficiently long. 
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1. Introduction 
Over the past 20 years, a fundamental shift has occurred in the study of virus-host relations. 
As scientists first began to identify and appreciate the clever tricks viral pathogens used to 
hide from the immune system, the terms immune evasion and immune avoidance became 
prevalent in the literature. More recently, we began to recognize and appreciate just how 
sophisticated and cunning some of these clever little tricks were, and the term immune 
modulation took center stage. This implies, correctly, that viruses are not just cowering in 
dark corners to avoid immune detection by the host, but rather that they are actively 
manipulating host conditions to create situations that favor virus persistence and make 
virus clearance difficult or even impossible.  
1.1 Human cytomegalovirus and its bag of tricks 
Once known as “salivary gland virus”, HCMV was first isolated from the salivary glands 
and kidneys of a dying infant with greatly enlarged cells, or cytomegalic inclusion bodies, 
in affected tissues (Brennan, 2001). A member of the beta subgroup of the Herpesviridae 
family, HCMV is composed of a large double-stranded DNA genome surrounded by an 
icosahedral capsid. The linear genome of approximately 230 kb has terminal repeats 
flanking two unique segments, designated unique long (UL) and unique short (US), with 
open reading frames in each segment numbered sequentially. The nucleocapsid is covered 
by a protein layer termed the tegument, and the entire particle, approximately 200 nm in 
diameter, is enclosed by a membrane envelope featuring numerous glycoprotein spikes. 
HCMV infects multiple cell types, including epithelial cells, fibroblasts, monocytes, 
macrophages, and lymphocytes. The virus is transmitted between individuals via all body 
fluids (saliva, blood, breast milk, semen), as well as through bone marrow and solid organ 
transplants.  
Infection with HCMV is often asymptomatic in the healthy host and a large percentage of 
the general population is seropositive (Staras et al., 2006). In contrast, serious disease 
frequently occurs in the immune suppressed. Diagnoses of life-threatening HCMV 
pneumonitis and retinitis are increasing among transplant recipients and persons living 
with AIDS (de la Hoz et al., 2002). Congenital HCMV infection is the leading viral cause of 
deafness and mental retardation in newborn infants (Damato and Winnen, 2002).  
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Like other herpesviruses, at some point following initial infection, HCMV establishes latent 
infection. Latency may be defined as the inability to detect infectious virus, despite the 
presence of viral DNA. All of the specific sites for HCMV latency are not well characterized, 
but myeloid progenitor cells in the bone marrow are believed to be the main reservoir of 
latent virus (Sinclair, 2008). Latent genomes have been detected in mononuclear cells in the 
peripheral blood, but not in neutrophils and other peripheral blood cells (Taylor-Wiedeman 
et al., 1993; Taylor-Wiedeman et al., 1991).  
HCMV encodes over 180 genes, but only a subset of these is required for basic replication 
and generation of infectious progeny virions (Yu et al., 2003). The remaining viral genes 
have roles in mediating various aspects of the interaction between the virus and the host. 
Cellular processes that are affected by CMV gene products include the cell cycle, apoptosis, 
and immune recognition and response.  
HCMV has developed numerous mechanisms for manipulating the host immune system 
(Scalzo et al., 2007). The virally encoded US2, US3, US6 and US11 gene products all interfere 
with antigen processing and presentation, resulting in reduced major histocompatibility 
complex (MHC) class I presentation (Ahn et al., 1996). This causes decreased recognition by 
cytotoxic T lymphocytes, which was recently found to enable superinfection by multiple 
virus strains in the same individual (Hansen et al., 2010). In addition, the UL18 gene product 
is a homolog of the MHC class I protein that is postulated to act as a decoy on the cell 
surface to assist in the evasion of natural killer cells (Beck and Barrell, 1988). 
This chapter will focus on four HCMV genes: UL111A, UL144, UL146, and US28 (Figure 1). 
These genes encode a viral cytokine, cytokine receptor, chemokine, and chemokine receptor, 
respectively. Before expanding on each of these viral genes, an introduction to the human 
cytokine and chemokine system and its importance in immune responses is briefly 
discussed. 
1.2 Cytokines, chemokines, and their receptors – Critical immune mediators 
During World War II, the United States used the Navajo language to keep military 
communications from being intercepted by the enemy. Because the Navajo language had 
never been written down, it was virtually indecipherable without the help of a native 
speaker. The human immune system, on the other hand, relies on a system of secreted 
proteins to mediate the interactions required to coordinate and mount an effective immune 
response. Hundreds of different cytokines are constantly being secreted to regulate, 
stimulate, suppress, and control the many aspects of cell development, inflammation, and 
immunity.  
Cytokines are produced by a wide variety of cell types , including monocytes, macrophages, 
lymphocytes, fibroblasts, mast cells, platelets, and the endothelial cells lining the walls of the 
blood vessels. Release of cytokines is an effective way to send information to multiple cells 
simultaneously, and only cells with the appropriate receptor can receive the signal, usually 
by binding to the cytokine at the plasma membrane and then transmitting the signal inside 
the cell via cellular pathways. Chemokines are a subtype of cytokine that function mainly as 
chemoattractants to induce migration of immune cells; in fact, the name is a contraction of 
the term “chemotactic cytokine”. When released into the bloodstream, chemokines help to 
recruit monocytes, neutrophils, and other immune effector cells to sites of infection or 
damage. Chemokine receptors on target cells have seven transmembrane domains and 
belong to the G-protein coupled receptor superfamily.  
Trojan Horses and Fake Immunity Idols:  




Fig. 1. An HCMV-infected cell displaying immunomodulatory viral proteins. 1) The 
UL111A gene product, cmvIL-10, is secreted from infected cells and binds to the cellular IL-
10 receptor as a dimer. 2) The UL144 gene product is a TNF receptor homolog found 
primarily inside the cell. 3) The UL146 gene product, vCXC-1, is secreted and acts as an -
chemokine to attract neutrophils. 4) The US28 gene product is a seven-transmembrane 
chemokine receptor. A green icosahedron represents a virus nucleocapsid. 
Despite its many complexities, the human cytokine system is not nearly as effective as the 
Navajo language was at confounding the enemy. Viruses like HCMV have not only broken 
the code, they produce their own cytokines, chemokines, and receptors during the course of 
infection to claim victory. Or, in viral terms, they render host immune responses ineffective 
and maintain persistent infection.  
2. The UL111A gene product: CMV IL-10 
Human cellular interleukin-10 (IL-10) is a pleiotropic cytokine that is important to the 
regulation of the immune response (Mosser and Zhang, 2008). Although stimulatory effects 
on the proliferation of B cells and mast cells have been reported, the primary function of IL-
10 appears to be limiting the inflammatory response, in part by opposing interferon gamma 
(IFN) mediated effects. While IL-10 has effects on many cell types, monocytes in particular 
are a major target for IL-10 activity. IL-10 inhibits production of many cytokines by activated 
monocytes, including IL-1, IL-1, IL-6, TNF, and even IL-10 itself (de Waal Malefyt et al., 
1991a). Inhibition of IL-1 and TNF are crucial to the anti-inflammatory effect, as these 
cytokines can have synergistic effects on other inflammatory pathways. Various cell surface 
molecules are also down-regulated by IL-10, including class II MHC and co-stimulatory 
molecules (de Waal Malefyt et al., 1991b), contributing to decreased T cell effector activity. A 
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virally controlled IL-10 would enable the virus to direct immune activity to its advantage by 
inhibiting inflammation and evading T cell detection, thus providing a window of 
opportunity in which more virus could be produced and transmitted to other cells 
(Slobedman et al., 2009). 
2.1 Gene structure and expression 
The UL111 gene was originally designated as the coding region for ORF79, a 79 amino acid 
protein (Chee et al., 1990a). Another protein product from this region of the viral genome 
was later identified through searches for possible homologs to human IL-10 (Kotenko et al., 
2000; Lockridge et al., 2000). Three exons separated by intervening sequences were 
identified and found to give rise to a 175 amino acid protein product with 27% identity to 
human IL-10 which has been designated cmvIL-10 (Figure 2). Interestingly, a homolog of IL-
10 was identified in the genome of Epstein-Barr Virus a decade earlier, but the BCRF1 gene 
lacked introns and gave rise to a protein with 90% amino acid sequence identity to human 
IL-10 (Hsu et al., 1990). The human IL-10 gene, which is located on chromosome 1, is 
comprised of four introns and five exons.  
The UL111A gene was found to be expressed with late kinetics in productively infected cells 
(Lockridge et al., 2000). The cmvIL-10 protein is secreted at sufficient levels to induce serum 
antibody responses in infected individuals (de Lemos Rieper et al., 2011). In addition to the full 
length cmvIL-10 protein, an alternative transcript is also produced from the UL111A gene, 
giving rise to a 139 amino acid protein (Jenkins et al., 2004). The smaller protein, designated 
LAcmvIL-10, results from read-through of the second intron and then premature termination. 
LAcmvIL-10 is co-linear with cmvIL-10 for the first 127 residues, then diverges in sequence at 
C-terminal domain (Figure 3). The name LAcmvIL-10 was based on the observation that this 
 
 
Fig. 2. Structure of the UL111A gene. The UL111A gene has two introns, but the 
organization is similar to the human IL-10 gene, which has four introns, and the ebvIL-10 
gene, which has no introns. Also shown is the transcript for the LAcmvIL-10 gene, which 
reads through the second intron and encounters a stop codon, indicated by the asterisk (*).  
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shorter transcript was initially detected during latent infection of granulocyte-
macrophage progenitors (and was therefore latency associated). However, it was 
subsequently found that LAcmvIL-10 is expressed during productive infection as well 
(Jenkins et al., 2008a). While the transcript encoding full length cmvIL-10 is expressed with 
late kinetics during infection, the transcript encoding LAcmvIL-10 is expressed with early 
kinetics during productive infection and continues to be expressed during latent infection. 
2.2 Cell signaling 
Despite having only 27% sequence identity to human IL-10, cmvIL-10 binds to the cellular 
IL-10 receptor and displays many of the immune suppressive functions of cellular IL-10 
(Slobedman et al., 2009; Spencer et al., 2002). IL-10 effects are mediated via interaction 
with the cellular IL-10 receptor, a member of the interferon receptor superfamily, which 
consists of two subunits, a ligand binding subunit (IL-10R1) and a signaling subunit (IL-
10R2), as shown in Figure 4. The IL-10/IL-10R interaction engages the Janus-family 
tyrosine kinases Jak1 and Tyk2, which are constitutively associated with IL-10R1 and IL-
10R2, respectively. Ligand-induced oligomerization results in Jak1 activation leading to 
phosphorylation of the intercellular IL-10R1 chains. The transcription factor Stat (signal 
transducer and activator of transcription) is then recruited to the receptor complexes 
based on specific interaction of Stat SH2 domains with phosphotyrosine motifs in the 
receptor. Stats become phosphorylated, dissociate from receptor, form homo-or 
heterodimers, and translocate to the nucleus. IL-10 binding induces activation of Stat3, 
leading to suppression of IFN-inducible genes, such as those encoding class II MHC 
antigens (Donnelly et al., 1999; Mosser and Zhang, 2008).  
CmvIL-10 engagement of the IL-10 receptors also leads to Stat3 activation (Spencer, 2007). 
Downstream immunomodulatory effects include inhibition of PBMC proliferation and 
inflammatory cytokine production, down-regulation of class I and class II MHC molecules, 
and impaired dendritic cell maturation (Chang et al., 2009; Chang et al., 2004; Raftery et al., 
2001; Raftery et al., 2004; Spencer et al., 2002). Although Stat3 phosphorylation is mediated by 
Jak1, inhibition of cytokine synthesis also involves signaling through the phosphatidylinositol 
3-kinase (PI3K) pathway (Spencer, 2007). Additional studies have shown that cmvIL-10 can 
inhibit NF-B signaling in monocytes (Nachtwey and Spencer, 2008). Like human IL-10, the 
cmvIL-10 protein forms a dimer, and evidence suggests that cmvIL-10 can form heterodimers 
with human IL-10 that actually enhance Stat3 phosphorylation (Lin et al., 2008).  
 
 
Fig. 3. Amino acid sequence comparison of the C-terminal domain of full length cmvIL-10 
and LAcmvIL-10. The proteins are identical from amino acids 1-127. Identical residues are 
shown in blue; residues that contact the cellular IL-10 receptor are shown in red.  
LAcmvIL-10 retains some but not all of the immune suppressive properties of full length 
cmvIL-10 (Jenkins et al., 2008b; Spencer et al., 2008). LAcmvIL-10 can trigger down-regulation 
of class II MHC from the surface of monocytes and granulocyte-macrophage progenitor cells; 
however, this effect does not involve Stat3 phosphorylation and is independent of the IL-10 
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Fig. 3. Amino acid sequence comparison of the C-terminal domain of full length cmvIL-10 
and LAcmvIL-10. The proteins are identical from amino acids 1-127. Identical residues are 
shown in blue; residues that contact the cellular IL-10 receptor are shown in red.  
LAcmvIL-10 retains some but not all of the immune suppressive properties of full length 
cmvIL-10 (Jenkins et al., 2008b; Spencer et al., 2008). LAcmvIL-10 can trigger down-regulation 
of class II MHC from the surface of monocytes and granulocyte-macrophage progenitor cells; 
however, this effect does not involve Stat3 phosphorylation and is independent of the IL-10 
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
46
receptor. In addition, LAcmvIL-10 failed to inhibit maturation of dendritic cells and had no 
impact on the expression of co-stimulatory molecules (Jenkins et al., 2008b).  
2.3 Role in infection 
The UL111A gene is not required for virus replication in vitro, which supports the notion that 
cmvIL-10 and LAcmvIL-10 probably function in modifying host immune responses in vivo 
(Avdic et al., 2011). Studies with a UL111A deletion mutant virus have shown up-regulation of 
cytokines involved in dendritic cell formation and a higher proportion of myeloid dendritic 
cells compared to wild type virus. The results suggest that the UL111A gene products actively 
limit the ability of the host to respond to infection and clear virus, which is consistent with the 
observations of other groups that IL-10 is a key determinant of virus persistence (Brooks et al., 
2008; Brooks et al., 2006). Vaccination studies of rhesus macaques also support the notion that 
the IL-10 pathway plays an important role in virus clearance (Barry, 2011). The Rhesus CMV 
genome also encodes an IL-10 homolog, designated RhcmvIL-10 (Lockridge et al., 2000). 
Uninfected rhesus macaques were immunized with a strategy designed to prevent 
engagement of the cellular IL-10 receptor by RhcmvIL-10 (Barry, 2011). Upon challenge with 
RhCMV, vaccinated animals had significantly fewer infected cells and infiltrate at the 
inoculation site, as well as reduced levels of virus in saliva and urine compared to control 
animals. Therapeutic strategies that neutralize cmvIL-10 activity hold great potential for 
enhancing the control or elimination of this persistent pathogen.  
 
 
Fig. 4. Depiction of cmvIL-10 signaling through the cellular IL-10 receptor. The viral 
cytokine binds as a dimer, pulling together receptor chains to create a functional tetrameric 
receptor complex. The receptor associated kinase JAK1 phosphorylates Stat3, which then 
dimerizes and translocates to the nucleus to stimulate gene transcription. 
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2.4 Role in latent infection 
Expression of the UL111A gene plays a role in maintaining a reservoir of virus by protecting 
latently infected cells from CD4+ T cell recognition (Cheung et al., 2009). A UL111A deletion 
mutant virus was able to establish latent infection in myeloid progenitor cells and also 
reactivate from latency just as effectively as wild type virus. However, cells infected with the 
deletion mutant expressed higher levels of class II MHC on the cell surface. This effect was 
confirmed to be due to the lack of viral IL-10, since the addition of recombinant IL-10 (both 
full length cmvIL-10 and LAcmvIL-10) resulted in lower levels of class II MHC expression 
that was comparable to that of cells infected with wild type virus. Reduced class II 
expression correlated with diminished CD4 T cell responses, as measured by proliferation 
and interferon- production by purified allogeneic CD4 T cells co-cultured with the infected 
cells. CD4+T cells cultured with cells infected with the UL111A deletion virus exhibited 
significantly higher levels of proliferation and cytokine production, suggesting that UL111A 
gene products limit recognition of HCMV-infected cells by CD4+ T cells, thereby enhancing 
the pool of latently infected cells. 
2.5 Role in cancer  
The possible relationship between HCMV and cancer has been investigated for some time. 
The development of more sensitive detection methods has recently shown a very strong link 
between HCMV infection and glioblastoma and prostate cancer (Cobbs et al., 2002; Cobbs et 
al., 2007; Mitchell et al., 2008; Samanta et al., 2003). While HCMV is not generally regarded 
as an oncogenic virus, the term oncomodulation has been proposed to describe the 
increased malignancy associated with HCMV-infected tumor cells (Michaelis et al., 2009). 
The possible molecular mechanisms for oncomodulation include altered cell cycle regulation 
by immediate early proteins IE1 and IE2 (Sanchez and Spector, 2008), which promote entry 
into S phase, as well as the activity of the UL97 protein, which phosphorylates and 
inactivates tumor suppressor Rb (Hume et al., 2008). In addition, the UL36, UL37, and UL38 
gene products all interfere with caspase function and convey resistance to apoptosis 
(McCormick, 2008; Skaletskaya et al., 2001). HCMV-infected neuroblastoma cells have been 
observed to down-regulate adhesion molecules and exhibit increased motility (Blaheta et al., 
2004). In infected prostate cancer and glioma cells, HCMV infection resulted in increased 
migration and invasion that was dependent on phosphorylation of focal adhesion kinase 
(FAK) (Blaheta et al., 2006; Cobbs et al., 2007). Most recently, evidence points to a role of 
cmvIL-10 in promoting cancer progression.  
HCMV has been shown to infect both glioma cancer stem cells (gCSCs) and 
macrophage/migroglial populations present in malignant gliomas (Dziurzynski et al., 2011). 
Production of cmvIL-10 by the gCSCs may convert peripheral blood monocytes into an 
immune suppressive, tumor-promoting cell type. The cmvIL-10 present in gCSC 
conditioned medium was shown to trigger activation of Stat3 and production of immune 
suppressive cytokines (Dziurzynski et al., 2011). At this point, the tumor promoting role of 
cmvIL-10 is largely associated with activation of Stat3. The Stat3 pathway is known to be 
active in a number of cell types in the tumor microenvironment and contributes to general 
immune suppression hindering anti-tumor responses (Kortylewski et al., 2005). In a murine 
model of glioma, Stat3 has been demonstrated to promote an influx of macrophages, which 
correlated negatively with survival (Kong et al., 2010). In addition, Stat3 activation is 
associated with poor prognosis in ovarian cancer and considered a key factor in metastasis 
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receptor. In addition, LAcmvIL-10 failed to inhibit maturation of dendritic cells and had no 
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the IL-10 pathway plays an important role in virus clearance (Barry, 2011). The Rhesus CMV 
genome also encodes an IL-10 homolog, designated RhcmvIL-10 (Lockridge et al., 2000). 
Uninfected rhesus macaques were immunized with a strategy designed to prevent 
engagement of the cellular IL-10 receptor by RhcmvIL-10 (Barry, 2011). Upon challenge with 
RhCMV, vaccinated animals had significantly fewer infected cells and infiltrate at the 
inoculation site, as well as reduced levels of virus in saliva and urine compared to control 
animals. Therapeutic strategies that neutralize cmvIL-10 activity hold great potential for 
enhancing the control or elimination of this persistent pathogen.  
 
 
Fig. 4. Depiction of cmvIL-10 signaling through the cellular IL-10 receptor. The viral 
cytokine binds as a dimer, pulling together receptor chains to create a functional tetrameric 
receptor complex. The receptor associated kinase JAK1 phosphorylates Stat3, which then 
dimerizes and translocates to the nucleus to stimulate gene transcription. 
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2.4 Role in latent infection 
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reactivate from latency just as effectively as wild type virus. However, cells infected with the 
deletion mutant expressed higher levels of class II MHC on the cell surface. This effect was 
confirmed to be due to the lack of viral IL-10, since the addition of recombinant IL-10 (both 
full length cmvIL-10 and LAcmvIL-10) resulted in lower levels of class II MHC expression 
that was comparable to that of cells infected with wild type virus. Reduced class II 
expression correlated with diminished CD4 T cell responses, as measured by proliferation 
and interferon- production by purified allogeneic CD4 T cells co-cultured with the infected 
cells. CD4+T cells cultured with cells infected with the UL111A deletion virus exhibited 
significantly higher levels of proliferation and cytokine production, suggesting that UL111A 
gene products limit recognition of HCMV-infected cells by CD4+ T cells, thereby enhancing 
the pool of latently infected cells. 
2.5 Role in cancer  
The possible relationship between HCMV and cancer has been investigated for some time. 
The development of more sensitive detection methods has recently shown a very strong link 
between HCMV infection and glioblastoma and prostate cancer (Cobbs et al., 2002; Cobbs et 
al., 2007; Mitchell et al., 2008; Samanta et al., 2003). While HCMV is not generally regarded 
as an oncogenic virus, the term oncomodulation has been proposed to describe the 
increased malignancy associated with HCMV-infected tumor cells (Michaelis et al., 2009). 
The possible molecular mechanisms for oncomodulation include altered cell cycle regulation 
by immediate early proteins IE1 and IE2 (Sanchez and Spector, 2008), which promote entry 
into S phase, as well as the activity of the UL97 protein, which phosphorylates and 
inactivates tumor suppressor Rb (Hume et al., 2008). In addition, the UL36, UL37, and UL38 
gene products all interfere with caspase function and convey resistance to apoptosis 
(McCormick, 2008; Skaletskaya et al., 2001). HCMV-infected neuroblastoma cells have been 
observed to down-regulate adhesion molecules and exhibit increased motility (Blaheta et al., 
2004). In infected prostate cancer and glioma cells, HCMV infection resulted in increased 
migration and invasion that was dependent on phosphorylation of focal adhesion kinase 
(FAK) (Blaheta et al., 2006; Cobbs et al., 2007). Most recently, evidence points to a role of 
cmvIL-10 in promoting cancer progression.  
HCMV has been shown to infect both glioma cancer stem cells (gCSCs) and 
macrophage/migroglial populations present in malignant gliomas (Dziurzynski et al., 2011). 
Production of cmvIL-10 by the gCSCs may convert peripheral blood monocytes into an 
immune suppressive, tumor-promoting cell type. The cmvIL-10 present in gCSC 
conditioned medium was shown to trigger activation of Stat3 and production of immune 
suppressive cytokines (Dziurzynski et al., 2011). At this point, the tumor promoting role of 
cmvIL-10 is largely associated with activation of Stat3. The Stat3 pathway is known to be 
active in a number of cell types in the tumor microenvironment and contributes to general 
immune suppression hindering anti-tumor responses (Kortylewski et al., 2005). In a murine 
model of glioma, Stat3 has been demonstrated to promote an influx of macrophages, which 
correlated negatively with survival (Kong et al., 2010). In addition, Stat3 activation is 
associated with poor prognosis in ovarian cancer and considered a key factor in metastasis 
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formation and chemo-resistance (Zhang et al., 2010). This is one of the most exciting new 
areas of research involving cmvIL-10, and additional studies are currently underway to 
define the role of cmvIL-10 in potentiating tumor progression.  
3. The UL144 gene product: TNF receptor homolog 
Tumor necrosis factor (TNF) is an inflammatory cytokine that exists in both a membrane-
bound and soluble form (Caminero et al., 2011). The biological effects of this cytokine are 
mediated through interactions with two receptors, TNF receptor 1 (TNFR1) and TNF 
receptor 2 (TNFR2). TNFR1 is expressed in a wide variety of cell types whereas TNFR2 is 
expressed only in cells of the immune system. Ligand-binding induces receptor 
trimerization and conformational changes that lead to dissociation of the inhibitory protein 
suppressor of death domain (SODD) followed by association of TRADD, or TNFR 
associated death domain protein (Wajant et al., 2003). Following TRADD binding, there are 
several possible outcomes, including activation of the NF-B pathway, activation of the 
MAPK pathway, or induction of apoptosis. Both HSV-1 and HCMV target the TNF pathway 
(Figure 5); HSV-1 through glycoprotein D (Montgomery et al., 1996) and a TNFR homolog, 
HVEM (herpesvirus entry mediator) and HCMV through the UL144 gene product, also a 
TNFR homolog (Benedict et al., 1999; Cheung et al., 2005). 
3.1 Gene structure and expression 
The UL144 gene is one contiguous open reading frame located in the ULb’ region of the 
HCMV genome (Figure 6). This region contains 19 ORFs first identified in the Toledo strain 
that are found in other clinical isolates yet deleted from laboratory strains (Cha et al., 1996). 
The UL144 gene product was identified through database searches and has regions of 
homology with the TNF receptor superfamily, especially the herpesvirus entry mediator, 
HVEM (Benedict et al., 1999), although the UL144 protein does not facilitate entry by HSV-1. 
UL144 is expressed early in HCMV infection with protein detected four hours post-infection 
(Benedict et al., 1999). Transcription from the UL144 gene is complex, with at least four 
differentially regulated transcripts expressed (He et al., 2011). One of these transcripts 
encompasses UL142 through UL145, and all transcripts contain both UL144 and UL145. 
Recent evidence also suggests that the UL144 gene is expressed by specific viral strains 
during experimental models of latency (Poole, 2011).  
3.2 Cell signaling 
The UL144 gene gives rise to a 176 amino acid protein with a transmembrane domain and 
short cytoplasmic tail. Despite the presence of an N-terminal signal sequence and multiple 
N-linked glycosylation sites in the ectodomain, the protein appears to be retained in an 
intracellular compartment (Benedict et al., 1999). Retention is mediated by tyrosine based 
sorting motif at the C-terminus of the protein (aa 173-176, YRTL), as demonstrated by a 
Y173A mutant expressed in 293T cells that displayed significantly higher levels of cell 
surface protein. The protein also contains two cysteine rich domains (CRDs) which are 
characteristic of TNFR family members, although many family members have as many as 
four CRDs. The CRD-2 region of the UL144 protein also shares significant homology with 
the ligand binding domain of another TNFR family member, TRAIL-R2. Although no TNF 
family ligands have been found to bind to the UL144 receptor, a member of the 
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immunoglobulin superfamily known as BLTA, for B and T lymphocyte attenuator, was 
identified as a ligand for UL144 (Cheung et al., 2005). Presumably the UL144 protein would 
have to present on the cell surface in order to mediate this signaling. Despite its apparent 
intracellular localization, the UL144 protein must be exposed at some point during the 
infection since antibodies to this protein can be detected in HIV and HCMV co-infected 
individuals (Benedict et al., 1999). 
 
 
Fig. 5. TNF receptor superfamily members and their ligands. HVEM is the herpesvirus entry 
mediator of HSV-1. The UL144 gene product of HCMV is predominantly found inside the 
cell, but could interact with BLTA if present on the cell surface. Yellow trapezoids represent 
the CRD (cysteine rich domains) conserved throughout the TNFR superfamily. 
 
 
Fig. 6. Organization of the ULb’ region of the HCMV Toledo strain genome.  
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3.3 Role in infection 
In addition to the inhibitory effects on T-cell activation through engagement of BLTA 
(Cheung et al., 2005), UL144 also serves as an immune modulator during infection by 
triggering production of CCL22/MDC (or macrophage-derived chemokine) (Poole et al., 
2008; Poole et al., 2006). CCL22 was detected in the supernatants from cells infected with 
a Toledo strain virus, but not in supernatants from cells infected with AD169, which 
lacks the ULb’ region. This effect was found to be mediated by NF-B and is dependent 
on TRAF (TNFR associated factor). Induction of CCL22, which attracts Th2 and 
regulatory T cells expressing the CCR4 receptor (Yoshie et al., 2001), may aid in 
thwarting host immune responses by antagonizing the more effective TH1 antiviral 
response. The LMP1 protein of EBV also induces CCL2 expression (Nakayama et al., 
2004), suggesting yet another common mechanism for manipulation of host responses 
among herpesviruses.  
3.4 Polymorphisms as a measure of virulence 
There have been conflicting reports regarding the correlation between UL144 genotype and 
clinical outcome. Genes in the ULb’ region, and the UL144 gene in particular, show a high 
level of variability among clinical strains. Three main genotypes have been described based 
on the extracellular region of the UL144 protein: type A, type B, and type C (Arav-Boger et 
al., 2006; Lurain et al., 1999). While some groups found that polymorphisms in the UL144 
gene were not predictive of clinical outcome (Bale et al., 2001; Heo et al., 2008), others have 
found that types A and C do correlate with higher viral load and clinical sequelae (Arav-
Boger et al., 2006; Waters et al., 2010). Differences in outcome may be attributable to sample 
size and population. Additionally, to date studies have been conducted only on congenitally 
infected infants, and so it is not clear how UL144 strain polymorphisms correlate with 
disease in other patient populations, such as transplant recipients or persons with 
HIV/AIDS.  
4. The UL146 gene product: -chemokine vCXC-1 
Chemokines are a family of small soluble proteins that are secreted by immune cells in 
response to infection (Salazar-Mather and Hokeness, 2006). Members of the chemokine 
family fall mainly into one of two categories: -chemokines or -chemokines. The β-
chemokines induce migration of monocytes, natural killer cells, and dendritic cells; they 
have two adjacent cysteines near the amino terminus of the protein and are also known 
as CC chemokines. In contrast, -chemokines induce chemotaxis of neutrophils; they 
have the two cysteines separated by one amino acid and are known as CXC chemokines. 
CXC chemokines also generally have an ELR motif (glutamic acid – leucine – arginine) 
before the first cysteine. Interleukin-8 was the first CXC chemokine discovered, although 
its systemic designation is CXCL8. It is produced mainly by monocytes and lymphocytes, 
and it functions to induce neutrophil chemotaxis and degranulation through the 
chemokine receptors CXCR1 and CXCR2. Chemokines are important for controlling 
virus infection because they direct immune cells to sites of infection. However, for 
viruses that infect immune cells, chemokines may provide a vehicle for attracting host 
cells, or for directing infected cells to distribute virus to other parts of the body (Lusso, 
2000; Murphy, 2001).  
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4.1 Gene structure, expression, and signaling 
The UL146 gene, which is also located in the ULb’ region of the HCMV genome (Figure 6), 
encodes a functional -chemokine (Penfold et al., 1999). The UL146 gene is expressed with 
late kinetics during infection and gives rise to a 117 amino acid protein. The protein contains 
an N-terminal signal sequence as well as the ELRCXC motif found in IL-8 that is known to 
be important for neutrophil binding and activation (Clark-Lewis et al., 1991). The UL146 
gene product, which is also known as vCXC-1, was found to induce calcium flux and 
migration of neutrophils (Penfold et al., 1999). Since neutrophils express both CXCR1 and 
CXCR2, cells expressing each receptor separately were employed to dissect which receptor 
was mediating the effects of vCXC-1. While the initial studies identified CXCR2 as the 
primary receptor (Penfold et al., 1999), subsequent studies have found that vCXC-1 also 
binds to and effectively signals through the CXCR1 receptor (Luttichau, 2010). Although the 
adjacent gene, UL147, has a CXC motif, it lacks the ELR sequence and has not been shown to 
elicit signaling through human chemokine receptors (Penfold et al., 1999). 
4.2 Role in infection  
The UL146 gene product has been shown to encode a potent -chemokine that induces 
neutrophil migration, calcium mobilization, and degranulation (Luttichau, 2010; Penfold et 
al., 1999). While it has been suggested that UL146 may function to recruit neutrophils to 
sites of infection to provide a vehicle for virus dissemination to distant sites in the body 
(Figure 7), this has yet to be examined in the context of virus infection in vivo, mainly 
because the species specificity of HCMV remains a barrier to its use with animal models. As 
discussed earlier, there is one model system that is particularly well-suited for investigating 
CMV-host interactions; the natural infection of Rhesus macaques (Macaca mulatta) by 
RhCMV (Powers and Fruh, 2008).  
 
 
Fig. 7. Possible role for vCXC-1 in virus dissemination. Virus infected cells attract 
neutrophils via secretion of vCXC-1. Neutrophils could either become infected or 
phagocytose infected cells, then travel through the bloodstream, transporting virus to 
distant sites in the body.  
The human and rhesus macaque genomes share about 95% sequence similarity. The complete 
genome of RhCMV strain 68.1 was sequenced in 2003, revealing 230 potential open reading 
frames, of which 138 were homologous to known HCMV proteins (Hansen et al., 2003). A 
more pathogenic isolate, RhCMV strain 180.92, was subsequently sequenced, revealing 10 
additional open reading frames (Rivailler et al., 2006). A consensus map of both strains reveals 
that they each contain open reading frame designated Rh157.4, which was identified as having 
some homology to HCMV UL146 (Oxford et al., 2008). Most recently, RhCMV strains isolated 
from naturally infected macaques have recently been found to contain an additional genome 
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disease in other patient populations, such as transplant recipients or persons with 
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family fall mainly into one of two categories: -chemokines or -chemokines. The β-
chemokines induce migration of monocytes, natural killer cells, and dendritic cells; they 
have two adjacent cysteines near the amino terminus of the protein and are also known 
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4.1 Gene structure, expression, and signaling 
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elicit signaling through human chemokine receptors (Penfold et al., 1999). 
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because the species specificity of HCMV remains a barrier to its use with animal models. As 
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CMV-host interactions; the natural infection of Rhesus macaques (Macaca mulatta) by 
RhCMV (Powers and Fruh, 2008).  
 
 
Fig. 7. Possible role for vCXC-1 in virus dissemination. Virus infected cells attract 
neutrophils via secretion of vCXC-1. Neutrophils could either become infected or 
phagocytose infected cells, then travel through the bloodstream, transporting virus to 
distant sites in the body.  
The human and rhesus macaque genomes share about 95% sequence similarity. The complete 
genome of RhCMV strain 68.1 was sequenced in 2003, revealing 230 potential open reading 
frames, of which 138 were homologous to known HCMV proteins (Hansen et al., 2003). A 
more pathogenic isolate, RhCMV strain 180.92, was subsequently sequenced, revealing 10 
additional open reading frames (Rivailler et al., 2006). A consensus map of both strains reveals 
that they each contain open reading frame designated Rh157.4, which was identified as having 
some homology to HCMV UL146 (Oxford et al., 2008). Most recently, RhCMV strains isolated 
from naturally infected macaques have recently been found to contain an additional genome 
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segment not found in laboratory strains (Oxford et al., 2008). This segment, located between 
the Rh157.4 gene and the Rh161 gene, contains three open reading frames encoding proteins 
that exhibit 21-44% amino acid sequence identity with human IL-8 and/or HCMV UL146. 
Each of these three genes contains the ELRCXC motif (or a closely related sequence). 
Interestingly, these new genes (designated Rh161a, b, and c) also have homology to Rh161, 
which itself has low-level homology with human IL-8, suggesting that a gene duplication 
event may have occurred. Including RhUL146 and RhUL147 (rh158), this makes a total of 6 
genes with homology to -chemokines encoded by RhCMV. It is unclear why the virus would 
require six -chemokine genes; however, such gene duplication events have been reported, 
notably in the case of the RhCMV US28 locus, where only one of the five genes was found to 
encode a functional receptor (Penfold et al., 2003). Additional studies are ongoing to determine 
which of these RhCMV genes encode functional chemokines and to discern their role in virus 
infection in vivo.  
4.3 Polymorphisms as a measure of virulence 
Like the UL144 gene, divergence of the UL146 has been noted in a large number of clinical 
strains (Aguayo et al., 2010; Arav-Boger et al., 2008; Bradley et al., 2008; He et al., 2006; Heo 
et al., 2008). In two of these studies, no connection between UL146 polymorphisms and 
clinical disease was noted (He et al., 2006; Heo et al., 2008). Arav-Boger et al developed an 
artificial neural network system to analyze variability of four different CMV genes (US28, 
UL144, UL146, and UL147) from congenitally infected infants in the Unites States and Italy 
(Arav-Boger et al., 2008). The results showed that UL144 and UL146 predicted the outcome 
of CMV disease in more than 80% of cases, when used separately, and specific nucleotide 
positions played a key role in these analyses. Despite the high degree of sequence variation 
noted for UL146, chemokine functionality is generally retained (Prichard et al., 2001). 
5. The US28 gene product: Chemokine receptor 
Chemokine receptors belong to the GPCR superfamily, one of the largest families of cell 
surface receptors. Receptors of this type relay signals from the cell surface to intracellular 
effectors and are found in all eukaryotic cells, from yeast to man. The human genome 
encodes over a thousand GPCRs, including receptors in the visual, olfactory, and gustatory 
(taste) systems, as well as many neurotransmitter, hormone, and chemokine receptors 
(Pierce et al., 2002). Members of this superfamily interact with heterotrimeric intracellular G 
proteins comprising , , and -subunits. In the inactive state, the G subunit binds to GDP 
(Gether, 2000). However, upon ligand binding, a conformational change occurs that 
promotes association of the intracellular domain of the receptor with a G-protein and 
catalyzes the exchange of GTP for bound GDP in the G subunit. Following receptor 
activation, the GTP-G subunit dissociates from both the receptor and the  subunits, 
which bind to each other very tightly. Each subunit can then interact with and activate 
specific downstream cellular effectors, depending on the nature of the receptor-ligand 
interaction. Intrinsic GTPase activity in the G subunit converts it to the inactive GDP-
bound form, and re-association of the heterotrimeric complex terminates the signal and 
restores the receptor to its resting state. In addition to ligand dependent signaling, some 
GPCR, including HCMV US28, have been shown to signal in a ligand-independent, 
constitutive manner (Casarosa et al., 2001; Vischer et al., 2006a; Waldhoer et al., 2002). 
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5.1 Gene structure and expression 
Of the four genes described here, only US28 was identified in the initial sequencing of the 
genome of HCMV strain AD169 (Chee et al., 1990a). Found within the unique short region 
of the HCMV genome, US28 is one of four genes with homology to the cellular G-protein 
coupled receptor (GPCR) superfamily (Chee et al., 1990b). Of the four HCMV GPCR (UL33, 
UL78, US27, and US28), only US28 has been shown to be a bona fide chemokine receptor. 
US28 has been extensively studied and is the subject of numerous reviews (Beisser et al., 
2008; Vischer andLeurs and Smit, 2006a; Vischer et al., 2006b; Vomaske et al., 2009); only a 
brief overview of the current literature on US28 is provided here.  
Expression of US28 transcripts occurs throughout the infection cycle, at immediate early, 
early, and late time points (Bodaghi et al., 1998; Zipeto et al., 1999), as well as during latency 
in THP-1 monocytes (Beisser et al., 2001). Although no homologs of this receptor exist in the 
genomes of rodent CMVs, five tandem homologs of US28 have been identified in the 
genome of Rhesus CMV (Penfold et al., 2003).  
Because US27 and US28 are directly adjacent to one another in the HCMV genome and share 
31% sequence identity, there has been some speculation that the two are a result of a gene 
duplication event. There is evidence for expression of both proteins in infected cells (Fraile-
Ramos et al., 2001; Fraile-Ramos et al., 2002), suggesting that each receptor may have evolved 
(or is evolving) a distinct role in viral pathogenesis. US28 is expressed throughout the lytic and 
latent infection cycle, while US27 is expressed late in lytic infection only (Beisser et al., 2001; 
Welch et al., 1991), indicating that the two genes are independently regulated.  
5.2 Cell signaling 
US28 has been shown to bind to several human chemokines, including CX3CL/fractalkine, 
CCL5/RANTES, CCL3/MIP-1, CCL2/MCP-1, and CCL7/MCP-3 (Beisser et al., 2002; Gao 
and Murphy, 1994; Neote et al., 1993). In addition, US28 is promiscuous in G protein coupling 
and has been shown to signal through Gq, Gi/o, G12, and G16 (Billstrom et al., 1998; 
Casarosa et al., 2001; Melnychuk et al., 2004). Chemokine binding to US28 induces a wide 
range of intracellular responses, including calcium mobilization, MAP kinase activation, cell 
migration, and activation of transcription factors such as NFAT, CREB, and NF-B (Billstrom 
et al., 1998; Casarosa et al., 2001; Gao and Murphy, 1994; Streblow et al., 2003; Vieira et al., 
1998). NF-B activation has been shown to stimulate IL-6 production followed by a cascade 
including Stat3 phosphorylation and VEGF production (Figure 7) (Slinger et al., 2010).  
Ligand-independent signaling has been found to include constitutive phospholipase C 
activation and inositol phosphate (IP3) production (Casarosa et al., 2001; Minisini et al., 
2003). US28 can also promote cell-cell fusion (Pleskoff et al., 1998) and was found to serve as 
a co-factor for entry of HIV into CD4+ cells (Pleskoff et al., 1997).  
For some types of GPCR, most notably the -aminobutyric acid (GABA) receptor, dimerization 
has been documented to be critical for effector activation and signaling (Kaupmann et al., 1998; 
Kuner et al., 1999; White et al., 1998). Chemokine receptors have also been shown to form 
functional dimers and oligomers that affect different aspects of receptor physiology, such as 
ligand affinity and signal transduction (Kramp et al., 2011; Mellado et al., 2001). Recent 
evidence suggests that US28 forms multimers with other GPCR (Tschische et al., 2011). UL33 
and UL78 were both able to block US28-mediated activation of the transcription factor NF-B, 
although constitutive signaling via the Gq/phospholipase C pathway by US28 was not 
affected by receptor heteromerization (Tschische et al., 2011).  
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segment not found in laboratory strains (Oxford et al., 2008). This segment, located between 
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which of these RhCMV genes encode functional chemokines and to discern their role in virus 
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surface receptors. Receptors of this type relay signals from the cell surface to intracellular 
effectors and are found in all eukaryotic cells, from yeast to man. The human genome 
encodes over a thousand GPCRs, including receptors in the visual, olfactory, and gustatory 
(taste) systems, as well as many neurotransmitter, hormone, and chemokine receptors 
(Pierce et al., 2002). Members of this superfamily interact with heterotrimeric intracellular G 
proteins comprising , , and -subunits. In the inactive state, the G subunit binds to GDP 
(Gether, 2000). However, upon ligand binding, a conformational change occurs that 
promotes association of the intracellular domain of the receptor with a G-protein and 
catalyzes the exchange of GTP for bound GDP in the G subunit. Following receptor 
activation, the GTP-G subunit dissociates from both the receptor and the  subunits, 
which bind to each other very tightly. Each subunit can then interact with and activate 
specific downstream cellular effectors, depending on the nature of the receptor-ligand 
interaction. Intrinsic GTPase activity in the G subunit converts it to the inactive GDP-
bound form, and re-association of the heterotrimeric complex terminates the signal and 
restores the receptor to its resting state. In addition to ligand dependent signaling, some 
GPCR, including HCMV US28, have been shown to signal in a ligand-independent, 
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5.3 Role in infection 
Despite the extensive in vitro characterization of US28, discerning a role for this protein in 
vivo during infection has been difficult since rodent CMVs do not encode a US28 
homolog. However, murine CMV does encode homologs of two other HCMV GPCR, 
UL33 and UL78 (M33 and M78, respectively), suggesting that perhaps these genes were 
hijacked from an ancient host by an ancestral virus. Recent studies have shown that 
MCMV mutants lacking M33 exhibit a replication defect resulting in a significant 
reduction in virus replication in the salivary gland, as well as reduced reactivation from 
tissue explants (Farrell et al., 2011). Interestingly, HCMV US28 was found to complement 
the M33 mutant virus and restore both salivary gland replication and explant reactivation. 
These findings support the widely held view that the US28 receptor aids in virus 
dissemination by enabling infected cells to respond to chemokines and transport virus to 






Fig. 8. US28 activates NF-kB inducing IL-6 expression. IL-6 can bind to its receptor in either 
an autocrine manner, as shown above, or act on nearby cells in a paracrine manner, to 
stimulate Stat3 and induce VEGF.  
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5.4 Role in atherosclerosis and cancer 
The formation of atherosclerotic plaques resembles a chronic inflammatory response 
characterized by infiltration of monocytes, macrophages, and T lymphocytes recruited to the 
site via the secretion of chemokines from the vascular endothelium (Gautier et al., 2009; 
Zernecke and Weber, 2010). Both molecular and epidemiological data strongly links HCMV 
infection to atherosclerosis (Cheng et al., 2009; Epstein et al., 2009; Froberg et al., 2001; 
Gredmark-Russ et al., 2009; Hendrix et al., 1990; Hosenpud, 1999; Mattila et al., 1998; Straat 
et al., 2009; Streblow et al., 2008; Streblow et al., 2001a; Yi et al., 2008). Significant evidence 
now supports the notion that US28 may exacerbate atherosclerotic plaque formation by 
enhancing smooth muscle cell migration, and this subject has been reviewed elsewhere 
(Melnychuk et al., 2004; Streblow et al., 2001b; Streblow et al., 2007; Streblow et al., 1999; 
Streblow et al., 2003; Vischer andLeurs and Smit, 2006a).  
In addition to a potential role in cardiovascular disease, HCMV infection has also been 
implicated in several types of cancer (see section 2.5). In particular, US28-expressing cells 
have been shown to promote tumorigenesis when injected into mice (Maussang et al., 2006). 
Activation of NF-B by US28 contributed to increased expression of cyclooxygenase-2 
(COX-2), an inflammatory mediator that plays a central role in several types of cancer 
(Maussang et al., 2009). Activation of Stat3 via the same pathway also has implications for 
cancer development, as previously discussed. Therapeutics blocking US28 activity may have 
utility for a number of diseases.  
6. Conclusion 
HCMV is endemic in the human population and may be associated with various human 
diseases. Most of the time, however, the virus peacefully co-exists with its human host. This 
interaction is governed by viral gene products that take an active role in establishing latency 
and modifying host immune responses in favor of virus persistence. Like the mythical 
Trojan horse that enabled the Greeks to conquer Troy, HCMV encodes many genes that 
seem innocuous, yet may have the power to decisively determine the outcome of virus 
infection.  
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1. Introduction 
Epstein-Barr Virus (EBV) is a human herpesvirus, infecting 95% of humans, that is causally 
associated with the benign B-cell proliferative disorder, infectious mononucleosis. EBV has 
also been etiologically associated with several cancers, such as Burkitt's lymphoma, AIDS-
related immunoblastic lymphomas, post-transplant lymphomas, nasopharyngeal carcinoma, 
and gastric carcinoma.  Very few viral genes are expressed in these malignancies and 
infectious virus is rarely released, defining a state of infection termed latency. Many EBV-
associated malignancies respond poorly to treatment with large variability in success rates 
dependent on disease stage, viral gene expression patterns, and concurrent 
immunosuppressive therapy.  Developing broadly effective strategies to suppress cell 
proliferation induced by EBV requires careful consideration of viral factors common to 
many malignancy types.  One interesting viral therapeutic target is the viral protein Epstein-
Barr nuclear antigen 1 (EBNA1), which is expressed in all EBV-associated malignancies and 
has been extensively characterized. Upon association with a region on EBV's genome, 
termed oriP, EBNA1 facilitates the licensed replication and mitotic segregation of EBV 
genomes in proliferating tumor cells. EBNA1 bound to oriP also activates transcription from 
two major EBV promoters. Finally, EBNA1 is known to suppress apoptosis of EBV-positive 
tumor cells. In this review, we have described the molecular mechanisms by which EBNA1's 
functions are operant.  
2. Malignancies associated with Epstein-Barr virus (EBV) 
EBV is a double-stranded lymphotropic gammaherpesvirus with a 172-kb linear DNA 
genome that is widely distributed in the human population (Kieff and Rickinson 2007; 
Rickinson and Kieff 2007). EBV was discovered through its association with B-cell 
lymphomas in children and young adults in sub-Saharan Africa. These tumors, now termed 
Burkitt's lymphoma, were recognized by Denis Burkitt, a British surgeon, as occurring at an 
unusually high rate in regions of Africa where malaria was endemic.  Postulating that an 
infectious agent was the cause, Burkitt provided tumor biopsies to Anthony Epstein and 
Yvonne Barr, who screened them for the presence of viral-like particles using electron 
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microscopy (Epstein, Achong et al. 1964). EBV subsequently became the first virus to be 
isolated from human cancer (Henle, Henle et al. 1968). Soon after this discovery, 
epidemiological studies revealed that a primary acute infection with EBV was causally 
associated with the development of infectious mononucleosis in adolescence and adulthood 
(Niederman, McCollum et al. 1968). Similar studies revealed a causal association between 
EBV and Burkitt's lymphoma (de-The, Geser et al. 1978). Molecular studies conducted since 
1975 have revealed EBV genomes and expressed genes to be present in several other 
malignancies.  
EBV is currently associated with Hodgkin's lymphoma, non-Hodgkin's lymphoma, AIDS-
related immunoblastic lymphomas, primary effusion lymphomas, post-transplant 
lymphomas, CNS lymphomas, gastric carcinoma, and nasopharyngeal carcinoma 
(Crawford, Thomas et al. 1980; Purtilo and Klein 1981; Ernberg and Altiok 1989; Glaser, 
Lin et al. 1997; Dockrell, Strickler et al. 1998; Taylor, Marcus et al. 2005; Navarro and 
Kaplan 2006). Indeed, together with Kaposi's sarcoma, lymphomas caused by EBV were 
the first malignancies identified as AIDS-defining clinical conditions (1987). In Figure 1, 
we have depicted a brief overview of the EBV life-cycle.  During primary infection, EBV is 
transmitted by saliva to oral epithelial cells in which it replicates lytically (Kieff and 
Rickinson 2007; Rickinson and Kieff 2007). Released virus infects circulating B-
lymphocytes using the B-cell surface proteins MHC class II and complement receptor 2 
(CR2/CD21) as viral receptors (Fingeroth, Weis et al. 1984; Li, Spriggs et al. 1997). A small 
subset of viral genes, including EBNA1, are expressed in these infected B-cells that 
concurrently home to the closest lymphoid tissue, such as the Waldeyer's tonsillar ring, 
where they proliferate (Laichalk, Hochberg et al. 2002). These latently infected B-cells 
proliferate rapidly, a process driven by the expression of viral proteins that are described 
in the next section.  
It is pertinent to note that these infected B-cells are latently infected; while they express viral 
genes that drive cell proliferation, they do not express the large number of viral genes 
required for production of infectious virus. Cytokines released by rapidly proliferating 
infected B-cells promote a strong primary CTL response that suppresses their proliferation 
(Rickinson, Lee et al. 1996; Steven, Leese et al. 1996). Infected B-cells that are not deleted by 
the CTL response exist in peripheral circulation as quiescent memory B-cells in which 
EBNA1 is typically the only viral protein expressed (Babcock, Decker et al. 1999). With a 
very low frequency, EBV's lytic replication is activated in these latently infected cells, 
releasing virus that is ultimately transmitted through oral mucosa (Laichalk, Hochberg et al. 
2002). If EBV-positive memory B-cells transit to a regional lymph node or back to the tonsils, 
they can return to a highly proliferative state (ibid). When this occurs, a strong secondary 
CTL response limits their proliferation. 
Under immunosuppressive conditions, such as a prior malarial infection, HIV-disease, or 
post-transplantation immunosuppressive therapy, an impaired CTL response permits the 
unimpeded proliferation of EBV-infected cells (Rickinson, Lee et al. 1996; Kieff and 
Rickinson 2007). Mutations in cellular genes caused by errors in DNA replication initially 
result in oligoclonal proliferative disorders, such as post-transplant lymphoproliferative 
disease; the progressive acquisition of additional mutations ultimately results in clonal 
malignancies, such as Burkitt's lymphoma (Hammerschmidt 2011; Vereide and Sugden 
2011) 
Contributions of the EBNA1 Protein of  




After lytic replication in epithelial cells, the virus is transmitted to circulating B-cells that undergo blast 
transformation in the nearest lymphoid tissue. A subset of viral genes, including EBNA1, is expressed 
in these proliferating blasts. A primary CTL response limits blast proliferation, and the surviving cells 
reside as quiescent, memory B-cells in the peripheral circulation. EBNA1 is the only viral protein 
expressed in EBV-positive memory B-cells. Additional details are in the text. 
Fig. 1. Schematic overview of the EBV life-cycle.  
2.1 EBV genes necessary for B-cell immortalization and patterns of viral gene 
expression 
The capacity of EBV to drive unfettered B-cell proliferation is recapitulated during infections 
of naive B-cells in cell culture. EBV efficiently immortalizes naive B-cells to yield cell-lines 
termed lymphoblastoid cell-lines (LCLs) (Sugden and Mark 1977). Genetic studies have 
been used to identify the viral proteins required to immortalize naive B-cells in cell culture. 
Although the EBV genome encodes for approximately 90 proteins, only eight of these 
proteins are expressed when EBV infects naive B-cells (Mark and Sugden 1982). Of these, 
only six are required for naive B-cells’ immortalization (Kieff and Rickinson 2007). Five of 
these genes are nuclear proteins, collectively referred to as the Epstein-Barr nuclear antigens 
(EBNAs). The five proteins are expressed from the same EBNA1-responsive viral promoter 
(Woisetschlaeger, Strominger et al. 1989). The sixth protein is membrane-associated, and 
termed latent membrane protein 1 (LMP1) that is also expressed from an EBNA1-responsive 
promoter (Abbot, Rowe et al. 1990). 
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The EBV proteins expressed during immortalization have numerous functions that are 
described briefly here. LMP1 is a homolog of the B-cell membrane protein CD40. While 
CD40 requires a ligand to be activated, LMP1 is constitutively active (Kaye, Izumi et al. 
1993; Zimber-Strobl, Kempkes et al. 1996; Gires, Zimber-Strobl et al. 1997). Akin to 
activated CD40, it activates NFκB, AP-1, and JNK pathways, and their cellular targets, to 
sustain B-cell proliferation (Laherty, Hu et al. 1992; Mosialos, Birkenbach et al. 1995; 
Kieser, Kaiser et al. 1999). The five EBNA proteins have distinct, as well as some 
overlapping, functions. EBNA2 subverts the cellular Notch pathway (Grossman, 
Johannsen et al. 1994; Henkel, Ling et al. 1994). Like the intracellular domain of Notch, 
Notch-IC, EBNA2 associates with the transcription repressor human suppressor of 
hairless (hSH) converting it into an activator. This complex activates transcription from 
the same two viral promoters activated by EBNA1, and the cellular Enhancer of Split 
complex genes. While EBNA-LP greatly augments the efficiency with which EBV 
immortalizes naive B-cells, it is not required for immortalization (Hammerschmidt and 
Sugden 1989). In either event, it acts in concert with EBNA2 at specific viral promoters 
(Harada and Kieff 1997; Ling, Peng et al. 2005; Peng, Moses et al. 2005).  EBNA3A and 
EBNA3C are similar in sequence and have some overlapping functions. They can both act 
to modulate the activation of hSH-responsive genes by EBNA2 by interacting with hSH 
(Robertson, Lin et al. 1996; Zhao, Marshall et al. 1996; Dalbies-Tran, Stigger-Rosser et al. 
2001). However, only EBNA3C alters the expression of the metastatic suppressor Nm23-
H1 (Murakami, Kaul et al. 2009). Finally, recent evidence indicates that EBNA3A and 
EBNA3C can individually, and cooperatively, down-modulate the expression of the pro-
apoptotic cellular protein Bim (Paschos, Smith et al. 2009).  
 
 
Subsets of viral genes are expressed in cells infected latently with EBV. Different viral promoters are 
used to express EBNA1 in Type III and Type 0/I/II latency. The EBERs and BARTs are expressed from 
their own promoters that are not listed above. 
Table 1. EBV gene expression programs in latency. 
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In addition to the five EBNA proteins and LMP1, there are three other EBV proteins expressed 
during latent infection. These proteins are EBNA3B, LMP2A and LMP2B (Kieff and Rickinson 
2007; Rickinson and Kieff 2007). Two non-coding RNAs, termed EBER1 and EBER2, as well as 
a variable number of viral microRNAs, are also expressed during latency (ibid). The six 
proteins required for immortalization (EBNA1, EBNA2, EBNA3A, EBNA3C, EBNA-LP, 
LMP1) are expressed in four distinct programs termed Latency types 0, I, II, and III (ibid). 
These programs, indicated in Table I, are associated with specific cellular phenotypes. All six 
proteins are expressed in type III latency, which is a gene expression pattern observed in 
lymphoblastoid cell lines immortalized by EBV. Type III latency is also observed in post-
transplant lymphomas and AIDS-related immunoblastic lymphomas. A more restricted 
pattern of gene expression is observed during the other latency types. Only EBNA1 is 
expressed in most Burkitt's lymphoma cells, which is a pattern termed type I latency. Latency 
type 0 is observed in infected memory B-cells where only EBNA1 expression is detected, and 
that too only when cells divide. No other viral proteins are expressed during latency type 0. 
Finally, latency type II is observed in rare T-cell lymphomas and EBV-associated carcinomas. 
In this pattern, the expression of EBNA1, LMP1, LMP2A, and LMP2B is detected. 
The differential expression of the EBNA proteins in these latency types results from the use 
of two different promoters for the expression of EBNA1. During latency type III, the 
chromatin conformation and epigenetic markup of the viral genome favors the activation of 
the viral BamHI-C promoter (BamHI-Cp) by EBNA1 and EBNA2 (Day, Chau et al. 2007; 
Tempera, Klichinsky et al. 2011). All the six EBNA proteins are expressed from spliced 
transcripts that originate at BamHI-Cp. During latency type I, an alternative conformation 
and markup represses BamHI-Cp (ibid). When this occurs, the viral BamHI-Q promoter 
(BamHI-Qp) is activated; splicing of BamHI-Qp transcripts permits the expression of 
EBNA1 but not the other EBNAs (ibid). Irrespective of the promoter used, EBNA1 is the only 
viral protein expressed in all four latency types, rendering it an excellent target for therapies 
directed against EBV-infected cells.  
3. EBNA1, its domains, and their functions 
A schematic representation of EBNA1 is shown in Figure 2. EBNA1 from the prototypic B95-
8 strain of EBV is 641 amino-acids (a.a.) long, and can be divided into several functional 
domains. EBNA1 associates with several cognate binding sites on the EBV genome through 
its DNA binding and dimerization domain (DBD), which lies from a.a. 451-641 (Ambinder, 
Shah et al. 1990; Ambinder, Mullen et al. 1991). The capacity of this domain, when expressed 
by itself, to bind EBNA1 binding sites was first demonstrated by the studies of Ambinder 
and Hayward (Ambinder, Shah et al. 1990) . While sufficient to bind EBNA1 binding sites, 
DBD alone does not support the replication & mitotic segregation of EBV genomes, nor can 
it activate EBNA1-responsive EBV promoters (Kirchmaier and Sugden 1997; Aiyar and 
Sugden 1998; Sears, Ujihara et al. 2004) . Indeed, when co-expressed with wild-type EBNA1, 
DBD functions as a dominant-negative by displacing EBNA1 from its binding sites 
(Kirchmaier and Sugden 1997).  
The DBD is also the only domain of EBNA1 whose structure has been determined 
(Bochkarev, Barwell et al. 1995); it has a beta-barrel core region that is used for dimerization, 
flanked by a long alpha-helix that extends into the major groove of the binding site 
(Bochkarev, Barwell et al. 1996). Surprisingly, this structure is remarkably close to the 
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structure of the DNA binding domain of the E2 protein (E2DBD) from bovine 
papilomavirus (BPV) (Hegde, Grossman et al. 1992), despite a lack of sequence conservation. 
In this context, it should be noted that BPV, a small DNA virus, is very distantly related to 
EBV, and the related structure of DBD and E2DBD is proposed to result from convergent 
evolution (Grossman and Laimins 1996). The modular nature of the DBD is reflected by 
several observations. Sugden and co-workers demonstrated that the DBD could be 
substituted by DNA-binding domain from the yeast GAL4 protein (Mackey, Middleton et 
al. 1995; Mackey and Sugden 1997). The chimeric protein displayed several biochemical 
properties of EBNA1 when bound to GAL4 binding sites. In a similar observation, we have 
shown that a chimeric protein in which a.a. 1-450 of EBNA1 was fused to E2DBD activated 
transcription from a cluster of E2 binding sites in a manner similar to WT EBNA1 (Aras, 
Singh et al. 2009). We have also demonstrated that a chimeric protein in which a strong 
heterologous acidic activation domain was fused to DBD activated transcription with the 
characteristics of the heterologous activation domain (ibid). 
 
 
(A) EBNA1 is 641 a.a. in length. ATH1 and ATH2 are two AT-hooks, and UR1 is a domain necessary for 
transactivation. The GAr is a repeat of glycine and alanine, which can vary in length between EBV 
isolates. The DBD is used to bind defined sites on EBV's genome. N represents EBNA1's NLS. (B) ATH1 
and ATH2 are highly conserved, 80% and 77% respectively, in EBNA1 orthologs from other EBV-like 
gammaherpesviruses. These regions have a repeated sequence of glycine and arginine. A portion of 
UR1 is also highly conserved in EBNA1 orthologs. UR1 contains a conserved cys-x-x-cys motif. (C) In 
addition to DBD, genome replication and segregation requires ATH1 and ATH2. For transactivation, 
EBNA1 needs both AT-hooks and UR1. 
Fig. 2. Schematic diagram of EBNA1 and its domains.  
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EBNA1 contains at least one nuclear localization sequence (NLS) between a.a. 379-386. 
When fused to a cytoplasmic protein, the NLS is sufficient to render it nuclear (Ambinder, 
Mullen et al. 1991). Consistent with its function, the NLS interacts with the nuclear 
transporters karyopherin alpha1 and alpha2 (Fischer, Kremmer et al. 1997; Kim, Maher et al. 
1997). However, an EBNA1 NLS mutant that is substantially reduced in its association with 
the karyopherins remains nuclear and is functional (Kim, Maher et al. 1997). Therefore, it is 
likely that EBNA1 has additional NLS signals that are currently unknown. 
While B95-8 EBNA1 is 641 a.a. long, EBNA1 proteins from other EBV strains and isolates 
vary in size. This difference in size arises from differences in the length of a central glycine-
alanine repeat region (GAr) (Falk, Gratama et al. 1995). Reductions in the length of the GAr 
to just 15 a.a. have no effect on the efficiency of B-cell immortalization by EBV (Lee, 
Diamond et al. 1999), EBNA1's capacity to activate transcription (Aiyar and Sugden 1998), or 
its ability to support replication and mitotic segregation of EBV genomes (Yates, Warren et 
al. 1985). It is now appreciated that the GAr reduces the efficiency with which EBNA1 
epitopes are presented on the surface of EBV-infected cells. This reduction in efficiency is 
either a consequence of the GAr affecting processing by the proteosome (Levitskaya, 
Sharipo et al. 1997), or by reducing the efficiency with which EBNA1 is translated (Yin, 
Manoury et al. 2003; Apcher, Komarova et al. 2009; Apcher, Daskalogianni et al. 2010). 
Peculiarly, while cell-culture studies indicate that long GAr sequences substantially reduce 
proteosome processing and EBNA1 translation, the presence of a long GAr reduces the 
recognition of EBV-infected cells by EBNA1-specific CTLs by 50% or less (Lee, Brooks et al. 
2004). Therefore, the conservation of long GArs in various EBV isolates may reflect other 
GAr functions, in addition to reduced epitope presentation, that are not recapitulated in cell 
culture.  
The GAr is flanked by positively charged domains. These domains were originally termed 
linking regions 1 and 2 (LR1/LR2) (Figure 2) because they had the capacity to link DNAs 
bound by EBNA1 into large multimeric complexes (Mackey, Middleton et al. 1995; Mackey 
and Sugden 1997; Mackey and Sugden 1999) . Linking is dependent on the capacity of LR1 
and LR2 to directly bind nucleic acids. LR1 and LR2 contain within them repeats of glycine 
and arginine (GR repeats) that can associate specifically with AT-rich DNA and G-
quadruplex RNA (Sears, Ujihara et al. 2004; Norseen, Thomae et al. 2008) . These nucleic 
acid binding properties are observed for cellular AT-hook proteins that also contain GR 
repeats (Huth, Bewley et al. 1997; Reeves 2001; Norseen, Thomae et al. 2008). For this reason, 
the GR repeats of EBNA1 are referred to as AT-hook 1 and 2 (ATH1, ATH2) in this review. 
Deletion of ATH1 or ATH2 reduces the capacity of EBNA1 to transactivate EBV promoters 
and to support genome replication/segregation (Sears, Ujihara et al. 2004; Singh, Aras et al. 
2009). Deletion of both ATH1 and ATH2 eliminates both functions (Sears, Kolman et al. 
2003). A chimeric protein in which ATH1 and ATH2 are replaced by the cellular AT-hook 
protein HMGA1 supports transactivation and genome replication/segregation when bound 
to EBNA1 binding sites (Hung, Kang et al. 2001; Sears, Kolman et al. 2003). In contrast, a 
chimeric protein in which EBNA1's AT-hooks were replaced by a non-sequence specific 
cellular DNA binding protein, HMG1, does not support either function (Sears, Kolman et al. 
2003). Therefore, an association between EBNA1's AT-hooks and specific nucleic acids, such 
as AT-rich DNA or G-quadruplex RNA, is necessary for EBNA1's functions. 
While initially considered to be a single positively-charged domain, it is now appreciated 
that LR1 contains two distinct domains: 1) ATH1; and 2) A short unique region (UR1) that 
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lies between ATH1 and GAr (Figure 2) (Kennedy and Sugden 2003; Singh, Aras et al. 2009). 
Deletion mutagenesis has revealed that UR1 is essential for EBNA1 to transactivate, but is 
not required for EBNA1 to support genome replication/segregation (Kennedy and Sugden 
2003). Recent studies have revealed that UR1 contains a short sequence with a cys-x-x-cys 
motif that is conserved in the EBNA1 orthologs from other EBV-like primate 
gammaherpesviruses (Aras, Singh et al. 2009). Mutation of the conserved cysteines is 
sufficient to abrogate EBNA1's capacity to activate transcription, emphasizing the 
importance of the conserved cys-x-x-cys motif (ibid). 
EBNA1's ability to transactivate EBV promoters and to support EBV genome 
replication/segregation is dependent upon its association with two clusters of cognate 
binding sites on the EBV genome (Figure 3). The organization of these two clusters is critical 
to EBNA1's EBV-specific functions and therefore is detailed below. 
4. OriP, the family of repeats (FR), and the dyad symmetry element (DS) 
Adams observed that akin to eukaryotic chromosomes, EBV genomes are replicated once 
per cell-cycle during latency, by a process termed licensed DNA replication (Lindner and 
Sugden 2007). This pattern of genome replication in which genomes are precisely duplicated 
during S phase had not been observed previously for other DNA viruses such as 
polyomaviruses, papilomaviruses, and alphaherpesviruses. EBV's unique mode of 
replication, coupled with an efficient segregation mechanism, permits viral genomes to be 
distributed equally to daughter cells when latently infected cells proliferate (Figure 4) (Sears, 
Kolman et al. 2003; Sears, Ujihara et al. 2004; Nanbo, Sugden et al. 2007; Norseen, Thomae et 
al. 2008). To identify EBV sequences necessary for licensed replication and mitotic 
segregation, Yates and Sugden screened for EBV fragments that conferred these properties 
to small plasmids introduced into EBV-positive cells (Yates, Warren et al. 1984).  Their 
screen identified a fragment with 24 similar sequences arranged in two clusters.  This 
fragment was termed oriP and is depicted in Figure 3. Upon determining oriP to be sufficient 
for the licensed replication and mitotic segregation of plasmids in EBV-positive cells, these 
investigators identified EBNA1 as the sole EBV protein necessary for licensed replication 
and mitotic segregation of oriP-plasmids (Yates, Warren et al. 1985). Later, it was 
determined that EBNA1 bound each of the repeated sequences within oriP as a dimer 
(Rawlins, Milman et al. 1985; Ambinder, Shah et al. 1990; Ambinder, Mullen et al. 1991). The 
repeats in oriP are arranged in two clusters (Figure 3): 1) A cluster with 20 EBNA1-binding 
sites, termed the Family of Repeats (FR); and 2) A cluster with four EBNA1-binding sites 
arranged as a dyad (DS) (Lupton and Levine 1985; Reisman, Yates et al. 1985). 
Deletion and complementation experiments revealed that EBNA1 bound to FR and DS has 
distinct functions. Plasmids containing only DS undergo DNA replication in cells expressing 
EBNA1, but are mitotically unstable and lost within 1-2 cell-cycles. Plasmids containing FR 
alone are distributed as EBNA1-expressing cells divide, but do not replicate, and therefore 
ultimately diluted out of a proliferating culture (Yates, Camiolo et al. 2000). These studies 
indicate that DS functions primarily as a licensed replication origin, and FR functions as an 
element similar to a chromosomal centromere in that it permits newly-replicated oriP-
plasmids to be mitotically stable and segregated (Wysokenski and Yates 1989; Aiyar, Tyree 
et al. 1998). The studies of Calos and co-workers reiterate these functional assignations 
(Krysan, Haase et al. 1989; Krysan and Calos 1993). Similar to DS-only plasmids, plasmids 
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containing putative chromosomal replication origins undergo licensed replication but are 
mitotically unstable and lost within 1-2 cell cycles. Introducing FR into these plasmids 
permitted them to undergo licensed replication and become mitotically stable in EBNA1-
expressing cells (ibid). 
 
 
(A) OriP contains two clusters of EBNA1 binding sites, represented by the purple and pink filled circles. 
OriP is approximately 3 kb removed from the BamHI-C promoter, which is used to transcribe all the 
EBNA proteins, and 10 kb removed from the LMP1 promoter that is used to transcribe LMP1. (B) An 
expanded view of the two clusters of EBNA1 binding sites with oriP. The family of repeats (FR) contains 
20 high-affinity binding sites, and is approximately 1 kb removed from the dyad symmetry element 
(DS) that contains four low-affinity binding sites. (C) Each EBNA1 binding site is 16 bp is length, and 
represented by a purple or pink filled circle. The distance between adjacent binding sites in FR is 14 bp, 
and therefore EBNA1 dimers bound to adjacent sites are on the same phase of the DNA double helix. 
The four sites in DS are configured as two pairs of two sites. The EBNA1 binding sites within each pair 
are 5 bp apart, and this distance is essential for DS to function as a replication origin. 
Fig. 3. Schematic representation of OriP, and the two EBV promoters transactivated by 
EBNA1 bound to OriP.  
Although FR contains 20 EBNA1-binding sites, numerous studies by others and us have 
revealed that it must contain a minimum of 7 EBNA1-binding sites to provide mitotic 
stability in EBNA1-expressing cells. These studies also revealed that plasmids with a 
modified FR, which only contained 10 EBNA1-binding sites, were more stable than 
plasmids containing a wild-type FR (Wysokenski and Yates 1989; Hebner, Lasanen et al. 
2003). This is because EBNA1 dimers bound to 20 contiguous EBNA1-binding sites in FR 
impede, but do not completely abrogate, the migration of replication forks through FR 
(Aiyar, Aras et al. 2009). 10 contiguous EBNA1-binding sites are not an effective 
replication fork-block; therefore, replication initiating from DS is completed efficiently 
(ibid). Because EBV isolates contain a minimum of 20 EBNA1-binding sites, it is likely that 
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lies between ATH1 and GAr (Figure 2) (Kennedy and Sugden 2003; Singh, Aras et al. 2009). 
Deletion mutagenesis has revealed that UR1 is essential for EBNA1 to transactivate, but is 
not required for EBNA1 to support genome replication/segregation (Kennedy and Sugden 
2003). Recent studies have revealed that UR1 contains a short sequence with a cys-x-x-cys 
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the capacity of 20 or more contiguous binding sites to limit genome replication is of 
importance to EBV. 
The four EBNA1-binding sites in DS are of lower affinity than the binding sites in FR 
(Ambinder, Shah et al. 1990).  The four sites are arranged in two pairs in which the 
distance between the centers of the two sites in each pair is 21 base-pairs (bp) (Figure 3). 
Either pair is sufficient for DS to function as an origin, but alterations of the spacing 
between them blocks origin function (Harrison, Fisenne et al. 1994; Bashaw and Yates 
2001). When EBNA1 binds the sites in DS, it induces a large symmetrical bend in the DNA 
and forms a structure necessary for the cellular licensed DNA replication machinery to 
function at DS (Bashaw and Yates 2001). There is an additional sequence juxtaposed 3' to 
DS, termed Rep*, which can associate with EBNA1 (Kirchmaier and Sugden 1998). The 
non-canonical EBNA1 binding sites in Rep* are also 21 bp apart, and multiple copies of 
Rep* can substitute for DS for the licensed replication of oriP-plasmids (Wang, Lindner et 
al. 2006). 
5. Contributions of EBNA1 to the licensed replication and segregation of 
oriP-plasmids 
Although it bends DS, DBD alone is not sufficient to support replication from DS 
(Kirchmaier and Sugden 1998). The latter requires contributions from other EBNA1 
domains, particularly ATH1 and ATH2. Investigations into the mechanism by which DS 
functions as a cell-cycle controlled licensed replication origin have revealed it is similar to 
the mechanism that restricts chromosomal replication origins to "fire" only once per cell-
cycle (Lindner and Sugden 2007). During licensed replication of chromosomal DNA, the 
cellular origin recognition complex (ORC) marks replication origins throughout the cell-
cycle. Late in mitosis or early in G1, the cellular minichromosome maintenance complex 
(MCM) associates with ORC. Phosphorylation events at the G1/S boundary convert the 
MCM complex into an active helicase that opens the replication origin and permits DNA 
polymerase /primase to be recruited to the origin. MCM functions as the leading strand 
helicase and can reassociate with ORC only at the end of mitosis. The inability for MCM to 
be re-used during S phase prevents any single origin from being used more than once in a 
single cell-cycle. Studies by the groups of Dutta, Lieberman, Schepers, and Yates have 
provided insights into the mechanism which DS functions as an origin through (Chaudhuri, 
Xu et al. 2001; Dhar, Yoshida et al. 2001; Schepers, Ritzi et al. 2001; Ritzi, Tillack et al. 2003; 
Zhou, Chau et al. 2005; Norseen, Thomae et al. 2008). It is now clear that EBNA1 recruits 
ORC to DS, with the subsequent cell-cycle dependent recruitment of MCM, thus ensuring 
that oriP is subject to the same cell-cycle controlled replication as cellular chromosomes. 
Studies from several groups, including ours, indicated that EBNA1's AT-hooks were 
essential to recruit ORC to DS (Sears, Ujihara et al. 2004; Norseen, Thomae et al. 2008). This 
conclusion has been reiterated by our observations that chimeric proteins in which ATH1 
and ATH2 were substituted by cellular AT-hook proteins support licensed replication from 
DS (Sears, Kolman et al. 2003; Kelly, Singh et al. 2011). Lieberman and co-workers have 
demonstrated that EBNA1 uses its AT-hooks to recruit the ORC complex to DS via a G-
quadruplex RNA intermediate, underscoring a critical role for these domains in oriP-
replication (Norseen, Thomae et al. 2008). 
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EBV genomes, represented by an orange circle, are tethered by EBNA1 to cellular chromosomes. The 
AT-hooks of EBNA1 are shown in blue, and the DBD in purple. EBNA1 recruits ORC/MCM to permit 
duplication of EBV genomes in S-phase. Replicated genomes are tethered to sister chromatids by 
EBNA1 and piggy-back on the mitotic spindle to partition into daughter cells. 
Fig. 4. Model for piggy-back partitioning of EBV genomes.  
ATH1 and ATH2 are also essential for the mitotic stability and partitioning of newly-
replicated oriP-plasmids (Sears, Kolman et al. 2003; Sears, Ujihara et al. 2004).  The studies of 
Miller and co-workers were the first to indicate that EBNA1 associates with mitotic 
chromosomes in a punctate manner (Grogan, Summers et al. 1983). This observation, which 
has been recapitulated by others and us, is used as the basis of the piggy-back partitioning 
model depicted in Figure 4 (Sears, Kolman et al. 2003; Sears, Ujihara et al. 2004; Nanbo, 
Sugden et al. 2007). In this model, oriP-plasmids are proposed to be tethered to cellular 
chromosomes throughout the cell-cycle. Tethered plasmids are duplicated during 
chromosomal replication, and distributed to sister chromatids after replication. Plasmids 
then piggy-back on chromatids being partitioned by the mitotic apparatus. The association 
of EBNA1 with chromosomes is central to this model. Two alternative mechanisms have 
been proposed for this association. In the first, it was observed using a yeast two-hybrid 
screen that the ATH2 domain of EBNA1 associates with the cellular nucleolar protein 
EBP2/p40 (Shire, Ceccarelli et al. 1999). Expression of human EBP2 in budding yeast 
permitted EBNA1 to partition FR-containing plasmids in yeast, suggesting a role for EBP2 in 
partitioning of oriP-plasmids in human cells (Kapoor, Shire et al. 2001). The second model 
relies on the nucleic acid binding properties of ATH1 and ATH2. EBNA1 mutants in which 
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screen that the ATH2 domain of EBNA1 associates with the cellular nucleolar protein 
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permitted EBNA1 to partition FR-containing plasmids in yeast, suggesting a role for EBP2 in 
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either ATH1 or ATH2 is deleted retain the capacity to bind mitotic chromosomes and 
support the segregation of oriP-plasmids (Sears, Ujihara et al. 2004). Further, both ATH1 and 
ATH2 can be substituted by cellular AT-hook proteins, and the resulting chimeras associate 
with mitotic chromosomes and support segregation of oriP-plasmids (Hung, Kang et al. 
2001; Sears, Kolman et al. 2003; Kelly, Singh et al. 2011). Because both ATH1 and ATH2 
function equivalently to support oriP-plasmid segregation, but only ATH2 associates with 
EBP2/p40, it is likely that EBP2 does not mediate the partitioning of oriP-plasmids or EBV 
genomes. This interpretation is supported strongly by recent observations examining the 
segregation of oriP-plasmids in live cells. Derivatives of EBNA1 lacking ATH2 were found 
to segregate oriP-plasmids in a mechanism that could not be distinguished from the function 
of wild-type EBNA1 (Nanbo, Sugden et al. 2007). It remains to be determined whether an 
association with AT-rich DNA or G-quadruplex RNA underlies EBNA1's binding of cellular 
chromosomes. 
5.1 Transcription activation by EBNA1 
Shortly after identification of oriP, it was recognized that FR functioned as an enhancer 
when placed 5' to a promoter-luciferase reporter in cells that expressed EBNA1, but not 
control cells (Reisman and Sugden 1986). Transactivation by FR-bound EBNA1 is not 
restricted to specific promoters from EBV, but has also been observed for multiple 
heterologous promoters when they are juxtaposed to FR (ibid). In the context of the EBV 
genome and promoter-reporter constructs, EBNA1 bound to FR transactivates EBV's 
BamHI-C promoter (BamHI-Cp) that is approximately 3 kb distal to FR, and the LMP1 
promoter (LMP1p), which is more than 10 kb removed from FR (Figure 3) (Gahn and 
Sugden 1995; Puglielli, Woisetschlaeger et al. 1996). All the proteins necessary for EBV to 
immortalize naive B-cells are expressed from these two promoters, and therefore EBNA1's 
capacity to transactivate is essential for B-cell immortalization (Altmann, Pich et al. 2006). 
The failure to find cellular co-activators that bound EBNA1 led to the proposal that EBNA1's 
capacity to "transactivate" reflected its capacity to retain FR-containing plasmids or the EBV 
genome, in the nuclei of proliferating cells. In this model, retention of FR-containing 
plasmids in nuclei provides additional transcription templates and therefore increased 
reporter activity. The plasmid retention model was tested by querying whether EBNA1 
could transactivate a chromosomally integrated FR-dependent reporter (Kennedy and 
Sugden 2003; Sears, Kolman et al. 2003). The outcome from these studies indicated that 
EBNA1 transactivated the integrated reporter (ibid). Further, EBNA1 mutants that are 
replication/segregation competent, but transactivation defective, do not transactivate the 
integrated reporter or episomal reporters (ibid). While it is now accepted that EBNA1 is a 
genuine transactivator, the precise mechanism of transactivation remains to be clearly 
defined. Nevertheless, recent studies identifying domains of EBNA1 necessary for 
transactivation, and the regulation of transactivation, have provided glimpses into this 
mechanism. These studies, detailed below, support a structural role for EBNA1 in the 
activation of transcription, similar to the formation of enhanceosomes by the cellular AT-
hook protein, HMGA1. 
In addition to DBD, two other EBNA1 domains are necessary to activate FR-dependent 
transcription: 1) The AT-hooks (ATH1/ATH2); and 2) UR1. Deletion of either ATH1 or 
ATH2 reduces transactivation by about 50% (Aras, Singh et al. 2009; Singh, Aras et al. 2009); 
deletion of both ATH1 and ATH2 reduced transactivation to 5% of wild-type EBNA1 (ibid). 
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Similarly, deletion of UR1 reduced transactivation to 5% of WT EBNA1 (Kennedy and 
Sugden 2003; Aras, Singh et al. 2009; Singh, Aras et al. 2009). These studies also indicate that 
UR1 and the AT-hooks are individually insufficient to activate transcription; deletion of 
either domain eliminates the capacity of the remaining domain to promote transactivation 
(Singh, Aras et al. 2009). Studies using chimeric proteins indicate the nucleic-acid binding 
properties of ATH1/ATH2 are critical for EBNA1 to transactivate. The chimeric protein 
HMGA1-UR1-DBD, in which ATH1/ATH2 are replaced by the cellular AT-hook protein, 
HMGA1, can transactivate when bound to FR (Altmann, Pich et al. 2006). 
The UR1-deleted EBNA1 mutant was used to establish definitively that EBNA1's capacity to 
transactivate was necessary for EBV to immortalize naive B-cells. A recombinant EBV in 
which WT EBNA1 was replaced by this protein established latent infection in transformed 
B-cell lymphomas, but failed to immortalize naive B-cells (Altmann, Pich et al. 2006). 
Consistent with immortalization requiring both AT-hooks and UR1, a recombinant EBV in 
which WT EBNA1 was replaced by HMGA1-UR1-DBD was competent to immortalize naive 
B-cells (ibid).  
5.2 AT-hooks and transactivation 
Cellular AT-hook proteins function as architectural proteins in transactivation. This 
structural function was first revealed for the cellular AT-hook protein, HMGA1, at the -
interferon enhancer by the studies of Thanos and Maniatis (Kim and Maniatis 1997; Yie, 
Liang et al. 1997; Yie, Merika et al. 1999). The β-interferon enhancer contains sites bound by 
the transactivators ATF2, NFκB, and IRF1, and contains four short AT-rich sites bound by 
HMGA1, previously referred to as HMG-I(Y) (Kim and Maniatis 1997; Yie, Merika et al. 
1999). A basal level of transcription was observed during in vitro transcription reactions in 
which ATF2, NFκB, and IRF1 were provided individually, or as a combination of all three. 
Similarly, addition of HMGA1 alone also resulted in basal transcription. However, a 
dramatic increase in transcription was observed when all four factors were provided at the 
same time. DNA phasing experiments were used to establish a structural role for HMGA1 in 
transactivation. A six bp deletion that changed the phasing between two HMGA1-binding 
sites by a half-turn of DNA double helix decreased transactivation by 50%. In contrast, a 10 
bp deletion, which restored the original DNA phasing, also restored transactivation (ibid). 
On this basis, it was proposed that structural changes imposed in the enhancer by HMGA1-
induced DNA bending, and HMGA1 self-association, formed a transactivation complex 
termed an "enhanceosome" (Maniatis, Falvo et al. 1998). Other proteins that bind the β-
interferon enhancer, namely ATF2, IRF1, and NFκB, recruited transcription co-activators 
only in the context of this enhanceosome (Merika, Williams et al. 1998). The role of HMGA1 
at the β-interferon enhanceosome has been recapitulated at other promoters, such as the 
early promoter of human papilomavirus type 18 (Bouallaga, Massicard et al. 2000; 
Bouallaga, Teissier et al. 2003). Six bp deletions or insertions between HMGA1 binding sites 
at this promoter reduce transcription by about 50%. In contrast, no change in transcription is 
observed consequent to 10 bp deletions or insertions (Bouallaga, Massicard et al. 2000). At 
this enhanceosome as well, HMGA1 is necessary to recruit transcription co-activators 
(Bouallaga, Teissier et al. 2003).  
The unusual property of phasing dependent transactivation that was previously observed 
only for HMGA1 has been observed for EBNA1 (Hebner, Lasanen et al. 2003). The center-to-
center distance between adjacent EBNA1-binding sites in FR is 30 bp, or three turns of the 
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
76
either ATH1 or ATH2 is deleted retain the capacity to bind mitotic chromosomes and 
support the segregation of oriP-plasmids (Sears, Ujihara et al. 2004). Further, both ATH1 and 
ATH2 can be substituted by cellular AT-hook proteins, and the resulting chimeras associate 
with mitotic chromosomes and support segregation of oriP-plasmids (Hung, Kang et al. 
2001; Sears, Kolman et al. 2003; Kelly, Singh et al. 2011). Because both ATH1 and ATH2 
function equivalently to support oriP-plasmid segregation, but only ATH2 associates with 
EBP2/p40, it is likely that EBP2 does not mediate the partitioning of oriP-plasmids or EBV 
genomes. This interpretation is supported strongly by recent observations examining the 
segregation of oriP-plasmids in live cells. Derivatives of EBNA1 lacking ATH2 were found 
to segregate oriP-plasmids in a mechanism that could not be distinguished from the function 
of wild-type EBNA1 (Nanbo, Sugden et al. 2007). It remains to be determined whether an 
association with AT-rich DNA or G-quadruplex RNA underlies EBNA1's binding of cellular 
chromosomes. 
5.1 Transcription activation by EBNA1 
Shortly after identification of oriP, it was recognized that FR functioned as an enhancer 
when placed 5' to a promoter-luciferase reporter in cells that expressed EBNA1, but not 
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transactivation, and the regulation of transactivation, have provided glimpses into this 
mechanism. These studies, detailed below, support a structural role for EBNA1 in the 
activation of transcription, similar to the formation of enhanceosomes by the cellular AT-
hook protein, HMGA1. 
In addition to DBD, two other EBNA1 domains are necessary to activate FR-dependent 
transcription: 1) The AT-hooks (ATH1/ATH2); and 2) UR1. Deletion of either ATH1 or 
ATH2 reduces transactivation by about 50% (Aras, Singh et al. 2009; Singh, Aras et al. 2009); 
deletion of both ATH1 and ATH2 reduced transactivation to 5% of wild-type EBNA1 (ibid). 
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Similarly, deletion of UR1 reduced transactivation to 5% of WT EBNA1 (Kennedy and 
Sugden 2003; Aras, Singh et al. 2009; Singh, Aras et al. 2009). These studies also indicate that 
UR1 and the AT-hooks are individually insufficient to activate transcription; deletion of 
either domain eliminates the capacity of the remaining domain to promote transactivation 
(Singh, Aras et al. 2009). Studies using chimeric proteins indicate the nucleic-acid binding 
properties of ATH1/ATH2 are critical for EBNA1 to transactivate. The chimeric protein 
HMGA1-UR1-DBD, in which ATH1/ATH2 are replaced by the cellular AT-hook protein, 
HMGA1, can transactivate when bound to FR (Altmann, Pich et al. 2006). 
The UR1-deleted EBNA1 mutant was used to establish definitively that EBNA1's capacity to 
transactivate was necessary for EBV to immortalize naive B-cells. A recombinant EBV in 
which WT EBNA1 was replaced by this protein established latent infection in transformed 
B-cell lymphomas, but failed to immortalize naive B-cells (Altmann, Pich et al. 2006). 
Consistent with immortalization requiring both AT-hooks and UR1, a recombinant EBV in 
which WT EBNA1 was replaced by HMGA1-UR1-DBD was competent to immortalize naive 
B-cells (ibid).  
5.2 AT-hooks and transactivation 
Cellular AT-hook proteins function as architectural proteins in transactivation. This 
structural function was first revealed for the cellular AT-hook protein, HMGA1, at the -
interferon enhancer by the studies of Thanos and Maniatis (Kim and Maniatis 1997; Yie, 
Liang et al. 1997; Yie, Merika et al. 1999). The β-interferon enhancer contains sites bound by 
the transactivators ATF2, NFκB, and IRF1, and contains four short AT-rich sites bound by 
HMGA1, previously referred to as HMG-I(Y) (Kim and Maniatis 1997; Yie, Merika et al. 
1999). A basal level of transcription was observed during in vitro transcription reactions in 
which ATF2, NFκB, and IRF1 were provided individually, or as a combination of all three. 
Similarly, addition of HMGA1 alone also resulted in basal transcription. However, a 
dramatic increase in transcription was observed when all four factors were provided at the 
same time. DNA phasing experiments were used to establish a structural role for HMGA1 in 
transactivation. A six bp deletion that changed the phasing between two HMGA1-binding 
sites by a half-turn of DNA double helix decreased transactivation by 50%. In contrast, a 10 
bp deletion, which restored the original DNA phasing, also restored transactivation (ibid). 
On this basis, it was proposed that structural changes imposed in the enhancer by HMGA1-
induced DNA bending, and HMGA1 self-association, formed a transactivation complex 
termed an "enhanceosome" (Maniatis, Falvo et al. 1998). Other proteins that bind the β-
interferon enhancer, namely ATF2, IRF1, and NFκB, recruited transcription co-activators 
only in the context of this enhanceosome (Merika, Williams et al. 1998). The role of HMGA1 
at the β-interferon enhanceosome has been recapitulated at other promoters, such as the 
early promoter of human papilomavirus type 18 (Bouallaga, Massicard et al. 2000; 
Bouallaga, Teissier et al. 2003). Six bp deletions or insertions between HMGA1 binding sites 
at this promoter reduce transcription by about 50%. In contrast, no change in transcription is 
observed consequent to 10 bp deletions or insertions (Bouallaga, Massicard et al. 2000). At 
this enhanceosome as well, HMGA1 is necessary to recruit transcription co-activators 
(Bouallaga, Teissier et al. 2003).  
The unusual property of phasing dependent transactivation that was previously observed 
only for HMGA1 has been observed for EBNA1 (Hebner, Lasanen et al. 2003). The center-to-
center distance between adjacent EBNA1-binding sites in FR is 30 bp, or three turns of the 
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DNA double-helix (Figure 3). Reduction of this distance to 24 bp alters transactivation by 
50% without affecting EBNA1's capacity to bind adjacent sites (ibid). EBNA1's phasing-
dependent transactivation provided the first indication that it functions as an architectural 
transactivator. Studies with inhibitors indicate the AT-rich DNA binding property of 
ATH1/ATH2 to be critical for EBNA1 to transactivate. The peptidomimetic netropsin, 
which displaces AT-hook proteins from AT-rich DNA (Wartell, Larson et al. 1974; Freyer, 
Buscaglia et al. 2007), also reduces the capacity of EBNA1 to transactivate at BamHI-Cp 
(Sears, Ujihara et al. 2004). Deletion of ATH1 reduces transactivation to 50% of WT EBNA1, 
and the reduction is reversed when ATH1 is substituted by AT-hooks from HMGA1 (Singh, 
Aras et al. 2009). While it is apparent that EBNA1's AT-hooks are necessary for 
transactivation, how they function bears clarification. AT-hook proteins typically bind AT-
rich sequences that are close to the transcription start-site. Although AT-rich sequences are 
found juxtaposed to BamHI-Cp, and increase BamHI-Cp activity in reporter assays (Walls 
and Perricaudet 1991), it is yet to be determined if this increase is EBNA1-dependent and if 
EBNA1 associates with these sequences. 
5.3 The role of UR1 in transactivation 
Because the UR1-deleted EBNA1 mutant is transactivation defective, efforts have focused on 
cellular transcription co-activators that associate with UR1. However, several yeast two-
hybrid screens (Fischer, Kremmer et al. 1997; Kim, Maher et al. 1997; Aiyar, Tyree et al. 
1998), and proteomic analyses, have failed to identify co-activators that bind EBNA1. It has 
been reported recently that the chromatin remodeling protein Brd4 interacts with EBNA1 in 
yeast (Lin, Wang et al. 2008). While both over-expression and depletion of Brd4 reduced 
EBNA1's capacity to transactivate (ibid), these conditions also cause a striking reduction in 
cell viability (Schweiger, Ottinger et al. 2007). Therefore, it is currently not possible to assign 
a role for Brd4 in EBNA1's capacity to transactivate.  
 
 
UR1 is highly conserved in the EBNA1 orthologs from other gammaherpesviruses, whose Genbank 
accession numbers are in blue. The conserved domain closely matches one-half a zinc finger from the DNA 
polymerase  active subunit from many eukaryotic species, whose accession numbers are shown in orange 
Fig. 5. The UR1 domain of EBNA1.   
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During our studies to identify co-activators that associated with UR1, we observed that a 
sub-sequence within UR1 was highly conserved in the UR1 domains of EBNA1 orthologs 
from other EBV-like gammaherpesviruses (Aras, Singh et al. 2009). The conserved sequence, 
KRPSCIGCK, also resembles one-half of a C4 zinc-finger present in the catalytic subunit of 
DNA polymerase  from multiple eukaryotes (Figure 5). In zinc fingers, the group 12 metal 
zinc is coordinated between two cys-x-x-cys containing sequences of a protein, bringing 
these two segments together. Because EBNA1 and its orthologs do not contain another pair 
of cysteines in a cys-x-x-cys configuration, it is unlikely that zinc is coordinated by a single 
molecule of EBNA1. Sometimes, zinc coordination between dicysteine motifs in two 
separate proteins is used to mediate an association between the two proteins. This is 
exemplified by the interaction between the C-terminal cytoplasmic tail of CD4 or CD8 with 
the Lck kinase (Huse, Eck et al. 1998; Lin, Rodriguez et al. 1998; Kim, Sun et al. 2003). 
Therefore, we postulated, and experimentally confirmed, that: 1) UR1 bound zinc; and 2) 
Zinc coordination resulted in UR1 self-association (Aras, Singh et al. 2009). The role of the 
cys-x-x-cys motif within UR1 for both properties was confirmed by replacing both cysteines 
with serines. This mutant UR1 did not bind zinc or self-associate (ibid).  
Zinc is essential for EBNA1 to transactivate. Chelation of zinc using the cell-permeable zinc 
chelator N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) severely reduced 
EBNA1's capacity to transactivate without affecting levels of EBNA1 or cell viability (ibid). 
The specific effect of TPEN on EBNA1-dependent transactivation was confirmed by 
determining it had no effect on transcription from EBNA1-independent promoters, on the 
function of zinc-independent transactivators. Consistent with the chelation studies, an 
EBNA1 mutant in which both UR1 cysteines were altered to serine transactivates as poorly 
as UR1-deleted EBNA1 (ibid). Biochemical studies indicate that zinc is coordinated 
intermolecularly between adjacent EBNA1 dimers bound to adjacent sites in FR, rather than 
intramolecularly within an EBNA1 dimer bound to a single site in FR (ibid). Intermolecular 
coordination results in a large structured array of EBNA1 at FR that is essential for EBNA1 
to transactivate cooperatively. Confirming this conclusion, the EBNA1 mutant in which UR1 
cysteines were changed to serines does not transactivate cooperatively. On this basis, it is 
proposed that a zinc-coordinated array of EBNA1 at FR creates a structured complex within 
which EBNA1's AT-hooks can form an enhanceosome at promoter proximal sequences 
(Aras, Singh et al. 2009; Singh, Aras et al. 2009). The model mechanistically explains the co-
dependent roles of UR1 and the AT-hooks in transactivation. In the absence of UR1, 
EBNA1's AT-hooks cannot form a structured complex at promoter proximal AT-rich 
sequences. In the absence of the AT-hooks, EBNA1 bound to FR lacks the domains necessary 
to bind such sequences. This model also explains why alteration of phasing between 
adjacent EBNA1-binding sites in FR affects transactivation. Adjacent EBNA1 dimers bound 
to sites that lie on opposite sides of DNA will coordinate zinc with different kinetics than 
dimers bound to adjacent sites on the same side of DNA. This in turn will alter the structure 
necessary for effective enhanceosome formation, as observed previously for the function of 
HMGA1 in enhanceosomes (Kim and Maniatis 1997; Bouallaga, Massicard et al. 2000). 
5.4 Regulation of transactivation by phosphorylation 
EBNA1 contains multiple serine and threonine residues in sequence contexts that 
resemble recognition sites for protein kinases including cAMP-dependent protein kinase, 
protein kinase C, glycogen synthase kinase, and mitogen activated protein kinase (PKA) 
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(Duellman, Thompson et al. 2009). Indeed, a sequence recognized by PKA, KRxS, is 
conserved in UR1 (Figure 5), and the conserved serine is phosphorylated in vivo (ibid). 
Because this sequence is juxtaposed to the critical cys-x-x-cys motif within UR1, we 
created three mutants of EBNA1 in which this serine was altered to alanine, aspartic acid, 
or threonine (Singh, Aras et al. 2009). These substitutions were chosen because alanine 
resembles an unphosphorylated serine, aspartic acid resembles a phosphorylated serine, 
and threonine restores a PKA recognition site. All three substitutions did not affect the 
half-life of EBNA1, its nuclear localization, or the efficiency of transactivation (ibid). 
Therefore, although this site is phosphorylated in vivo, phosphorylation does not affect 
any property or function of EBNA1. Subsequent to our analysis, Duellman and Burgess 
created a mutant derivative of EBNA1 in which all 10 serines known to be phosphorylated 
were simultaneously substituted by alanine (Duellman, Thompson et al. 2009). This 
mutant EBNA1 displayed no defects in half-life, expression level, or nuclear localization. 
There were minor reductions in the efficiency of replication/segregation of oriP-plasmids 
and transactivation (ibid). Therefore, it appears unlikely that phosphorylation is a major 
mechanism that regulates the activities of EBNA1. This conclusion was also drawn from 
studies in which activators and inhibitors of various kinases were observed to not affect 
EBNA1's capacity to transactivate. 
5.5 Transactivation is sensitive to oxidative stress and regulated by cellular redox 
effectors 
Many viral and mammalian transactivators, including AP-1, NFκB, the Tat protein of 
human immunodeficiency virus (HIV), and the E2 protein of papillomavirus, are regulated 
by redox (Hutchison, Matic et al. 1991; Xanthoudakis and Curran 1992; Xanthoudakis, Miao 
et al. 1992; Huang and Adamson 1993; Mitomo, Nakayama et al. 1994; Xanthoudakis and 
Curran 1996; Jayaraman, Murthy et al. 1997; Okamoto, Tanaka et al. 1999; Kalantari, 
Narayan et al. 2008; Wan, Ottinger et al. 2008; Washington, Singh et al. 2010). These proteins 
contain one or several cysteine residues susceptible to oxidation, whose redox status 
regulates the capacity to transactivate, due to the effect of oxidative stress on protein 
structure. Upon exposure to superoxide and hydroxyl radicals, the thiol groups of cysteine 
can either be oxidized to form a disulfide bond, or progressively oxidized to form sulfenic 
acid, sulfinic acid, and finally sulfonic acid via the Fenton reaction (Held, Sylvester et al. 
1996). Proteins containing zinc fingers essential for their function are especially sensitive to 
oxidative stress because the thiol group, but not oxidized thiol adducts, can coordinate zinc 
(Kiley and Storz 2004).  In light of EBNA1's UR1 domain containing two conserved cysteines 
that are critical for transactivation, we tested whether transactivation was susceptible to 
oxidative stress or alterations in environmental oxygen tension (Aras, Singh et al. 2009; 
Washington, Singh et al. 2010). Exposure of EBNA1-expressing cells to low levels of agents 
that generate intracellular hydroxyl and superoxide radicals, such as menadione and 
paraquat, dramatically reduced transactivation without substantially affecting cell survival 
or proliferation. In contrast, lowering the oxygen tension by placing EBNA1 expressing cells 
in hypoxic conditions extended the half-life of transactivation (ibid). The latter result 
suggests that although EBNA1 is very stable, the critical cysteines within UR1 are subject to 
intracellular oxidative stress, reducing EBNA1's capacity to transactivate over time. Hypoxic 
conditions reduce the generation of intracellular oxidative radicals, and therefore prolong 
the activity of EBNA1 as a transactivator (ibid). 
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Cellular and viral transactivators with redox-sensitive cysteines are often regulated by 
cellular redox effectors such as thioredoxin, thioredoxin reductase and the bifunctional 
enzyme AP-endonuclease 1 (APE1) (Hutchison, Matic et al. 1991; Xanthoudakis and Curran 
1992; Xanthoudakis, Miao et al. 1992; Huang and Adamson 1993; Mitomo, Nakayama et al. 
1994; Xanthoudakis and Curran 1996; Jayaraman, Murthy et al. 1997; Okamoto, Tanaka et al. 
1999; Kalantari, Narayan et al. 2008; Wan, Ottinger et al. 2008; Washington, Singh et al. 
2010). Thioredoxin and thioredoxin reductase can reduce disulfide bridges that result from 
cysteine oxidation, and therefore function similarly to small molecules such as b-
mercaptoethanol (b-ME) and dithiothreitol (DTT) (Lothrop, Ruggles et al. 2009). APE1 is a 
bifunctional enzyme with two activities: 1) It is an AP-endonuclease that participates in 
DNA damage repair (Bhakat, Mantha et al. 2009); and 2) It can reduce the oxidized cysteine 
adduct sulfenic acid back to a thiol (ibid). Therefore, oxidized cysteine adducts reduced by 
APE1 are not acted on by b-ME and DTT. 
We determined that treating cells with b-ME or DTT did not alter EBNA1's ability to 
transactivate, or ameliorate the effect of oxidative stress on transactivation (Washington, 
Singh et al. 2010). Therefore, it is unlikely that oxidative stress reduces EBNA1's ability to 
transactivate by creating intra- or intermolecular disulfide bridges. Consistent with this, 
over-expression of thioredoxin or thioredoxin reductase also did not increase 
transactivation, or rescue transactivation from intracellular oxidative stress generated by 
menadione or paraquat exposure (ibid). In striking contrast, over-expression of APE1 
increases EBNA1's ability to transactivate, and curtails the effect of oxidative stress on 
EBNA1's function as a transactivator (Aras, Singh et al. 2009; Washington, Singh et al. 2010). 
It is relevant to note that cysteine residues regulated by APE1 are often adjacent to arginine 
or lysine residues, as observed for the cysteines in UR1 (Figure 5).  
6. Functions of EBNA1 in EBV-positive lymphomas  
Two patterns of gene expression predominate in EBV-positive lymphomas: 1) The type III 
latency pattern of gene expression; and 2) The type I latency pattern of gene expression, in 
which EBNA1 is the only viral protein expressed. In type III lymphomas, EBNA1 drives the 
expression of other EBV genes necessary for cell proliferation and facilitates virus genome 
replication/segregation into daughter cells. It is not clear what functions are provided by 
EBNA1 in type I lymphomas. It is possible that EBNA1 itself provides functions necessary 
for cell survival and proliferation. One function indicated by the studies of Kennedy and 
Sugden is that EBNA1 can inhibit or reduce p53-dependent apoptosis (Kennedy, Komano et 
al. 2003). In addition, it is possible that by facilitating genome replication/segregation, 
EBNA1 permits the expression of EBV microRNAs in type I lymphoma cells (Cai, Schafer et 
al. 2006; Choy, Siu et al. 2008; Pratt, Kuzembayeva et al. 2009). Finally, as described in the 
next section, several studies indicate that EBNA1 can transactivate some cellular genes, and 
it is possible that one or a combination of these genes is necessary for lymphoma 
survival/proliferation (Wood, O'Neil et al. 2007; Baumforth, Birgersdotter et al. 2008; 
Flavell, Baumforth et al. 2008; O'Neil, Owen et al. 2008; Gruhne, Sompallae et al. 2009). 
In either event, it is of interest that introduction of a dominant-negative derivative of 
EBNA1 into EBV-positive Burkitt's lymphoma cells severely decreases their rate of 
proliferation, and dramatically increases their apoptosis, reiterating the utility of devising 
therapies against EBNA1 (Kennedy, Komano et al. 2003; Nasimuzzaman, Kuroda et al. 
2005). 
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Cellular and viral transactivators with redox-sensitive cysteines are often regulated by 
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EBNA1 in type I lymphomas. It is possible that EBNA1 itself provides functions necessary 
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Sugden is that EBNA1 can inhibit or reduce p53-dependent apoptosis (Kennedy, Komano et 
al. 2003). In addition, it is possible that by facilitating genome replication/segregation, 
EBNA1 permits the expression of EBV microRNAs in type I lymphoma cells (Cai, Schafer et 
al. 2006; Choy, Siu et al. 2008; Pratt, Kuzembayeva et al. 2009). Finally, as described in the 
next section, several studies indicate that EBNA1 can transactivate some cellular genes, and 
it is possible that one or a combination of these genes is necessary for lymphoma 
survival/proliferation (Wood, O'Neil et al. 2007; Baumforth, Birgersdotter et al. 2008; 
Flavell, Baumforth et al. 2008; O'Neil, Owen et al. 2008; Gruhne, Sompallae et al. 2009). 
In either event, it is of interest that introduction of a dominant-negative derivative of 
EBNA1 into EBV-positive Burkitt's lymphoma cells severely decreases their rate of 
proliferation, and dramatically increases their apoptosis, reiterating the utility of devising 
therapies against EBNA1 (Kennedy, Komano et al. 2003; Nasimuzzaman, Kuroda et al. 
2005). 
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6.1 Modulation of cellular gene expression by EBNA1  
Recent studies show that EBNA1 alters the transcriptional pattern of several cellular genes 
(Dawson, Rickinson et al. 1990; Falk, Gratama et al. 1995; Wood, O'Neil et al. 2007; 
Baumforth, Birgersdotter et al. 2008; Flavell, Baumforth et al. 2008; O'Neil, Owen et al. 2008). 
These include increasing the expression of STAT1 and AP-1 family transcription factors c-
Jun and ATF2. EBNA1 has been demonstrated to bind the promoters of the latter two genes 
in carcinoma cells (Wood, O'Neil et al. 2007; O'Neil, Owen et al. 2008). If these genes are also 
activated in the context of an EBV infection, they may contribute to the proliferation of cells 
transformed by EBV and the immortalization of naive B-cells by EBV. One pro-oncogenic 
function of EBNA1 is predicted by the recent observation that EBNA1 induces the 
expression of NOX2, resulting in the generation of reactive oxygen species (ROS) that cause 
genome instability (Gruhne, Sompallae et al. 2009).  The cellular enzyme complex, 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, produces ROS by 
transferring electrons from cytosolic NADPH to O2 (Geiszt and Leto 2004). NOX2 is the β-
subunit of flavocytochrome b558, which forms the catalytic core of NADPH oxidase 
(D'Autreaux and Toledano 2007). While all the components of NADPH oxidase are 
expressed in B-cells, NOX2 is expressed at very low levels (Suzuki and Ono 1999). 
Therefore, by inducing NOX2 expression, EBNA1 causes a significant increase in ROS 
production, which in turn causes pro-oncogenic DNA damage (Gruhne, Sompallae et al. 
2009; Gruhne, Sompallae et al. 2009). 
Several sequences bound by EBNA1's DBD have been identified in the human genome 
(Canaan, Haviv et al. 2009; Dresang, Vereide et al. 2009; Lu, Wikramasinghe et al. 2010), 
permitting the creation of a position-weighted matrix that has been used to predict 
additional binding sites (Dresang, Vereide et al. 2009). The relevance of EBNA1 binding to 
these sites is yet to be established because it does not transactivate any genes within 10 kb of 
the sites bound with highest affinity (ibid). Curiously, there are no sequences predicted to be 
recognized by EBNA1's DBD within the promoter/enhancer regions of genes that are 
transactivated by EBNA1, suggesting that EBNA1 may associate with these promoters 
without using its DBD. It is possible that EBNA1 associates with the promoters for these 
genes through its AT-hooks, similar to the association of HMGA1 with AT-rich sequences at 
several promoters (Skalnik and Neufeld 1992; Siddiqa, Sims-Mourtada et al. 2001; Martinez 
Hoyos, Fedele et al. 2004; Tesfaye, Di Cello et al. 2007; Henriksen, Stabell et al. 2010). In this 
context, it may be of relevance that HMGA1 binds to the NOX2 promoter (Skalnik and 
Neufeld 1992). 
7. Conclusions 
In this review, we have focused on the biological functions and biochemical properties of 
the EBNA1 protein of EBV. Genetic studies have indicated that EBNA1 is essential for EBV 
to immortalize naive B-cells, and EBNA1 is the only EBV protein that is expressed in all cells 
infected latently by EBV, including lymphomas. EBNA1 provides two major functions 
necessary for EBV to immortalize naive B-cells: 1) It permits replication/segregation of virus 
genomes; and 2) It activates transcription from two critical viral promoters. Current 
therapies against EBV have severe side-effects, and recurrent tumors are often resistant to 
therapy (O'Reilly, Connors et al. 1997; Khanna, Moss et al. 1999; Gottschalk, Rooney et al. 
2005; Heslop 2005; Mounier, Spina et al. 2006; Mounier, Spina et al. 2007; Spina, Simonelli et 
al. 2007). It is therefore desirable to develop new therapies that are specific to EBV-positive 
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cells, and are highly effective at disrupting their proliferation and survival. Its unique 
expression pattern and critical functions render EBNA1 an excellent target for the 
development of such therapies. 
Molecular and biochemical analyses have provided insights into the mechanisms by which 
EBNA1 functions to support replication/segregation and transactivate viral promoters. For 
both replication and transactivation, EBNA1 needs to bind the oriP region of EBV's genome. 
Therefore, small molecules that interfere with the capacity of DBD to bind its cognate 
binding sites are predicted to block EBNA1's functions, and indeed, several candidate 
inhibitors have already been identified (Li, Thompson et al. 2010). EBNA1 needs its AT-
hook domains for replication, segregation and transactivation, and therefore these domains 
are good targets for therapies against EBV-positive lymphomas. Laemmli and co-workers 
have designed peptidomimetics that interfere with the function of specific AT-hook proteins 
in Drosophila, with three desirable properties: 1) high specificity; 2) low toxicity; and 3) oral 
delivery (Janssen, Cuvier et al. 2000; Janssen, Durussel et al. 2000; Blattes, Monod et al. 
2006). They also provide a framework for the development of small molecules that disrupt 
the functions of EBNA1's AT-hooks.  
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was found in patients’ specimens as a causative agent of Kaposi’s sarcoma by 
representational difference analysis (RDA) (Chang et al., 1994). Initially identified fragments 
by RDA were KS330Bam and KS631Bam, which showed a sequence similarity to a portion 
of the open reading frame (ORF) 26 open reading frame encoding the capsid protein VP23 of 
herpesvirus saimiri (HVS) and the amino acid sequence encoded by the corresponding 
BDLF1 ORF of Epstein-Barr virus (EBV), and to the tegment protein, ORF75 and also the 
tegment protein of EBV, BNRF1 (p140), respectively.  The following full sequence analysis 
revealed that KSHV was belonging to the -herpesvirus subfamily, the genus rhadinovirus 
rather than lymphocryptic virus and could be a new oncogenic DNA virus (Moore et al., 
1996; Russo et al., 1996). 
KSHV is supposed to infect various kinds of tissue in vitro at least by using integrin V as a 
receptor (Garrigues et al., 2008) and establishes latency in B cells (Chen and Lagunoff, 2005).   
KSHV has been reported to infect a primary endothelial cell and can transform it into a spindle 
cell which is a characteristic feature of the oncogenic activity of KSHV in endothelial cells 
(Lagunoff et al., 2002) However, it has not been revealed effective in vitro infection to primary 
peripheral blood mononuclear cells (PBMC), which of course include B cell, as EBV can form 
lymphoblastoid cell lines (LCL).  Extensive studies so far have revealed that KSHV should be 
an etiologic agent for Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD), and 
primary effusion lymphoma (PEL) (Hengge et al., 2002a; Hengge et al., 2002b).   
It is quite a big question how oncogenic viruses are involved in their related cancers.  
Especially limited host ranges of viruses only infecting with humans make this question 
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gene expression profiles of viruses-associated tumors.  Recently, we analyzed three types of 
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T cell leukemia cell lines (TCL), Burkitt lymphoma (BL) cell lines-and two sets of PBMCs-in 
order to know how PEL was generated by searching characteristic gene expression profiles.  
Our approach, however, might be just to show typical gene expression profiles after 
establishment of PEL cell lines and it may be very difficult to account for viral pathogenesis 
only by gene expression profiles.  Needless to say, we need an experimental model to 
observe the whole process from virus infection to cancer formation.  In this chapter, we 
discuss about how KSHV is involved in PEL formation and what to do next to solve 
questions about viral oncogenesis.   
2. Characteristic features of KSHV 
KSHV is a -herpesvirus mentioned above and the genome is double stranded linearized 
DNA about 170kb long including GC-rich repetitious repeat called terminal sequences (TR), 
the unit of which is 801bp and repeated 30~50 times at the end of the genome though the 
sequence and the repeated unit might be different among clones.  The unique region of the 
genome is about 140kb long and encodes more than 80 genes, most of which are lytic genes 
(Russo et al., 1996).  The linearized genome is circularized at the TR after entry into cells and 
usually stealthies as an episome not going to full lytic replication.   
2.1 KSHV life cycles 
Like the other herpesviruses, KSHV has two typical life cycles called lytic infection (or 
reactivation from latency) and latent infection.  Lytic infection/reactivation is a virus 
producing cycle and probably all viral genes are expressed from immediate early (IE), early (E) 
and late (L) genes in a cascade-like fashion.  A key factor for lytic replication is Reactivation 
Transcription Activator (RTA) (Chen et al., 2001; Lukac et al., 1998; Sun et al., 1998).  RTA is a 
very strong transactivator and trans-activates the other viral E genes such as K-bZIP (K8), orf57, 
pan including kaposin (k12), a latent gene, not only through specific binding sequences but also 
through an indirect mechanism (Sakakibara et al., 2001).  When L genes are successfully 
expressed, it leads to explosive daughter virus production, which is a final end of the viral life 
cycle to disseminate viral infection and survive as its virus itself in nature.   
On the other hand, latent infection is a viral stealthing state.  The viral genome replicates 
according to the host cell cycle and is partitioned into divided cells at least in KSHV infected 
PEL cell lines (Ballestas, Chatis, and Kaye, 1999).  The viral copy number per cell appears to 
be maintained at the same (Ueda et al., 2006).  In this state, expressing viral genes are 
extremely limited to a few genes such latency-associated nuclear antigen (lana), viral cyclin 
(v-cyc), viral flip (v-flip), kaposin (k12) and viral interferon regulatory factor 3 (v-irf-3) 
(Paulose-Murphy et al., 2001).  The former three genes are actually in one unit of gene (Fig. 
1).  lana and v-cyc-v-flip expression is regulated by alternative splicing.  v-cyc-v-flip is in one 
transcript and v-FLIP is translated through internal ribosome entry site (IRES).  Although 
k12 is an independent gene, these four genes are present in one region and actively 
expressed.  It remains to be solved how latent genes are regulated, since neighbor genes just 
upstream or downstream are tightly inactivated in a high density of genes in the genome.  
Epigenetic marking might be important to establish this state but it is unclear how such an 
effect itself is controlled (Toth et al., 2010).  As for a virus, latency is a kind of poised state 
waiting for lytic replication, because it could be unfavorable for the virus to disseminate and 
expand its generation. 
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Fig. 1. The active gene locus around lana. 
The viral latency might be the places for KSHV-associated malignancies mentioned below, 
since such malignancies usually show viral latent infection.  And therefore, it seems to be 
quite important to understand what the viral latency is and it will give us hints to 
investigate functions of the viral latent genes products.  Nevertheless, if the viral latenct 
genes products work for cellular immortalization and/or transformation, there may be more 
patients in KSHV infected people suffering from KSHV-associated malignancies.  Thus, it 
should be kept in our mind to take this idea into consideration when thinking how KSHV is 
involved in cancer formation. 
2.2 Latency-associated nuclear antigen (LANA) 
LANA is one of the most actively produced viral factors and controls the viral latency.  
Though LANA seems to be a multifunctional protein, important functions of LANA in the 
latency are to support the viral genome replication, to partition the replicated viral genome 
and to maintain the same genome copy number per cell, and to regulate the viral genes 
expression (Han et al., 2010).   
LANA has two binding sites called LANA binding sequences (LBS) in TR and replication 
origin of the KSHV genome in latency (ori-P) consists of the LBS and the following 32bp GC-
rich segment (32GC) (Garber, Hu, and Renne, 2002; Garber et al., 2001).  One of two LBS is 
required for the viral replication at least but it is not enough, i.e., 32GC is also required (Hu 
and Renne, 2005).  Though it remains to be solved how the viral ori-P is determined among 
repeated TR sequences and how 32GC is functioning, LANA has been reported to interact 
with components of cellular replication machinery; origin recognition complex 1 to 6 
(ORC1~ORC6) (Verma et al., 2006).  Probably LANA binds with LBS and recruits ORCs on the 
ori-P to start replication.  It is, however, very questionable whether LANA binds all ORCs at 
the same time.  LANA also interacts with a histone acetyltransferase binding to ORC1 (HBO1) 
and epigenetic control around ori-P is may be more important (Stedman et al., 2004). 
LANA is supposed to interact with a chromosome component, since the viral genomes are 
found in the vicinity of chromosomes and actually reported to bind with a histone such as 
H2B, and with Bub1, CENP-F and so on (Barbera et al., 2006; Xiao et al., 2010).  Such 
interaction might account for the viral genome partition and maintenance, though the detail 
is unclear. 
LANA regulates the viral genes expression and maybe cellular gene expression by interacting 
with components involved in heterochromatin formation such as heterochromatin protein 1 
(HP1) and histone methyl transferase, suv39H1.  LANA binds with LBS and recruits such 
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factors on the viral genome, which forms heterochromatin-like environment of the genome 
and as a whole inactive gene expression (Sakakibara et al., 2004).   
Viral genes expressed in the latency might have oncogenic activities because KSHV-associated 
malignancies are usually in latency setting.  Multifunctional LANA interacts with many 
cellular factors other than those mentioned above.  Several mechanisms are thought how 
LANA works in the viral oncogenesis.  LANA interacts with suppressive oncogenes such as 
p53 (Friborg et al., 1999) as the other oncogenic DNA viral genes products.  We have 
confirmed that LANA interacts with p53 to degradade (Suzuki et al., 2010) but not pRb (our 
personal observation).  It was also reported that LANA interacted with glycogen synthase 
kinase 3 (GSK3) and blocked -catenin degradation pathway that was promoted -catenin 
phosphorylation by GSK3(Liu et al., 2007).  On the other hand, stably LANA expressing cells 
are, however, very difficult to establish, which means that LANA expression might give 
disadvantage for cell growth rather than cell growth promotion (our personal observation).   
2.3 Viral cyclin (v-CYC) 
KSHV encodes a cyclin D homologue termed v-cyclin, which is translated from alternatively 
spliced mRNA covering the lana-v-cyc-v-flip region (Li et al., 1997) (Fig. 1).  v-CYC interacts 
with cyclin dependent kinase 6 (CDK6) and promotes G1-S progression (Godden-Kent et al., 
1997; Swanton et al., 1997).  The Cyclin D-CDK6 complex is to function to exit from G0 to G1 
phase (Laman et al., 2001) and the v-cyc/CDK6 complex is resistant to inhibition by CDK 
inhibitors by p16, p21 and p27 (Jarviluoma et al., 2004).  Thus, its real function has not been 
elucidated and it was reported that ectopic or overexpression of c-CYC evokes rather 
cell/DNA damage (Koopal et al., 2007).   
2.4 Viral FLICE inhibitory protein (v-FLIP) 
KSHV encoded v-flip, a homologue of cellular flip (c-flip) is expressed as co-transcript with 
v-cyc and translated via internal ribosome entry site (IRES). v-FLIP activates NF-kB  to 
maintain PEL cell tumor phenotype (Guasparri, Keller, and Cesarman, 2004).  Inhibition of 
NF-kB activity and knocking down v-FLIP lead to KSHV infected PEL cell death (Keller, 
Schattner, and Cesarman, 2000).  NF-kB activity is also required for maintenance of KSHV 
latency (Ye et al., 2008) and v-FLIP, thus, may sustain the viral latency in B cells to stand by 
for oncogenic transformation and maintain the transformed phenotype (de Oliveira, Ballon, 
and Cesarman, 2010).  Oncogenic activity of v-FLIP was also reported and in transgenic 
mice models, v-FLIP expression induces B cell transdifferentiation and tumorigenesis 
(Ballon et al., 2011).  Furthermore, v-FLIP represses cell death with autophagy by interacting 
Atg3 (Lee et al., 2009).   
2.5 Kaposin (K12) 
Kaposin is a uniquely transcribed at the edge of the active transcription region of the KSHV 
genome (Li et al., 2002).  There are three frames around this region and probably a major 
gene is so-called kaposin B whose C-terminal region is corresponding to K12 ORF.  Open 
reading frame (ORF) of KAPOSIN B contains reiterated proline-rich, 23-amino acid direct 
repeats, since this region includes one of two ori-Lyt sequences (lytic replication origin) 
(Sadler et al., 1999).  KAPOSIN B activates p38 mediated mitogen-activated protein kinase 
[MAPK]-associated protein kinase 2 (MK2) make AU-rich 3’ UTR containing mRNA 
stabilize (McCormick and Ganem, 2005).  Activation of p38, on the other hand, was reported 
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to induce lytic cycle of the virus (Yoo et al., 2010).  Thus, although there is a conflict in 
KAPOSIN B function in the KSHV latency, a lot of transcripts including T0.7 polyA (-) RNA 
and k12 mRNA are generated in this region.  
2.6 KSHV microRNAs 
Importantly, the region between ori-LytR and v-flip ORF is the region for the KSHV 
microRNA cluster and supplies with 17 mature microRNAs that do something in the viral 
latency (Boss, Plaisance, and Renne, 2009).  As the cellular genomes produce various kinds 
of microRNA, especially DNA viruses also do (Cullen, 2009).  Among them, some of them 
are targeting cellular genes; miR-K12-11 to BACH1, miR-K12-6-3p to THBS1, miR-K12-4-5p 
to Rbl2 (Lu et al., 2010), miR-K12-6 and miR-K12-11 to MAF (Hansen et al., 2010) and miR-
K9 to rta to tune lytic reactivation finely (Lin et al., 2011), though their accurate transcription 
units or mechanisms have not been cleared.  From now on, micro deletion mutant viruses in 
which each microRNA is precisely deleted will be required to understand their real 
sufficiency and necessity for their function, because gross deletion might have an effect on 
gene expression program around it. 
2.7 v-IRF3 (K10.5) 
KSHV encodes four genes with homology to human interferon regulatory factors (IRFs) 
called vIRF-1, -2, -3, -4 whose genes are clustered totally different region far from a lana 
including locus.  And interestingly, one of them, vIRF-3 is expressed in the KSHV latency 
(Fig. 2).  vIRF-3 was reported to be required for the survival of KSHV infected PELs (Wies et 
al., 2008), suggesting that it is a growth promoting factor by disabling type I and II 
interferon responses (Schmidt, Wies, and Neipel, 2011) , PML-mediated transcriptional 
repression of suvivin (Marcos-Villar et al., 2009), and inhibiting p53 function (Rivas et al., 
2001) as well.   
 
 
Fig. 2. vIRF region of the KSHV genome 
2.8 Lytic viral genes and oncognesis 
As mentioned, viral latency genes seems to have pivotal roles for the viral oncogenesis 
partly because the KSHV related malignancies usually happen in cells with the viral 
latency.  Such genes products, however, do not have immortalizing and/or transforming 
activity either in vitro or in vivo except v-flip (Ballon et al., 2011).  Putative KSHV 
oncogenes are rather encoded in lytic viral genes.  KSHV k1 and v-gpcr (orf72) showed real 
oncogenic activities (Mutlu et al., 2007).  Thus, lytic genes should not be forgot and rather 
KSHV oncogenic activities should be considered on the pathway of reactivation from 
latency. 
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to induce lytic cycle of the virus (Yoo et al., 2010).  Thus, although there is a conflict in 
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2001) as well.   
 
 
Fig. 2. vIRF region of the KSHV genome 
2.8 Lytic viral genes and oncognesis 
As mentioned, viral latency genes seems to have pivotal roles for the viral oncogenesis 
partly because the KSHV related malignancies usually happen in cells with the viral 
latency.  Such genes products, however, do not have immortalizing and/or transforming 
activity either in vitro or in vivo except v-flip (Ballon et al., 2011).  Putative KSHV 
oncogenes are rather encoded in lytic viral genes.  KSHV k1 and v-gpcr (orf72) showed real 
oncogenic activities (Mutlu et al., 2007).  Thus, lytic genes should not be forgot and rather 
KSHV oncogenic activities should be considered on the pathway of reactivation from 
latency. 
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3. KSHV-associated malignancies 
Since KHSV was found, extensive studies were performed to prove the involvement of 
KSHV in many cancers.  Related diseases, however, are confined to a few cancers or cancer-
like diseases; KS, MCD, and PEL.  The other diseases such as multiple myeloma, sarcoidosis 
and primary pulmonary hypertension could not be KSHV-associated diseases.  The former 
three diseases are certainly related to KSHV, though not hundred percent.  Here, we would 
like to discuss about two B lymphocyte-originated tumors associated with KSHV infection.   
3.1 Multicentric castleman’s diesease (MCD) 
MCD is a disease in which KSHV is involved.  But KSHV is not necessarily associated in 
MCD and KSHV associated MCD is usually seen in AIDS setting (Dupin et al., 1999).  
KSHV-associated MCD is not associated with Epstein-Barr virus (EBV) (Oksenhendler et al., 
1996).  In contrast, PEL is usually coinfected with KSHV and EBV in vivo (Ansari et al., 
1996).  MCD is a B cell lymphoma morphologically resembling plasmablasts without 
undergoing a germinal center reaction (Parravicini et al., 2000).  It is unclear how this 
disease is established but a KSHV viral load is a decisive factor for exacerbation of MCD 
(Grandadam et al., 1997) and thus KSHV should have a role in MCD pathogenesis.   
High level interleukin 6 (IL-6) is a well-known fact in MCD and should do something in 
MCD pathogenesis (Oksenhendler et al., 1996).  B cell markers, CD20 and the memory B cell 
marker CD27 are usually expressed, but B cell activation markers such as CD23, CD38 and 
CD30 are not.  KSHV gene expression profiles are different from those in KS and PEL.  It 
was reported that viral lytic genes; v-IRF-1 and v-IL-6 and ORF59 (a polymerase 
processivity factor, PF8) as well as a latent gene; LANA were expressed, suggesting that not 
a few cells in MCD are in the lytic phase.   
3.2 Primary effusion lymphoma (PEL) 
PEL is a rare B-cell originated lymphoma, most of which are infected with KSHV and 
usually emerges in patients suffering from acquired immunodeficiency syndrome (Carbone 
and Gloghini, 2008) by human immunodeficiency virus-1 (HIV-1) infection.  PEL, used to be 
called body cavity-based lymphoma (BCBL), has been differentiated from the other 
lymphomas based on a sine qua non etiologic agent, KSHV.  This rare lymphoma does not 
form a solid mass and is spreading along the serous membrane as PEL initially rises in one 
serous cavity such as a pleural cavity and a peritoneal cavity. 
Cytologically, it is supposed that the tumor cells are derived from postgerminal center B 
cells and show a large cell immunobalstic plasmacytoid lymphoma and anaplastic large cell 
lymphoma and display a non-B, non-T phenotype (Brimo et al., 2007). 
70 percent of PEL cases were co-infected with Epstein-Barr virus (EBV) in vivo (Ascoli et al., 
1998).  However, tightness with KSHV/HHV-8 infection suggests that KSHV/HHV-8 should 
have an important role for PEL pathogenesis with no doubt, taking into consideration that PEL 
frequently loses EBV but not KSHV after in vitro establishment of PEL cell lines. 
Analyses on gene expression profiles of this rare tumor would give us a lot of information 
on how PEL was formed (Naranatt et al., 2004; Uetz et al., 2006) and we also analyzed three 
types of typical lymphocyte-originated tumor cell lines-primary effusion lymphoma (PEL) 
cell lines, T cell leukemia cell lines (TCL), Burkitt lymphoma (BL) cell lines and two sets of 
normal peripheral blood mononuclear cells (PBMCs)-in order to know how PEL was 
generated by searching characteristic gene expression profiles (Ueda et al., 2010).  As a 
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result, these cell lines showed respective typical gene expression profiles and classified into 
clear four groups, PEL, TCL, BL and normal PBMCs.  Two B lymphocyte-originated tumor 
cell lines, PEL and BL cell lines, clearly exhibited distinct gene expression profiles, 
respectively, which could be consistent with the fact that each was originated from different 
B-cell stages.   KSHV seemed to govern the gene expression profile of the co-infected cell 
line, even though PEL is often co-infected with EBV in vivo and there was only one line that 
was co-infected with both KSHV and EBV.  This suggests that existence of KSHV promotes 
PEL formation but not BL.  Gene expression profiles of PEL were also distinct from those of 
KS, suggesting that cell environment affects a gene expression pattern.  These data 
suggested not only that established typical tumor cell lines showed a distinct gene 
expression profile but also that this profile may be governed by a certain virus.   
 
 
Fig. 3. Typical genes expression levels in PEL, BL and TCL 
About sixty genes were prominently expressed in PEL cell lines, including Angiopoietin 1 
(Ang-1, NM001146)), methyl CpG binding protein 1 (MBD1, NM015845), interleukin 2 
receptor  (IL2R, NM000878) and so on, compared with the other cell lines.  The Ang-1 
receptor, TIE-2 was not increased in PEL cell line, meaning that an autocrine loop could be 
unlikely but Ang-1 expression might take an effect in the AIDS environment.  CD79A, B and 
BCL6 were remarkably reduced in PEL cell lines as reported (Du et al., 2002).  CD138 
(syndecan), CD22 and interferon regulatory factor 4 (IRF4) were relatively higher and CD38 
and CD71 were lower in PEL cell lines and might reflect the difference between in vitro and 
in vivo (Fig. 3).  c-myc was certainly higher in BL as BCL6, and IL-6 expression level was not 
so different but IL-6 receptor genes seemed to be more expressed in PEL and therefore, 
sensitivity to IL-6 could be higher in PEL.   
4. Conclusion 
It is very difficult to talking about viral oncogenesis, since we do not have a useful system 
for observation of the virus infection to pathogenesis, especially for high host-specific 
viruses.  And our DNA array data suggest just that tumor cells show typical gene 
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expression profiles after establishment of PEL cell lines at an RNA level and it is may be 
very difficult to account for viral pathogenesis only by gene expression profiles.  
Furthermore, lytic gene expression should be taken into consideration to understand how 
PEL is formed and thus, it would be meaningful to find what kinds of gene were typically 
induced in lytic induction and for much better understanding, convenient viral infection to 
oncogenesis models in which we can observe continuously.   
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1. Introduction 
The members of the Herpesvirales containing more than 130 different herpesviruses have 
already been isolated from all animal species representing the higher steps of evolution. 
According to our knowledge, eight herpesviruses are classified as human herpesviruses: 
Herpes simplex virus 1 (Human herpesvirus 1, HHV-1), Herpes simplex virus 2 (Human 
herpesvirus 2, HHV-2), Varicella-zoster virus (Human herpesvirus 3, HHV-3), Epstein-Barr 
virus (Human herpesvirus 4, HHV-4), Cytomegalovirus (Human herpesvirus 5, HHV-5), 
Human herpesvirus 6 (HHV-6A and HHV-6B), Human herpesvirus 7 (HHV-7), and Human 
herpesvirus 8 (HHV-8 or Kaposi's sarcoma associated herpesvirus, KSHV).  
It is a characteritic of herpesviral infections that after the frequently fulminant initial 
infection, they persist in the neurons or the B- and T-cells of the body throughout life. 
Sometimes they reactivate. With respect to lymphotropic human herpesviruses, HHV-4 and 
HHV-8 reproduce mainly in the B-cells, while HHV-5, HHV-6 and HHV-7 reproduce in T-
cells. HHV-4 causes most of the infectious mononucleosis cases and can immortalize B-
lymphocytes. HHV-5 can also cause infectious mononucleosis. A significant part of primary 
infections occurs in an asymptomatic way. Immunsuppression makes virus reproduction 
easier.  
A wide range of diseases may appear in an immunodeficient state. HHV-6 was first 
described in 1986 and was isolated from patients suffering from lymphoproliferative 
disease. It infects CD4+ T-lymphocytes and it reproduces in them. Two variants of it, HHV-
6A and HHV-6B, are known. Variant B is the pathogen of exanthema subitum (roseola 
infantum) and it can also cause latent infection with fever, diarrhoea, neural symptoms, and 
hepatitis. After transplantation, HHV-6 can reactivate and it is able to replicate in liver-cells. 
HHV-6 can activate the replication of HHV-4; it reduces or increases the replication of HIV, 
and accelerates the expression of antigens coded by HPV. HHV-7 was isolated from CD4+ 
cells in 1990 and was purified from a healthy patient. It is the pathogen of pityriasis rosea, 
but it can also cause exanthema subitum. Additionally, it can create latent infection in T-
lymphocytes and productive infection in salivary gland epithelial cells. During pregnancy, 
viremia is more frequent and may adopt urogenital, perigenital and congenital 
transmission.  
HHV-7 may play a role in cases of immunodeficient patients; in the case of 
immunosuppression HHV-6 and HHV-7 play the role of cofactor in states accompanied by 
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pneumonia. HHV-8 is the latest identified human tumorvirus; since its discovery in 1994 it 
has been in the limelight of research. It plays a critical role in the AIDS-associated body 
cavity B-cell lymphoma (BCBL). The new virus was named Kaposi's sarcoma associated 
herpesvirus (KSHV). Four clinical forms of Kaposi's sarcoma are known: 1. classical type 
(described by Kaposi), 2. epidemic-African type, 3. iatrogen, and 4. AIDS associated type. It 
is possible that KSHV plays a direct or indirect stimulating role: in BCBL in elderly patients 
or ones suffering from AIDS, and in Castleman disease. 
Viral infections are important causes of morbidity and mortality for patients with 
haematological diseases and haematological malignancies. However, the true incidence 
and consequences of human herpesviral infections for these patients who undergo 
conventional nontransplantant therapy are poorly defined. The difference in incidence 
and outcome of viral infections among patient groups is wide, but dependent upon the 
infections among the intensity and duration of T-cell-mediated immune suppression. 
Infections are caused mainly by cytomegalovirus (CMV), herpes simplex virus (HSV), 
varicella-zoster virus (VZV) and less Epstein-Barr virus (EBV), human herpesvirus 6, 7, 8 
(HHV-6, HHV-7, HHV-8). 
Fortunately, a growing number of antiviral medications and vaccines are allowing for more 
effective prophylaxis against these pathogens. 
Modern virology diagnostics use multiple methods for detecting viral infections. These 
include viral isolation in culture, cytologic staining, detection of viral antigens, nucleic acids, 
and viral antibodies. 
Science has been examining the role of herpesviruses in haematologic malignant cases and 
in plasma-cell dyscrasias for decades now. Plasma-cell diseases (monoclonal gammopathies) 
are multiple myeloma (MM), Waldenstörm macroglobulinaemia (WM), and monoclonal 
gammopathy with unknown significance (MGUS). A potential role of HHV-8 has emerged 
in the pathogenesis of these diseases.  
The increase in the number of histiocytes is characteristic of eosinophil granuloma 
(Langerhans cell histiocytosis, LCH). The causal role of lymphotropic herpesviruses has also 
been suggested in the pathogenesis of LCH. The rate of HHV-8 reactivation in patients 
suffering from monoclonal gammopathies significantly exceeds that of those suffering from 
Non-Hodgkins lymphoma. HHV-8 reactivation may refer to immunological lesion in 
patients suffering from monoclonal gammopathies. During its pathogenesis, HHV-8 might 
play a role in the formation of pathographies. HHV-4 is proportionately present in 
haematological pathographies. The data also indicate that in addition to HHV-8, the 
transient reactivation of HHV-4 might also play a role in the pathogenesis of monoclonal 
gammopathies. 
2. Epidemiology, diagnosis and prevention of human herpesviruses 
infections in hematologic diseases 
2.1 Human herpesvirus 1 (HHV-1) and human herpesvirus 2 (HHV-2)  
[Herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2)] 
Herpes simplex viruses were the first of the human herpesviruses to be discovered and are 
among the most intensively investigated of all viruses. Herpes simplex virus (HSV) was first 
isolated by Lowenstein (Lowenstein, 1919). The ability of HSV to establish a life-long latent 
infection in its human host is one of the most intellectually challenging aspects of HSV 
biology. 
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Herpes simplex virus (HSV) belongs to the Simplexvirus genus of the Alphaherpesvirinae 
subfamily of the Herpesviridae family. It has two serotypes, HSV-1 and HSV-2. It was 
classified into two serologically distinct types by Schneweiss (Schneweiss, 1962). HSV-1 and 
HSV-2 are phylogenetically ancient viruses that have evolved together with their human 
host (Davison, 2002). In humans, latent virus is reactivated after local stimuli such as injury 
to tissues innervated by neurons harboring latent virus, or by systemic stimuli (e.g., physical 
or emotional stress, hyperthermia, exposure to UV light, menstruation, or hormonal 
imbalance), which may reactivate virus simultaneously in neurons of diverse ganglia (e.g., 
trigeminal and sacral). 
Transmission of HSV depends on intimate, personal contact between a susceptible 
individual (namely, one who is seronegative) and someone excreting HSV. Thus, virus must 
come in contact with mucosal surfaces or abraded skin for infection to be initiated. 
Following oropharyngeal infection, usually caused by HSV-1, the trigeminal ganglion 
becomes colonized and harbors latent virus. Acquisition of HSV-2 infection is usually the 
consequence of transmission by genital contact. The epidemiology and clinical 
characteristics of primary infection are distinctly different from those associated with 
recurrent infection. HSV-1 causes acute gingivostomatitis, recurrent herpes labialis (cold 
sores), keratoconjunctivitis, blepharitis, iridocyclitis, encephalitis, tracheobroncitis, 
pneumonia, esophagitis, pharingitis, disseminalt infections, mucocutaneus lesions, herpetic 
whitlow, herpes gladiatorum, genital disease, neonatal infectio, and meningitis. HSV-2 
causes genital disease, anal and perianal infection, proctitis, neonatal herpes, meningitis, 
mucocutaneus lesions, herpetic whitlow, oral disease, keratoconjunctivitis, esophagitis, 
pharingitis, and encephalitis.  
A reappearance of HSV, known as recurrent infection, results in a limited number of 
vesicular lesions as occurs with HSV labialis or recurrent HSV genitalis. Reinfection with a 
different strain of HSV occurs, but it is uncommon in the normal host. Herpes simplex virus 
disease ranges from the usual case of mild illness, nondiscernible in most individuals, to 
sporadic, severe, and life-threatening disease in a few infants, children, and adults. 
Although HSV-1 and HSV-2 are usually transmitted via different routes and involve 
different areas of the body, much overlap is seen between the epidemiology and clinical 
manifestations of these two viruses. Historically, primary HSV-1 infections usually occurred 
in the young child, less than 5 years of age, and were most often asymptomatic. When the 
oropharynx is involved, the mouth and lips are the most common sites of HSV-1 infections, 
causing gingivostomatitis; however, any organ can become infected with this virus. Primary 
infection in young adults has been associated with only pharyngitis and a mononucleosis-
like syndrome (McMillan et al., 1993). Genital herpes can be caused by either HSV-1 or 2. As 
infections with HSV-2 are usually acquired through sexual contact, antibodies to this virus 
are rarely found before ages of onset of sexual activity. Recurrent HSV-2 infection, as with 
HSV-1, can be either symptomatic or asymptomatic. 
HSV-1 accounts for the majority of nongenital HSV-induced infections in humans, with 45% 
to 98% of the world population and 40% to 63% of the people in the United States reported 
HSV-1 seropositive (Ribes et al., 2001). Worldwide HSV-1 prevalence varies with age, race, 
geographic location, and socioeconomic status; a higher rate of seropositivity has been 
reported for less industrialized countries (Fatahzadeh & Schwartz, 2007; Chayavichitsilp et 
al., 2009). By the age of sixty, 60% to 85% of adults in the United States demonstrate HSV-1 
seroconversion. Incidence is not seasonal. Over the past thirty years, HSV-2 seroprevalence 
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has increased dramatically, with 20% to 25% of US adults tested positive for HSV-2 
antibodies by the age of forty (Fleming et al., 1997).  
Risk factors for HSV-2 infection include older age, female gender, black race, poor 
socioeconomic status, low level of education, prior sexually transmitted disease, early age at 
first intercourse, and a higher number of lifetime sexual partners (Corey & Handsfield, 
2000). Prepubertal detection of HSV-2 antibodies is rare. Prevalence of HSV2 seropositivity 
is strongly correlated with sexual maturity and promiscuity. Prevalence of HSV-2 antibodies 
is reported to be higher in women (Hettmann et al., 2008). 
Patients compromised by immunosuppressive therapy, underlying disease, or malnutrition 
are at increased risk of severe HSV infections. Renal, hepatic, bone marrow, and cardiac 
recipients are all at a particular risk of increased severity of transplant HSV infection. 
2.1.1 Epidemiology 
HSV-1 and HSV-2 commonly cause mucocutaneus lesions in patients with haematological 
malignancies, but HSV-1 is more frequent (Gnann, 2003). Up to 80% of adult patients with 
leukemia are HSV seropositive. The rate of HSV reactivation among HSV seropositive allo-Stem 
Cell Transplant recipients was reported to be approximately 80%, with the majority of these 
infections occurring during the first four weeks after transplant. They are also common, ranging 
from 15% among CLL (chronic lymphocytic leukemia) patients treated with fludarabine to 90% 
of patients with acute leukemia (Sandherr et al., 2006; Anaisse et al., 1998). Most individuals 
undergoing conventional chemotherapy are at low risk of HSV reactivation; however, those 
receiving T-cell depleting agents (e.g. fludarabine, alemtuzumab) or proteasome inhibitors are 
at high risk of reactivation of both HSV-1 and HSV-2 (Sandherr et al., 2006). 
The greatest risk of reactivation is seen in individuals with CD4 T-cell counts <50 cells/mm3, 
and other contribuiting risk factors are corticosteroid use, prolonged neutropenia, renal 
insufficiency, and age above 65 years. 
2.1.2 Clinical manifestations 
HSV reactivation in leukemic patients is usually associated with localizated mucocutaneous 
disease in the orofacial region (85-90%), and less frequently in the genital area (10-15%). The 
diagnosis of oropharyngeal HSV disease clinically can be difficult when severe mucositis is 
present. Mucositis and mucocutaneous ulcerations are common following high doses of 
chemotherapy, and occur at the same time as oral disease. Another frequent manifestation 
of HSV reactivations is esophageal disease. HSV esophagitis was found in about 10% of 
patients in studies of patients with leukaemia and other neoplastic disorders who had 
gastrointestinal symptoms. Uncommon HSV disease manifestations are pneumonia (2-3%), 
hepatitis, meningitis, and encephalitis (Kaufman et al., 1997; Angarone, 2011). 
Recurrent HSV infection is a major cause of morbidity and occasional mortality in the 
immunosuppressed patient who experiences frequent, persistent and severe recurrences of 
HSV-1 and HSV-2 infection. 
2.1.3 Monitoring and laboratory diagnosis of HSV infections 
An important characteristic of modern diagnostic virology is the use of multiple methods 
for detecting viral infections. These include viral isolation in culture, cytologic staining for 
viral infection with the Tzanck smear (Tzanck & Aron-Brunietiere, 1949), detection of viral 
antigens, nucleic acids, and viral antibodies, which are all used to diagnose current viral 
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infection. Light microscopy is used to detect the effect of viral infection in tissue and to 
define the role of viral infection in producing disease. Clinicians may wish to utilize 
laboratory tests to establish definitive diagnosis when clinical presentation of HSV 
infections is atipical. Virus isolation remains the definitive diagnostic method; however, 
polymerase chain reaction (PCR) detection of viral DNA is gaining increased acceptance 
even for routine skin infections. If skin lesions are present, skin vesicles should be scraped 
and transferred in appropriate virus transport media to a diagnostic virology laboratory. 
Virus may be isolated from various samples including skin lesions, cerebrospinal fluid 
(CSF), ocular fluid, swabs from mucocutaneous lesions, blood, stool, urine, throat, 
nasopharynx, conjunctivae and cornea. The experience with PCR indicates that it is an 
especially useful tool for diagnosis of HSV encephalitis in cerebrospinal fluid (CSF). 
The Tzanck smear is a rapid and reasonably priced diagnostic test that can confirm the 
presence of HSV infection. Although the test can confirm the presence of HSV or VZV, it 
cannot differentiate between the two herpes simplex serotypes and, therefore, cannot 
diagnose HSV-1 or HSV-2 infection definitively. The Tzanck smear has decreased in 
popularity as a diagnostic alternative to the direct fluorescent antibody assay (DFA) 
technique. In addition, DFA may be employed to serotype the HSV infection. Because DFA 
testing is rapid, inexpensive, and virally selective, it is often used to substantiate clinical 
suspicion and determine serotype. The biopsied cells are observed microscopically to detect 
degenerative cytopathologic changes commonly associated with the infection. The 
degenerative changes present in cells infected with HSV-1 and HSV-2 also are observed in 
cells infected with VZV. Thus, the specificity of the technique is low, and it cannot be used 
to serotype the infection. 
As HSV PCR becomes more readily available and less expensive, it has the potential to 
become the most widely used means of detecting HSV for all types of infection because it 
is rapid, highly reliable, and valid. Serologic assay is employed to detect the presence of 
HSV antibodies when other techniques are impractical or ineffective. Such assay takes 
longer to complete than other techniques and should be considered primarily for 
diagnosing recurrent infections, in the presence of healing lesions and the absence of 
active lesions, or when partners of a person who has clinical herpes are at risk. Sera are 
collected at two sepatate times. Acute serum is obtained within three to four days after the 
onset of initial symptoms, and convalescent serum is gathered several weeks after the 
symptoms have abted. To confirm a diagnosis of primary HSV infection, the acute sample 
should be devoid of HSV-positive antibodies due to the delayed humoral response, and 
the convalescent sample should demonstrate the presence of both immunoglobulin G and 
M antibodies to HSV proteins. If any quantities of antibodies are observed in the acute 
sample, primary infection is ruled out and the diagnosis is recurrent herpes infection. 
Measurement of antiviral antibodies was one of the first methods used for the specific 
diagnosis of viral infections and it remains an important tool in the diagnostic virology 
laboratory.  
The role of serology can be for the diagnosis of acute or current infection or for the 
determination of immune status to specific viruses. Serologic diagnosis of HSV infection is 
clinically valuable in the counseling of patients. Therapeutic decisions do not depend on the 
results of serologic studies. Immunoglobulin M (IgM) and IgG humoral responses have been 
well characterized. Antibodies [as detected by immunofluorescence assay (IFA), Enzyme 
immunoassay (EIA), enzyme-linked immunosorbent assays (ELISA)] are specific for HSV. 
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infection. Light microscopy is used to detect the effect of viral infection in tissue and to 
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nasopharynx, conjunctivae and cornea. The experience with PCR indicates that it is an 
especially useful tool for diagnosis of HSV encephalitis in cerebrospinal fluid (CSF). 
The Tzanck smear is a rapid and reasonably priced diagnostic test that can confirm the 
presence of HSV infection. Although the test can confirm the presence of HSV or VZV, it 
cannot differentiate between the two herpes simplex serotypes and, therefore, cannot 
diagnose HSV-1 or HSV-2 infection definitively. The Tzanck smear has decreased in 
popularity as a diagnostic alternative to the direct fluorescent antibody assay (DFA) 
technique. In addition, DFA may be employed to serotype the HSV infection. Because DFA 
testing is rapid, inexpensive, and virally selective, it is often used to substantiate clinical 
suspicion and determine serotype. The biopsied cells are observed microscopically to detect 
degenerative cytopathologic changes commonly associated with the infection. The 
degenerative changes present in cells infected with HSV-1 and HSV-2 also are observed in 
cells infected with VZV. Thus, the specificity of the technique is low, and it cannot be used 
to serotype the infection. 
As HSV PCR becomes more readily available and less expensive, it has the potential to 
become the most widely used means of detecting HSV for all types of infection because it 
is rapid, highly reliable, and valid. Serologic assay is employed to detect the presence of 
HSV antibodies when other techniques are impractical or ineffective. Such assay takes 
longer to complete than other techniques and should be considered primarily for 
diagnosing recurrent infections, in the presence of healing lesions and the absence of 
active lesions, or when partners of a person who has clinical herpes are at risk. Sera are 
collected at two sepatate times. Acute serum is obtained within three to four days after the 
onset of initial symptoms, and convalescent serum is gathered several weeks after the 
symptoms have abted. To confirm a diagnosis of primary HSV infection, the acute sample 
should be devoid of HSV-positive antibodies due to the delayed humoral response, and 
the convalescent sample should demonstrate the presence of both immunoglobulin G and 
M antibodies to HSV proteins. If any quantities of antibodies are observed in the acute 
sample, primary infection is ruled out and the diagnosis is recurrent herpes infection. 
Measurement of antiviral antibodies was one of the first methods used for the specific 
diagnosis of viral infections and it remains an important tool in the diagnostic virology 
laboratory.  
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Serological tests are used for identification of seropositive patients before chemotherapy or 
hematopoietic stem cell transplantation (HSCT), but are not helpful in confirming the 
diagnosis of HSV reactivation. Routine surveillance for HSV reactivation could be done by 
culture or PCR, single (sPCR), nested PCR (n-PCR) and real-time or quantitative PCR (RT-
PCR or Q-PCR). PCR for HSV DNA in CFS is indicated in the diagnosis of HSV meningitis 
and encephalitis. 
2.1.4 Prevention of HSV diseases 
Vaccination remains the ideal method for prevention of viral infection; however, prevention 
of HSV infections introduces unique problems because of recurrences in the presence of 
humoral immunity. Nevertheless, protection from life-threatening infection can be achieved 
in animal models with avirulent, inactivated, or subunit glycoprotein vaccines, each of 
which has unique differences. Future study of the immune response induced by natural 
HSV infections in both adults and neonates is needed to provide insight into the 
requirements for vaccination against acute disease and recurrences. Attempts to produce an 
effective vaccine against HSV have been largely unsuccessful. Perhaps a most effective 
vaccine will be needed to stimulate most, if not all, key parameters of innate and adaptive 
immunity, both systematic and mucosal (Jones & Cunningham, 2004; Stanberry, 2004). 
HSV seronegative patients should attempt to prevent exposure to HSV. Early studies of 
intravenosus acyclovir in hematopetic stem cell transplantation recipients clearly 
documented its clinical efficacy: 0% to 2.5% of patients treated with acyclovir versus 50% to 
70% of those treated with placebo developed HSV lesions (Lundgren et al., 1985; Angarone 
& Ison, 2008). 
HSV seropositive patients: Based on the data, most cancer centers routinely use antiviral 
prophylaxis against HSV reactivation for leukemia patients' chemotherapy, especially those 
at high risk of ractivation such as those treated with purine analogs or alemtuzumab 
(Styczynski et al., 2009). Antiviral agents are routinely used as prophylaxis against HSV 
reactivation, using either i.v. acyclovir, oral acyclovir or valacyclovir, until three–five weeks 
after chemotherapy has been stopped (Angarone, 2011). 
2.1.5 Therapy of HSV diseases 
Advances in the treatment of HSV infections have led the way in the development of 
antiviral therapeutics. In the 1970s, vidarabine (adenine arabinoside) became the first 
licensed antiviral therapeutic for the treatment for herpes simplex encephalitis and neonatal 
HSV infections. Quickly, however, vidarabine was replaced by acyclovir in the the treatment 
of all HSV infections. Today acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, 
valganciclovir, cidofovir and foscarnet are the most useful and widely used therapeutics for 
the treatment of HSV-1 and HSV-2 infections (Knipe & Howley, 2007; Gilbert et al., 2010; 
Jancel & Penzak, 2009; Angarone, 2011). 
2.2 Human herpesvirus 3 (HHV-3) [Varicella-zoster virus (VZV)] 
Varicella-zoster virus (VZV) is a human alphaherpesvirus, which belongs to the 
Varicellovirus genus of the Alphaherpesvirinae subfamily of the Herpesviridae family. It causes 
varicella, commonly called chickenpox, during primary infection. Varicella, which is 
characterized by fever and a generalized, pruritic vesicular rash, is most prevalent in 
childhood. Varicella is highly contagious, producing annual epidemics among susceptible 
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individuals during winter and spring in temperate climates. Among the alphaherpesviruses, 
VZV is unique in its tropism for T lymphocytes, which allows dissemination of the virus to 
skin. VZV also infects and establishes latency in cells of the dorsal root ganglia. Its 
reactivation from latency produces herpes zoster, commonly referred to as shingles, an 
illness observed most often in older adults and immunocompromised patients of any age. 
The vesicular rash of herpes zoster is largely confined to regions of the skin served by a 
single sensory dermatome. Unlike varicella, herpes zoster infections are associated with 
acute pain that can be severe and prolonged. Pain that persists after the onset of herpes 
zoster for more than 30 days is called postherpetic neuralgia (PHN). 
Varicella and herpes zoster were described in very early medical literature. Once thought to 
be the same disorder, Heberden distinguished smallpox and varicella as two diseases in 
1867. In 1892, Bokay suggested an infectious etiology for varicella and herpes zoster and 
postulated that they were related (von Bokay, 1909), an idea supported by the 
demonstration that varicella occurs in children following inoculation with vesicular fluid 
from herpes zoster lesions and that virions from varicella and herpes zoster vesicle fluids 
are identical in appearance by electron microscopy (Almeida, 1962). The isolation of VZV in 
tissue culture was reported by Weller in 1953 (Weller, 1953). Primary VZV infection is 
presumed to be initiated by inhalation of respiratory droplets or by contact with infectious 
vesicular fluid from an infected individual. The potential for aerosol transmission is 
suggested by epidemiologic reports, and VZV DNA is detected in air samples from rooms 
occupied by patients with varicella or disseminated herpes zoster (Sawyer, 1994). 
Varicella-zoster virus latency is established during primary infection. VZV persists in 
sensory nerve ganglia. VZV can access neural tissues, either hematogenously or by 
centripetal neural transport from mucocutaneous lesions. 
Varicella-zoster virus reactivation, although possibly asymptomatic at times, typically 
presents as herpes zoster, a vesicular rash that is usually confined to the dermatomal 
distribution of a single sensory nerve. Because herpes zoster is caused by the reactivation of 
latent virus, susceptibility requires previous primary VZV infection. Given the high 
incidence of varicella, most adults are at risk of VZV reactivation. Herpes zoster is rare in 
childhood, but varicella during the first year of life, or VZV infection acquired by 
intrauterine transmission, are associated with an increased risk. 
The attack rate for previously uninfected household or day care center contacts exposed to 
varicella is about 90%. Varicella pneumonia in healthy adults presents with fever, cough, 
tachypnea, and dyspnea and may be associated with cyanosis, pleuritic chest pain, or 
hemoptysis. Varicella pneumonia is often transient, resolving completely within 24 to 72 
hours, but interstitial pneumonitis with severe hypoxemia progresses rapidly to cause 
respiratory failure in severe cases. 
Varicella hepatitis can occur subclinically, although it may be associated with severe 
vomiting. Aspirin is contraindicated in children with varicella because it predisposes to liver 
damage (Reye's syndrome). Patients with encephalitis typically have a sudden onset of 
seizures and altered sensorium, whereas those with cerebellar disease show a gradual 
progression of irritability, nystagmus, and gait and speech disturbances. Some patients have 
fever, headache, and meningismus, only without any altered consciousness or seizures. 
Acute thrombocytopenia causes petechiae and purpuric skin lesions, hemorrhage into the 
varicella vesicles, epistaxis, hematuria, and gastrointestinal bleeding. Hemorrhagic 
complications are usually transient. Purpura fulminans, caused by arterial thrombosis and 
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hemorrhagic gangrene, is a rare but life-threatening complication. Postinfectious 
thrombocytopenia occurs from 1 to 2 weeks or longer after varicella. Varicella nephritis 
causes hematuria, proteinuria, diffuse oedema, and decreased renal function, with or 
without hypertension. A few cases of nephrotic syndrome and hemolytic-uremic syndrome 
have been reported in children with varicella. Varicella arthritis is rare; it resolves 
spontaneously, with no residual joint disease. Other unusual complications of varicella 
include myocarditis, pericarditis, pancreatitis, and orchitis. Varicella vesicles are common 
on eyelids and conjunctivae, but eye disease is unusual. 
Reactivation of VZV in the trigeminal ganglion can produce ophthalmic disease, including 
conjunctivitis, dendritic keratitis, anterior uveitis, iridocyclitis with secondary glaucoma, 
and panophthalmitis. Loss of vision associated with herpes zoster is predominantly caused 
by retrobulbar neuritis and optic atrophy.  
2.2.1 Epidemiology 
The high incidence of herpes zoster in elderly and immunocompromised patients suggests 
that waning host immune responses to the virus have a significant impact on whether 
reactivation occurs and whether it will lead to symptomatic disease. Herpes zoster in young 
children after intrauterine or early postnatal varicella and the short interval between 
primary and recurrent VZV infections in children with HIV infection probably reflect their 
development of suboptimal cell-mediated immunity. Diminished in vitro T-cell proliferation 
to VZV antigens in elderly patients and in patients receiving immunosuppressive therapy 
correlates with higher susceptibility to herpes zoster.  
The incidence of VZV infection ranges from 2% among patients with chronic myelogenous 
leukemia (CML) receiving imatinib mesylate, to 10-15% in patients with chronic 
lymphocytic leukemia (CLL) receiving flurdarabine or alemtuzumab, to 25% of patients 
with Hodgkin lymphoma, myeloma treated with bortezomib or autologous stem cell 
transplant recipients, and to 45-60% among allogenic stem cell transplant recipients 
(Locksley et al., 1985; Anaisse et al., 1998; Sandherr et al., 2006; Wade, 2006). Infection risk is 
the greatest within the first twelve months following treatment or transplant. The majority 
of VZV infections in adult patients with a hematological malignancy are reactivation 
infections and 80% with localized disease (Locksley et al., 1985). After exposure to an 
individual with VZV infection (varicella or herpes zoster) seronegative leukemia patients 
and HSCT recipients are at risk of developing varicella, wich can be very severe. After 
HSCT, the risk of varicella is the highest in the first 24 months, or beyond this time if 
undergoing immunsuppressive therapy and having chronic graft-versus-host-disease 
(GVHD). Other risk factors include the pretransplantant diagnosis of leukemia and other 
lymphoproliferative disorders. 
2.2.2 Clinical manifestations 
Varicella manifests as a generalized, pruritic, vesicular rash. In leukemic patients and in 
those following HSCT, there is a risk of progressive severe varicella characterized by 
continuous eruptions of lesions, high fever, visceral dissemination, encephalitis, hepatitis, 
pneumonia, nausea, vomiting and diarrhea. Hemorrhagic varicella may sometimes occur. 
In herpes zoster, grouped painful vesicular lesions appear in the distribution of one to three 
dermatomes in the immuncompetent patients. In leukemia patients and HSCT recipients, 
varicella zoster may disseminate to several more dermatomes or throughout the whole 
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body, with the risk of visceral involvement, which may prove fatal. This visceral 
dissemination may sometimes occur without skin vesicles, which makes diagnosis difficult. 
2.2.3 Laboratory diagnosis 
Laboratory diagnosis is not necessary for the clinical management of most VZV infections in 
the immunocompetent host, but rapid diagnostic techniques are useful to guide decisions 
about antiviral treatment, especially for high-risk patients.  
The differentiation of the VZV infections from HSV and bullous dermatitis is an important 
indication for virological diagnosis. VZV infections of pregnant women and of newborn 
infants, atypical infections of immunodeficient patients, and suspected VZV infections of the 
central nervous system must be confirmed by laboratory diagnosis.  
VZV can be isolated in tissue culture, but it is not as easy as for HSV. Tzanck smear cannot 
differentiate between HSV and VZV. Nucleic acids are readily detected by PCR and 
detection of VZV antigens by immunohistochemical assays of cells from cutaneous lesions 
allows rapid diagnosis. The most sensitive methods are the fluorescent-antibody membrane 
antigen assay (FAMA) (Gershon et al., 1999). Latex agglutination methods provide a useful, 
sensitive alternative to FAMA (Steinberg & Gershon, 1991).  
Assays for VZV IgG antibodies are most useful for determining the immune status of 
individuals whose clinical history of varicella is unknown or equivocal. The enzyme-linked 
immunosorbent assay (ELISA) and the immunfluorescence technique are especially suited 
for the detection of VZV specific immunglobulin of classes IgG, IgM and IgA. Detection of 
IgM and high titered IgA anti-VZV antibodies usually indicates a reactivated VZV infection 
regardless of whether lesions are visible or not (Gross et al., 2003). 
PCR techniques (sPCR, n-PCR, RT- PCR or Q-PCR) for VZV DNA are considered the best 
diagnostic tools because they are very specific and sensitive and can detect viral DNA in 
vesicle samples, crusts, and throat swabs from patients with varicella or herpes zoster. PCR 
can be used for tissue specimens as well. VZV encephalitis following HSCT is diagnosed by 
PCR of cerebrospinal fluid. PCR of blood samples (serum, plasma) can document VZV DNA 
viremia in an HSCT recipient with herpes zoster, and quantitative monitoring (RT-PCR or 
Q-PCR) of circulating VZV DNA may be useful for the diagnosis and for assessing the 
response to treatment of visceral VZV infection without skin manifestation. PCR can also 
distinguish vaccine strain from wild-type VZV in clinical specimens (Kalpoe et al., 2006). 
2.2.4 Prevention 
The live attenuated Oka varicella vaccine is the first human herpesvirus vaccine licensed for 
clinical use in several countries. Its development and initial clinical evaluation were first 
reported by Takahashi in 1974 (Takahashi et al., 1974). The vaccine virus derived from a 
clinical isolate of VZV, the Oka strain; was isolated from a healthy Japanese child with 
varicella and atteunated by serial passage in cell culture; initially propagated in guinea pig 
embryo fibroblasts, and then in WI38 human cells. Clinical studies in Japan demonstrated 
the safety, immunogenicity, and clinical efficacy of Oka vaccine, which protected 
susceptibile immuncompetent and immuncompromissed children against varicella, even 
when administered shortly after exposure. Oka vaccine also boosted VZV specific cell-
mediated immunity in immunocompetent and immunocompromised adults. Varicella 
vaccine (Varivax; Merck) was licensed by the US Food and Drug Administration (FDA) in 
1995. Zoster vaccine (Zostavax; Merck) was licenced by the FDA in 2005. Recent 
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response to treatment of visceral VZV infection without skin manifestation. PCR can also 
distinguish vaccine strain from wild-type VZV in clinical specimens (Kalpoe et al., 2006). 
2.2.4 Prevention 
The live attenuated Oka varicella vaccine is the first human herpesvirus vaccine licensed for 
clinical use in several countries. Its development and initial clinical evaluation were first 
reported by Takahashi in 1974 (Takahashi et al., 1974). The vaccine virus derived from a 
clinical isolate of VZV, the Oka strain; was isolated from a healthy Japanese child with 
varicella and atteunated by serial passage in cell culture; initially propagated in guinea pig 
embryo fibroblasts, and then in WI38 human cells. Clinical studies in Japan demonstrated 
the safety, immunogenicity, and clinical efficacy of Oka vaccine, which protected 
susceptibile immuncompetent and immuncompromissed children against varicella, even 
when administered shortly after exposure. Oka vaccine also boosted VZV specific cell-
mediated immunity in immunocompetent and immunocompromised adults. Varicella 
vaccine (Varivax; Merck) was licensed by the US Food and Drug Administration (FDA) in 
1995. Zoster vaccine (Zostavax; Merck) was licenced by the FDA in 2005. Recent 
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development of genetic analysis of VZV Oka strains isolated from vaccine-associated rashes 
and cases of herpes zoster may help identify specific single nucleotid polymorphisms 
(SNPs) that differentiate Oka vaccine from wild-type strains of VZV, and which contribute 
to attenuation of the vaccine and the pathogenicity of wild type VZV (Oxman, 2010). 
Oka vaccine is the most attenuated of all currently licensed live, attenuated virus vaccines, 
and it has been safely administered to VZV-susceptible children and VZV-seropositive 
children and adults, including susceptible children with human immunodeficiency virus 1 
infection and leukemia. Oka vaccine strain of VZV is fully susceptible to acyclovir, 
famciclovir, and valacyclovir; thus, effective antiviral therapy is available if complications 
involving vaccine virus replication occur. 
Inactivated zoster vaccines for administration to immuncompromised patients are 
potentially beneficial. Heat-inactivated VZV vaccine has been safely administrated to 
autologous bone marrow transplant recipients, in whom it accelerated recovery of VZV-cell 
mediated immunity and reduced the occurence of herpes zoster (Hata et al., 2002). 
Encouraged by these results, several groups are exploring the development of inactivated 
VZV vaccines, with and without adjuvants, to permit immunization of profundly 
immunsuppressed patients. 
2.2.4.1 Passive antibody prophylaxis 
Varicella zoster immune globulin (VZIG) and the related product are made from high-titer 
immune human serum. VZV antibody prophylaxis is recommended for passive 
immunization of individuals at high risk of serious varicella who were recently exposed to 
people with acute varicella or herpes zoster.  
2.2.4.2 VZV seronegative patients 
Fortunately, VZV can be prevented by minimizing exposure, passive immunization, and 
antiviral prophilaxis. VZV seronegative family members and contacts of HSCT candidates 
should be vaccinated against VZV no later than four weeks before conditioning begins. Contact 
with patients after vaccination must be avoided, especially if post-vaccination eczema occurs. In 
VZV seronegative patients, who have been in contact with varicella or herpes zoster and hence 
potentially contagious, airborne precautions should be instituted seven days after the first 
contact and continued until 21 days after the last exposure or 28 days post-exposure if the 
patient received passive immunization against VZV (VZIG-varicella-zoster immune globulin or 
ZIG-zoster immune globulin). Prior to the start of chemotherapy, VZV serologies should be 
evaluated and, if negative, exposure should be minimized. The role of direct prophylaxis and 
duration of that has yet to be tested in clinical trials (Wade, 2006; Styczynski et al., 2009). 
2.2.4.3 VZV seropositive patients 
Most HSCT recipients are VZV seropositive, following varicella in their childhood or 
following immunization with varicella vaccine, and are at risk of virus reactivation. There 
have been several retrospective studies of the use of acyclovir prophylaxis to prevent VZV 
reactivation in HSCT recipients. Arguments for the use of passive immunisation for VZV-
seropositive leukemia and HSCT recipients include the theoretical potential for 
supplementing immunity against VZV. The arguments against include scarity of VZIG and 
ZIG, their cost, the low incidence of reinfection, lack of proven efficiency in VZV-
seropositive recipients, and the possible adverse effect and discomfort associated with 
passive immunization (Weinstock et al., 2004). 
 




Treatment of VZV disease should include the early institution of antiviral therapy 
(valacyclovir, acyclovir or famciclovir). Acyclovir therapy diminishes the clinical severity of 
varicella in immunocompromised children by ensuring that cell-associated viremia is 
terminated efficiently despite the impaired host response. Early antiviral therapy prevents 
progressive varicella and visceral dissemination. Acyclovir and valacyclovir are highly 
effective. Yet, despite its efficiency in preventing disease, antiviral prophylaxis is not 
routinely recommended by many of the clinical care guidelines (Sandherr et al, 2006). 
In addition to preventing life-threatening dissemination, early acyclovir therapy minimizes 
cutaneous disease, which may reduce the risk of secondary bacterial infections. 
Immunocompromised patients who have pneumonia, hepatitis, thrombocytopenia, or 
encephalitis require immediate treatment with intravenous acyclovir. Oral acyclovir can be 
used to diminish varicella symptoms in healthy children, adolescents, and adults when 
administered within 24 hours after the appearance of the initial cutaneous lesions. Adults 
with varicella pneumonia, including pregnant women, require immediate treatment with 
intravenous acyclovir. Acyclovir is effective for the treatment of recurrent VZV infection in 
healthy and immunocompromised patients. Among healthy individuals, the period of 
continued new lesions in the involved dermatome was shortened, as was the time to 
complete healing.  
Acyclovir treatment is especially important in patients who are immunocompromised 
because of their risk of disseminated disease, and it is important in healthy adults with 
ophthalmic zoster because of their risk of developing acute uveitis and chronic keratitis. 
Acute neuropathic pain is reduced by early treatment with acyclovir, valacyclovir, or 
famciclovir, but effects on rates of subsequent PHN are less obvious. Acyclovir is given 
intravenously to immunocompromised patients who are at high risk of disseminated 
disease. Daily acyclovir (or suitable alternative) appears to be effective at preventing herpes 
zoster virus in patients with myeloma who are receiving bortezomib, with or without 
corticosteroids (Vickrey et al., 2009). Acyclovir prophylaxis effectively prevented VZV 
disease after allogenic transplantation. This regimen is highly effective, safe, inexpensive, 
and does not appear to interfere with VZV specific immune reconstruction (Boeckh et al., 
2006). At present, acyclovir prophylaxis is not a universal practice in all transplant centers, 
because the prompt initiation of acyclovir for the treatment of recurrent VZV infections is 
effective (Weinstock et al., 2004) and long-term use can be associated with emergence of 
drug-resistant VZV mutants. 
2.3 Human herpesvirus 4 (HHV-4) [Epstein-Barr virus (EBV)] 
The discovery of Epstein-Barr virus (EBV) by Epstein, Achong, and Barr, reported in 1964 
(Epstein et al., 1964), was stimulated by Denis Burkitt’s recognition of novel African 
childhood lymphoma and his postulation that an infectious agent was involved in the tumor 
etiology. Human herpesvirus 4 (HHV-4 or EBV) was classified as belonging to the 
Lymphocryptovirus genus within the subfamily Gammaherpesvirinae of the Herpesviridae 
family. With respect to biology, it causes two types of infection: primary infection, mainly in 
children and adolescents, and reactivation of latent infection. The syndrome caused by 
primary infection includes infectious mononucleosis, chronic active EBV infection and X-
linked lymphoproliferative syndrome. Most EBV reactivations are subclinical and require 
no therapies; however, it may be manifest as encephalitis, myelitis, pneumonia, and 
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development of genetic analysis of VZV Oka strains isolated from vaccine-associated rashes 
and cases of herpes zoster may help identify specific single nucleotid polymorphisms 
(SNPs) that differentiate Oka vaccine from wild-type strains of VZV, and which contribute 
to attenuation of the vaccine and the pathogenicity of wild type VZV (Oxman, 2010). 
Oka vaccine is the most attenuated of all currently licensed live, attenuated virus vaccines, 
and it has been safely administered to VZV-susceptible children and VZV-seropositive 
children and adults, including susceptible children with human immunodeficiency virus 1 
infection and leukemia. Oka vaccine strain of VZV is fully susceptible to acyclovir, 
famciclovir, and valacyclovir; thus, effective antiviral therapy is available if complications 
involving vaccine virus replication occur. 
Inactivated zoster vaccines for administration to immuncompromised patients are 
potentially beneficial. Heat-inactivated VZV vaccine has been safely administrated to 
autologous bone marrow transplant recipients, in whom it accelerated recovery of VZV-cell 
mediated immunity and reduced the occurence of herpes zoster (Hata et al., 2002). 
Encouraged by these results, several groups are exploring the development of inactivated 
VZV vaccines, with and without adjuvants, to permit immunization of profundly 
immunsuppressed patients. 
2.2.4.1 Passive antibody prophylaxis 
Varicella zoster immune globulin (VZIG) and the related product are made from high-titer 
immune human serum. VZV antibody prophylaxis is recommended for passive 
immunization of individuals at high risk of serious varicella who were recently exposed to 
people with acute varicella or herpes zoster.  
2.2.4.2 VZV seronegative patients 
Fortunately, VZV can be prevented by minimizing exposure, passive immunization, and 
antiviral prophilaxis. VZV seronegative family members and contacts of HSCT candidates 
should be vaccinated against VZV no later than four weeks before conditioning begins. Contact 
with patients after vaccination must be avoided, especially if post-vaccination eczema occurs. In 
VZV seronegative patients, who have been in contact with varicella or herpes zoster and hence 
potentially contagious, airborne precautions should be instituted seven days after the first 
contact and continued until 21 days after the last exposure or 28 days post-exposure if the 
patient received passive immunization against VZV (VZIG-varicella-zoster immune globulin or 
ZIG-zoster immune globulin). Prior to the start of chemotherapy, VZV serologies should be 
evaluated and, if negative, exposure should be minimized. The role of direct prophylaxis and 
duration of that has yet to be tested in clinical trials (Wade, 2006; Styczynski et al., 2009). 
2.2.4.3 VZV seropositive patients 
Most HSCT recipients are VZV seropositive, following varicella in their childhood or 
following immunization with varicella vaccine, and are at risk of virus reactivation. There 
have been several retrospective studies of the use of acyclovir prophylaxis to prevent VZV 
reactivation in HSCT recipients. Arguments for the use of passive immunisation for VZV-
seropositive leukemia and HSCT recipients include the theoretical potential for 
supplementing immunity against VZV. The arguments against include scarity of VZIG and 
ZIG, their cost, the low incidence of reinfection, lack of proven efficiency in VZV-
seropositive recipients, and the possible adverse effect and discomfort associated with 
passive immunization (Weinstock et al., 2004). 
 




Treatment of VZV disease should include the early institution of antiviral therapy 
(valacyclovir, acyclovir or famciclovir). Acyclovir therapy diminishes the clinical severity of 
varicella in immunocompromised children by ensuring that cell-associated viremia is 
terminated efficiently despite the impaired host response. Early antiviral therapy prevents 
progressive varicella and visceral dissemination. Acyclovir and valacyclovir are highly 
effective. Yet, despite its efficiency in preventing disease, antiviral prophylaxis is not 
routinely recommended by many of the clinical care guidelines (Sandherr et al, 2006). 
In addition to preventing life-threatening dissemination, early acyclovir therapy minimizes 
cutaneous disease, which may reduce the risk of secondary bacterial infections. 
Immunocompromised patients who have pneumonia, hepatitis, thrombocytopenia, or 
encephalitis require immediate treatment with intravenous acyclovir. Oral acyclovir can be 
used to diminish varicella symptoms in healthy children, adolescents, and adults when 
administered within 24 hours after the appearance of the initial cutaneous lesions. Adults 
with varicella pneumonia, including pregnant women, require immediate treatment with 
intravenous acyclovir. Acyclovir is effective for the treatment of recurrent VZV infection in 
healthy and immunocompromised patients. Among healthy individuals, the period of 
continued new lesions in the involved dermatome was shortened, as was the time to 
complete healing.  
Acyclovir treatment is especially important in patients who are immunocompromised 
because of their risk of disseminated disease, and it is important in healthy adults with 
ophthalmic zoster because of their risk of developing acute uveitis and chronic keratitis. 
Acute neuropathic pain is reduced by early treatment with acyclovir, valacyclovir, or 
famciclovir, but effects on rates of subsequent PHN are less obvious. Acyclovir is given 
intravenously to immunocompromised patients who are at high risk of disseminated 
disease. Daily acyclovir (or suitable alternative) appears to be effective at preventing herpes 
zoster virus in patients with myeloma who are receiving bortezomib, with or without 
corticosteroids (Vickrey et al., 2009). Acyclovir prophylaxis effectively prevented VZV 
disease after allogenic transplantation. This regimen is highly effective, safe, inexpensive, 
and does not appear to interfere with VZV specific immune reconstruction (Boeckh et al., 
2006). At present, acyclovir prophylaxis is not a universal practice in all transplant centers, 
because the prompt initiation of acyclovir for the treatment of recurrent VZV infections is 
effective (Weinstock et al., 2004) and long-term use can be associated with emergence of 
drug-resistant VZV mutants. 
2.3 Human herpesvirus 4 (HHV-4) [Epstein-Barr virus (EBV)] 
The discovery of Epstein-Barr virus (EBV) by Epstein, Achong, and Barr, reported in 1964 
(Epstein et al., 1964), was stimulated by Denis Burkitt’s recognition of novel African 
childhood lymphoma and his postulation that an infectious agent was involved in the tumor 
etiology. Human herpesvirus 4 (HHV-4 or EBV) was classified as belonging to the 
Lymphocryptovirus genus within the subfamily Gammaherpesvirinae of the Herpesviridae 
family. With respect to biology, it causes two types of infection: primary infection, mainly in 
children and adolescents, and reactivation of latent infection. The syndrome caused by 
primary infection includes infectious mononucleosis, chronic active EBV infection and X-
linked lymphoproliferative syndrome. Most EBV reactivations are subclinical and require 
no therapies; however, it may be manifest as encephalitis, myelitis, pneumonia, and 
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hepatitis. HHV-4 associated tumors (reactivation syndromes) include lymphoproliferative 
disease (LPD), Burkitt’s lymphoma, non-Hodgkin’s lymphoma, nasopharyngeal carcinoma, 
natural killer (NK)-cell leukemia, Hodgkin’s disease, hemophagocytic lymphohistiocytosis, 
and angioblastic T-cell lymphoma (Ambinder, 2007; Delecluse et al., 2007). 
2.3.1 Epidemiology 
EBV infection occurs in more than 90% of the normal population, and immuncompromised 
patients are predominantly at risk of disease due to EBV reactivation. The incidence of 
PTLD (post-transplant lymphoprolifertaive disease) varies with the organ transplanted, and 
ranges from 1% for renal to 14% small bowel transplant recipients. 
2.3.2 Clinical manifestations 
A significant number (at least 25%) of serologically confirmed primary infections in 
adolescence or early adult life are manifested as infectious mononucleosis, as they are a 
small number of infections in childhood. Symptoms can range from mild transient fever to 
several weeks of pharyngitis, lymphodenopathy, and general malaise. The period of acute 
disease correlates much more closely with that of CD8 T lymphocytosis than with high virus 
shedding and, indeed, treating patients using infectious mononucleosis with oral acyclovir 
to block virus shedding brings little if any clinical benefit. 
The main manifestation of EBV infection after allogenic HSCT is the development of post-
transplant lymphoprolifertaive disease (PTLD) in the presence of reactivated infection, 
which has a very poor prognosis. The clinical manifestation of EBV-associated PLTD may 
include fever, lymphadenopathy, tonsillitis, hepatosplenomegaly, and symptoms and signs 
from other affected organs. Although the incidence is low (0.5-2.0 %), it may rise as high as 
20% in the presence of three or more risk factors. The morbidity risk is highest during the six 
months post HSCT (Islam et al., 2010). Risk factors for developing EBV related PLTD are: ex 
vivo T-cell depletion, treatment with antithymocyte globulin for preventing or treating 
GVHD, anti–CD3 antibodies for GVHD therapy, and unrelated or HLA-mismatched 
transplant. 
2.3.3 Laboratory diagnosis 
Viral detection and in situ hybridization techniques fall into the former category whereas 
immunohistochemistry is useful for distinguishing latent from replicative infection and for 
identifying the prevailing from of EBV latency. Fluorecence in situ hybridisation (FISH) is 
the method of choice for visualisation of viral nucleotide sequences in the infected cells, 
interphase nuclei or on chromosomes (Wilson & May 2001). Using PCR with this sensitivity 
can be used to quantitate absolute numbers of infected cells in a given population. Virus can 
be isolated on cell line.  
The serologic profile, therefore, can be a useful marker of past infection. Because patients 
who are B-cell deficient do not naturally acquire EBV, we have no direct information from 
clinical observation about the biological importance of the antibody response. Antibodies to 
VCA, EA, and the EBNAs target intracellular antigen complexes and, therefore, seem 
unlikely to play any major effector role in controlling virally infected cells in vivo. 
EBV reactivation prospective monitoring of EBV viraemia by Q-PCR is recommended after 
high risk allo HSCT. Screening for EBV DNA should start at the day of HSCT, and last for 
three months with frequency of at least once a week in high-risk cases. 
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Diagnosis of LPD or PTLD must be based on symptoms and/or signs consistent with 
lympoproloferative processdeveloping after HSCT, together with detection of EBV by an 
appropriate method applied to specimen from the involved tissue. EBV detection in a 
biopsy specimen requires detection of viral antigen or in situ hibridization for the EBER 
(Epstein-Barr-encoded RNA).  
2.3.4 Prevention 
The sheer range of EBV-associated diseases emphasizes the importance of developing either 
prophylactic vaccines to reduce disease burden or therapeutic strategies that specifically 
target virus-positive lesions. A number of approaches are currently being pursued. The first 
clinical testing of a gp350-expressing recombinant viral vaccine, based on the Chinese Tien 
Tan strain of vaccinia virus, was carried out on small groups of EBV-seronegative and EBV-
seropositive children (Gu et al., 1995). Phase I and II trials of a gp350 subunit vaccine in 
young adults have induced a neutralizing antibody response; this did not prevent primary 
infection within the vaccinated group, but it did significantly reduce the incidence of 
infectious mononucleosis symptoms compared with the placebo controls. 
2.3.4.1 EBV seronegative patients 
Seronegative individuals should undertake behaviour that minimizes the likelihood of EBV 
exposure. If a patient is found seronegative, the risk of PTLD is higher. Also, HSCT donors 
should be tested before transplantation for EBV serology. When there is choice, the selection 
of a seronegative donor might be beneficial as EBV might be transmitted with the graft. 
Prevention of PTLD has focused on EBV DNA monitoring and use of the donor–derived 
cytotoxic T-cells. 
2.3.4.2 EBV seropositive patients 
Reactivation of EBV is common after allo-HSCT, but rarely causes significant problems 
through direct viral end-organ disease. The important complication of EBV replication is 
PTLD. Poor or negative data are available regarding EBV prophylaxis. Ganciclovir can 
reduce EBV replication, but neither ganciclovir and foscarnet nor cidofovir therapy and 
prophylaxis have any impact on the development of PTLD. 
2.3.5 Therapy 
Anti-CD20 antibodies (rituximab), reduction of immunsuppression or adoptive 
immunotherapy are recommended as a first-line therapy for PTLD. Four to eight doses of 
rituximab are needed to obtain clincal improvement and reduce the EBV DNA load. 
Chemotherapy is a second–line option.  
2.4 Human herpesvirus 5 (HHV-5) [Cytomegalovirus (CMV)] 
Human herpesvirus 5 (HHV-5 or CMV) was classified as belonging to the 
Cytomegalovirus genus within the subfamily Betaherpesvirinae of the Herpesviridae family. 
The virus usually infects the population in early childhood, and later, at the time of 
sexual activity. The primary infection of immuncompetent patients is generally 
symptomless, or causes self-limiting diseases, such as certain cases of infectious 
mononucleosis. The primary CMV infections of seronegative pregnant women's 
transplacental transmission during pregnancy leading to fetal damage may cause severe 
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hepatitis. HHV-4 associated tumors (reactivation syndromes) include lymphoproliferative 
disease (LPD), Burkitt’s lymphoma, non-Hodgkin’s lymphoma, nasopharyngeal carcinoma, 
natural killer (NK)-cell leukemia, Hodgkin’s disease, hemophagocytic lymphohistiocytosis, 
and angioblastic T-cell lymphoma (Ambinder, 2007; Delecluse et al., 2007). 
2.3.1 Epidemiology 
EBV infection occurs in more than 90% of the normal population, and immuncompromised 
patients are predominantly at risk of disease due to EBV reactivation. The incidence of 
PTLD (post-transplant lymphoprolifertaive disease) varies with the organ transplanted, and 
ranges from 1% for renal to 14% small bowel transplant recipients. 
2.3.2 Clinical manifestations 
A significant number (at least 25%) of serologically confirmed primary infections in 
adolescence or early adult life are manifested as infectious mononucleosis, as they are a 
small number of infections in childhood. Symptoms can range from mild transient fever to 
several weeks of pharyngitis, lymphodenopathy, and general malaise. The period of acute 
disease correlates much more closely with that of CD8 T lymphocytosis than with high virus 
shedding and, indeed, treating patients using infectious mononucleosis with oral acyclovir 
to block virus shedding brings little if any clinical benefit. 
The main manifestation of EBV infection after allogenic HSCT is the development of post-
transplant lymphoprolifertaive disease (PTLD) in the presence of reactivated infection, 
which has a very poor prognosis. The clinical manifestation of EBV-associated PLTD may 
include fever, lymphadenopathy, tonsillitis, hepatosplenomegaly, and symptoms and signs 
from other affected organs. Although the incidence is low (0.5-2.0 %), it may rise as high as 
20% in the presence of three or more risk factors. The morbidity risk is highest during the six 
months post HSCT (Islam et al., 2010). Risk factors for developing EBV related PLTD are: ex 
vivo T-cell depletion, treatment with antithymocyte globulin for preventing or treating 
GVHD, anti–CD3 antibodies for GVHD therapy, and unrelated or HLA-mismatched 
transplant. 
2.3.3 Laboratory diagnosis 
Viral detection and in situ hybridization techniques fall into the former category whereas 
immunohistochemistry is useful for distinguishing latent from replicative infection and for 
identifying the prevailing from of EBV latency. Fluorecence in situ hybridisation (FISH) is 
the method of choice for visualisation of viral nucleotide sequences in the infected cells, 
interphase nuclei or on chromosomes (Wilson & May 2001). Using PCR with this sensitivity 
can be used to quantitate absolute numbers of infected cells in a given population. Virus can 
be isolated on cell line.  
The serologic profile, therefore, can be a useful marker of past infection. Because patients 
who are B-cell deficient do not naturally acquire EBV, we have no direct information from 
clinical observation about the biological importance of the antibody response. Antibodies to 
VCA, EA, and the EBNAs target intracellular antigen complexes and, therefore, seem 
unlikely to play any major effector role in controlling virally infected cells in vivo. 
EBV reactivation prospective monitoring of EBV viraemia by Q-PCR is recommended after 
high risk allo HSCT. Screening for EBV DNA should start at the day of HSCT, and last for 
three months with frequency of at least once a week in high-risk cases. 
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Diagnosis of LPD or PTLD must be based on symptoms and/or signs consistent with 
lympoproloferative processdeveloping after HSCT, together with detection of EBV by an 
appropriate method applied to specimen from the involved tissue. EBV detection in a 
biopsy specimen requires detection of viral antigen or in situ hibridization for the EBER 
(Epstein-Barr-encoded RNA).  
2.3.4 Prevention 
The sheer range of EBV-associated diseases emphasizes the importance of developing either 
prophylactic vaccines to reduce disease burden or therapeutic strategies that specifically 
target virus-positive lesions. A number of approaches are currently being pursued. The first 
clinical testing of a gp350-expressing recombinant viral vaccine, based on the Chinese Tien 
Tan strain of vaccinia virus, was carried out on small groups of EBV-seronegative and EBV-
seropositive children (Gu et al., 1995). Phase I and II trials of a gp350 subunit vaccine in 
young adults have induced a neutralizing antibody response; this did not prevent primary 
infection within the vaccinated group, but it did significantly reduce the incidence of 
infectious mononucleosis symptoms compared with the placebo controls. 
2.3.4.1 EBV seronegative patients 
Seronegative individuals should undertake behaviour that minimizes the likelihood of EBV 
exposure. If a patient is found seronegative, the risk of PTLD is higher. Also, HSCT donors 
should be tested before transplantation for EBV serology. When there is choice, the selection 
of a seronegative donor might be beneficial as EBV might be transmitted with the graft. 
Prevention of PTLD has focused on EBV DNA monitoring and use of the donor–derived 
cytotoxic T-cells. 
2.3.4.2 EBV seropositive patients 
Reactivation of EBV is common after allo-HSCT, but rarely causes significant problems 
through direct viral end-organ disease. The important complication of EBV replication is 
PTLD. Poor or negative data are available regarding EBV prophylaxis. Ganciclovir can 
reduce EBV replication, but neither ganciclovir and foscarnet nor cidofovir therapy and 
prophylaxis have any impact on the development of PTLD. 
2.3.5 Therapy 
Anti-CD20 antibodies (rituximab), reduction of immunsuppression or adoptive 
immunotherapy are recommended as a first-line therapy for PTLD. Four to eight doses of 
rituximab are needed to obtain clincal improvement and reduce the EBV DNA load. 
Chemotherapy is a second–line option.  
2.4 Human herpesvirus 5 (HHV-5) [Cytomegalovirus (CMV)] 
Human herpesvirus 5 (HHV-5 or CMV) was classified as belonging to the 
Cytomegalovirus genus within the subfamily Betaherpesvirinae of the Herpesviridae family. 
The virus usually infects the population in early childhood, and later, at the time of 
sexual activity. The primary infection of immuncompetent patients is generally 
symptomless, or causes self-limiting diseases, such as certain cases of infectious 
mononucleosis. The primary CMV infections of seronegative pregnant women's 
transplacental transmission during pregnancy leading to fetal damage may cause severe 
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congenital damage in the neonates, including deafness and mental retardation. 
Reactivation or primary CMV infection in immunocompromised patients can give rise to 
a wide range of complications in many organs of the host. Ho provides a comprehensive 
summary of work leading to the recognition of CMV as a separate medically important 
herpesvirus subfamily (Ho, 1991).  
By the early 1950s, cytomegalic inclusion disease was diagnosed based on the presence of 
inclusion-bearing cells in urine, and viral etiology was predicted based on the detection of 
approximately 100 nm viruslike particles with low-resolution electron microscopy (EM). The 
unrelenting efforts of Margaret Smith, which led to isolation of this virus from urine of 
congenitally damaged newborns, followed her earlier success isolating the related mouse 
salivary gland virus (now called murine CMV) commonly used a viral strain that bears her 
name (Knipe & Howley, 2007). As with all herpesviruses, CMV latency is likely to be 
maintained in everyone who experiences primary infection. The propensity of virus to 
reactivate following immunosuppression or immunodeficiency is an important factor 
leading to CMV-associated diseases. CMV also remains medically prominent as an 
opportunistic infection in the immunocompromised host and this drives initiatives for 
therapeutic intervention. 
CMV reactivation remains a significant cause of morbidity and mortality due to the 
extended period of immunodeficiency after allogenis HSTC. The CMV status of the 
recipients before HSCT has strong influence on HSCT outcome (Zhou et al., 2009). 
2.4.1 Epidemiology 
CMV has a worldwide distribution and infects up to 50-85% of the population in 
industrialized countries. CMV is predictably transmitted in settings where susceptible 
persons have contact with body fluids from persons excreting virus. Transmission appears 
to require direct contact with infectious material; spread by the airborne route or through 
aerosols does not occur. Following initial acquisition of CMV, infectious virus is present in 
urine, saliva, tears, semen, and cervical secretions for months to years. Two types of 
exposures have consistently been linked with horizontal transmission of CMV: sexual 
activity and contact with young children. Vertical transmission from mother to fetus or 
newborn not only occurs but is common and plays an important role in maintaining 
infection in the population. In this context, CMV is spread by three routes: transplacental, 
intrapartum, and via human milk.  
Immuncompromised hosts are at elevated risk of serious CMV disease following primary 
infection, reinfection, or reactivation of latent virus (Sandherr et al., 2006). CMV is a 
leading infectious cause of morbidity and mortality in patients after HSCT and solid 
organ transplantation, and is an emerging problem in adults with leukaemia. CMV 
infection occurs in 60-70% of allogenic HSCT recipients when patient or donor are CMV 
seropositive, and is documented in about 50-60% of CMV seropositive autograph 
recipients. Other predisposing factors include the occurrence of acute GVHD, HLA-
mismatched transplant, and a positive CMV serology of the graft donor in seronegative 
patients (Ng et al. 2005). The majority of CMV infections occur during the first three to 
four months after transplant largely controlled by preventive strategies using antiviral 
drugs; CMV infection remains a significant problem in this setting because of 
breakthrough disease in high risk patients, late onset disease, and indirect effects that 
adversely affect outcome. 
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2.4.2 Clinical manifestations 
CMV infection is manifested clinically in the normal host. The illness is similar to 
mononucleosis that occurs with EBV infection. Estimates indicate that CMV is responsible 
for 20% to 50% of heterophile-negative mononucleosis and that it accounts for 
approximately 8% of all cases of mononucleosis. It is characterized by fever for more than 
10 days, malaise, myalgias, headache, and fatigue. Splenomegaly, hepatomegaly, 
adenopathy, and rash are present in some patients. Compared to EBV-induced 
mononucleosis, pharyngitis, adenopathy, and splenomegaly are noted less commonly 
with CMV. 
CMV disease manifestation includes pneumonia, enteritis, encephalitis, retinitis, hepatitis, 
cholangitis, cystitis, nephritis, sinusitis, and marrow suppression. CMV pneumonia was also 
increased among patients with lymphoma and acute leukemia. CMV-attributable mortality 
for these patients ranged from 30% to 60%. 
Primary CMV infection is when CMV is detected in a previously CMV seronegative patient. 
Recurrent CMV infection is when CMV is detected in a CMV seropositive patient. At 
symptomatic CMV infection, patients develop symptoms (fever with or without bone 
marrow suppression) and carry detectable CMV virions, antigens or nucleic acid, but with 
no sign of CMV endorgan disease. CMV disease is when CMV can be detected by test with 
appropriate sensitivity and specificity in an organ, in a biopsy, or in samples from other 
invasive procedures, bronco-alveolar lavage (BAL), cerebrospinal fluid (CSF) together with 
symptoms and/or sings from the affected organ. For CMV retinitis, typical findings by 
ophtalmologic examination are sufficient. 
2.4.3 Laboratory diagnosis 
Several techniques exist allowing rapid diagnosis of CMV with high sensitivity. Serologic 
tests for antibody to CMV are useful for determining whether a patient had CMV infection 
in the past, a determination of great clinical importance for organ and blood donors, and in 
the pretransplant evaluation of prospective transplant recipients. The avidity of IgG 
antibody increases with time after initial infection and demonstration of low CMV-IgG 
avidity can improve the accuracy of identification of recent primary infection. Antibody 
tests are not useful in the diagnosis of CMV disease in the immunocompromised host. 
Serology determination of either IgG or IgM has no place in the diagnosis of CMV infection 
or disease but is useful to determine the risk of subsequent CMV infection. The most 
commonly used tests for diagnosis of CMV infection are the detection of antigen (pp65 
antigenaemia assay), DNA, or mRNA. Use of a quantitative assay (Q-PCR) gives additional 
information valuable for patient management. CMV gastrointestinal disease is the 
combination of clinical symptoms, findings of macroscopic mucosal lesions on endoscopy, 
and demonstration of CMV by culture, histopathologic testing, immunohistochemistry or in 
situ hybridization in a biopsy specimen. PCR on biopsy material is insufficient for the 
diagnosis of CMV gastrointestinal disease. 
2.4.4 Prevention 
The different preventive strategies for CMV disease include the use of antiviral agents, such 
as chemoprophylaxis, pre-emptive therapy or treatment of symptomatic CMV infection. The 
currently available aniviral agents for prevention of CMV infection and disease are 
ganciclovir, valganciclovir, foscarnet and cidofovir (Ljungman et al.,2008). 
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congenital damage in the neonates, including deafness and mental retardation. 
Reactivation or primary CMV infection in immunocompromised patients can give rise to 
a wide range of complications in many organs of the host. Ho provides a comprehensive 
summary of work leading to the recognition of CMV as a separate medically important 
herpesvirus subfamily (Ho, 1991).  
By the early 1950s, cytomegalic inclusion disease was diagnosed based on the presence of 
inclusion-bearing cells in urine, and viral etiology was predicted based on the detection of 
approximately 100 nm viruslike particles with low-resolution electron microscopy (EM). The 
unrelenting efforts of Margaret Smith, which led to isolation of this virus from urine of 
congenitally damaged newborns, followed her earlier success isolating the related mouse 
salivary gland virus (now called murine CMV) commonly used a viral strain that bears her 
name (Knipe & Howley, 2007). As with all herpesviruses, CMV latency is likely to be 
maintained in everyone who experiences primary infection. The propensity of virus to 
reactivate following immunosuppression or immunodeficiency is an important factor 
leading to CMV-associated diseases. CMV also remains medically prominent as an 
opportunistic infection in the immunocompromised host and this drives initiatives for 
therapeutic intervention. 
CMV reactivation remains a significant cause of morbidity and mortality due to the 
extended period of immunodeficiency after allogenis HSTC. The CMV status of the 
recipients before HSCT has strong influence on HSCT outcome (Zhou et al., 2009). 
2.4.1 Epidemiology 
CMV has a worldwide distribution and infects up to 50-85% of the population in 
industrialized countries. CMV is predictably transmitted in settings where susceptible 
persons have contact with body fluids from persons excreting virus. Transmission appears 
to require direct contact with infectious material; spread by the airborne route or through 
aerosols does not occur. Following initial acquisition of CMV, infectious virus is present in 
urine, saliva, tears, semen, and cervical secretions for months to years. Two types of 
exposures have consistently been linked with horizontal transmission of CMV: sexual 
activity and contact with young children. Vertical transmission from mother to fetus or 
newborn not only occurs but is common and plays an important role in maintaining 
infection in the population. In this context, CMV is spread by three routes: transplacental, 
intrapartum, and via human milk.  
Immuncompromised hosts are at elevated risk of serious CMV disease following primary 
infection, reinfection, or reactivation of latent virus (Sandherr et al., 2006). CMV is a 
leading infectious cause of morbidity and mortality in patients after HSCT and solid 
organ transplantation, and is an emerging problem in adults with leukaemia. CMV 
infection occurs in 60-70% of allogenic HSCT recipients when patient or donor are CMV 
seropositive, and is documented in about 50-60% of CMV seropositive autograph 
recipients. Other predisposing factors include the occurrence of acute GVHD, HLA-
mismatched transplant, and a positive CMV serology of the graft donor in seronegative 
patients (Ng et al. 2005). The majority of CMV infections occur during the first three to 
four months after transplant largely controlled by preventive strategies using antiviral 
drugs; CMV infection remains a significant problem in this setting because of 
breakthrough disease in high risk patients, late onset disease, and indirect effects that 
adversely affect outcome. 
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2.4.2 Clinical manifestations 
CMV infection is manifested clinically in the normal host. The illness is similar to 
mononucleosis that occurs with EBV infection. Estimates indicate that CMV is responsible 
for 20% to 50% of heterophile-negative mononucleosis and that it accounts for 
approximately 8% of all cases of mononucleosis. It is characterized by fever for more than 
10 days, malaise, myalgias, headache, and fatigue. Splenomegaly, hepatomegaly, 
adenopathy, and rash are present in some patients. Compared to EBV-induced 
mononucleosis, pharyngitis, adenopathy, and splenomegaly are noted less commonly 
with CMV. 
CMV disease manifestation includes pneumonia, enteritis, encephalitis, retinitis, hepatitis, 
cholangitis, cystitis, nephritis, sinusitis, and marrow suppression. CMV pneumonia was also 
increased among patients with lymphoma and acute leukemia. CMV-attributable mortality 
for these patients ranged from 30% to 60%. 
Primary CMV infection is when CMV is detected in a previously CMV seronegative patient. 
Recurrent CMV infection is when CMV is detected in a CMV seropositive patient. At 
symptomatic CMV infection, patients develop symptoms (fever with or without bone 
marrow suppression) and carry detectable CMV virions, antigens or nucleic acid, but with 
no sign of CMV endorgan disease. CMV disease is when CMV can be detected by test with 
appropriate sensitivity and specificity in an organ, in a biopsy, or in samples from other 
invasive procedures, bronco-alveolar lavage (BAL), cerebrospinal fluid (CSF) together with 
symptoms and/or sings from the affected organ. For CMV retinitis, typical findings by 
ophtalmologic examination are sufficient. 
2.4.3 Laboratory diagnosis 
Several techniques exist allowing rapid diagnosis of CMV with high sensitivity. Serologic 
tests for antibody to CMV are useful for determining whether a patient had CMV infection 
in the past, a determination of great clinical importance for organ and blood donors, and in 
the pretransplant evaluation of prospective transplant recipients. The avidity of IgG 
antibody increases with time after initial infection and demonstration of low CMV-IgG 
avidity can improve the accuracy of identification of recent primary infection. Antibody 
tests are not useful in the diagnosis of CMV disease in the immunocompromised host. 
Serology determination of either IgG or IgM has no place in the diagnosis of CMV infection 
or disease but is useful to determine the risk of subsequent CMV infection. The most 
commonly used tests for diagnosis of CMV infection are the detection of antigen (pp65 
antigenaemia assay), DNA, or mRNA. Use of a quantitative assay (Q-PCR) gives additional 
information valuable for patient management. CMV gastrointestinal disease is the 
combination of clinical symptoms, findings of macroscopic mucosal lesions on endoscopy, 
and demonstration of CMV by culture, histopathologic testing, immunohistochemistry or in 
situ hybridization in a biopsy specimen. PCR on biopsy material is insufficient for the 
diagnosis of CMV gastrointestinal disease. 
2.4.4 Prevention 
The different preventive strategies for CMV disease include the use of antiviral agents, such 
as chemoprophylaxis, pre-emptive therapy or treatment of symptomatic CMV infection. The 
currently available aniviral agents for prevention of CMV infection and disease are 
ganciclovir, valganciclovir, foscarnet and cidofovir (Ljungman et al.,2008). 
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CMV seronegative patients have low risk of contracting CMV infection. To reduce the risk 
of CMV transmission, blood product from CMV seronegative donors or leukocyte-depleted 
blood product should be used. CMV seronegative patients with CMV seronegative stem-cell 
donors have a lower risk of post transplant complications both from CMV and from the 
effect of CMV associated immunsuppression with its concomitant increased risk of bacterial 
and fungal infections. 
Hyperimmune globulin preparations with high levels of antibody to CMV (CMVIG) have 
been evaluated for prevention of CMV disease in organ transplant recipients, premature 
newborns at risk for postnatal infection and pregnant women. Although attempts to 
develop a vaccine for prevention of maternal and congenital CMV have been pursued for 
more than 25 years, no vaccine is currently licensed or near licensure. Improved 
understanding of the role of specific viral proteins in eliciting protective immune responses 
and recent recognition of the potential benefit to society and cost-effectiveness of CMV 
vaccines, however, are stimulating development of new vaccines. Investigational vaccines 
using different formats have been evaluated in clinical trials; these include attenuated live 
virus, a recombinant protein in a fowl pox vector, a DNA vaccine, and a recombinant 
protein given with a new adjuvant (Sung & Schleiss, 2010). 
2.4.4.1 CMV seropositive patients 
The use of preemptive monitoring for CMV reactivation in patients receiving 
alemtuzumab for at least two months following the receipt of chemotherapy is 
recommended. Once CMV reactivation is recognized, either oral valganciclovir or 
intravenous ganciclovir may be used. 
2.4.5 Therapy 
The four antiviral agents (Ganciclovir, Valganiclovir, Foscarnet, and Cidofovir) are currently 
approved for treatment of CMV disease (Fellay et al. 2005; Knipe & Howley, 2007). Antiviral 
agents are commonly used in transplant medicine to prevent CMV disease, either as a daily 
prophylactic regimen or in a preemptive approach in which laboratory surveillance for 
CMV in blood is used to identify patients for antiviral therapy (Reusser 2002). 
2.5 Human herpesvirus 6 (HHV-6) 
Human herpesvirus 6 (HHV-6) belongs to the Roseolovirus genus of the Betaherpesvirinae 
subfamily of the Herpesviridae family. HHV-6 was first isolated in 1986 from B-
lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative disorders 
(Salahuddin et al., 1986). Because of tropism to B lymphocytes, the virus was first named 
human B-lymphotropic virus, but was later found mainly to infect and replicate in 
lymphocytes of the T-cell lineage. HHV-6 isolates are classified into two closely related 
groups, variants A (HHV-6A) and B (HHV-6B). HHV-6B is the major causative agent of 
exanthem subitum (roseola infantum), which is characterized by high fever, diarrhoea, 
and a mild skin rash along the trunk, neck, and face (Yamanishi et al., 1988). HHV-6A 
has been associated with several adult diseases, including cofactor in AIDS progression, 
and various neurological disorders including encephalitis, ataxia, seizure, liver 
disfunction, and chronic fatigue syndrome; however, the causal link between human 
diseases and virus infection remains to be fully elucidated (De Bolle et al., 2005; Ablashi 
et al, 2010).  
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Following primary infection, the genome of herpesviruses establishes latency as a nuclear 
circular episome. The in vivo and in vitro integration of HHV-6A and HHV-6B into the 
telomers of human chromosomaes during latency was demonstrated by Arbuckle et al. 
(Arbuckle et al., 2010; Arbuckle & Medveczky 2011). The integrate HHV-6 genome was 
also found to be vertically transmitted from parent to child in the germ-line. 
Characterisation of the integration sites in tumor samples and long-term follow up studies 
may elucidate the relationship between integration and leukemogenesis (Minarovits et al., 
2007) 
2.5.1 Epidemiology 
Seroprevalence of HHV-6 decreases at five months of age, as maternal antibody wanes. 
Beginning at about 6 months, seroprevalence increases rapidly, with almost all children 
becoming positive by 2 years of age. Internationally, HHV-6 seroprevalence is high in 
almost all areas, but ranges from approximately 39% to nearly 100% among some ethnically 
diverse adult populations. 
HHV-6 genomes and antigens are detectable in lymph nodes of patients with sinus 
histiocytosis with massive lymphadenopathy tubular epithelial cells, endothelial cells and 
histiocytes in kidney salivary glands and central nervous system tissues, where viral gene 
products have been localized to neurons and oligodendrocytes (Levine et al., 1992; Kurata et 
al., 1990). HHV-6 is also detected in lesions of Langerhans cell histiocytosis in the syndrome 
of Langerhans cell histiocytosis (Leahy et al., 1993; Csire et al., 2007a). 
2.5.2 Clinical manifestations 
Asymptomatic HHV-6 reactivation is common after allogeneic bone marrow transplantation 
(Cone et al.,1999), but reactivation has also been linked to bone marrow suppression, 
encephalitis, gastroduodenitis, colitis, pneumonitis, rash, and acute graft-versus-host 
disease, all of which have been reviewed by others (De Bolle et al., 2005). Liver dysfunction 
is also associated with HHV-6 infection; although usually mild, it can be fatal hepatitis and 
chronic hepatitis. Primary HHV-6 infection has also been associated with cases of idiopathic 
thrombocytopenic purpura. Further, human herpesvirus 6 infection has also been associated 
with pneumonitis, with the infected cells being primarily intraalveolar macrophages, plus 
some lymphocytes.  
Concentrations of HHV-6 genomes in lung tissue and their relation to changes in serologic 
titers support an association between HHV-6 infection and idiopathic pneumonitis in 
immunocompromised hosts. HHV-6 reactivates early after HSCT and is found in the 
blood in about half of all allo-HSCT recipients, making it difficult to make disease 
association. Two viral variants of HHV-6 have been identified (A and B), but the HHV-6B 
is most frequently associated with disease among immuncompromised patients. 
Longitudinal studies in HSCT recipients found the viral reactivation to occur at a median 
of 20 days after transplantation, and that viral shedding for some patients was prolonged, 
and correlated poorly with clinical improvement (Zerr et al., 2005). A clinical syndrome 
consisting of central nervous system dysfunction, impaired memory, secondary 
hypothyroidism, and delayed platelet engrafment are common disease manifestations. 
HHV-6 viraemia among allogenic transplant recipients is associated with the increase in 
all-cause mortality, and viraemia appears to be increased when patients are transplanted 
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CMV seronegative patients have low risk of contracting CMV infection. To reduce the risk 
of CMV transmission, blood product from CMV seronegative donors or leukocyte-depleted 
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Hyperimmune globulin preparations with high levels of antibody to CMV (CMVIG) have 
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develop a vaccine for prevention of maternal and congenital CMV have been pursued for 
more than 25 years, no vaccine is currently licensed or near licensure. Improved 
understanding of the role of specific viral proteins in eliciting protective immune responses 
and recent recognition of the potential benefit to society and cost-effectiveness of CMV 
vaccines, however, are stimulating development of new vaccines. Investigational vaccines 
using different formats have been evaluated in clinical trials; these include attenuated live 
virus, a recombinant protein in a fowl pox vector, a DNA vaccine, and a recombinant 
protein given with a new adjuvant (Sung & Schleiss, 2010). 
2.4.4.1 CMV seropositive patients 
The use of preemptive monitoring for CMV reactivation in patients receiving 
alemtuzumab for at least two months following the receipt of chemotherapy is 
recommended. Once CMV reactivation is recognized, either oral valganciclovir or 
intravenous ganciclovir may be used. 
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The four antiviral agents (Ganciclovir, Valganiclovir, Foscarnet, and Cidofovir) are currently 
approved for treatment of CMV disease (Fellay et al. 2005; Knipe & Howley, 2007). Antiviral 
agents are commonly used in transplant medicine to prevent CMV disease, either as a daily 
prophylactic regimen or in a preemptive approach in which laboratory surveillance for 
CMV in blood is used to identify patients for antiviral therapy (Reusser 2002). 
2.5 Human herpesvirus 6 (HHV-6) 
Human herpesvirus 6 (HHV-6) belongs to the Roseolovirus genus of the Betaherpesvirinae 
subfamily of the Herpesviridae family. HHV-6 was first isolated in 1986 from B-
lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative disorders 
(Salahuddin et al., 1986). Because of tropism to B lymphocytes, the virus was first named 
human B-lymphotropic virus, but was later found mainly to infect and replicate in 
lymphocytes of the T-cell lineage. HHV-6 isolates are classified into two closely related 
groups, variants A (HHV-6A) and B (HHV-6B). HHV-6B is the major causative agent of 
exanthem subitum (roseola infantum), which is characterized by high fever, diarrhoea, 
and a mild skin rash along the trunk, neck, and face (Yamanishi et al., 1988). HHV-6A 
has been associated with several adult diseases, including cofactor in AIDS progression, 
and various neurological disorders including encephalitis, ataxia, seizure, liver 
disfunction, and chronic fatigue syndrome; however, the causal link between human 
diseases and virus infection remains to be fully elucidated (De Bolle et al., 2005; Ablashi 
et al, 2010).  
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for disease other than first remission, when donor and recipient are sex mismatched, and 
among younger patients. 
2.5.3 Laboratory diagnosis 
HHV-6 virus isolation is easily recovered from peripheral blood mononuclear cells of 
patients with exanthema subitum during the acute phase. Cytopathic effect (CPE) develops 
within 7 to 10 days. The refractile giant cells usually contain one or two nuclei and, after the 
occurrence of the CPE, lytic degeneration of the cells takes place. The rate of virus isolation 
from mononuclear cells was 100% on days 0 to 2 (just before appearance of skin rash), 82% 
on day 3, and 20% on day 4. 
Numerous HHV-6 serologic assays have been described, including IFA, ELISA, 
neutralization, and immunoblot. IFA is the most commonly applied method, with HHV-6 
infected cells being used as the antigens. For detection of IgM, separation of serum IgM 
from IgG and IgA significantly increases the specificity.  
Antigenemia tests: such tests have been used for the diagnosis of HHV-6 infection in blood, 
but there is limited experience as their use has not been widespread. 
HHV-6 DNA can be detected via PCR techniques (sPCR, n-PCR) from blood, cerebrospinal 
fluid (CSF), tissue samples, and other samples in view of the differing natural histories of 
variants A and B. Quantitative PCR (Q-PCR or real-time PCR) analysis on blood and CSF is 
the method of choice for diagnosis. 
Possibile techniques include in situ hybridization and immunohistochemistry, but these are 
not generally available. 
2.5.4 Prevention 
Antiviral prophylaxis against HHV-6: foscarnet, ganciclovir and cidofovir have been shown 
to inhibit HHV-6 replication. Data from two small non-randomized studies of HSCT 
recipients suggest that prophylactic gancyclovir can prevent recurrent HHV-6 infection 
(Tokimasa et al., 2002, Rapaport et al., 2002). 
2.5.5 Therapy 
Foscarnet and gancyclovir, alone or in combination, have been used as treatment for HHV-6 
infection. For treatment of HHV-6 encephalitis foscarnet or ganciclovir are recommended as 
first-line therapies after HSCT. Cidofovir is recommended as a second-line therapy. 
2.6 Human herpesvirus 7 (HHV-7) 
Human herpesvirus 7 (HHV-7) belongs to the Roseolovirus genus of the Betaherpesvirinae 
subfamily of the Herpesviridae family. HHV-7 was first described in 1990 (Frenkel et al., 1990). 
HHV-7 was isolated in 1990 from a healthy individual whose cells were stimulated with 
antibody against CD3 and then incubated with interleukin-2. The virus is one of the 
causative agents of exanthema subitum (Tanaka et al., 1994) and has been associated with 
febrile convulsions in young children (Ward et al., 2005). After primary infection of CD 4+T 
lymphocytes, HHV-7 infects (similar to HHV-6) epithelial cells of salivary glands and 
various organs (lungs, skin, mammary gland, liver, kidney and tonsils). HHV-7 could be 
reactivated from lately infected peripheral blood mononuclear cells by T-cell activation. 
Thus, HHV-7 can provide transacting functions, mediating HHV-6 reactivation from latency 
(Tanaka-Taya et al., 2000). 
 




HHV-7 infection appears to occur slightly later than HHV-6. As for HHV-6, seroprevalence 
declines over the first 5 to 6 months, as maternal antibody wanes, then increases fairly 
rapidly up to 4 years of age. HHV-7 is ubiquitous, with more than 44%-91% of adults having 
antibody to virus.  
2.6.2 Clinical manifestations 
Although the frequency of clinical illness is lower, primary infection with HHV-7 causes 
illness similar to that of HHV-6, including exanthem subitum, high fever, and neurologic 
symptoms (e.g., febrile convulsions).  
In 1997, Drago et al. reported the association of pityriasis rosea with HHV-7 infection and 
proposed that it is a clinical presentation of HHV-7 reactivation. Peripheral blood 
mononuclear cell (PBMC) from patients with pityriasis rosea showed ballooning cells and 
syncytia after 7 days in culture, whereas PBMC from controls and patients recovered from 
pityriasis rosea did not. PCR identified HHV-7 DNA in PBMC, plasma, and skin from all 
patients with active pityriasis rosea, and only in the PBMC 10 to 14 months later. HHV-7 
detection after HSCT is relatively infrequent, and there are only a handful of cases in which 
HHV-7 is associated with central nervous system disease (Yoshikawa et al., 2003). 
2.6.3 Laboratory diagnosis 
HHV-7 is sometimes isolated from peripheral blood of patients with exanthema subitum, 
and can be readily isolated from saliva by using methods as described above for HHV-6. 
Isolation of HHV-6 from saliva is uncommon, although its DNA is often detectable there. 
HHV-7 serology techniques are immunoblot, IFA, and ELISA assays for HHV-7 antibodies. 
The ELISA was the most sensitive, whereas the immunoblot was the most specific. As 
mentioned, antibody avidity assays enable identification of recent primary infections (Ward 
2005). PCR techniques (sPCR, n-PCR, Q-PCR or RT-PCR) can be used to detect HHV-7 DNA 
of blood, cerebrospinal fluid (CSF), tissue, or other samples.  
2.6.4 Prevention 
In view of the limited data, no recommendations can be made regarding HHV-7 as a 
potential pathogen in leukemia patients or after HSCT. 
2.6.5 Therapy 
The majority of conditions due to infection do not require antiviral medication, but the severe 
complications may be treated with ganciclovir and its derivates or foscarnet and cidofovir.  
2.7 Human herpesvirus 8 (HHV-8) [Kaposi’s sarcoma associated herpesvirus (KSHV)] 
Kaposi's sarcoma associated herpesvirus (KSHV; human herpesvirus 8, HHV-8) is the most 
recently discovered human herpesvirus (Chang et al., 1994). Kaposi's sarcoma (KS) is a 
complex, angioproliferative and inflammatory lesion that was first described by Kaposi in 
the late 19th century (Kaposi, 1872). HHV-8 belongs to the Rhadinovirus genus of the 
Gammaherpesvirinae subfamily of the Herpesviridae family. HHV-8 is the ethiologic agent of 
Kaposi’s sarcoma, and has been implicated in other B-cell lymphoproliferative disorders 
including primary effusion lymphoma and a subset of multricentric Castleman disease. 
HHV-8 has been implicated in the pathogenesis of several other diseases, including multiple 
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for disease other than first remission, when donor and recipient are sex mismatched, and 
among younger patients. 
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to inhibit HHV-6 replication. Data from two small non-randomized studies of HSCT 
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2.6 Human herpesvirus 7 (HHV-7) 
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HHV-8 has been implicated in the pathogenesis of several other diseases, including multiple 
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myeloma, Waldenstörm macroglobulinaemia, and monoclonal gammopathy with unknown 
significance (Mikala et al., 1999).  
2.7.1 Epidemiology 
The prevalence of HHV-8 infection is very high in older children and adults in Africa and 
the Amazon basin (50-100%), medium in the Mediterranean (5-25%), and low in North 
America, North and West Europe (2-5%). Transmission of the virus is sexual; in homosexual 
and bisexual persons, seroprevalence rates are substantially lower among women than men. 
Transmission is possible via saliva in areas of high epidemicity. HHV-8 may be transmitted 
by blood transfusion and solid organ transplantation (Hladik et al., 2006). 
2.7.2 Clinical manifestations 
Transplant patients may acquire HHV-8 from the allograft, blood products, caregivers, or 
from family members. Cutaneuous or visceral Kaposi’s sarcomas develop with a reported 
incidence of 0.5-5.0% in solid organ recipients (Jenkins et al., 2002). 
2.7.3 Laboratory diagnosis 
The first successful cultivation of HHV-8 used PEL cell lines explanted from patients with 
advanced AIDS (Renne et al., 1996). HHV-8 diagnostic serology techniques may include 
immunoblot, IFA, and ELISA assays for HHV-8 antibodies (Sarmati 2001; Juhasz et al., 
2001). These are useful for donors and recipients in at risk population, but wherever 
available, are of variable sensitivity and specificity (Sergerie et al., 2004). 
HHV-8 DNA can be detected via PCR techniques (sPCR, n-PCR, Q-PCR or RT-PCR) from 
the whole blood, plasma or serum, cerebrospinal fluid (CSF), tissue or other samples. 
Possible techniques may include in situ hybridization and immunohistochemistry, but these 
are not generally available. 
2.7.4 Prevention 
In view of the limited data, no recommendations can be made regarding HHV-8 as a 
potential pathogen in leukemia patients or after HSCT. 
2.7.5 Therapy 
Antiviral agents that target herpesvirus DNA synthesis, such as ganciclovir, foscarnet and 
cidofovir, inhibit HHV-8 lytic replication and can prevent Kaposi sarcoma (Cohen & 
Powderly 2004). Several HIV protease inhibitors may interfere with tumor growth and 
angiogenesis, and one protease inhibitor, nelfinavir, directly inhibits HHV-8 replication in 
vitro (Gantt & Casper, 2011). 
3. Conclusion 
The spectrum of viral infections for patients with haematological diseases is expanding and 
diagnosis has increased because of new molecular diagnostic techniques. The group of human 
herpesviruses consists of eight members. Primary and reactivation infections are characteristic 
of these pathogens. Viral latency can be predicted by serological screening and it is useful for 
disease management. Antiviral therapy is now routinely used for prevention and therapy. Viral 
immunization remains investigational, except for the VZV vaccination (Cheuk et al., 2011).  
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Human herpesviruses are a major cause of related morbidity and mortality in hematologic 
diseases. This chapter focuses on the epidemiology and prevention strategies for human 
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per day, TID-three times per day, QID-four times per day, VZIG-Varicella-zoster immunoglobulin, 
IVIG-intravenous immunoglobulin, FAM-Famciclovir, CNS-central nervous system, GI-gastrointestinal 
Table 1. Recommendations for Surveillance and Prophylaxis in Patients with Hematologic 
Diseases 
Viral infections remain a common complication in patients with hematologic diseases, 
especially in those receiving intensive chemotherapy. Fortunately, there are effective 
prophylactic and preventative mesures available to help control these infections. 
Human herpesviruses have been implicated in the pathogenesis of several diseases. An 
increasing number of malignancies are being associated with EBV (e.g. LPD, non-Hodgkin’s 
lymphoma, Hodgkin’s diseases, Burkitts’s lymphoma, NK-cell leukemia). HHV-8 has been 
suggested as a possible etiologic agent of several diseases. These include multiple myeloma, 
Waldenstörm’s macroglobulinaemia, and monoclonal gammopathy with unknown 
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significance. Multiple myeloma is a genetically and clinically heterogeneous disease. 
Recently, (at least) 5 prognostically and biologically different subgroups have been 
described based on karyotype and type of cyclin expression (Gertz & Greipp 2004). HHV-8 
infection may play a role in the disease process of only one or more subgroups of myeloma 
patients while not in others. In the history of HHV-8 research, it has been exceedingly 
difficult to obtain lymphoid cell lines (e.g. effusion lymphoma) devoid of EBV genome 
(Renne et al. 1996).  
This brings up the point of possible interaction between these two lymphotropic 
herpesviruses, at least in diseases of the lymphoid system. A similar interaction of HHV-6 
and 8 has been described in vitro. EBV-seronegative patients may be prone to HHV-8 
reactivation, the possible interaction of EBV early proteins with the activation of latently 
harbored HHV-8 genomes. This might occur also in such cases when the two viruses are not 
replicating in the same cell, but viral membrane proteins i.e. ZEBRA or interleukin-like 
molecules shed (IL10) by the EBV producing B-cells might interact with B cells or bone 
marrow cells carrying latent HHV-8 mini-chromosomes.  
It may be possible that the continuously replicating myeloma cells release both EBV and 
HHV-8, since latent virus infected cells are usually blocked in the G0-G1 phases of the cell 
cycle. When myeloma cells enter the S-phase, the availability of DNA replication machinery 
may activate the DNA viruses persisting in a small proportion of cells. The absence of CMV 
reactivation can be understood, since the sites of latency are the CD34+ progenitor cells of 
monocytes. The main site of replication is the B lymphocytes and many other cells in the 
human body. In conclusion, the data also indicate that in addition to HHV-8, the transitional 
reactivation of EBV may also play a role in the pathogenesis of MM (Csire et al. 2007b). 
Prospective studies are needed to clarify the spectrum of viral infections and risk factors for 
disease better, and to define effective prevention and treatment strategies. Fortunately, 
clinicians and virologists are increasingly aware of the most appropriate therapeutic options 
based on improved monitoring and characteriziation of the antiviral therapy. 
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1. Introduction  
Herpes zoster (HZ, shingles) is a disease characterized by monolateral vesicular rash and 
pain, due to reactivation of VZV in the context of a waning specific anti-VZV cell-mediated 
immunity. Reactivation of VZV produces a new wave of viral replication within the dorsal 
root ganglia where latency was established after primary infection and its spread 
downwards to peripheral metameric fibers through the skin, all sensorial manifestations 
being the expression of VZV-related inflammatory response in sensory ganglia and nerve 
fibers. Systemic symptoms (fever, headache, malaise) are rare, being observed in some 20% 
of patients. Other manifestations as facial palsy can be observed in peculiar localizations as 
zoster oticus, or in particular categories of patients, such as vesicular dissemination in 
severely immunodepressed patients (Dworkin et al., 2007). 
2. Epidemiology 
HZ is a common disease, and HZ incidence was estimated in up to 1 million new cases 
every year in the United States (Schmader et al., 2008). The average lifetime risk was 
estimated as high as 30% in the general population; as a consequence, it affects almost half 
of the population aged over 65 during lifetime (Insinga et al., 2005; Yawn et al.,  2007; 
Dworkin et al., 2007). Incidence all around the world was estimated in several studies, being 
calculated as 1.2-5.2 cases/person-years (Hope-Simpson, 1965; di Luzio Paparatti et al., 1999; 
Chidiac et al., 2001; Insinga et al., 2005; Yawn et al., 2007; Gauthier et al., 2009). Most of these 
studies were retrospective, based on health research or insurance databases. This may have 
possibly introduced selection biases, as some HZ cases, such as mild cases not ever seeking 
medical care, may have not been recorded or may have been incorrectly coded under the 
CDC ICD-9 or similar coding systems (Joesoef et al., 2011). Detailed information about pain, 
clinical aspects and therapy are not usually present in such databases, even though these 
studies usually include larger number of patients in comparison with prospective 
collections. In at least two cases, however, prospective evaluation of the incidence of HZ has 
been attempted in recent years (Oxman et al., 2005; Parruti et al., 2010). The Shingles 
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1. Introduction  
Herpes zoster (HZ, shingles) is a disease characterized by monolateral vesicular rash and 
pain, due to reactivation of VZV in the context of a waning specific anti-VZV cell-mediated 
immunity. Reactivation of VZV produces a new wave of viral replication within the dorsal 
root ganglia where latency was established after primary infection and its spread 
downwards to peripheral metameric fibers through the skin, all sensorial manifestations 
being the expression of VZV-related inflammatory response in sensory ganglia and nerve 
fibers. Systemic symptoms (fever, headache, malaise) are rare, being observed in some 20% 
of patients. Other manifestations as facial palsy can be observed in peculiar localizations as 
zoster oticus, or in particular categories of patients, such as vesicular dissemination in 
severely immunodepressed patients (Dworkin et al., 2007). 
2. Epidemiology 
HZ is a common disease, and HZ incidence was estimated in up to 1 million new cases 
every year in the United States (Schmader et al., 2008). The average lifetime risk was 
estimated as high as 30% in the general population; as a consequence, it affects almost half 
of the population aged over 65 during lifetime (Insinga et al., 2005; Yawn et al.,  2007; 
Dworkin et al., 2007). Incidence all around the world was estimated in several studies, being 
calculated as 1.2-5.2 cases/person-years (Hope-Simpson, 1965; di Luzio Paparatti et al., 1999; 
Chidiac et al., 2001; Insinga et al., 2005; Yawn et al., 2007; Gauthier et al., 2009). Most of these 
studies were retrospective, based on health research or insurance databases. This may have 
possibly introduced selection biases, as some HZ cases, such as mild cases not ever seeking 
medical care, may have not been recorded or may have been incorrectly coded under the 
CDC ICD-9 or similar coding systems (Joesoef et al., 2011). Detailed information about pain, 
clinical aspects and therapy are not usually present in such databases, even though these 
studies usually include larger number of patients in comparison with prospective 
collections. In at least two cases, however, prospective evaluation of the incidence of HZ has 
been attempted in recent years (Oxman et al., 2005; Parruti et al., 2010). The Shingles 
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Prevention Study (Oxman et al., 2005) was a randomized double-blind placebo-controlled 
trial set up to demonstrate that vaccination against VZV can decrease the incidence and 
severity of HZ and post herpetic neuralgia (PHN), its more frequent complication. In this 
study 38,546 healthy subjects aged >60 years were randomly assigned to receive either a 
mock vaccine or an investigational live-attenuated VZV vaccine. In the large placebo arm 
(19,276 subjects) the incidence of HZ was 11.12 cases/1000 person-years (Oxman et al., 
2005). An Italian cohort (Parruti et al., 2010) prospectively enrolled HZ patients of any age 
(mean age was 58 years, with 46% of patients aged <60 years) presenting to general 
practitioners, pediatricians or hospital specialists (dermatology, infectious diseases, pain 
management center) in a Local Health District. Incidence of HZ was prospectively 
calculated in a subset of that study, that is considering only cases consecutively enrolled by 
general practitioners, whose reference population is known. HZ incidence was 3.99 
cases/person-years, over a total reference population of nearly 35,000 persons (Tontodonati, 
unpublished personal data). These data are largely congruent with those reported using 
different experimental models (di Luzio Paparatti et al., 1999; Chidiac et al., 2001; Insinga  et 
al., 2005; Yawn et al., 2007; Gauthier et al., 2009). It is widely accepted that HZ incidence 
increases with age: even though HZ is not rare among young people, median age at 
presentation is around 64 years (Dworkin et al.,  2007). Some decades ago, Hope-Simpson 
(Hope-Simpson, 1965) conducted a longitudinal study among his own outpatients, being a 
general practitioner, and estimated an increasing incidence of HZ from pediatric to older 
age: he estimated an incidence of 0.74 cases/person-years in children aged ≤10 years, 2.5 in 
patients aged 20-45 years, up to 7.8 cases/person-years in patients aged ≥65. HZ estimates in 
different countries (Iceland, France, Netherlands, United Kingdom, USA) and with different 
methodologies confirmed that HZ incidence rises with age (Hegalsson et al., 2000; Chidiac et 
al., 2001; Opstelten et al., 2002; Insinga et al.,  2005; Yawn et al.,  2007; Gauthier et al., 2009; 
Oxman et al., 2005). HZ incidence is known to increase in immunodepression, being more 
frequent and aggressive in transplant recipients, cancer patients, HIV-infected people, and 
in patients with autoimmune diseases (rheumatoid arthritis and lupus erythematosus 
sistemicus among others), diabetes, hypertension, renal failure and chronic obstructive 
pulmonary disease (Hata et al., 2011; Yi et al., 2010; Yang et al., 2011; Schmader et al., 2008). 
Notwithstanding this evidence, HZ can be considered a disease involving 
immunocompetent subjects in the vast majority of cases (Hegalsson et al., 2000; Oxman et 
al.,  2005; Yawn et al., 2007; Parruti et al., 2010; Drolet et al., 2010). Contacts with patients 
with Varicella, more frequent for some professionals as pediatricians and teachers, turned 
out to be protective (Thomas et al., 2004), in line with the biological assumption that 
exposure to VZV may boost and strengthen natural cell-mediated immunity (Vossen et al., 
2004). Recent studies investigated the role of Varicella vaccination programs in the 
epidemiology of HZ. Pediatric Varicella vaccination with a live attenuated vaccine was first 
introduced in the United States in 1995 and in many other countries in the following years. 
Universal Varicella vaccination programs will decrease the number of wild type Varicella 
cases (Jumaan et al., 2005; Schmader et al., 2008,; Reynolds et al.,  2008). As contacts with 
patients with Varicella may be protective for HZ (Thomas & Hall, 2004), the decrease of 
Varicella in the general population will likely produce an increase in the incidence of HZ in 
the absence of parallel plans of population-wide HZ vaccination (Reynolds et al., 2008; van 
Hoek et al., 2011; n Schmader et al., 2008). Some other factors have been associated with an 
increased incidence of HZ. Trauma and surgical interventions have been suggested in 
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several case reports, case series and a single case-control study (Foye et al., 2000; Levy & 
Smyth, 2002; Evans & Lee, 2004; Thomas et al.,  2004; Godfrey et al., 2006). Psychological 
stress was also associated with an increasing incidence of HZ (Thomas & Hall, 2004). Finally 
it is unclear whether a real difference exist in the incidence of HZ between sexes, female sex 
purportedly representing a predisposing factor in some studies (Thomas & Hall, 2004). 
Post Herpetic Neuralgia (PHN) is the most common complication of HZ, ensuing in 10 to 
20% of patients on average. Its prevalence has been estimated to range from 500,000 up to 1 
million cases in United States (Schmader et al., 2008). Its incidence has been calculated in 
several studies in parallel with the incidence of HZ (Hope-Simpson, 1975; Hegalsson et al., 
2000; Opstelten et al., 2002; Scott et al., 2003; Parruti et al, 2010). The first study deserving 
quotation is again by Hope-Simpson in 1975 (Hope-Simpson, 1975). Among his outpatients, 
he observed HZ and kept note of PHN during a period of over 25 years: he calculated the 
incidence of PHN as 14.3% and he observed an increase in PHN in older patients, with 
incidence raising up to 34.4% in patients aged >80. This observation was later confirmed in 
several studies. A large prospective population-based study was conducted in Iceland some 
years ago on local residents (Hegalsson et al., 2000). Lost to follow up were really few, and 
the study period was extraordinary long. They found a relatively low incidence of PHN in 
421 HZ patients (6.95% in subjects aged >60), followed up to 7.6 years and gave formal 
evidence that PHN may last for as long as 5 to 7 years in a small proportion of patients 
(Hegalsson et al., 2000). A Dutch study estimated an incidence of 6.5% or 2.6% according to 
different definitions of PHN used (pain persisting at 1 and 3 months after HZ rash onset, 
respectively) (Opstelten et al., 2002). A significantly higher proportion of incident cases was 
reported in an English study, whereby PHN incidence was calculated in a prospective 
sample of patients referring to general practitioners in East London (Scott et al.,  2003). The 
authors observed a 38% incidence at 6 weeks and 27% at 3 months after rash onset. Such 
differences may partly be due to different definitions of PHN (as discussed below), to a 
proactive search for pain persistence in some prospective studies, and to the lack of data on 
pain severity in most studies. All these methodological issues may have well hampered 
reporting of cases with less intense pain persistence, making comparisons difficult, as well 
as a meta-analytic evaluation of the incidence of PHN hardly obtainable. Finally, a wide 
array of factors influencing the incidence of PHN has been described in recent years (see 
below). A significant variation in the distribution of such factors in different populations 
may well contribute to the variability in the incidence of PHN in different studies. 
3. Prodromal and acute pain in herpes zoster 
Moving from the epidemiological to the clinical perspective, pain in HZ is the main element 
as it severely impacts patients’ life in the acute phase, as well as within prodromic phases 
and possibly during persistence after rash healing. As the predominant HZ clinical feature, 
pain has been described as prodromal, acute and post herpetic; more recently, some authors 
proposed a new classification (Jung et al., 2004) as acute, subacute and post herpetic 
neuralgia (120 days after rash healing). More comprehensively, however, pain can be 
considered as a continuum from its prodromal phase to its latest presence in post herpetic 
neuralgia. The definition of post herpetic neuralgia has been questioned until recently, the 
most important matter of discussion being the time threshold to define its onset. Pain often 
begins in the same area as cutaneous lesions, even before rash appearance, being the only 
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Prevention Study (Oxman et al., 2005) was a randomized double-blind placebo-controlled 
trial set up to demonstrate that vaccination against VZV can decrease the incidence and 
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mock vaccine or an investigational live-attenuated VZV vaccine. In the large placebo arm 
(19,276 subjects) the incidence of HZ was 11.12 cases/1000 person-years (Oxman et al., 
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practitioners, pediatricians or hospital specialists (dermatology, infectious diseases, pain 
management center) in a Local Health District. Incidence of HZ was prospectively 
calculated in a subset of that study, that is considering only cases consecutively enrolled by 
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unpublished personal data). These data are largely congruent with those reported using 
different experimental models (di Luzio Paparatti et al., 1999; Chidiac et al., 2001; Insinga  et 
al., 2005; Yawn et al., 2007; Gauthier et al., 2009). It is widely accepted that HZ incidence 
increases with age: even though HZ is not rare among young people, median age at 
presentation is around 64 years (Dworkin et al.,  2007). Some decades ago, Hope-Simpson 
(Hope-Simpson, 1965) conducted a longitudinal study among his own outpatients, being a 
general practitioner, and estimated an increasing incidence of HZ from pediatric to older 
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pulmonary disease (Hata et al., 2011; Yi et al., 2010; Yang et al., 2011; Schmader et al., 2008). 
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immunocompetent subjects in the vast majority of cases (Hegalsson et al., 2000; Oxman et 
al.,  2005; Yawn et al., 2007; Parruti et al., 2010; Drolet et al., 2010). Contacts with patients 
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out to be protective (Thomas et al., 2004), in line with the biological assumption that 
exposure to VZV may boost and strengthen natural cell-mediated immunity (Vossen et al., 
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several case reports, case series and a single case-control study (Foye et al., 2000; Levy & 
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he observed HZ and kept note of PHN during a period of over 25 years: he calculated the 
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authors observed a 38% incidence at 6 weeks and 27% at 3 months after rash onset. Such 
differences may partly be due to different definitions of PHN (as discussed below), to a 
proactive search for pain persistence in some prospective studies, and to the lack of data on 
pain severity in most studies. All these methodological issues may have well hampered 
reporting of cases with less intense pain persistence, making comparisons difficult, as well 
as a meta-analytic evaluation of the incidence of PHN hardly obtainable. Finally, a wide 
array of factors influencing the incidence of PHN has been described in recent years (see 
below). A significant variation in the distribution of such factors in different populations 
may well contribute to the variability in the incidence of PHN in different studies. 
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Moving from the epidemiological to the clinical perspective, pain in HZ is the main element 
as it severely impacts patients’ life in the acute phase, as well as within prodromic phases 
and possibly during persistence after rash healing. As the predominant HZ clinical feature, 
pain has been described as prodromal, acute and post herpetic; more recently, some authors 
proposed a new classification (Jung et al., 2004) as acute, subacute and post herpetic 
neuralgia (120 days after rash healing). More comprehensively, however, pain can be 
considered as a continuum from its prodromal phase to its latest presence in post herpetic 
neuralgia. The definition of post herpetic neuralgia has been questioned until recently, the 
most important matter of discussion being the time threshold to define its onset. Pain often 
begins in the same area as cutaneous lesions, even before rash appearance, being the only 
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clue possibly leading to the early diagnosis of HZ until rash appears: in this phase it is 
referred to as prodromal pain. Its characteristics are similar to that of acute pain during 
rash: it is described as sharping, burning, lancinating, shooting or throbbing, with a variable 
duration from 1-2 days up to one week (Volpi et al.,  2007; Benbernou et al., 2011). It has 
been extensively investigated because of its important role in the diagnosis and of its 
predictive value for HZ severity and complications (see discussion below). A recent study 
(Benbernou et al., 2011) investigated prodromal pain and its burden of illness in a 
prospective sample of HZ patients referring to general practitioners and specialists: 
prodromal pain was common, occurring in almost 75% of patients aged ≥50 years, its mean 
duration before rash onset being 5 days and nearly half of patients rating their pain as 
severe. The authors clearly showed that the intensity of prodromal pain was related to the 
number of cutaneous lesions, as well as to the intensity of acute HZ pain. Prodromal pain is 
probably the clinical expression of the beginning of VZV reactivation and subsequent 
inflammatory responses in latently infected ganglia (Garry et al., 2005): its duration is likely 
to reflect the time necessary to VZV to replicate, run downwards along sensory nerve fibers, 
replicate in the skin and produce inflammatory damage and necrosis that is expressed in the 
appearance of the rash. Prodromal pain has also been associated with the risk of PHN: the 
higher its intensity and the longer its duration, the higher gets the probability that PHN may 
ensue after rash healing (Decroix et al., 2000; Jung et al., 2004; Katz et al., 2005; Volpi et al., 
2008). This association may suggest that in patients destined to establish PHN replication of 
VZV in the ganglia and nerve fibers may be more long-lasting (Kleischmidt-Demasters & 
Gilden,  2001; Gilden et al., 2000). Pain accompanies the typical rash from onset to 
resolution. Typically, HZ appears as a monolateral dermatomeric papulo-vesicular rash, 
spreading proximal to distal in the involved regions (see Figure 1). First erythematous at its 
onset, rash rapidly evolves into papules and then vesicles, usually within 12-24 hours; 
vesicles tend to be confluent, clusters appearing more often where nerve fibers reach on skin 
surface (e.g. parasternal, median axillary, paravertebral; see Figure 1.A). They finally develop 
into ulcers and crusts. New waves of vesicles can ensue up to 3-7 days after rash onset in 
immunocompetent patients, so that lesions in different evolutive stages can be observed at 
the same time. Crusts detach in the following 3-4 weeks, leaving long-lasting scars and 
dischromic alterations in few cases. Pain has been reported as more intense when HZ is 
localized in the cranial dermatomes, that are involved in approximately 10 to 15 % of cases, 
whereas thoracic dermatomes are involved in over one half of cases (Dworkin et al.,  2007). 
Pain can worsen into the rash phase, or it can appear for the first time in patients not 
experiencing prodromal pain. It has the same features as prodromal pain and may be 
accompanied by pruritus. The acute phase is dominated by a typical neuropathic pain, 
sharply confined along the involved dermatome(s) in the immunocompetent patient. Pain is 
often associated with neighboring allodynia and hyperalgesia, with an area of hypoalgesia 
surrounding all the involved areas. Patients often report that even a slight contact with 
clothes or with sheets can produce profound discomfort. Indeed in HZ this is the major 
cause of sleep disturbances and loss of working days. In a small proportion of patients, 
VZV-related pain can appear in the complete absence of cutaneous lesions, being then 
referred to as “zoster sine herpete”: this entity has been supported by serological and 
molecular evidence of VZV reactivation in some acute pain syndromes, clinically very 
similar to HZ (Nagel et al., 2007; Dworkin et al., 2007).  
 




Fig. 1. Different clinical manifestations and localization of HZ rash. A. Minimally expressive 
rash, expressing in only few papules in the median axillary region. B. Typical dermatomeric 
rash, with a high number of lesions in the vesicular phase. Note that HZ rash never crosses 
the median line. C. Multidermatomeric rash, highly skin-destructing with a large number of 
lesions expressing in purulent vesicles; typical in immunodepressed patients. D. HZ oticus, 
vesicle within the ear. E. HZ ophtalmicus, involving the first branch of trigeminal nerve and 
the eye. F. Devastating maxillary HZ, involving with vesicles, crusts and ulcers the skin 
surface, the internal mucosa of the mouth and the tongue surface until the median line. 
Personal clinical experience. 
4. Post herpetic neuralgia 
HZ is usually a self limiting disease, with pain quenching at the end of vesicular eruptions. 
In a significant proportion of patients, however, it can persist or relapse months to years 
after rash healing, being then referred to as PHN. Pain in PHN is described as burning, 
throbbing or lancinating, similarly to that in acute HZ, or electric-shock-like, intermittent or 
continuous, sometimes associated with allodynia or hyperesthesia; it spreads along the 
interested dermatome(s) in the same way as during HZ. PHN has been variously defined as 
pain persisting or resuming 4, 6, 8, 12 weeks, and up to 6 months after rash healing. At the 
end of the 90’s, Dworkin and Portenoy proposed a definition that was widely accepted: they 
set the time point for the diagnosis of PHN at 3 months after rash healing (Dworkin & 
Portenoy, 1996), referring to pain persisting at earlier time points as Zoster-Associated Pain 
(ZAP). More recently this definition has been revised, with a further distinction (Arani et al., 
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Gilden,  2001; Gilden et al., 2000). Pain accompanies the typical rash from onset to 
resolution. Typically, HZ appears as a monolateral dermatomeric papulo-vesicular rash, 
spreading proximal to distal in the involved regions (see Figure 1). First erythematous at its 
onset, rash rapidly evolves into papules and then vesicles, usually within 12-24 hours; 
vesicles tend to be confluent, clusters appearing more often where nerve fibers reach on skin 
surface (e.g. parasternal, median axillary, paravertebral; see Figure 1.A). They finally develop 
into ulcers and crusts. New waves of vesicles can ensue up to 3-7 days after rash onset in 
immunocompetent patients, so that lesions in different evolutive stages can be observed at 
the same time. Crusts detach in the following 3-4 weeks, leaving long-lasting scars and 
dischromic alterations in few cases. Pain has been reported as more intense when HZ is 
localized in the cranial dermatomes, that are involved in approximately 10 to 15 % of cases, 
whereas thoracic dermatomes are involved in over one half of cases (Dworkin et al.,  2007). 
Pain can worsen into the rash phase, or it can appear for the first time in patients not 
experiencing prodromal pain. It has the same features as prodromal pain and may be 
accompanied by pruritus. The acute phase is dominated by a typical neuropathic pain, 
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lesions expressing in purulent vesicles; typical in immunodepressed patients. D. HZ oticus, 
vesicle within the ear. E. HZ ophtalmicus, involving the first branch of trigeminal nerve and 
the eye. F. Devastating maxillary HZ, involving with vesicles, crusts and ulcers the skin 
surface, the internal mucosa of the mouth and the tongue surface until the median line. 
Personal clinical experience. 
4. Post herpetic neuralgia 
HZ is usually a self limiting disease, with pain quenching at the end of vesicular eruptions. 
In a significant proportion of patients, however, it can persist or relapse months to years 
after rash healing, being then referred to as PHN. Pain in PHN is described as burning, 
throbbing or lancinating, similarly to that in acute HZ, or electric-shock-like, intermittent or 
continuous, sometimes associated with allodynia or hyperesthesia; it spreads along the 
interested dermatome(s) in the same way as during HZ. PHN has been variously defined as 
pain persisting or resuming 4, 6, 8, 12 weeks, and up to 6 months after rash healing. At the 
end of the 90’s, Dworkin and Portenoy proposed a definition that was widely accepted: they 
set the time point for the diagnosis of PHN at 3 months after rash healing (Dworkin & 
Portenoy, 1996), referring to pain persisting at earlier time points as Zoster-Associated Pain 
(ZAP). More recently this definition has been revised, with a further distinction (Arani et al., 
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2001; Jung et al., 2004, Niv & Maltsman-Tseikhin, 2005): pain present within 30 days from 
the onset of rash is defined as acute herpetic neuralgia; pain present between 30 and 120 
days is defined as subacute herpetic neuralgia; pain persisting after 120 days from the onset 
of HZ is defined as PHN. Moreover other authors introduced the concept that only clinically 
relevant pain should be defined as PHN, to avoid overestimation of the problem: they 
proposed PHN to be defined as pain ≥3 on a 10-point VAS scale persisting 120 days after 
rash healing (Coplan et al., 2004; Oxman et a.,  2005; Thyregod et al., 2007). All these 
definitions, however, introduce purely arbitrary partitions of an entity that is a continuum, 
from prodromal to post herpetic pain. According to this more comprehensive view, in 
recent years PHN has been considered and valued differently. Some authors proposed to 
measure its total burden with a single comprehensive parameter. Coplan et al. used an area-
under-the-curve (AUC) method to combine measures of HZ pain intensity and duration 
(Coplan et al., 2004). The AUC was calculated by multiplying the average of two consecutive 
worst pain scores by the number of days between the scores. AUC highly correlated with 
other pain, quality-of-life and activities-of-daily-living validated questionnaires, showing its 
efficacy to take into account the total burden of HZ pain. This approach was developed and 
validated to assess and quantify HZ burden of illness (HZBOI) in the Shingles Prevention 
Study (Oxman et al., 2005). The prospective Italian study already quoted had a very similar 
approach, using verbal rating pain scores instead of worst pain scores in the calculation of 
AUC (Parruti et al., 2010). A recent study (Drolet et al., 2010) used a slightly different 
measure (HZ severity of illness, HZSOI) in which scores below 3 on a 0-to-10 scale were 
considered as zero, as they have been demonstrated not to affect relevantly quality of life 
and activities of daily living (Thyregod et al., 2007). The predictive role of HZSOI for greater 
acute and post herpetic pain burden was assessed in 261 HZ patients enrolled within 14 
days of rash onset, strictly followed with different pain questionnaires up to 6 months 
(Drolet et al., 2010). Greater acute burden was significantly associated with higher pain 
intensity at presentation, higher number of cutaneous lesions, lower income and conditions 
o f  immunodepress ion .  Higher  acute  pain  sever i ty ,  lower  income,  be ing 
immunocompromised, older age and not receiving antivirals were also predictors of greater 
post herpetic burden. All these attempts introduced a potentially relevant tool to better 
estimate  the impact of HZ and PHN in real life and to thoroughly assess the cost-efficacy of 
preventive extensive vaccination for HZ. In this approach to ZAP and PHN, structured tools 
for pain assessment have been valued. Verbal rating scales, asking to the patient to define 
his pain as no pain, mild, moderate, intense or very intense, are easy to handle in real 
clinical life, but don’t allow to stratify and better characterize pain. Visual Analogue Scales 
(VAS) have been extensively investigated and used in various settings of pain clinical 
management (Hao et al., 1994; Thyregod et al., 2007), allowing a more precise identification 
of the single patient’s pain level, and being easily understood by patients. Other structured 
tools have been defined in recent years: McGill Pain Questionnaire and its Short Form 
(Melzack 2005) are widely used for pain evaluation in a consistent part of more recent 
studies (Melzack & Togerson, 1971; Thyregod et al., 2007; Ursini et al., 2010) as they allow to 
evaluate different pain dimensions (sensory, affective and mixed features).  Zoster Brief Pain 
Inventory (ZBPI) is the more specific tool designed on-purpose for HZ pain (Coplan et al., 
2004): it includes discomfort other than pain, such as itch, occurring in the same area as HZ 
rash. It measures the severity of pain (current, least and worst) in the last 24 hours on an 0-
to-10 scale, together with HZ pain interference with various activities of daily life. This tool 
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 was shown to have a good validity in the context of ZAP and PHN (Coplan et al.,  2004; 
Oxman et al., 2005). Both HZ and PHN have a considerable impact on patients’ quality of 
life and daily life activities. A few studies investigated this impact, especially in recent years, 
in order to assess the total burden of these conditions and possibly to establish the cost-
effectiveness of HZ vaccination. Poorer physical, role and social functioning and greater 
emotional distress was reported in a sample of 110 patients with intense acute pain in HZ 
(Katz et al., 2004), using a composite measure of overall pain burden in the first 30 days after 
rash onset. In this sample, patients experienced average pain of moderate intensity most of 
the time. In a multicenter prospective study enrolling 261 HZ patients followed up to 6 
months, HZ had a major impact on the quality of life, especially on sleep (64%), enjoyment 
of life (58%) and general activities (53%). In the same study, PHN mostly affected enjoyment 
of life, mood and sleep (Drolet et al., 2010). An interesting study with a different 
methodology was conducted in Germany, enrolling patients by means of telephone 
interviews (Weinke et al., 2010). More than 11,000 subjects were contacted and 280 were 
enrolled, having experienced HZ in the previous 5 years. They were asked about ZAP and 
its characteristics and impact on quality of life. Both HZ and PHN had substantial impact on 
daily activities, mobility, work, sleep, social relationships and overall quality of life. Authors 
agreed that more attention should be paid to this aspect of HZ and PHN in designing 
research studies and health and prevention policies, as it is certainly the most important 
element from the patient’s perspective. 
The understanding of the pathophysiological mechanisms underlying the onset of chronic 
pain typical of PHN is still an open challenge. The initial viral replication causes direct damage 
by neuritic inflammation on the rear dorsal root, resulting in the involvement of the 
corresponding nerve and of spinal cord metamers. Necrosis of neural and scaffolding cells in 
the posterior root ganglia occurring during the acute phase of HZ is followed by fibrosis and 
destruction of nerve tissue at all levels of pain transmission, from peripheral afferent fibers to 
the spinal cord (Johnson, 2003; Bartley, 2009). Several studies have documented atrophy of the 
posterior horn in the spinal cord, fibrosis of the posterior root ganglia and loss of cutaneous 
innervation, with pathological degeneration of cell bodies and axons of primary afferent 
neurons (Dworkin et al., 2007). Therefore, patients with PHN often experience hypoesthesia 
(mainly as a result of peripheral denervation) and pallestesia (mainly for non-uniform loss of 
the various nerve fibers resulting in impaired sensory discrimination) in association with pain. 
Anyway, the precise mechanisms at the basis of typical pain in PHN remains still unclear and 
attempts to explain this by a single unifying theory elusive. The pathophysiology of PHN may 
involve both peripheral and central mechanisms. According to the gate control theory, a 
sensory input reduction from peripheral nerves starting from Aβ fibers causes an increase of 
Aδ and C fibers firing onto the posterior horn of the spinal cord: this last event, in turn, "opens 
the gate" to pain "from deafferentation". PHN, then, could be viewed as a chronic pain 
syndrome due to deafferentation (Oaklander et al., 2001). Other authors have tried to clarify 
the central mechanisms underlying the genesis and persistence of pain in PHN. Sensitized C 
fibers would not be responsible for hyperalgesia in PHN, but the mechanism involved would 
stand in the strengthening of existing synaptic connections between the central pain pathways 
and peripheral Aβ fibers (Baron & Saguez, 1993). The traditional theories of pain in PHN, as 
exposed above, have mainly focused on anatomical and functional changes of nerve cells and 
pain pathways. However, several studies revealed interesting aspects about CNS support cells 
and structures. It is known that glia (astrocytes and oligodendrocytes) and their receptors 
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 was shown to have a good validity in the context of ZAP and PHN (Coplan et al.,  2004; 
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research studies and health and prevention policies, as it is certainly the most important 
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The understanding of the pathophysiological mechanisms underlying the onset of chronic 
pain typical of PHN is still an open challenge. The initial viral replication causes direct damage 
by neuritic inflammation on the rear dorsal root, resulting in the involvement of the 
corresponding nerve and of spinal cord metamers. Necrosis of neural and scaffolding cells in 
the posterior root ganglia occurring during the acute phase of HZ is followed by fibrosis and 
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syndrome due to deafferentation (Oaklander et al., 2001). Other authors have tried to clarify 
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fibers would not be responsible for hyperalgesia in PHN, but the mechanism involved would 
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and peripheral Aβ fibers (Baron & Saguez, 1993). The traditional theories of pain in PHN, as 
exposed above, have mainly focused on anatomical and functional changes of nerve cells and 
pain pathways. However, several studies revealed interesting aspects about CNS support cells 
and structures. It is known that glia (astrocytes and oligodendrocytes) and their receptors 
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produce factors influencing neuronal functioning. A study in 2001 showed that persistent 
inflammation in glial cells is involved in the induction and maintenance of various 
conditions characterized by chronic pain (Watkins et al., 2001). At the level of the peripheral 
nervous system, Schwann cells and satellite cells in dorsal root ganglia of the posterior roots 
constitute together the peripheral glia, with many similarities with oligodendrocytes and 
astrocytes (Sorkin et al ., 2007). Damage of myelinated  fibers would activate Schwann cells 
and satellite cells, releasing in turn neuro-excitatory mediators such as TNF-α (Hanani et al., 
2005). According to this hypothesis, these substances would act as the mediators of neuronal 
damage (Oaklander et al., 1998). Other support structures putatively involved in the 
pathogenesis of chronic pain are vasa nervorum and nervi nervorum,  which are responsible 
for vascular and nervous support, respectively, of the nervous system itself. All the layers of 
a nerve are "innervated" and have a subtle but important complex of nociceptors: nervi 
nervorum are potentially able to induce a neurogenic inflammatory reaction (Sauer et al., 
1999; Bove et al. 2008), through the release of substance P, calcitonin gene-related peptide 
and nitric oxide,  increasing permeability of vasa nervorum of the neighboring blood vessels 
(Zochodne et al., 1997; Bove et al., 2008). The hypothesis that the activation of trophic (vasa 
nervorum and nervi nervorum) and support structures (Schwann and satellite cells) of the 
peripheral nerve would play an important pathogenic role in PHN may have important 
therapeutic implications (Bartley, 2009). In recent years, another interesting hypothesis has 
been worked out. In 2003, Gilden et al. reported the case of a patient with PHN  followed for 
11 year (Gilden et al., 2003). In the initial phase, the detection of VZV DNA in blood 
mononuclear cells in 2 consecutive occasions suggested the use of antivirals in an attempt to 
quenching pain. In random blood assays following treatment with famciclovir, VZV DNA 
was not detected. The patient, however, discontinued treatment for 5 five times: on all these 
occasions, the VZV genome was again detectable in blood mononuclear cells and pain 
resumed. Considering the recurrence of VZV DNA after discontinuation of treatment in 
parallel with the presence of segments of the VZV genome in blood mononuclear cells, the 
increase of cell-mediated response to VZV and the positive clinical response to the 
resumption of antiviral therapy induced the authors to speculate that PHN could be 
supported by chronic ganglionitis induced by VZV. Although this hypothesis was based on 
the persistence of VZV DNA in blood mononuclear cells, the mechanisms involved in the 
development of this syndrome are still unknown. To this end, several studies in recent years 
attempted to evaluate the role of the immune system in the pathogenesis of PHN. A Chinese 
work published in 2009 analyzed the relationship between the trigger pro-inflammatory 
cytokine produced by T lymphocytes in the acute phase of HZ and the development of 
PHN. The 74 subjects enrolled in the study were divided into 3 groups: a first group of 
patients who developed PHN, a second group with HZ in the acute phase and a control 
group. All subjects underwent clinical evaluation of pain (by VAS) and determination of 
serum levels of T-lymphocyte-derived cytokines. This study showed that patients with PHN 
had IL-6 serum levels higher than subjects with HZ. The levels of other cytokines (TNF-α, 
IL-1β, IL-8) were, however, similar between the two groups. These findings would indicate 
that these cytokines are implicated in the pathogenesis of HZ but not in that of PHN. 
However IL-6, a pro-inflammatory cytokine considered an early tissue damage marker, 
would play an important role in the pathophysiological mechanisms underlying the 
development of chronic pain in PHN, as demonstrated by the correlation between serum 
levels of this cytokine and the VAS scores obtained in patients with PHN (Zhu et al., 2009).  
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The different hypotheses so far postulated are not mutually exclusive, so that  the factors 
involved in the pathophysiology of chronic pain in PHN may well be multifactorial. 
Therefore, further studies are needed to link all these findings together, to allow a more 
comprehensive view of this severe and disrupting condition and to develop targeted  
therapies for PHN. 
Beyond PHN, other complications of HZ have been described, although much rarer that 
PHN (Dworkin et al., 2007, Gilden et al., 2000,; Nagel & Gilden, 2007). All of these are 
related to the endothelial and vascular involvement that relapsing bursts of VZV replication 
in HZ may cause, having been exploratory described both in vivo and in vitro (Gilden et al., 
2009).  They include stroke in its extreme manifestation, that is when endothelial damage 
lead to large vessel occlusion(s) (Kang et al., 2009). Other neurological syndromes with a 
vascular genesis have been related to VZV, including large vessel granulomatous arteritis, 
causing multifocal encephalitis in the immunocompetent host, and small-vessel encephalitis, 
relatively more frequent in the immunocompromised hosts (Gilden et al., 2000, Nagel & 
Gilden, 2007). Transverse myelitis is another fortunately rare but invalidating expression of 
small vessel involvement in the spinal cord (Gilden et al., 2000).  Finally, retinal necrosis 
may occur in a small proportion of patients (Nagel & Gilden, 2007). 
In summary, the updated epidemiology and clinical appraisal of HZ manifestations 
generate a renewed picture of a frequent disease that has per se a very relevant impact on 
the quality of life and social functioning of the affected patients. Adding to that the 
invalidating impact of PHN, still poorly treatable and ultimately incurable, as well as the 
major impact of the rarer but even more serious vascular and neurological complications of 
HZ, the questions as to whether HZ and its complications can be predicted and prevented 
become of the highest clinical interest. 
5. Can ZAP and PHN be predicted? 
Predictors of PHN in the acute phase of HZ have been extensively investigated in order to 
point out patients who are at higher risk of developing this painful syndrome and need to 
be monitored more carefully during follow-up. ZAP gained due attention only recently, 
even though pain at presentation was assessed in most of trials and cohorts on HZ and PHN 
(Dworkin et al., 1998; Chidiac et al., 2001; Dworkin et al., 2001). Acute pain at HZ 
presentation is rated as severe in a consistent proportion of patients (25%, 41%, 70%, …) and 
has been addressed for its impact on quality of life (Chidiac et al., 2001; Dworkin et al., 2001). 
Recently, an Italian study on 519 HZ patients showed that female patients who were older, 
present or past smokers, with a history of trauma or surgery at the site of HZ were more 
likely to have moderate-severe pain at HZ presentation (Parruti et al., 2010). In another 
Italian study on 533 HZ patients,  the intensity of pain at presentation was associated with 
the extent of rash, presence of prodromal pain, dysesthesia, education level and depression, 
but not with gender, anxiety or quality of life (Volpi et al., 2007). In a Dutch study on 598 
patients, female gender, younger age, severity of rash, shorter duration of rash prior to 
inclusion, longer duration of prodromal pain, and an anxious character were independently 
associated with higher intensity of acute zoster pain (Opstelten et al., 2007). Pain severity at 
presentation has not been investigated in other settings and more attention should be given 
to this element that dominates HZ clinics. More recently, acute HZ pain has been considered 
as a continuum and not only as a single point measure, and acute pain burden has been 
evaluated in a prospective study conducted across Canada (Drolet et al., 2010): greater acute 
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 burden was associated with greater pain intensity at presentation, greater number of 
lesions, lower income and being immunocompromised. Further studies on acute pain in 
different settings could be similarly useful. PHN, on the other hand, has been extensively 
investigated in different settings and a great deal of information is now available. PHN has 
been repeatedly associated with older age (Dworkin & Portenoy, 1996; Choo et al., 1997,; 
Dworkin et al., 1998; Decroix et al., 2000; Opstelten et al., 2002; Kurokawa et al., 2002; Scott 
et al., 2003; Jung et al., 2004; Opstelten et al., 2007; Volpi et al.,  2008; Parruti et al., 2010; 
Drolet et al., 2010). Some decades ago,  Hope-Simpson already envisaged this association 
observing his own HZ outpatients (Hope-Simpson, 1975), and in the following years older 
age has been one of the factors more frequently associated in almost all studies where it was 
investigated. Indeed several cohort studies (Choo et al., 1997, Dworkin et al., 1998; Decroix 
et al., 2000; Opstelten et al., 2002; Kurokawa et al., 2002; Scott et al., 2003; Jung et al., 2004; 
Opstelten  et al., 2007; Volpi et al., 2008; Parruti et al., 2010; Drolet et al., 2010) found 
significantly older age in patients developing PHN, in samples up to 1,900 patients. The SPS 
placebo arm, as well, provided evidence as to the predictive role of older age: enrolled 
subjects were stratified in two subgroups (60-69 years and ≥70 years), and PHN incidence in 
the 19,247 subjects was 0.74 cases/1,000 person-years in the first subgroup and 2.13 
cases/1,000 person-years in the older (Oxman et al., 2005). Central and peripheral nervous 
systems in the elderly may probably tolerate less efficiently the damage associated to VZV 
reactivation and the consequent burst of immune response (Baron et al., 1997).  Pain at 
presentation, together with older age, is the other best-established risk factor for PHN (see 
Figure 2 and 3): the more severe pain is at presentation, the more frequent PHN will be. It has 
to be considered that there are some difficulties in lumping up data from studies using 
different definitions and designs: trials have larger number of patients compared to cohort 
studies, but cohorts allow to search for a larger number of variables, even though not all 
planned at the beginning of the study. Some years ago, trials on antiviral therapy for HZ 
suggested the importance of pain intensity at presentation in predicting PHN (Dworkin et 
al., 1998; Whitley et al., 1999); several cohort studies confirmed these data in real life 
(Decroix et al., 2000; Scott et al., 2003; Jung et al., 2004; Katz et al., 2005; Opstelten et al., 2007; 
Volpi et al., 2008; Parruti et al., 2010) (see Figure 2 and 3). The pathogenesis of this correlation 
is still unclear: the intensity of acute pain may reflect central structural and functional 
processes, such as excitotoxic damage in the dorsal horn, and damage to primary afferent 
nociceptors (Bennett , 1994). 
Other factors have been proposed as possible predictors of PHN. Severity of rash, assessed 
as the number of lesions appearing on the patients’ skin at presentation, has been 
significantly associated with PHN in several studies (see Figure 3) (Dworkin et al., 1998; 
Whitley et al., 1999; Nagasako et al., 2002; Kurokawa et al., 2002; Jung et al., 2004; Opstelten 
et al., 2007; Volpi et al., 2008). HZ patients with greater rash severity at presentation have a 
greater risk of PHN, suggesting a relationship between the extent of neural damage and the 
development of PHN; this interesting and comprehensive hypothesis, however, has not 
been yet demonstrated (Nagasako et al., 2002). In a recent survey, rash severity was 
correlated with age and  immunodepression but not with use of steroids and diabetes 
(Tontodonati, unpublished personal data). The presence of prodromal symptoms (pain, 
dysesthesia, allodynia, …) and their duration before the appearance of rash had a negative 
predictive value for PHN of 95% (Jung et al., 2004; Volpi et al., 2007; Decroix et al., 2000; 
Katz et al., 2005): this association may reflect a more intense involvement of nerve fibers by 
 




Fig. 2. Pain intensity at presentation and risk of PHN at different time-points. Pain at 
presentation predicts PHN: the higher pain at HZ presentation is, the higher risk of 
developing PHN will be (Parruti et al., 2010, with permission). 
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Katz et al., 2005): this association may reflect a more intense involvement of nerve fibers by 
 




Fig. 2. Pain intensity at presentation and risk of PHN at different time-points. Pain at 
presentation predicts PHN: the higher pain at HZ presentation is, the higher risk of 
developing PHN will be (Parruti et al., 2010, with permission). 
  









Fig. 3. Evidence confirming predictors of PHN. Several studies with different size and 
designs have investigated predictors of PHN. Older age and greater pain at presentation are 
the best well-established risk factors, emerging in most studies with no regards to different 
designs. 
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Viral reactivation in the early phases of HZ, leading to extended damage and PHN (Watson 
et al., 1991). Uncertainties still remain about antiviral therapy for preventing the occurrence 
of PHN in ordinary clinical settings. Most data come from clinical trials where antivirals 
were administered ≤72 hours from the onset of rash: this could have been a bias as most 
patients in real practice seek for medical attention after 72 hours (Volpi et al., 2008), 
antivirals being anyhow prescribed usually in the first 7 days from rash onset. As a 
consequence, the preventive role of antiviral therapy has been questioned until recently: a 
recent meta-analysis including most of these trials concluded that the role of therapy in 
preventing PHN is still uncertain (Li et al., 2009). However, different data came from 
different study designs. Conflicting results emerged even in trials on antivirals (Gnann, 
2007): in a famciclovir trial (Dworkin et al., 1998), treatment of acute HZ significantly 
reduced both the incidence and the duration of PHN, whatever defined. A recent cohort 
prospective study (Parruti et al., 2010) collected all the incident cases of HZ in a specifically 
created network of General Practitioners and Hospital Centers in a local health service in 
Central Italy, resuming data from 519 cases on an estimated reference population of nearly 
35,000 persons. In multivariate analyses for both PHN and the total pain burden due to HZ 
and PHN, PHN appeared to be significantly more frequent in patients who did not receive 
antiviral therapy and  total ZAP was much higher in this small proportion of patients. 
Indeed, antiviral therapy is now largely prescribed for its documented positive effect in 
reducing viral shedding, new vesicular eruptions and pain intensity in the acute phase of 
HZ; these results suggest that antiviral therapy may be useful even in reducing the 
incidence of PHN and total ZAP. Further studies are needed, however, as the best way to 
assess this point would be an on purpose designed RCT. Localization of HZ has been 
associated with PHN, being more frequent in ophthalmic and thoracic zoster (Volpi et al.,  
2008). Serological and laboratory findings have been investigated, in order to identify novel 
predictors among elements easily accessible in a blood sample, as specific antibodies or VZV 
viremia. A prospective observational cohort study collecting HZ cases occurring among a 
network of General Practitioners in East London (Scott et al., 2003) suggested that higher 
levels of VZV DNA at HZ presentation may be a strong independent predictor of pain 
persistence (see Figure 3). Surgical interventions and mechanical trauma have been 
suggested as predictors of VZV reactivation, but their possible role in predicting PHN has 
been poorly investigated. In a recent prospective survey on 519 HZ patients (Parruti et al., 
2010), trauma and surgical interventions were associated with higher pain intensity at 
presentation, only trauma being associated with a higher risk of PHN. Furthermore 
cigarette smoking has been scantly evaluated as a possible risk factor for pain intensity at 
presentation or PHN. In the same survey (Parruti et al., 2010), it was associated with both 
higher pain at presentation and higher risk of PHN, probably due to the prospective and 
proactive nature of the investigation. Indeed, smoking has not been searched for PHN 
prediction in other studies, in spite of data suggesting a possible role in chronic pain 
syndromes (Weingarten et al., 2008), subclinical peripheral neuropathy (Agrawal et al., 2007) 
and smoke-induced impairment of cell-mediated immunity (Sopori & Zozak, 1998). Further 
studies are needed to confirm these interesting and novel predictors. Psychosocial factors 
have been proposed to be associated both with a higher ZAP burden and higher risk of 
PHN.  Depression, together with the severity of HZ disease at presentation, was 
 associated with higher pain intensity and ZAP burden (Volpi et al., 2007). In a small 
prospective study (Dworkin et al., 1992), greater anxiety, greater depression, lower life 
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syndromes (Weingarten et al., 2008), subclinical peripheral neuropathy (Agrawal et al., 2007) 
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studies are needed to confirm these interesting and novel predictors. Psychosocial factors 
have been proposed to be associated both with a higher ZAP burden and higher risk of 
PHN.  Depression, together with the severity of HZ disease at presentation, was 
 associated with higher pain intensity and ZAP burden (Volpi et al., 2007). In a small 
prospective study (Dworkin et al., 1992), greater anxiety, greater depression, lower life 
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satisfaction and greater disease conviction were predictors at baseline for chronic zoster 
pain. In a large prospective sample of HZ patients in the Netherlands (Opstelten et al., 2007), 
investigating different psychological predictors for PHN, only trust in healthcare was 
associated with PHN risk, that is patients who expect that others will find remedies to their 
own pain could have a higher incidence of chronic pain. Hence, psychological factors may 
be useful in evaluating patients with HZ, even though further studies are needed. Finally, 
female sex has been proposed as a predictor of PHN, not yet reaching, however, a 
convincing level of evidence so far (Jung et al., 2004;  Volpi et al., 2008; Parruti et al., 2010).  
6. What is the best therapy for acute HZ to control ZAP and PHN?  
6.1 Antiviral therapy 
HZ is a self limiting disease, as patient’s immune response usually contains viral replication. 
Treatment of the acute phase with antiviral drugs is widely recommended at present to 
contain vesicular eruption and diffusion and to reduce acute pain and malaise in the affected 
patients. The FDA approved acyclovir, valacyclovir (prodrug of acyclovir), famcyclovir 
(prodrug of penciclovir) and brivudin for HZ therapy. All these molecules are nucleoside 
analogues needing phosphorylation from viral thymidin-kinase. Their triphosphate forms 
inhibit viral DNA synthesis by competing as a substrate for viral DNA polymerase (Gnann, 
2007). There have been no serious adverse reactions to these drugs, nausea and headache 
being the most common side effects  in 10-20% of patients (Gnann, 2007). Dosage reduction is 
required in patients with renal insufficiency according to creatinine serum levels because of 
their renal excretion. Clinical trials did not find any difference in their cutaneous and analgesic 
effect. In clinical practice, however, some factors should be considered in the choice of HZ 
antiviral therapy. Acyclovir is the cheapest antiviral, with 5 doses of 800 mg per day necessary 
to achieve adequate serum levels. Therapy with acyclovir should last for 7-10 days. 
Furthermore acyclovir is the only one available in parenteral formulation. Valacyclovir has a 
higher bio-availability, allowing 3 doses of 1,000 mg per day for 7 days. Famcyclovir 
recommended schedule for HZ is 500 mg 3 times daily for 7 days. Brivudin can be prescribed 
once daily, 125 mg for 7 days. Valacyclovir, famcyclovir and brivudin have been shown to 
achieve higher blood concentration, compared with acyclovir. This may be relevant, due to 
physiological barriers hampering antiviral penetration in VZV-infected tissues (nervous tissue, 
CNS) and to relatively poor sensitivity of VZV to these drugs.  Pharmacokinetic differences 
among drugs may be relevant as to their impact on patient’s compliance to therapy, always 
related to final efficacy. Oral antiviral therapy for HZ is widely recommended for all 
immunocompetent patients aged ≥50 years, with moderate to severe pain intensity at 
presentation, as they have been shown to have higher risk of complications. However, given 
the safety profile of antivirals, and the persistent risk of complications even in patients with no 
demonstrated risk factors, antiviral therapy is recommended at present for every patient with 
HZ onset to reduce the duration of viral shedding, promote resolution of skin lesions, and 
limit the duration of pain (Gnann, 2007). Most trials in the literature considered antivirals as 
worth prescribing only  <72 hours from rash onset. This time-points, however, do not 
necessarily reflect the end of viral replication in the skin. In clinical practice nearly half of 
patients get to medical observation and start antiviral therapy within this time-point, the 
others starting in general within the first 7 days from rash onset (Volpi et al., 2007; Parruti et 
al., 2010). A recent trial on 156 HZ patients, investigating the effect of antiviral therapy started 
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before and after 72 hours from rash onset, showed no significant difference in pain reduction,  
healing of lesions and PHN incidence (Rasi et al., 2010), thus providing valuable evidence for 
prescription of antivirals even beyond the 72-hour threshold. In immunocompromised 
patients with a higher incidence of HZ per se, antiviral therapy reduces dissemination, severity 
of disease and mortality. Acyclovir is the first choice in its intravenous formulation, 10-15 
mg/kg every 8 hours, to administer up to 7 days after the ending of new vesicular eruptions or 
until healing is complete (Gnann, 2007). Valacyclovir in immunocompromised patients has 
been valued in a small trial (Arora et al., 2008). Its use needs further evidence, acyclovir 
remaining the best recommended drug in such patients.  
The end of viral replication is the main aim of antiviral therapy in acute HZ: this objective 
should be pursued in parallel with the attempt to reduce the pain perceived, which mainly 
influences patient's quality of life. The classes of drugs currently available for this purpose are 
the following: corticosteroids, tricyclic antidepressants, anticonvulsants,  opioid analgesics. 
6.2 Corticosteroids 
Although corticosteroids have limited effectiveness in reducing chronic pain, they may have 
some beneficial effect on acute pain: a number of studies in the literature have shown their 
positive action in association with antiviral therapy. The addition of prednisolone to the 
treatment with acyclovir was effective in reducing pain, in accelerating the regression of skin 
lesions and facilitating the return of the patient to normal daily activities (Whitley et al., 1996). 
Dworkin et al. (Dworkin et al., 2007) have shown that the use of corticosteroids in combination 
with antiviral therapy reduced the time to return to a restful sleep and normal activities of 
daily life and the use of analgesics. The German Society of Dermatology recommended the use 
of corticosteroids in acute herpetic pain, based on the results of two large prospective studies 
that showed the efficacy of high-dose corticosteroids is association with antiviral therapy both 
in alleviating Zoster – related pain and in accelerating rash healing (Gross et al., 2003). No 
study has, however, showed a preventive role of corticosteroids for PHN. 
6.3 Tricyclic antidepressants (TCAs) 
Tricyclic antidepressants (amitriptyline, nortriptyline) have a documented effect in the 
treatment of neuropathic pain syndromes, but their use in the acute phase of HZ has not yet 
been adequately investigated. In fact, although TCAs reduce pain by inhibiting reuptake of 
serotonin and norepinephrine (Stankus et al., 2000), they require at least 3 months  to exert 
positive effects. In a randomized trial of patients older than 60 years, it was observed that 25 
mg amiptriptyline, administered within 48 hours of rash onset and continued for 90 days, 
yielded a 50% reduction in pain at 6 months compared to placebo (Bowsher, 1997). In this 
context, it is important to emphasize that such drugs should be used with extreme caution, 
taking into account the severe anticholinergic side effects associated with their use, as they 
may precipitate an acute confusional state and may cause cardiac arrhythmias up to sudden 
cardiac death, especially in elderly patients (Wareham & Breuer, 2007).  
6.4 Opioids 
Opioid analgesics, such as oxycodone, morphine and tramadol are widely used in acute 
herpetic pain, often in combination with acetaminophen (paracetamol) or other nonsteroidal 
anti-inflammatory drugs (NSAIDs). However, among these drugs, only oxycodone and 
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tramadol have been the subject of studies specifically designed for acute herpetic pain. 
Oxycodone reduces acute pain, but there is yet no evidence of a possible role of this drug in 
the prevention of PHN. A recent randomized placebo-controlled trial compared the 
effectiveness of oxycodone and gabapentin in reducing acute pain, showing that oxycodone 
provided a greater pain relief (Dworkin et al., 2009). Tramadol, however, is effective in the 
treatment of PHN, but its efficacy in the treatment of acute herpetic pain has not been 
evaluated (Boureau et al., 2003). 
6.5 Antiepileptics 
Among the antiepileptic drugs, pregabalin and gabapentin have a demonstrated effect on 
chronic neuropathic pain, documented in several clinical studies and lack of significant side 
effects or drug interactions. Based on these data and considering the effectiveness of these drugs 
in other conditions of acute pain, gabapentinoids are also used for acute herpetic pain. Berry et 
al. showed that gabapentin reduced acute HZ pain (Berry et al., 2005). Preliminary evidences 
suggest a similar efficiency of pregabalin, in conjunction  with an even better tolerability profile 
(Jensen-Dahm et al., 2011). Further prospective and on purpose designed  evaluations, however, 
appear opportune before their use for acute herpetic pain may be widely recommended. 
6.6 Nerve blocks 
Use of nerve block injections is another option in the conventional medical armamentary for 
acute herpetic pain. Local anaesthetics may be injected around the affected nerves, 
providing immediate pain relief, typically lasting 12-24 hours (Roxas, 2005). Location of the 
nerve block is dependent on the involved dermatome. If head, neck or arms are affected, a 
stellate ganglion block is performed, with injections placed at the base of the neck, just 
above the collarbone. Dermatomal patterns involving chest, trunk or lower extremities are 
addressed via epidural blocks. Long term relief can be accomplished by repeating the 
procedure 2-3 times within a two-week period, provided it is administered at an early stages 
of the disease (Roxas, 2005). Although epidural, intrathecal, and sympathetic nerve blocks 
have all been used in the treatment of pain caused by HZ and PHN, the effectiveness of 
nerve blocks in reducing or preventing PHN is still somewhat controversial (Johnson, 1997). 
However, there are a few controlled randomized trials of nerve blocks in the prevention of 
PHN. Yanagida et al. reported no prophylactic effect of early sympathetic blockade on PHN 
(Yanagida et al., 1987). Two randomized trials have been performed for the prevention of 
PHN by single or repetitive epidural injections of anesthetics and steroids in the acute HZ 
(van Wijck et al., 2006; Pasqualucci et al., 2000). Van Wijck et al. showed no significant effect 
of epidural injections in reducing the incidence of PHN; Pasqualucci et al. reported that 
repetitive epidural administration of bupivacaine and methylprednisolone was significantly 
more effective in preventing PHN at 12 months compared with acyclovir and prednisolone. 
More recently, Genlin and colleagues examined the effectiveness of repetitive paravertebral 
injections with local anaesthetics and steroids for the prevention of PHN in patients with 
acute HZ. The findings of this randomized study show that repetitive paravertebral 
injections with bupivacaine and methylprednisolone in acute herpetic phase within 7 days 
of rash onset reduce the incidence of PHN more effectively than standard treatments (oral 
administration of acyclovir and analgesics) (Genlin et al., 2009).  This preliminary evidence, 
in conclusion, would suggest that the repetition of the blockade procedure may be crucial to 
the long-term efficacy of ZAP control. Further data, however, are auspicable. 
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6.7 Other treatment options 
In addition to the use of the above mentioned medications, alternative medical practices 
have been recently investigated for controlling acute herpetic pain (Ursini et al, 2011; 
Fleckenstein et al., 2009). Acupuncture, an ancient form of medicine that originated in China 
several thousand years ago, has been used by Canadian physicians since the 1970s. Research 
on the neurophysiology of acupuncture analgesia supports the theory that it is primarily 
mediated via the selective release of neuropeptides in the central nervous system. 
Furthermore, evidence is rapidly accumulating on the immunomodulating actions of 
acupuncture, as well as on its effects on neuroendocrine regulation, muscle and 
cardiovascular tone and the psycho-emotional sphere (Rapson et al., 2008). Acupuncture has 
long been regarded as an effective therapy for pain management in different conditions. 
Although several reports documented its use in HZ and PHN (Coghlan, 1992; He et al., 
2007), sizes in investigated samples were generally very small. A recent three-armed, 
partially blinded trial, known as ACUZoster, which is still ongoing and whose study 
protocol was recently published, represents the first randomized, controlled study 
attempting to directly compare acupuncture and standard analgesia (gabapentin) for acute 
herpetic pain (Fleckenstein et al., 2009). The first evidence of a potential role of acupuncture 
in the treatment of acute herpetic pain was provided by a randomized, controlled, open-
label trial (Ursini et al., 2011). Patients with intense or very intense pain at presentation of 
HZ were randomized to receive acupuncture or standard pharmacological treatment. 
Despite the limited dimensions of the study populations (105 patients randomized, 66 
patients treated), no significant differences in pain reduction after 4 weeks of treatment 
between the two study arms were evidenced  Furthermore, under the assumption that 
acupuncture may have an immune-modulating activity (Quirico et al., 1996; Yan et al., 
1991), evaluation of the incidence of PHN at 3, 6 and 12 months after rash onset, as well as  
of the total pain burden during follow-up, might have revealed an ability of this medical 
tool to influence the rate of pain persistence and relapses. However, the incidence of PHN at 
3, 6 and 12 months, as well as the mean pain burden during follow-up, were overlapping in 
the 2 arms. Given that patients treated with acupuncture carry a lower risk of cumulative 
drug toxicity, should these findings be confirmed by the ensuing ACUZoster trial and/or by 
other investigations, acupuncture might be appropriately considered among the available 
therapeutic options for the control of severe acute HZ related pain. 
6.8 Synthetic approach to acute herpetic pain 
Under a practical point of view, the approach to the patient can be summarized as follows 
(Dworkin et al., 2007): in patients with mild to moderate pain, pain therapy may be based on 
the use of paracetamol or other NSAIDs, possibly associated with mild opioids as codeine; 
antiviral therapy should be added whatever the time interval between pain onset and 
patient's presentation (Dworkin et al., 2007; Parruti et al., 2010). In patients with moderate to 
severe pain, pain therapy should consider fist-line opioid analgesics (oxycodone), which can 
be administered in combination with gabapentin or pregabalin, nortriptyline or 
corticosteroids, associated in various possible combinations for those patients who do not 
respond promptly to single agent therapy. Only in severe pain, uncontrolled by antiviral 
and analgesic combinations, the use  of  nerve blocks may be taken into account, and better 
practised repeatedly (Dworkin et al., 2007). The acquisition of a growing body of evidence in 
favour of the effectiveness of  acupuncture may make the management of acute herpetic 
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tramadol have been the subject of studies specifically designed for acute herpetic pain. 
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provided a greater pain relief (Dworkin et al., 2009). Tramadol, however, is effective in the 
treatment of PHN, but its efficacy in the treatment of acute herpetic pain has not been 
evaluated (Boureau et al., 2003). 
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Among the antiepileptic drugs, pregabalin and gabapentin have a demonstrated effect on 
chronic neuropathic pain, documented in several clinical studies and lack of significant side 
effects or drug interactions. Based on these data and considering the effectiveness of these drugs 
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6.7 Other treatment options 
In addition to the use of the above mentioned medications, alternative medical practices 
have been recently investigated for controlling acute herpetic pain (Ursini et al, 2011; 
Fleckenstein et al., 2009). Acupuncture, an ancient form of medicine that originated in China 
several thousand years ago, has been used by Canadian physicians since the 1970s. Research 
on the neurophysiology of acupuncture analgesia supports the theory that it is primarily 
mediated via the selective release of neuropeptides in the central nervous system. 
Furthermore, evidence is rapidly accumulating on the immunomodulating actions of 
acupuncture, as well as on its effects on neuroendocrine regulation, muscle and 
cardiovascular tone and the psycho-emotional sphere (Rapson et al., 2008). Acupuncture has 
long been regarded as an effective therapy for pain management in different conditions. 
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partially blinded trial, known as ACUZoster, which is still ongoing and whose study 
protocol was recently published, represents the first randomized, controlled study 
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herpetic pain (Fleckenstein et al., 2009). The first evidence of a potential role of acupuncture 
in the treatment of acute herpetic pain was provided by a randomized, controlled, open-
label trial (Ursini et al., 2011). Patients with intense or very intense pain at presentation of 
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1991), evaluation of the incidence of PHN at 3, 6 and 12 months after rash onset, as well as  
of the total pain burden during follow-up, might have revealed an ability of this medical 
tool to influence the rate of pain persistence and relapses. However, the incidence of PHN at 
3, 6 and 12 months, as well as the mean pain burden during follow-up, were overlapping in 
the 2 arms. Given that patients treated with acupuncture carry a lower risk of cumulative 
drug toxicity, should these findings be confirmed by the ensuing ACUZoster trial and/or by 
other investigations, acupuncture might be appropriately considered among the available 
therapeutic options for the control of severe acute HZ related pain. 
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(Dworkin et al., 2007): in patients with mild to moderate pain, pain therapy may be based on 
the use of paracetamol or other NSAIDs, possibly associated with mild opioids as codeine; 
antiviral therapy should be added whatever the time interval between pain onset and 
patient's presentation (Dworkin et al., 2007; Parruti et al., 2010). In patients with moderate to 
severe pain, pain therapy should consider fist-line opioid analgesics (oxycodone), which can 
be administered in combination with gabapentin or pregabalin, nortriptyline or 
corticosteroids, associated in various possible combinations for those patients who do not 
respond promptly to single agent therapy. Only in severe pain, uncontrolled by antiviral 
and analgesic combinations, the use  of  nerve blocks may be taken into account, and better 
practised repeatedly (Dworkin et al., 2007). The acquisition of a growing body of evidence in 
favour of the effectiveness of  acupuncture may make the management of acute herpetic 
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pain (and PHN, as described below) even more complex, allowing the patient suffering with 
VZV-related painful conditions to be eligible for acupuncture, in addition to conventional 
therapy (see Figure 4 ). 
 
 
Fig. 4. Step-by-step strategy for management of acute herpetic pain.  
Finally, it is important to underline that antiviral therapy can now be regarded as a 
cornerstone in the treatment of ZAP, according to recent acquired data on the genesis of 
pain and its persistence (Dworkin et al., 2007; Parruti et al., 2010). 
7. What is the best therapy for PHN? 
A large body of evidence indicates that some pharmacologic agents, including opioids, 
TCAs, antiepileptic drugs and lidocaine patches, may result in at least partial pain relief for 
a significant but limited proportion of patients with PHN, and that some of these patients 
may find the adverse effects of the above medications outweighing their benefits 
(Hempenstall et al., 2005; Wu & Raja, 2008). Therefore, the most formidable challenge in the 
framework of HZ is the treatment of PHN. The lack of fully effective treatments stands in 
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the nature of PHN, whose exact patho-physiological mechanisms are still elusive. 
Consequently, it is difficult to establish specifically targeted therapies, a task calling for 
further research efforts. Indeed, as this condition does not adequately respond in many 
cases to none of the conventional agents tested, many efforts are ongoing even in the field of 
alternative therapeutic options. The management of PHN, however, is and will be complex, 
requiring a multidisciplinary approach, including drug therapy and non-pharmacological 
adjunctive therapies. 
7.1 Antidepressants 
Several systematic reviews indicate that TCAs are effective in neuropathic pain and PHN 
(Attal et al., 2010; Hempenstall et al., 2005; Niv & Maltsman-Tseikhin, 2005), being superior 
to Selective Serotonin Reuptake Inhibitors (SSRI) (Attal et al., 2006; Saarto & Wiffen, 2010). 
No studies assessed the use of Serotonin-Noradrenalin Reuptake Inhibitors (SNRI) for this 
condition. It is believed that TCAs have an analgesic action by blocking the re-uptake of 
serotonin and norepinephrine, a blockade enhancing the inhibition of spinal cord neurons 
involved in pain perception (Basmaum & Fields, 1978). Among this class, the most 
commonly used compounds are amitriptyline, nortriptyline and desipramine. Amitriptyline 
led to a reduction in pain in 47-66% of patients, desipramine and nortriptyline in 55% to 63% 
(Schamder, 2001; Watson et al., 1998). Nortriptyline and desipramine are generally preferred 
to amitriptyline because of lower incidence of anticholinergic side effects such as sedation, 
orthostatic hypotension, cognitive decline, and constipation (Watson et al., 1998). 
Furthermore, despite amitriptyline is probably the most widely studied TCA for the 
treatment of PHN, nortriptyline and desipramine have recently been shown to be equally 
effective (Watson & Oaklander, 2002; Hempenstall et al., 2005; Rowbotham et al., 2005). A 
limiting factor in the clinical use of TCAs is represented by their side effects, including dry 
mouth, fatigue, dizziness, sedation, constipation, urinary retention, and palpitations. Other 
side effects include orthostatic hypotension, weight gain, blurred vision, and QT 
prolongation. Such side effects may be of particular concern in the elderly population and in 
patients with a history of cardiac arrhythmia or ischemic heart disease. Although there is no 
standard guidance for ECG screening prior to their administration, TCAs may cause ECG 
changes (prolonged QT) and it may be prudent to obtain a baseline ECG in patients with 
cardiac disease (Sansone et al., 2002; Vieweg et al., 2003; Dworkin & Schmader, 2003).  
7.2 Antiepileptics 
Among anticonvulsants, gabapentin and pregabalin have established efficacy in PHN, 
several trials showing the non inferiority of gabapentin versus nortriptyline (Gilron et al., 
2009; Hempenstall et al., 2005). Although the precise mechanism of analgesia of gabapentin 
is uncertain, it is believed that gabapentin may act at the α2δ subunits of voltage-dependent 
channels to decrease calcium influx, which in turn inhibits the release of neurotransmitters 
(such as glutamate) from the central terminals of primary afferent fibers in the spinal cord 
(Fink et al., 2002). Several randomized controlled trials (RCTs) and a few meta-analyses have 
established the analgesic efficacy of gabapentin for the treatment of pain in PHN. RCTs have 
shown that a daily dose of 1800-3600 mg given for 1-2 weeks, is effective in reducing pain 
and improving sleep, mood and patients' quality of life (Rowbotham et al., 1998; Rice et al., 
2001; Johnson, 2003). More recent studies have shown that a dose of 3600 mg daily can 
reduce pain by 43% (Niv & Maltsman-Tseikhin, 2005). The main reported side effects are 
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drowsiness, dizziness, ataxia, mild peripheral edema, and a worsening of cognitive 
impairment in elderly patients. To reduce adverse events and increase compliance, 
gabapentin should be initially used at lower doses (100-300 mg in a single dose at bedtime) 
and then continued at a dose of 100-300 mg three times a day (Mustafa et al., 2009), titring 
the analgesic effect and the occurrence of side effects (Dworkin & Schmader, 2003). 
Adjustment of its dose on the basis of renal function tests is also recommended, since the 
drug is excreted unchanged in urine (Johnson, 2003). Among gabapentinoids, both 
gabapentin and pregabalin are likely to provide analgesia by a similar mechanism of action. 
Although there are no meta-analyses examining the analgesic efficacy of pregabalin in PHN, 
there are a few RCTs in support. In 2004, the use of pregabalin for the treatment of diabetic 
neuropathy and PHN was approved in Europe and the United States. A randomized 
controlled trial in 2004 showed the effectiveness of this drug in the treatment of PHN: 
pregabalin was superior to placebo in reducing pain and improving mood, pain interference 
with sleep and patients' quality of life (Sabatowski et al., 2004). Pregabalin was well 
tolerated even by elderly patients. The commonly reported side effects were drowsiness, 
dizziness and mild peripheral edema. Studies conducted to date have shown an analgesic 
efficacy and good tolerability profile at doses of 150/600 mg, administered in 2 or 3 daily 
doses. The optimal dose to be administered, however, has not yet been thoroughly assessed. 
Other recently studied antiepileptic drugs are sodium divalproate and oxcarbazepine, 
which demonstrated a significant efficacy in reducing pain and improving patients' quality 
of life (Criscuolo et al., 2005; Kochar et al., 2005). Both of them have shown a good safety 
profile, with few side effects (dizziness and nausea, in particular). The use of other 
anticonvulsants such as phenytoin, carbamazepine, lamotrigine and sodium valproate for 
PHN is not adequately supported by the literature. 
7.3 Opioids 
Although opioid analgesics are accepted as a cornerstone for the treatment of nociceptive 
and cancer pain, their role in the management of chronic neuropathic pain such as that of 
PHN has been debated, as some clinicians consider neuropathic pain to be resistant to 
the analgesic effects of opioids. The controversy over their efficacy in relieving 
neuropathic pain reflects the use of multiple definitions and pain assessment 
methodologies for neuropathic pain in experimental trials and interindividual 
differences in opioid responsiveness (Wu & Raja, 2008). In addition, many other factors, 
such as opioid-related side effects, development of tolerance, exaggerated fear of 
addiction, and differences in governmental health policies contribute to such controversy 
(Wu & Raja, 2008). In spite of that, opioids may be considered as part of a comprehensive 
plan for the treatment of PHN (Cohen et al., 2006; Niv & Maltsman-Tseikhin, 2005; 
Johnson, 2003; Dworkin & Schmader, 2003), when pain is moderate to severe, with 
significant impact on quality of life after proven inefficacy of first-line agents. Among the 
investigated formulations, oxycodone, morphine, fentanyl, buprenorphine, methadone, 
and weaker opioids such as dihydrocodeine and tramadol were found to be effective. 
Treatment should be started with a short-acting opioid, replaced after 1-2 weeks with a 
long-acting formulation (controlled-release morphine, controlled-release oxycodone, 
methadone, transdermal fentanyl) when the first was not fully effective. Constipation, 
nausea, and sedation are common adverse effects associated with opioid use for chronic 
neuropathic pain. Tramadol has a unique pharmacological profile, which makes it one of 
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the most effective drug of its class in controlling neuropathic pain. It is a synthetic 
derivative of codeine with a dual mechanism of action: one of the opioid type (is a weak 
μ receptors agonist), and the other similar to that of TCAs (inhibition of norepinephrine 
and serotonin reuptake). An additional way of action of this compound consists in 
activating post-synaptic α2 adrenergic receptors. Such an activation results in a block of 
transmission of nociceptive stimuli to the central level. Several studies have shown the 
effectiveness of tramadol in reducing neuropathic pain, particularly PHN and diabetic 
neuropathy (Hempenstall et al., 2005; Boreau et al., 2003; Harati et al., 1998). As side 
effects, tramadol may causes nausea, vomiting, dizziness, constipation, drowsiness and 
headache; it also increases the risk of serotonin syndrome in patients using 
antidepressants such as SSRIs, TCAs or inhibitors of mono-amino oxidase in combination 
(Christo et al., 2007) (see Table 1). 
 
DRUG INITIAL DOSAGE TITRATION ADVERSE EFFECTS 
TCAs 10 mg every evening 
Increase by 10 mg 
every 7 days to 50 mg, 
then to 100 mg and 
then to 150 mg nightly 
Sedation, xerostomia, 
confusion, weight gain, 
dizziness 
GABAPENTIN 100 mg three times daily 
100-300 mg increases 
every 5 days to total 




PREGABALIN 75 mg twice daily 
Increase to 150 mg 





10 mg every 12 
hours 
As needed for pain 
while balancing 









changed every 3 
days 
As needed for pain 
while balancing 











changed every 3 
days 
As needed for pain 
while balancing 











Increase by 50 mg 
every 3-4 days to total 
dose between 100-400 





Table 1. Summary of effective systemic drugs for PHN. Initial dosage, titration and adverse 
effects are reported. 
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7.4 Topical therapies 
Local anesthetics may provide analgesia in neuropathic pain states, where an accumulation 
of neuronal-specific sodium channels may contribute to pain, including that of PHN (Mao & 
Chen, 2000). Topical treatments including lidocaine patches and capsaicin cream/patches 
have been studied for the treatment of PHN (Niv & Maltsman-Tseikhin, 2005). Topical 
adhesive patches containing 5% lidocaine (700 mg) have been used for the treatment of PHN 
with benefit (Comer & Lamb, 2000). Although there are few studies on their efficacy, the 
available clinical trials in patients with allodynia suggest that lidocaine is effective in 
providing pain relief with minimal systemic absorption and few side effects, the most 
frequent being mild skin irritation at the side of application (Khaliq et al., 2007; Binder et al., 
2009; Hans et al., 2009). Furthermore, patients may respond well to topical lidocaine even if 
the skin is completely deprived of nociceptors (Wasner et al., 2005).  
Capsaicin, the pungent ingredient in hot chili pepper, results in excitation of nociceptive 
afferents when applied topically. However, repeated application of capsaicin results in 
desensitization of unmyelinated epidermal nerve fibers and hypoalgesia (Nolano et al., 
1999; Knotkova et al., 2008). Low-concentration (0.025% or 0.075) capsaicin creams have 
demonstrated efficacy in the topical treatment of PHN and neuropathic pain conditions 
(Knotkova et al., 2008). Recently, a high-concentration (8%) synthetic capsaicin dermal patch 
has been developed with the aim of providing more rapid and long-lasting pain relief after a 
single application. Banckonja et al. (Backonja et al., 2009) evidenced that a one–off 
application of high concentration (8%) of capsaicin patch for 60 minutes was more effective 
than a low concentration patch over 12 weeks. Adverse events reported were local reactions 
at the application site (pain, erythema). Therefore, as evidenced by a Cochrane review, 
capsaicin either as repeated application of a low dose (0.075%) cream, or even a single 
application of a high dose (8%) patch may provide a good degree of pain relief to some 
patients with painful neuropathic conditions (Derry et al., 2009). Capsaicin dermal patches 
have been approved in the EU for the treatment of peripheral neuropathic pain in non-
diabetic adults either alone or in combination with other pain medications. Capsaicin 
dermal patches are also approved in the US only for management of neuropathic pain 
associated with PHN (McCormack, 2010). 
7.5 Interventional management 
A wide variety of interventional options, such as sympathetic and other nerve block, 
intrathecal injections and spinal cord stimulations have been analyzed as potential treatments 
for PHN. Interventional options are part of a comprehensive (invasive e non invasive) strategy 
for the treatment of PHN (see Figure 5). Selective sympathetic nerve blocks have been one of 
the more common interventional strategies used for pain relief for both acute HZ and PHN. 
Although the precise mechanisms by which the sympathetic nervous system contributes to 
neuropathic pain are unclear, experimental data indicate that abnormal activation of the -
adrenergic receptors in primary afferent neurons, direct interactions between primary afferent 
neurons and efferent sympathetic nerves resulting from neuronal regeneration and sprouting 
after nerve injury and tissue trauma may all contribute to sympathetically mediated pain 
(Janig et al., 1996; Wu et al., 2000). The incidence of severe complications from sympathetic 
nerve blocks is extremely low and, depending on the location of the nerve block, may consist 
of local anesthetic toxicity (such as seizures), pneumothorax, intraspinal/neuraxial injection, or 
neurologic injury (van Wijck et al., 2010; Wu & Raja, 2008). Some data suggest a link between 
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sympathetic activity and pain in PHN, as patients with PHN demonstrate increased levels of 
pain and worsening of their allodynia after local administration of adrenergic agonists (Choi et 
al., 1997). Thus, administration of sympathetic nerve blocks may theoretically interrupt the 
sympathetic-sensory interactions contributing to pain of HZ and PHN. Sympathetic nerve 
blocks for the treatment of PHN were evaluated mainly in retrospective studies. In a few of 
them, a reduction in pain was initially noted, but this effect was not maintained in the long 
run. Therefore, there is inadequate evidence for a long-term effect of sympathetic nerve blocks 
in PHN (van Wijck et al., 2010; Wu & Raja, 2008; Wu et al., 2000). 
 
 
Fig. 5. Strategy for management of PHN. 
Use of epidural blocks (through injections of corticosteroids with or without local 
anesthetics) has been reported for the treatment of acute HZ (Ahn et al., 2001) as an 
effective treatment shortening the total duration and reducing the severity of pain in 
combination with antiviral agent. A single epidural injection of steroids and local 
anesthetics in the acute phase of HZ may have a modest effect in reducing zoster-
associated pain for 1 month after injection and is not effective for prevention of PHN. 
Furthermore, the value of epidural injections for the treatment of existing PHN has not 
been evaluated (van Wijck et al., 2010).  
Continuous infusions of analgesic agents (typically an opioid or local anesthetic) via an 
externalized intrathecal catheter or internalized intrathecal pump may also be used for the 
treatment of PHN, although no controlled trials examining the analgesic efficacy of these 
modalities are available (Angel et al., 1998; Nitescu et al., 1998). 
In extreme cases, refractory to all treatment options, other interventional strategies were 
described in the literature. Although there are limitations in the quality and quantity of 
available data, current evidence suggests that Spinal Cord Stimulation be effective in the 
management of severe neuropathic pain (Grabow et al., 2003). 
The effect of subcutaneous injections, transcutaneous nerve stimulations, percutaneous 
nerve stimulations, and radiofrequency on HZ and PHN has not been established. There is 
minor anecdotal evidence for the efficacy of these techniques, and the risk for complications, 
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7.4 Topical therapies 
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such as exacerbation of pain, is unknown. There are no controlled studies for any of these 
interventional procedures (van Wijck et al., 2010). 
Reported surgical options for PHN include trigeminal or spinal peripheral neurectomy, 
deep brain stimulation, dorsal root entry zone lesions, cordotomy, and mesencephalotomy. 
Microsurgical DREZotomy or dorsal root entry zone lesions may interrupt small nociceptive 
fibers and neurons in the dorsal horn of the spinal cord. General indications for this 
procedure include well-localized pain, neuropathic pain including PHN, and excessive 
spasticity associated with severe pain The role of these invasive surgical treatments in the 
management of PHN is uncertain, as there are no controlled studies to date (Wu & Raja, 
2008). 
7.6 Other therapies 
A number of other therapies have been explored, such as NMDA receptor antagonists, 
topical NSAIDs and TCAs, vincristine iontophoresis, botox, minocycline and 
cryoanalgesia. There is, however, little evidence that justifies evaluation of the efficacy of 
these therapeutic options. Acupuncture is another option to treat PHN. A clinical report 
(Lewith et al., 1983), the only one to date retrievable in English, on the possible role of 
acupuncture in PHN, lacks of sufficient methodological consistency to be quoted in terms 
of efficacy. A current Cochrane project, however, is due in the near future on this topic 
(Wang et al., 2009). 
7.7 Psychological interventions 
Neuropathic pain reduces quality of life, including mood, physical and social 
functioning. Depression and pain coping strategies, such as catastrophizing and social 
support, predict pain severity in chronic pain states. Therefore, the importance of 
psychosocial support and long-term follow- up for severe cases should, however, not be 
overlooked as sometimes it is the final tool to resort on for otherwise intractable cases 
(Wu & Raja, 2008).  
7.8 Recommendations and combination therapies 
Recent guidelines on evidence-based management of neuropathic pain and PHN provide 
distinct recommendations for first, second, and third line treatment, including possible drug 
combinations for each step. European Federation of Neurological Societies (EFNS) 
guidelines recommend TCA or gabapentin/pregabalin as first line treatment in PHN (level 
A). Topical lidocaine (level A, less consistent results), with its excellent tolerability, may be 
considered first line in the elderly, especially if there are concerns regarding the CNS side 
effects of oral medications. In such cases, a trial of 2–4 weeks is justified. Strong opioids 
(level A) and capsaicin creams are recommended as a second choice. Capsaicin patches are 
promising (level A), but the long-term effects of repeated applications are not clarified, 
particularly on sensation. (Attal et al., 2010) (see Table 2). 
Although drugs and drug classes have been discussed individually for the purpose of this 
chapter, combination therapy associating more than 1 drug class may be useful in providing 
additive if not synergistic analgesia. The benefits of combination therapies are supported by 
a recent study, indicating that the combination of gabapentin and morphine achieved better 
analgesia at lower doses of each drug than either of the 2 drugs as a single agent in patients 
with PHN and diabetic neuropathy (Gilron et al.,2009).  
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Table 2. Classification of evidence for drug treatment in PHN and recommendations for use 
(adapted from EFNS guidelines, 2010). 
8. Can PHN be prevented? 
PHN is the most frequent complication of HZ, it hardly affects patients’ life and it is often 
refractory to current combination treatments, pain persisting in spite of any therapy 
nearly in half of patients. Several approaches have been investigated for PHN prevention. 
Prevention clearly appears so far the most interesting path to face with this condition. 
Antivirals have been addressed for their potential role in prevention as the stop on viral 
replication in acute phase was hypothesized to reduce pathological damage to nerve 
fibers and the subsequent onset of PHN. As their role in accelerating rash healing and 
acute pain resolution is widely recognized, results on their role in PHN prevention are 
still controversial: a recent Cochrane review (Li et al., 2009) raises some doubts about their 
efficacy, concluding that there is insufficient evidence from RCTs to support their use 
with this peculiar aim. In spite of that, studies with different designs suggest some 
opposite results. Another review (Vander Straten et al., 2001) suggested that antivirals in 
the acute phase of HZ appear to be effective in reducing PHN severity and duration, but 
not its incidence. Dworkin et al. (Dworkin et al., 1998) found that patients receiving 
antiviral therapy (famciclovir versus placebo) had a significant lower prevalence of PHN 
in a cohort study of 419 HZ patients. Parruti et al. (Parruti et al., 2010) showed that HZ 
patients not prescribed antivirals in the acute phase have a  significantly higher risk of 
developing PHN, in a prospective cohort of 519 HZ unselected patients addressing a real-
life clinical setting. The role of antivirals in preventing PHN is still a matter of debate. 
Corticosteroids prescribed in the acute phase of HZ have been shown to be uneffective in 
preventing PHN onset in several trials and in a recent review (Chen et al., 2010), as well as 
antidepressants (Saarto & Wiffen, 2010). As greater acute pain severity predispose to 
higher risk of PHN onset, pain relief in acute HZ has been investigated as to its possible 
preventive role. Interventional techniques, such as topical local anesthetics, subcutaneous 
local anesthetics and corticosteroids, percutaneous electrical nerve stimulation, 
sympathetic and epidural blocks, have been proposed as prevention: they can produce an 
effective short-term pain relief in the acute phase, thus reducing the important burden of 
pain in this time frame, but their effect in reducing PHN incidence remains unclear 
(Opstelten et al., 2004). 
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effective short-term pain relief in the acute phase, thus reducing the important burden of 
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In 1995, vaccination for varicella with a wild-type VZV Oka-strain was introduced under an 
FDA recommendation and at present a universal coverage vaccination program is ongoing in 
the USA and several other countries. Varicella vaccine at higher dosage (at least 14 times) than 
that used in Varicella vaccination was suggested to be protective for the development of HZ. 
The Shingles Prevention Study (Oxman et al. 2005) was a randomized double-blind placebo-
controlled trial designed  to demonstrate that vaccination against VZV  can decrease the 
incidence and severity of HZ and PHN. 38,546 healthy subjects aged over than 60 years were 
recruited and randomly assigned to receive a mock vaccine or an investigational anti-VZV 
vaccine. They were trained to recognize early HZ sings and to refer quickly to study sites in 
the evenience of HZ. After vaccination, they were followed for 3.13 years on average. The 
incidence of HZ was significantly reduced, from 11.12 per 1,000 person-years in the placebo 
arm to 5.42 per 1,000 person-years in the vaccine arm (Oxman et al. 2005). The incidence of 
PHN, defined as pain ≥30/100 at 90 days from the onset of rash, was markedly reduced in the 
vaccine arm, from 1.38 to 0.46 per 1,000 person-years. Moreover, vaccinated subjects 
developing HZ and PHN had significantly less pain and discomfort, with the burden of illness 
due to HZ, calculated as described by Coplan et al. (Coplan et al., 2004), being reduced by 
61.1%. Zoster vaccination reduced overall HZ and PHN incidence by 51.3% and 66.5%, 
respectively (see Figure 6) (Oxman et al., 2005), giving evidence for a major protective role. This 
cornerstone study, however, had some limitations, as it included only subjects aged >60 and 
excluded subjects with relevant and frequent comorbidities such as diabetes, chronic 
obstructive pulmonary diseases, cancer, HIV and other cases of immunodepression. For these 
reasons, it does not allow to draw conclusions as to safety and efficacy of HZ vaccine in these 
subsets of subjects that are relevant in real practice and that a priori would largely benefit from 
vaccine administration, having a higher risk to develop HZ and PHN and a heavier total 
burden of illness. Further studies are needed to better define these elements. 
 
 
Fig. 6. Kaplan-Meier estimates of the effect of HZ vaccine on HZ (A) and PHN incidence (B). 
HZ and PHN incidence were significantly lower in the vaccine group compared to the 
placebo group (waiting for permission from Oxman et al., 2005). 
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Since 2006, when HZ vaccine was approved by FDA and recommended for adults aged >60 
in the United States, the real cost-effectiveness of HZ vaccination for the general population 
has been widely investigated. Several studies assessed the economic burden of HZ and 
PHN, showing that they are frequent and costly conditions, also in terms of impact on 
quality of life, as discussed above (Scott et al., 2006; Stein et al.,2009; Gil et al., 2009; 
Gialloreti et al., 2010; Aunhachoke et al., 2011; Hornberger & Robertus, 2006). For instance, 
in Italy a recent study estimated that total annual costs for HZ and PHN were €41.2 Million, 
including both direct and indirect costs (Gialloreti et al., 2010).  Vaccine cost-effectiveness 
was determined by decision models in multiple large countries (Canada, England and 
Wales, Italy), suggesting that immunization would increase quality-adjusted life-years 
(QALYs) (Najafzadeh et al., 2009; van Hoek et al., 2009; Gialloreti et al., 2011). In general, 
studies evaluating vaccine cost-effectiveness agree on its relevance in the elderly population 
(Hornberger & Robertus, 2006; Pellissier et al., 2007; Rothberg et al., 2007; van Hoek et al., 
2011; Annemans et al., 2010; Gilden, 2011). Furthermore it has been supposed that 
vaccination could be equally cost-effective also in younger people, aged <50, as about 19% 
of HZ cases occur between 50 and 59 years of age. Further studies are once more needed to 
assess this point. 
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2011; Annemans et al., 2010; Gilden, 2011). Furthermore it has been supposed that 
vaccination could be equally cost-effective also in younger people, aged <50, as about 19% 
of HZ cases occur between 50 and 59 years of age. Further studies are once more needed to 
assess this point. 
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Varicella-zoster virus (VZV) is one of the eight herpesviruses that infect humans. The virus 
causes two diseases: the primary infection, varicella (chickenpox), and secondary or clinical 
manifestation of latent infection, herpes zoster (shingles). Though VZV infection rarely 
occurs during pregnancy, the disease is likely to be associated with significant complications 
for both mother and fetus: pregnant women are several times more likely to develop fatal 
varicella than non-pregnant patients, the fetus is at high risk of congenital varicella 
syndrome (CVS), and the neonate is at high risk of a severe or fatal form of varicella. 
1.1 Varicella 
Ninety percent of varicella cases occur in children between the age of 1 and 14 years. 
Varicella is a highly contagious disease and affects nearly all susceptible children with an 
attack rate approaching 90% following a household exposure to the illness. Transmission 
occurs mainly via direct contact and through respiratory droplets that contain the virus, 
making the disease highly contagious even before the first onset of rash. Varicella is 
generally regarded as a mild, self-limited viral illness with occasional complications in 
healthy children, and it is usually characterized by fever, malaise, and vesicular rash on the 
trunk, face, scalp, extremities, and oropharynx. The incubation period is usually 14-16 days, 
but can range from 10 to 21 days. The incubation period may be prolonged to 28 days if 
varicella zoster immunoglobulin (VZIG) has been administered. Transplacental 
transmission from mother to fetus occurs during maternal viraemia, and the incubation 
period for neonatal infection is 11 days (range 9-15 days) from the onset of maternal disease. 
The period of infectivity begins 1-2 days before the appearance of rash until the lesions crust 
over, usually 4 to 5 days after the onset of the rash (Centers for Disease Control and 
Prevention [CDC], 1996; Riley, 1998). Initially, the lesions appear as macules which tend to 
progress to vesicules which may erupt every 1-2 days. Once ruptured, these vesicules crust 
over. The lesions may be at various stages in the same area of skin and the rash is 
characteristically pruritic. The illness normally evolves over about 5 days.  
Seroepidemiological studies performed between 1973 and 2000 in different industrial 
countries revealed that up to 26% of women of reproductive age do not possess VZV-
specific IgG class antibodies (Sauerbrei & Wutzler, 2005). Currently, most pregnant women 
living in the US and Europe are not susceptible to the development of varicella, because 
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Varicella-zoster virus (VZV) is one of the eight herpesviruses that infect humans. The virus 
causes two diseases: the primary infection, varicella (chickenpox), and secondary or clinical 
manifestation of latent infection, herpes zoster (shingles). Though VZV infection rarely 
occurs during pregnancy, the disease is likely to be associated with significant complications 
for both mother and fetus: pregnant women are several times more likely to develop fatal 
varicella than non-pregnant patients, the fetus is at high risk of congenital varicella 
syndrome (CVS), and the neonate is at high risk of a severe or fatal form of varicella. 
1.1 Varicella 
Ninety percent of varicella cases occur in children between the age of 1 and 14 years. 
Varicella is a highly contagious disease and affects nearly all susceptible children with an 
attack rate approaching 90% following a household exposure to the illness. Transmission 
occurs mainly via direct contact and through respiratory droplets that contain the virus, 
making the disease highly contagious even before the first onset of rash. Varicella is 
generally regarded as a mild, self-limited viral illness with occasional complications in 
healthy children, and it is usually characterized by fever, malaise, and vesicular rash on the 
trunk, face, scalp, extremities, and oropharynx. The incubation period is usually 14-16 days, 
but can range from 10 to 21 days. The incubation period may be prolonged to 28 days if 
varicella zoster immunoglobulin (VZIG) has been administered. Transplacental 
transmission from mother to fetus occurs during maternal viraemia, and the incubation 
period for neonatal infection is 11 days (range 9-15 days) from the onset of maternal disease. 
The period of infectivity begins 1-2 days before the appearance of rash until the lesions crust 
over, usually 4 to 5 days after the onset of the rash (Centers for Disease Control and 
Prevention [CDC], 1996; Riley, 1998). Initially, the lesions appear as macules which tend to 
progress to vesicules which may erupt every 1-2 days. Once ruptured, these vesicules crust 
over. The lesions may be at various stages in the same area of skin and the rash is 
characteristically pruritic. The illness normally evolves over about 5 days.  
Seroepidemiological studies performed between 1973 and 2000 in different industrial 
countries revealed that up to 26% of women of reproductive age do not possess VZV-
specific IgG class antibodies (Sauerbrei & Wutzler, 2005). Currently, most pregnant women 
living in the US and Europe are not susceptible to the development of varicella, because 
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more than 90% of women of childbearing age are protected by virus-specific IgG class 
antibodies. The average incidence of varicella in pregnant women has been calculated as 2-3 
per 1,000 pregnancies (Enders & Miller, 2000). The epidemiology of varicella differs between 
countries with temperate climates and those with tropical climates. VZV is acquired at less 
frequency and at older ages in tropical and subtropical geographical zones. The rate of 
susceptibility to VZV is 16% (CDC, 1996). The latest seroepidemiological study carried out 
in 7980 pregnant women from various regions of the word demonstrated  a prevalence of 
VZV antibodies of 93.1% in women born in Western European countries and 80.3% in 
women born in Central and Eastern Europe, Asia and Africa (Knowles et al., 2004). 
Although the clinical course of varicella in children is usually mild, it may be severe or fatal 
in pregnant women. Varicella is estimated to be 25 times more likely to be severe in adults 
than in children. There is thought to be an even greater risk associated with pregnancy, 
particularly during the third trimester. Presumably, this is caused by maternal 
immunosuppression, which is most intense during this period (Gershon, 2001). 
1.2 Herpes zoster  
Herpes zoster (HZ) is caused by reactivation of latent VZV infection in sensory nerve root 
ganglia, which resulted during the attack of primary varicella infection. It usually occurs in 
about 15% of people over their lifetime, most commonly in elderly and 
immunocompromised populations. People with herpes zoster are capable of transmitting 
VZV to varicella susceptible individuals, although the patients with zoster infection are 
thought to be less infectious than the patients suffering with the primary varicella.  Herpes 
zoster or shingles is characterized by a painful, unilateral vesicular rash that is usually 
restricted to unilateral dermatomal distribution and can occur on the trunk or face, although 
the rash may involve an extremity. The lesions, full of infectious virus, tend to coalesce. The 
individual is considered contagious to varicella susceptible until the skin lesions have dried. 
Most lesions may be present for days to weeks in immunocompromised patients. Pain is 
often a major complaint rather than itching. Zoster seems to increase in severity with 
increasing age; young people rarely have a severe form of the illness. Zoster is essentially 
not a fatal illness in otherwise healthy individuals. There is little information on the risk of 
developing zoster during pregnancy. Fortunately, herpes zoster during pregnancy and 
during the perinatal period is not associated with any known birth defect and problems for 
newborns, unless the women are immunocompromised (Enders et al., 1994; Miller et al., 
1989; Sauerbrei & Wutzler, 2000).  
2. Varicella in pregnancy  
If the pregnant women give a history of contact with varicella or shingles, a careful history 
including previous vaccinations must be taken to confirm the significance of the exposure 
and the susceptibility of the patient. The women should have a blood test to assess the 
presence or absence of the immunity to varicella. The algorithm for the assessment and 
management of varicella exposure during pregnancy is demonstrated in figure 1. 
Varicella is much less common in adults than in children; however, it is associated with 
greater morbidity and mortality. Varicella results in the death of 25 people/year in 
England and Wales and 75% of these deaths occur in adults (Rawson et al., 2001). The 
data suggest that 5–14% of adults with varicella develop pulmonary involvement, which 
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may vary in severity from a subclinical form, only detected on X-ray or lung function 
tests, to a severe and potentially fatal illness (Nathwani et al., 1998). The disease usually 
develops within 3-5 days of the rash and is associated with cough, dyspnea, fever, and 
tachypnea. Additionally, cyanosis, pleuritic pain in the chest, and hemoptysis can occur 
and secondary bacterial infections are frequent. The chest X-ray findings include a diffuse 
or nodular infiltrative pattern often seen in peribronchial distribution involving both 
lungs. The X-ray findings may be more severe than the clinical appearance (Daley et al., 
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more than 90% of women of childbearing age are protected by virus-specific IgG class 
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Pregnant women appear no more likely than other adults to develop pneumonia (Royal 
College of Obstetricians and Gynaecologists [RCOG], 2001) which can occur in up to 10% of 
pregnant women suffering with varicella (Harger et al., 2002); however, varicella pneumonia 
may be more severe in pregnant compared to non-pregnant women. The severity of this 
complication seems to increase in later gestation (Tan & Koren, 2005). Smoking and the 
occurrence of at least 100 skin lesions are well known risk factors for the development of VZV 
pneumonia (Harger et al., 2002).  The mortality rate in untreated pregnant women is as high as 
40% (Haake et al., 1990), therefore varicella pneumonia in pregnancy is considered a medical 
emergency. However, more recent studies suggest that the mortality has decreased to 10-11% 
for both non-pregnant and pregnant patients, most likely due to the effective antiviral therapy 
and better respiratory management (Chandra et al., 1998).  
Encephalitis causing acute cerebellar ataxia can occur up to 21 days after the onset of the 
varicella rash (Sissons, 2003). Fortunately, more severe forms of encephalitis are uncommon 
(0.1–0.2% of cases of varicella), but they have a mortality of around 5–20% (Sissons, 2003).  
Possible haemorrhagic complications of chickenpox include acute thrombocytopenia, or 
purpura fulminans associated with arterial thrombosis and haemorrhagic gangrene (Sissons, 
2003). Although encephalitis and haemorrhagic complications are rare, their development 
may severely complicate pregnancy. Multiorgan involvement including hepatitis, 
myocarditis, and pericarditis is associated with a high mortality. Fetal loss may result from 
maternal sepsis, fever and hypoxia (Daley et al., 2008). 
There is no evidence that uncomplicated chickenpox in the mother significantly increases 
the likelihood of spontaneous abortion during the first 20 weeks of pregnancy (3.0% in one 
study) or intrauterine death after the 20th week (0.7%) (Enders et al., 1994; Hinshaw & 
Fayyad, 2000; Office for National UK Statistics, 2005). 
3. Management of the pregnant woman who develops varicella or herpes 
zoster  
Most pregnant women who develop varicella illness do not require hospitalization; they can 
be reassured and sent home for daily or more frequent reviews if clinically indicated 
(Morgan-Capner et al., 2002). Indications for referral to hospital include the development of 
respiratory or/and neurological symptoms, a wide-spreading haemorrhagic rash or 
bleeding, a dense rash with or without mucosal lesions, the appearance of new lesions after 
6 days, and a history of significant immunosuppression. Also, the women close to term 
should be considered for hospitalization because of the risk of developing haemorrhagic 
complications or varicella of the newborn (RCOG, 2001). Furthermore, if the woman smokes 
cigarettes, has chronic lung disease, is taking corticosteroids, or is in the latter half of 
pregnancy, a hospital assessment should be considered, even in the absence of 
complications (Heuchan & Isaacs, 2001; RCOG, 2001).  
If the pregnant woman develops the first signs of chickenpox illness, an appropriate 
treatment should be decided in consultation with a multidisciplinary team: obstetrician or 
fetal medicine specialist, virologist, and neonatologist. Depending on the severity of the 
maternal condition, a respiratory physician, intensive care specialist, and infectious disease 
specialist may also be involved. Timing and mode of delivery must be individualized 
(Morgan-Capner et al., 2002; RCOG, 2001). 
As the only safe therapeutic agent, acyclovir is indicated for pregnant women with varicella. 
The studies suggest that acyclovir administered in a dosage of 800mg five times a day for 7 
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days reduces the duration of fever and symptomatology of varicella in immunocompetent 
patients if commenced within 24 hours of developing the rash when compared with placebo 
(Wallace et al. 1992). This randomized controlled trial did not have sufficient power to 
comment on the impact of early oral acyclovir on the serious complications of varicella. Data 
suggest that there is no increase in the risk of fetal malformation with acyclovir in 
pregnancy, although the theoretical risk of teratogenesis persists in the first trimester 
(Ratanajamit et al., 2003; Stone et al., 2004). Intravenous acyclovir (10mg/kg three times 
daily for at least 5 days (7-10)) is indicated for pregnant women with severe illness, 
complications and/or risk factors (Kempf et al., 2007; Morgan-Capner et al., 2002). VZIG has 
no therapeutic benefit once varicella has developed (Nathwani et al., 1998).  
The woman may also need symptomatic relief with paracetamol and/or ibuprofen, 
although ibuprofen should be avoided after 30 weeks of gestation because it may cause 
premature closure of the ductus arteriosus (Prodigy, 2005). Systemic antihistamines should 
also be avoided during the first trimester and breast-feeding (Prodigy, 2005; Drug and 
Therapeutics Bulletin [DTB], 2002).  
Delivery during the viraemic period may be extremely hazardous. There are significant 
maternal risks associated with bleeding, thrombocytopenia, disseminated intravascular 
coagulopathy, and hepatitis. Also, there is a high risk of varicella of the newborn with 
significant morbidity and mortality (Meyers, 1974; Miller et al., 1989). Therefore, where 
relevant and practical, the delivery should be delayed until 5 days after the onset of maternal 
illness to allow for passive transfer of antibodies that could protect the baby from the infection 
(RCOG, 2001). Supportive treatment and intravenous acyclovir is therefore desirable, allowing 
resolution of the rash, immune recovery, and transfer of protective antibodies from the mother 
to the fetus. Delivery may be required in women to facilitate assisted ventilation in cases 
where varicella pneumonia is complicated by respiratory failure (RCOG, 2001). 
There is no evidence available to us to inform decisions about the optimum method of 
anaesthesia for women requiring delivery by caesarean section. General anaesthesia may 
exacerbate varicella pneumonia. There is a theoretical risk of transmitting the VZV from 
skin lesions to the central nervous system via spinal anaesthesia. This results in advice that 
epidural anaesthesia may be safer than spinal anaesthesia, because the dura is not 
penetrated. A site free of cutaneous lesions should be chosen for needle placement (Brown 
et al., 2003).  
Women hospitalized with varicella should be nursed in isolation from babies or potentially 
susceptible pregnant women or non-immune staff (RCOG, 2001). 
Treatment of herpes zoster in imunocompetent pregnant women should be symptomatic; 
topical or systemic antiviral therapy is not recommended (Kempf et al., 2007).  
4. Consequences of varicella in pregnancy 
Varicella acquired during pregnancy may have serious consequences for fetus and neonate. 
Maternal varicella associated with viraemia can transmit the virus to the fetus by either 
transplacental route or by ascending infection from the lesions in the birth canal. The 
possible outcomes of VZV infection during pregnancy depends on the time of the disease 
and includes spontaneous abortion, fetal malformation, premature delivery, fetal growth 
restriction, or postnatal infection. In infancy, herpes zoster may be the first clinical 
manifestation of VZV infection after the primary infection in utero (Table 1). 
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
176 
Pregnant women appear no more likely than other adults to develop pneumonia (Royal 
College of Obstetricians and Gynaecologists [RCOG], 2001) which can occur in up to 10% of 
pregnant women suffering with varicella (Harger et al., 2002); however, varicella pneumonia 
may be more severe in pregnant compared to non-pregnant women. The severity of this 
complication seems to increase in later gestation (Tan & Koren, 2005). Smoking and the 
occurrence of at least 100 skin lesions are well known risk factors for the development of VZV 
pneumonia (Harger et al., 2002).  The mortality rate in untreated pregnant women is as high as 
40% (Haake et al., 1990), therefore varicella pneumonia in pregnancy is considered a medical 
emergency. However, more recent studies suggest that the mortality has decreased to 10-11% 
for both non-pregnant and pregnant patients, most likely due to the effective antiviral therapy 
and better respiratory management (Chandra et al., 1998).  
Encephalitis causing acute cerebellar ataxia can occur up to 21 days after the onset of the 
varicella rash (Sissons, 2003). Fortunately, more severe forms of encephalitis are uncommon 
(0.1–0.2% of cases of varicella), but they have a mortality of around 5–20% (Sissons, 2003).  
Possible haemorrhagic complications of chickenpox include acute thrombocytopenia, or 
purpura fulminans associated with arterial thrombosis and haemorrhagic gangrene (Sissons, 
2003). Although encephalitis and haemorrhagic complications are rare, their development 
may severely complicate pregnancy. Multiorgan involvement including hepatitis, 
myocarditis, and pericarditis is associated with a high mortality. Fetal loss may result from 
maternal sepsis, fever and hypoxia (Daley et al., 2008). 
There is no evidence that uncomplicated chickenpox in the mother significantly increases 
the likelihood of spontaneous abortion during the first 20 weeks of pregnancy (3.0% in one 
study) or intrauterine death after the 20th week (0.7%) (Enders et al., 1994; Hinshaw & 
Fayyad, 2000; Office for National UK Statistics, 2005). 
3. Management of the pregnant woman who develops varicella or herpes 
zoster  
Most pregnant women who develop varicella illness do not require hospitalization; they can 
be reassured and sent home for daily or more frequent reviews if clinically indicated 
(Morgan-Capner et al., 2002). Indications for referral to hospital include the development of 
respiratory or/and neurological symptoms, a wide-spreading haemorrhagic rash or 
bleeding, a dense rash with or without mucosal lesions, the appearance of new lesions after 
6 days, and a history of significant immunosuppression. Also, the women close to term 
should be considered for hospitalization because of the risk of developing haemorrhagic 
complications or varicella of the newborn (RCOG, 2001). Furthermore, if the woman smokes 
cigarettes, has chronic lung disease, is taking corticosteroids, or is in the latter half of 
pregnancy, a hospital assessment should be considered, even in the absence of 
complications (Heuchan & Isaacs, 2001; RCOG, 2001).  
If the pregnant woman develops the first signs of chickenpox illness, an appropriate 
treatment should be decided in consultation with a multidisciplinary team: obstetrician or 
fetal medicine specialist, virologist, and neonatologist. Depending on the severity of the 
maternal condition, a respiratory physician, intensive care specialist, and infectious disease 
specialist may also be involved. Timing and mode of delivery must be individualized 
(Morgan-Capner et al., 2002; RCOG, 2001). 
As the only safe therapeutic agent, acyclovir is indicated for pregnant women with varicella. 
The studies suggest that acyclovir administered in a dosage of 800mg five times a day for 7 
 
Varicella Zoster Virus Infection in Pregnancy 
 
177 
days reduces the duration of fever and symptomatology of varicella in immunocompetent 
patients if commenced within 24 hours of developing the rash when compared with placebo 
(Wallace et al. 1992). This randomized controlled trial did not have sufficient power to 
comment on the impact of early oral acyclovir on the serious complications of varicella. Data 
suggest that there is no increase in the risk of fetal malformation with acyclovir in 
pregnancy, although the theoretical risk of teratogenesis persists in the first trimester 
(Ratanajamit et al., 2003; Stone et al., 2004). Intravenous acyclovir (10mg/kg three times 
daily for at least 5 days (7-10)) is indicated for pregnant women with severe illness, 
complications and/or risk factors (Kempf et al., 2007; Morgan-Capner et al., 2002). VZIG has 
no therapeutic benefit once varicella has developed (Nathwani et al., 1998).  
The woman may also need symptomatic relief with paracetamol and/or ibuprofen, 
although ibuprofen should be avoided after 30 weeks of gestation because it may cause 
premature closure of the ductus arteriosus (Prodigy, 2005). Systemic antihistamines should 
also be avoided during the first trimester and breast-feeding (Prodigy, 2005; Drug and 
Therapeutics Bulletin [DTB], 2002).  
Delivery during the viraemic period may be extremely hazardous. There are significant 
maternal risks associated with bleeding, thrombocytopenia, disseminated intravascular 
coagulopathy, and hepatitis. Also, there is a high risk of varicella of the newborn with 
significant morbidity and mortality (Meyers, 1974; Miller et al., 1989). Therefore, where 
relevant and practical, the delivery should be delayed until 5 days after the onset of maternal 
illness to allow for passive transfer of antibodies that could protect the baby from the infection 
(RCOG, 2001). Supportive treatment and intravenous acyclovir is therefore desirable, allowing 
resolution of the rash, immune recovery, and transfer of protective antibodies from the mother 
to the fetus. Delivery may be required in women to facilitate assisted ventilation in cases 
where varicella pneumonia is complicated by respiratory failure (RCOG, 2001). 
There is no evidence available to us to inform decisions about the optimum method of 
anaesthesia for women requiring delivery by caesarean section. General anaesthesia may 
exacerbate varicella pneumonia. There is a theoretical risk of transmitting the VZV from 
skin lesions to the central nervous system via spinal anaesthesia. This results in advice that 
epidural anaesthesia may be safer than spinal anaesthesia, because the dura is not 
penetrated. A site free of cutaneous lesions should be chosen for needle placement (Brown 
et al., 2003).  
Women hospitalized with varicella should be nursed in isolation from babies or potentially 
susceptible pregnant women or non-immune staff (RCOG, 2001). 
Treatment of herpes zoster in imunocompetent pregnant women should be symptomatic; 
topical or systemic antiviral therapy is not recommended (Kempf et al., 2007).  
4. Consequences of varicella in pregnancy 
Varicella acquired during pregnancy may have serious consequences for fetus and neonate. 
Maternal varicella associated with viraemia can transmit the virus to the fetus by either 
transplacental route or by ascending infection from the lesions in the birth canal. The 
possible outcomes of VZV infection during pregnancy depends on the time of the disease 
and includes spontaneous abortion, fetal malformation, premature delivery, fetal growth 
restriction, or postnatal infection. In infancy, herpes zoster may be the first clinical 
manifestation of VZV infection after the primary infection in utero (Table 1). 
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Maternal disease Timing during pregnancy Consequences for mother, fetus, term neonate 
Varicella 




At any stage, especially in 
the third trimester 
 
Near term: ≥5 days before 
delivery 
 
Near term: ≤4-5 days 
before to 2 days after 
delivery 
Intrauterine death, neonatal or 
infantile zoster 
Congenital varicella sindrome (risk: 
2%, mortality: 30%) 
Maternal pneumonia (risk: 10-20%, 
mortality: 10-45%) 
Neonatal varicella at ages 10 (-12) days 
(risk: 20-50%, mortality: 0%) 
Neonatal varicella 0-4 days after birth 
(risk: 20-50%, mortality: 0-3%); 
neonatal varicella 5-10 (-12) days after 
birth (risk: 20-50%, mortality: 20-25%) 
Normal zoster At any stage No risk for severe maternal, fetal or neonatal infections 
Table 1. Potential consequences of varicella-zoster virus infections during pregnancy 
(Sauerbrei, 2010) 
4.1 Congenital varicella syndrome 
Since the first report in 1947 (Laforet & Lynch, 1947) more than 130 cases of congenital 
varicella syndrome have been described in the English and German literature (Sauerbrei & 
Wutzler, 2005). CVS can occur in about 12% of infected fetuses (Prober et al., 1990). 
Prospective studies in Europe and North America demonstrated that the incidence of 
congenital anomalies after maternal varicella in the first 20 weeks of pregnancy is about 1-
2% (Enders et al., 1994; Pastuszak et al., 1994). Before the 5th and after the 24th gestational 
weeks, the probability of CVS is extremely low (Sauerbrei, 2010). Overall the incidence of 
CVS in nine reported cohort studies was 0.55% in the first trimester, 1.4% in the second 
trimester, and 0% in the third trimester (Tan & Koren, 2006). 
Although a few cases of fetal abnormalities have been reported after maternal herpes zoster, 
clinical evidence suggests that herpes zoster infection during pregnancy does not cause the 
congenital varicella syndrome or neonatal varicella. This is because the fetus passively 
acquires, and is protected by, the mother’s varicella antibodies produced in response to the 
initial varicella infection (RCOG, 2001). 
Congenital varicella syndrome is usually characterized by unusual cutaneous defects with 
cicatricial skin scars in dermatomal distribution, neurological defects secondary to probable 
intrauterine VZV encephalitis (cortical atrophy, spinal cord atrophy, limb paresis, seizures, 
microcephaly, Horner’s syndrome, encephalitis, mental retardation), eye disease 
(microphthalmia, enophthalmia, chorioretinitis, cataract, nystagmus, anisocoria, optic 
atrophy), limb hypoplasia or diminished limb growth, and other skeletal anomalies. Less 
frequent abnormalities include muscle hypoplasia and affections of the internal organs as 
well as gastrointestinal, genitourinary, and cardiovascular manifestations (Sauerbrei, 2010).  
It is not known whether VZIG reduces the risk of CVS. A prospective study was carried out 
in 108 women who developed varicella infection despite VZIG prophylaxis. Eighty percent 
of these women received VZIG in the first and second trimester and there were no cases of 
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CVS or infants with IgM antibodies at birth reported (Enders & Miller, 2000). However, no 
conclusion can be drawn from this, given the rarity of CVS. Criteria for diagnosis of CVS 
listed in Table 2.  
 
- Appearance of maternal varicella during pregnancy 
- Neonate or fetus with 
  congenital skin lesions in dermatomal distribution and/or 
  neurological defects,  
  eye diseases,  
  limb hypoplasia 
 
- Proof of intrauterine VZV infection by 
  detection of viral DNA using polymerase chain reaction and/or 
  presence of specific IgM/persistence of IgG beyond 7 months of age 
  appearance of zoster during early infancy 
Table 2. Criteria used for diagnosis of congenital varicella syndrome (Sauerbrei, 2010) 
Prenatal diagnosis of CVS is possible using detailed fetal ultrasonography and/or fetal 
magnetic resonance imaging and can be useful to look for limb anomalies or other 
morphological abnormalities caused by intrauterine varicella. VZV DNA can be detected by 
PCR in fetal blood, amniotic fluid, or placental villi. VZV IgM in fetal blood can be detected. 
No cases of CVS occurred when the amniotic fluid obtained during amniocentesis was 
negative for VZV DNA. If the amniotic fluid is PCR positive for VZV and the ultrasound is 
normal at 17–21 weeks, the risk of CVS is still low. If the repeat ultrasound is normal at 23–24 
weeks the risk of CVS is remote. However, the risk of CVS increases significantly if the 
ultrasound scan reveals features compatible with CVS and the DNA is found in the amniotic 
fluid. (Mouly et al., 1997). A negative PCR for VZV in amniotic fluid, and a normal ultrasound 
scan results from 23 weeks onwards, suggest a low risk of intrauterine infection (Table 3). 
 
Weeks of gestation PCR High level ultrasound 




























Table 3. Prenatal diagnosis using ultrasound and PCR for risk of CVS (Enders & Miller, 2000) 
The prognosis of infants born with CVS is poor, with death in infancy resulting from 
intractable gastroesophageal reflux, severe recurrent aspiration pneumonia, and respiratory 
failure due to dysfunction of the autonomic nervous system (Smith & Arvin, 2009).  Nearly 
30% of neonates born with CVS died during the first months of life. A follow-up report in 
the literature showed that in spite of initially poor prognosis, a good long-term outcome can 
occur in patients with CVS (Schulze & Dietzsch, 2000). 
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4.2 Neonatal varicella  
If maternal varicella occurs 1–4 weeks before delivery, up to 50% of babies may be infected. 
Approximately 23% of these develop clinical varicella despite high titers of passively 
acquired maternal antibodies (Miller et al., 1989). When the mother’s rash appeared 7–3 
days before delivery, progressively fewer infants had antibodies.  
Infection may occur by transplacental viraemia, ascending infection from the birth canal, or 
through direct contact with infectious lesions during and after delivery. Varicella occurring 
in the first 12 days of life is described as intrauterine-acquired neonatal varicella infection. If 
the infection is diagnosed after the 12th day of the neonatal period, VZV is most likely  
acquired postnatally. (Enders & Miller, 2000). The severity of intrauterine-acquired neonatal 
varicella is closely related to the time of onset of the maternal infection, as transplacentally 
transmitted antibodies may reduce the severity of symptoms in the neonate (Table 1). 
Generalized neonatal varicella can be fatal if mothers develop varicella rash between 4-5 
days before and 2 days after delivery since these neonates are not protected   from severe 
disease by the maternal antibodies. A fatal outcome is more likely if the neonatal disease 
occurs between 5 and 10 days after delivery. Infants born to mothers with varicella within 
this high risk period are usually initially well-appearing. Varicella presents with the classical 
skin lesions, but can disseminate with pneumonia, hepatitis, encephalitis, and severe 
coagulopathy resulting from liver failure and thrombocytopenia (Prober & Arvin, 1987). 
Before VZV immunoglobulin was available, the risk of death among neonates born to 
mothers with the onset of rash up to four days before delivery was 31% (Meyers, 1974). The 
rate decreased to 7% when the use of VZIG was introduced and neonatal intensive care 
improved (Miller et al., 1989). Neonatal varicella within the first 4 days after birth has 
usually been found to be mild (Sauerbrei & Wutzler, 2001). 
When the history of maternal varicella is in the few weeks preceding delivery, the infants 
may be asymptomatic or may have cutaneous lesions at birth or developing shortly 
thereafter, but are at low risk of dissemination of varicella disease or complications (Smith & 
Arvin, 2008). 
Premature neonates younger than 28 weeks gestation must be considered to have an 
increased risk for severe neonatal varicella during the first 6 weeks after birth (Advisory 
Committee on Immunization Practices [ACIP], 1996; Deutsche Gesellschaft für Pädiatrische 
Infektologie [DGPI], 2003). They are unlikely to have  protecting maternal antibodies due to  
the reduced gestation period and the lack the transplacental transfer of maternal IgG to 
VZV.  
The diagnosis of neonatal varicella is usually based on typical clinical picture. The clinical 
findings may be confirmed by serological methods, detection of VZV DNA in skin swabs or 
biopsies, or liquor and tissue samples using PCR (Sauerbrei, 2010). When varicella pneumonia 
is suspected, broncho-alveolar lavage may be obtained for the VZV DNA detection. 
We report three clinical cases of neonatal varicella: two transmitted in utero and one 
acquired postnatally. 
4.2.1 Case report 1 
A 6-day-old baby boy was hospitalized on the first day of his illness with a history of a 
maculovesicular skin rash noticed on his face and back. On admission, he had normal 
temperature and he weighed 3960 g. The next day, he was noticed to have haemorrhagic 
fluid in some of the vesicles, and subsequently he developed pustules with infiltration as 
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well as necrosis of the surrounding tissues on the 5th day of the illness. He spiked 
temperatures up to 38ºC on day 4 and a few days later (day 6) his condition deteriorated 
even further. He was spiking fevers up to 39ºC; he had poor appetite and dropped his 
weight to 3440g. Peripheral blood analysis performed on the 1st, 5th and 11th day of his 
illness was within normal limits. His chest was clear on auscultation with no evidence of 
any obvious respiratory compromise. However, on day 7 a chest x-ray demonstrated fine 
bilateral foci with a minor reaction of interlobular pleura on the right side which was very 
suggestive of varicella pneumonitis. The patient received 2 ml (50 IU) of intravenous human 
varicella zoster immunoglobuline (VZIG; Varitect, Germany) on the 2nd day of the 
admission. He was also given a course of second generation cephalosporin between the day 
5 and 9 of his illness. The patient’s condition was significantly improved and he was 
discharged home on the 12th day of his illness.  
Of note, the mother had varicella infection 5 days before the delivery. The incubation period 


















Fig. 2. Newborn varicella aquired from the mother in prenatal period. Varicella of the 
pregnant woman started at 5 days before delivery; severe varicella of newborn, at 6 days of 
age. The incubation period of varicella for the newborn was 11days. 
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4.2.2 Case report 2 
A 2-day-old newborn presented with a widespread maculovesicular skin rash and was 
hospitalized on the first day of his illness (Figure 3).  
 
 
Fig. 3. Male neonate with intrauterine acquired varicella, day 3 of the illness. There was a 
history of maternal varicella 12 days before the delivery. 
On physical examination, the newborn was afebrile and generally appeared well. His 
peripheral blood analysis was entirely normal. He remained very well during the admission 
and he was discharged from the hospital on day 4.  
The mother had varicella 12 days before the delivery. The incubation period for the 
newborn was 14 day (Figure 4). 
 
 
Fig. 4. Prenatally acquired newborn varicella. The mother developed varicella 12 days 
before the delivery. Mild varicella illness of newborn was diagnosed at 2 days of age. The 
incubation period of varicella for the neonate was 14 days. 
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4.2.3 Case report 3 
We report a 22-day-old baby boy who at the age of 3 days was in a close contact with his 10-
year old sister who had clinically unrecognized varicella. Her serological investigation 
confirmed the diagnosis of varicella by detecting VZV- IgM class antibodies (ELISA, 
Enzygnost; Dade Behring, Germany). Serum VZV-IgM concentration was raised to 0.939 
(pos. > 0.200 OD) on the 9th day of his illness. Varicella of the neonate started after 14 days of 
the incubation period. A clinical course of the varicella illness was mild (Figure 5). 
 
 
Fig. 5. A 22 day old newborn with postnatally acquired varicella, day 5 of the illness. The 
index case was a 10 year old sister. 
Three days after the delivery, the mother was in direct contact with her daughter who was 
ill with varicella. As a result, the mother developed varicella thirteen days later, but 
fortunately the illness was mild (Figure 6).  
 
 
Fig. 6. Maternal varicella, day 4 of the illness. 
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4.3 Herpes zoster in young infants 
Nearly 20% of infants with intrauterine-acquired VZV primary infection develop herpes 
zoster in the first or second year of life, usually with uncomplicated course (Sauerbrei & 
Wutzler, 2003). The observed risk of zoster when maternal infection occurs before 24 
weeks was 0.8%, compared to a 1.7% observed risk if maternal varicella was after 25 
weeks (Enders et al., 1994). The risk of postnatal herpes zoster infection in infancy was 
3.8% in cases when maternal amniotic fluid had been positive for VZV DNA by PCR 
(Mouly et al., 1997). The symptoms are the same as in adults, although the skin lesions 
are less prominent and the symptoms of acute neuritis are mild or absent. Unlike adults, 
children do not suffer with post-herpetic neuralgia (Helgason et al., 2000). Serious 
complications have been reported in only one case of a four-month-old infant whose 
mother had had varicella at 17 weeks’ gestation. The infant was born full term without 
complications; however, aged three months, he developed herpes zoster associated with 
generalized seizures. The clinical picture and VZV DNA detected in his cerebrospinal 
fluid by PCR were consistent with central nervous system infection (Sauerbrei et al., 
2003).  
Herpes zoster in infants who acquired VZV in utero has been self-limited. If the zoster is 
extensive and painful, treatment with acyclovir (initially by intravenous, followed by oral) 
for seven to 10 days is recommended.  
We report two patients with typical herpes zoster, whose mothers had varicella during the 
second-third trimester of their pregnancy. 
4.3.1 Case report 4 
A thirteen and a half month old girl was hospitalized on the 7th day of her illness because 
of ongoing restlessness, disturbed sleep, and a rash, which she had developed on day 4 of 
her restlessness. On examination, she had a right-sided vesicular skin rash along T10-12, 
L1-2 dermatomes (Picture 2). Otherwise, she appeared generally well. Her peripheral 
blood analysis was completely normal. The patient received symptomatic treatment and 
was discharged home 4 days later. VZV-IgG and IgM class antibodies (ELISA, Enzygnost; 
Dade Behring, Germany) were detected in the blood serum on the 9th and 29th days of 
the illness. VZV-IgG concentration was 0.135 and 2.142; VZV-IgM was 0.038 and 0.704, 
respectively (pos. > 0.200 OD). Of note, she was born prematurely at week 36 of gestation 
via Caesarean section. Initially she required intubation and ventilation for her backbone 
injury identified at birth. The mother suffered with moderate varicella during the 26th 
week of her pregnancy. 
4.3.2 Case report 5 
A 10 month old girl was hospitalized on the 6th day of her illness due to her ongoing 
restlessness, fever, and a rash noticed on the right side of her chest. On the 5th day she 
developed a maculovesicular rash and started spiking temperatures up to 38.5ºC. On 
physical examination, she had vesicular skin lesions observed on the right side of her chest 
along T6-7 dermatomes. Otherwise, the girl appeared generally well. Peripheral blood 
analysis was entirely normal. Varicella immune status was established on the 8th and 22nd 
day of the illness. Her VZV-IgG concentrations were 0.200 and 2.462, and VZV-IgM levels 
were 0.122 and 0.412, respectively (pos. > 0.200 OD). The patient received symptomatic 
treatment for 6 days and was discharged in good health thereafter.  
 




Fig. 7. The patient with herpes zoster following maternal varicella acquired during 
pregnancy. Day 7 of the illness.  a) A typical anterior vesicular skin rash along the T10-12 
and L1-2 dermatomes on the right side. b) A typical posterior vesicular skin rash along the 
T10-12 and L1-2 dermatomes on the right side. c) Post inflammatory skin 
hyperpigmentation following zoster, day 29 of the illness. 
Early manifestation of herpes zoster may be explained by the immature cell-mediated 
immune response in young children and/or the decrease of maternally derived antibodies 
(Sauerbrei & Wutzler, 2000). The hypothesis was confirmed by our two clinical cases. 
Neither of them had detectable VZV-IgG antibodies at the beginning of the illness. High 
titers of serum VZV-IgG and IgM antibodies were discovered only 3–4 weeks later. 
5. Management of neonatal varicella  
Varicella zoster immunoglobulin, administered to the infants whose mothers developed 
varicella (but not herpes zoster) at around term, may attenuate infection and significantly 
reduce the risk of life-threatening neonatal varicella (Enders, 1985; Miller et al., 1989). VZIG 
should be given at birth to neonates who meet any of the following criteria (Sauerbrei, 2010): 
 their mothers develop rash  between 7 days before and 7 days after birth; 
 they were born within the last 7 days, the mother is seronegative and they have had 
significant non-maternal post-natal exposure (e.g. from a sibling); 
 they have been exposed to varicella and are at risk because of potentially inadequate 
transfer of maternal antibodies. This includes neonates born before 28 weeks gestation; 
or weighing less than 1,000g; or who have had repeated blood sampling with 
replacement by packed red cell infusion; or those requiring intensive or prolonged 
special care nursing. VZIG can be issued without antibody testing but, where possible, 
such infants should be tested. 
Other infants whose mothers have a positive history of varicella and/or a positive VZV 
antibody result will usually have maternal antibody and do not require VZIG. Severe 
neonatal varicella can occur despite VZIG administration (Reynolds et al., 1999). Neonatal 
varicella should be treated promptly with acyclovir (Table 4, Figure 8). 
Postnatally, the mother and neonate should be isolated from other mothers and babies on 
the ward, but not from each other. Breast-feeding of neonates exposed to maternal varicella 
should be encouraged. If the mother has varicella lesions close to the nipple, milk should be 
expressed until the lesions have crusted (Morgan-Capner et al., 2002). Where other members 
of the family have varicella at home and the mother is seronegative, discharge should be 
delayed until the baby is at least 7 days old (Morgan-Capner et al., 2002). 
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VZIG after intrauterine exposure to VZV 
Neonates whose mothers develop 
varicella within 5 days before and 
2 days after delivery 
Intravenously: 1 ml/kg or 
intramuscularly: 125 U or 0.5 
mg/kg  
Immediately after birth or 
onset of maternal rash 
VZIG after postnatal exposure 
Premature neonates with negative 
maternal varicella history  
Intravenously: 1 ml/kg or 
intramuscularly: 125 U or 0.5 
mg/kg 
Within 96 hours after exposure 
Premature neonates <28 weeks 
gestation or <1,000 g birth weight 
independent of maternal varicella 
history 
Intravenously: 1 ml/kg or 
intramuscularly: 125 U or 0.5 
mg/kg 
Within 96 hours after exposure 
Antiviral treatment of neonatal varicella 
Suspected neonatal varicella Acyclovir intravenously: 3 x 10-15 mg/kg Length of therapy: 5-7 days 
Table 4. Administration of VZIG and acyclovir in neonates to prevent neonatal varicella 
(Sauerbrei, 2010; ACIP, 1996; DGPI, 2003) 
 
 
Fig. 8. Measures in case of varicella during pregnancy depending on the point of time of 
infection (Sauerbrei , 2010) 
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All neonates with maternal or other exposure must be followed up for 14–16 days (by the 
GP, midwife, health visitor or in hospital) and acyclovir should be given if there is any 
evidence of infection (RCOG, 2001).  
6. Varicella prevention 
The aim of varicella immunisation is to protect from exposure those who are at the most risk 
of serious illness. Varicella vaccination prepregancy or postpartum is an effective 
prophylaxis of chickenpox in pregnant women and neonates, and should be considered for 
seronegative women before pregnancy or in the postpartum period. Live-attenuated 
varicella vaccine, made from the OKA strain, was licensed in the United States in 1995 and is 
currently recommended for universal administration in early childhood. Following its 
introduction, the incidence of primary varicella infection has fallen by 90% and the mortality 
related to the condition has decreased by two-thirds (Ngyuen et al., 2005). The vaccine has 
also been shown to be safe and effective in preventing chickenpox in adults (Gershon et al., 
1990). The two-dose varicella vaccine schedule administered to suseptible adolescents and 
adults provides about 75% protection, and the single-dose schedule in children about 95% 
protection against clinical varicella (Annunziato & Gershon, 2000). In both age groups, most 
of the breakthrough infections are modified, and vaccinated individuals who contract 
varicella develop fewer lesions and less systemic illness than unvaccinated individuals 
(Immunisation against infections disease, Varicella, online, updated 2011). Currently, a two-
dose regimen of varicella vaccine, given four to eight weeks apart, is recommended to 
susceptible individuals (Gardella & Brown, 2007; Department of Health, 2004). In the UK, 
varicella immunisation is only offered to specific individuals who are in regular or close 
contact with those at risk (Department of Health, 2004). 
Women who are pregnant should not receive varicella vaccine and pregnancy should be 
avoided for three months following the last dose (Department of Health, 2004). Studies have 
shown that the vaccine virus is not transferred to the infant through breast milk (Bohlke et 
al., 2003) and therefore breast feeding women can be vaccinated if necessary.  
Inadvert exposures to the vaccine in pregnancy have been reported to a register. No cases of 
congenital varicella have been reported so far. Furthermore, the rate of occurrence of 
congenital anomalies was similar to that reported in the general population (Merck 
Pregnancy Registry Program, 2003).  
The varicella immune status of women planning a pregnancy can be determined by 
obtaining a past history of primary varicella infection or by checking the serum for varicella 
antibodies in those who have no history or uncertain history of previous infection. A 
previous history of varicella infection is 97-99% predictive of the presence of serum varicella 
antibodies (CDC, 1996). Routine serologic testing is not recommended for pregnant women 
who received 2 doses of varicella vaccine, since seroconvertion rate after the second dose of 
varicella immunization is as high as 99% (Kuter et al., 1995). Non-immune pregnant women 
should be advised to avoid exposure to chickenpox or shingles and to immediately inform 
healthcare workers of a potential exposure. The US Advisory Committee on Immunization 
Practices recommends that postpartum women without evidence of immunity be given the 
first dose of vaccine before discharge from the hospital, and the second dose of vaccine at 
the follow-up postpartum visit six to eight weeks after delivery (Marin et al., 2007). 
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VZIG after intrauterine exposure to VZV 
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Fig. 8. Measures in case of varicella during pregnancy depending on the point of time of 
infection (Sauerbrei , 2010) 
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Practices recommends that postpartum women without evidence of immunity be given the 
first dose of vaccine before discharge from the hospital, and the second dose of vaccine at 
the follow-up postpartum visit six to eight weeks after delivery (Marin et al., 2007). 
If the pregnant woman has had a significant exposure to varicella infection or shingles, a 
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chickenpox or shingles, vaccination, and the susceptibility of the patient. Significant contact 
is defined as contact in the same room for 15 minutes or more, face-to-face contact and 
contact in the setting of a large open ward. The UK Advisory Group on Chickenpox 
considers any close contact during the period of infectiousness to be significant (Nathwani 
et al., 1998). If the woman’s immunity to chickenpox is unknown and if there is any doubt 
about previous infection, or if there is no previous history of chickenpox or shingles, serum 
should be tested for VZV IgG. At least 80–90% of women tested will have VZ IgG and can 
be reassured (McGregor et al., 1987). 
If the woman has a past history of chickenpox or shingles or two doses of a varicella containing 
vaccine, and is not immunosuppressed, protection can be assumed and reassurance given.  
If the pregnant woman is VZV negative, has indeterminate or unknown serologic status, she 
should be given VZIG as soon as possible (Figure 1), preferably within 72-96 h after the 
exposure (Smith & Arvin, 2009). VZIG is effective when given up to 10 days after contact 
(RCOG, 2001). VZIG recommended intramuscularly at a concentration of 125 U/10 kg of 
body weight, up to a maximum of 625 U (ACIP, 1996) or 0.5 ml/kg of body weight (DGPI, 
2003). A dosage of 1 ml/kg of body weight can be administered intravenously as alternative 
(DGPI, 2003). The primary reason for VZIG prophylaxis in pregnant women is to reduce 
severity of maternal disease and reduce the risk of fetal infection for women contracting 
varicella in the first 20 weeks of pregnancy. The risk of fatal varicella is estimated to be 
about five times higher in pregnant than non-pregnant adults, with fatal cases concentrated 
late in the second or early in the third trimester (Enders & Miller, 2000). One study showed a 
significant reduction in the risk of congenital VZV infection in women who developed 
varicella after VZIG prophylaxis compared with women who developed varicella without 
VZIG prophylaxis; however, the study was too small to assess whether the risk of CVS was 
reduced (Enders et al., 1994). A case of CVS has been reported in the infant of a woman 
exposed at the eleventh week of gestation and who developed clinical varicella despite post-
exposure prophylaxis with VZIG (Pastuszak et al., 1994). About 50% of susceptible pregnant 
women given VZIG after a household exposure to chickenpox will develop clinical varicella, 
although the disease may be attenuated; the clinical attack rates are similar whether VZIG is 
given within 72 hours or four to ten days after contact (Enders & Miller, 2000; Miller et al., 
1993). A further quarter will be infected sub-clinically (Miller et al., 1993). Severe maternal 
varicella may still occur despite VZIG prophylaxis. Prompt treatment with acyclovir is 
indicated in such cases. Women who have had exposure to chickenpox or shingles 
(regardless of whether or not they have received VZIG) should be asked to notify their 
doctor or midwife early if a rash develops (Nathwani et al., 1998).  
Neither immunoglobulin nor acyclovir treatment have been shown to prevent vertical 
transmission or CVS (McKendrick et al., 2007).  
If there is another exposure to chickenpox or shingles three weeks or more after the first use 
of VZIG, the need for VZIG needs to be reassessed.  If more than six weeks have elapsed 
since first issue, antibody testing should be performed using a new (recent) sample ((Health 
Protection Agency [HPA], 2011). 
As VZIG does not always prevent chickenpox, the woman should be managed as being 
possibly infectious 8–28 days after VZIG, and should be asked to contact her family doctor if 
she develops a rash. Up to 50% may develop a modified form of disease. Maternal 
pneumonia associated with chickenpox infection has been reported despite the timely VZIG 
administration (HPA, 2001). 
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1. Introduction 
In 1994, Chang and colleagues isolated two viral DNA fragments from Kaposi’s sarcoma 
(KS) patients which showed homologies to, but were distinct from, genes coding for capsid 
and tegument proteins of two herpesviruses - namely, Epstein-Barr virus and Herpesvirus 
saimiri (Y. Chang et al., 1994). These new herpesvirus-like sequences led to the definition of 
a new human herpesvirus, namely, Kaposi’s sarcoma-associated herpesvirus (KSHV, or 
human herpesvirus type-8, HHV-8). Shortly afterwards it was shown that KSHV is closely 
associated with KS tumours (Dupin et al., 1995; Huang et al., 1995; Moore & Chang, 1995), 
indicating that KSHV is the etiologic agent of KS.  
KSHV infection can be detected in several different cell types, including B-cells (Monini et 
al., 1999), T-cells (Harrington et al., 1996; Sirianni et al., 1997b), monocytes (Blasig et al., 
1997), macrophages (Sirianni et al., 1997a), endothelial cells (Boshoff et al., 1995), and 
dendritic cells (Rettig et al., 1997). Apart from KS, infection with KSHV leads to the 
development of two other tumour diseases: primary effusion lymphoma (PEL), and a subset 
of multicentric Castleman’s disease (MCD) (Cesarman et al., 1995; Soulier et al., 1995). While 
PEL and MCD are primary disorders of the B-cell lineage, KS originates from endothelium-
derived cells. KS is classified into four different epidemiological forms: classic KS, iatrogenic 
KS, African endemic KS, and AIDS-associated epidemic KS. All forms have the same 
histological features, but reveal different progression rates and risk factors, and evolve in 
different populations (Friedman-Kien & Saltzman, 1990).  
The classic KS primarily affects elderly men of Eastern European or Mediterranean origin 
and usually proceeds very slowly. Patients receiving immunosuppressive therapy (e.g. 
after solid-organ transplantation) are at increased risk for iatrogenic KS. This rare form of 
KS is more aggressive than classic KS (Stickler & Friedman-Kien, 1991). The interruption 
or modulation of the immunosuppressive therapy is usually sufficient for the regression 
of iatrogenic KS (Stallone et al., 2005; Wijnveen et al., 1987). The African endemic KS is 
much more aggressive and affects adults as well as children, predominantly in Sub-
Saharan Africa (Stickler & Friedman-Kien, 1991). In the endemic regions, KS accounts for 
up to 13% of all malignancies (Parkin et al., 2008). The most clinically aggressive form of 
KS is the AIDS-associated epidemic KS (AKS). This entity is the most common cancer in 
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
192 
pregnancy: a population based observational study. Scandinavian Journal of 
Infectious Diseases, Vol.35, No.4, pp. 255-259 
Rawson, H.; Crampin, A. & Noah, N. (2001). Deaths from chickenpox in England and 
Wales.1995-7: analysis of routine mortality data. Britsh Medical Journal, Vol.323, pp. 
1091-1093 
Reynolds, L.; Struik, S. & Nadel, S. Neonatal varicella: varicella zoster immunoglobulin 
(VZIG) does not prevent disease. (1999). Archives of Disease in Childhood. Fetal and 
Neonatal Ed, Vol.81, No.1 (Jul), F69-70  
Riley, L. (1998). Varicella-zoster virus infection in pregnancy. Available from: UptoDate, 34 
Washington St., Suite 100, Wellesley, MA 02481, on CD-ROM and by subscription 
at www.uptodate.com 
Royal College of Obstetricians and Gynaecologists. (2001). Chickenpox in pregnancy 
 [online]. Available: 
http://www.rcog.org.uk/resourses/Public/pdf/Chickenpox_No13.pdf  
[Accessed 18 August 2005] 
Sauerbrei, A. & Wutzler, P. (2000). The congenital varicella sindrome. Journal of Perinatology, 
Vol.20 (8 Pt 1), pp. 548-554 
Sauerbrei, A. & Wutzler, P. (2003). Das fetale Varizellensyndrom. Monatsschrift fur 
Kinderheilkunde, Vol.151, pp. 209-213 
Sauerbrei, A,; Pawlak, J.; Luger, C. & Wutzler, P. (2003). Intracerebral varicella-zoster virus 
reactivation in congenital varicella sindrome. Development Medicine and Child 
Neurology, Vol.45, No.12 (Dec), pp. 837-840   
Sauerbrei, A. & Wutzler, P. (2005). Varicella-zoster virus infections during pregnancy: 
Epidemiology, clinical symptoms, diagnosis, preventon and therapy. Current 
Pediatric Reviews, Vol.1, pp. 205-216 
Sauerbrei, A. & Wutzler, P. (2001). Neonatal varicella. Journal of Perinatology, Vol.21, No.8 
(Dec), pp. 545-549 
Sauerbrei, A. (2010). Review of varicella-zoster virus infections in pregnant women and 
neonates. Health, Vol.2, No.2, pp. 143-152  
Schulze, A. & Dietzsch, H.J. (2000). The natural history of varicella embryopathy: A 25-year 
follow-up. Journal of Pediatrics, Vol.137, No.6 (Dec), pp. 871-874 
Sissons, J.G. (2003). Herpesviruses (ecluding Epstein-Barr virus). In: Oxford Textbook of 
Medicine, D.A. Warrell et al. (Eds.), Fourth Editon, Vol.1, Sections 1-10, Oxford 
University press, Oxford 
Smith, C.K. & Arvin, M.A. (2009). Varicella in the fetus and newborn. Seminars in Fetal & 
Neonatal Medicine, Vol.14, No.4 (Aug), pp. 209-217 
Stone, K.M.; Reiff-Eldridge, R.; White, A.D.; Cordero, J.F.; Brown, Z.; Alexander, E.R. & 
Andrews, E.B. (2004). Pregnancy outcomes following systemic prenatal acyclovir 
exposure: conclusions from the International acyclovir pregnancy registry, 1984- 
1999. Birth Defects Research.Part A, Clinical and Molecular Teratology, Vol.70, No.4 
(Apr), pp. 201-207. 
Tan, M.P. & Koren, G. (2006). Chickenpox in pregnancy: revisited. Reproductive Toxicology, 
Vol.21, No.4 (May), pp. 410-420 
Wallace, M.R.; Bowler, W.A.; Murray, N.B.; Brodine, S.K. & Oldfield, E.C. (1992). Treatment 
of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. 
Annals of Internal Medicine, Vol.117, No.5 (Sep 1), pp. 358-363 
9 
KSHV Paracrine Effects on Tumorigenesis 
Ramona Jochmann1, Peter Lorenz3, Priya Chudasama1,  
Christian Zietz2, Michael Stürzl1 and Andreas Konrad1 
1Division of Molecular and Experimental Surgery, Department of Surgery,  
University Medical Centre Erlangen, Erlangen,  
2Institute for Pathology, University Medical Centre Carl Gustav Carus, Dresden,  
3Gefäßzentrum Münchner Freiheit, Munich,  
Germany 
1. Introduction 
In 1994, Chang and colleagues isolated two viral DNA fragments from Kaposi’s sarcoma 
(KS) patients which showed homologies to, but were distinct from, genes coding for capsid 
and tegument proteins of two herpesviruses - namely, Epstein-Barr virus and Herpesvirus 
saimiri (Y. Chang et al., 1994). These new herpesvirus-like sequences led to the definition of 
a new human herpesvirus, namely, Kaposi’s sarcoma-associated herpesvirus (KSHV, or 
human herpesvirus type-8, HHV-8). Shortly afterwards it was shown that KSHV is closely 
associated with KS tumours (Dupin et al., 1995; Huang et al., 1995; Moore & Chang, 1995), 
indicating that KSHV is the etiologic agent of KS.  
KSHV infection can be detected in several different cell types, including B-cells (Monini et 
al., 1999), T-cells (Harrington et al., 1996; Sirianni et al., 1997b), monocytes (Blasig et al., 
1997), macrophages (Sirianni et al., 1997a), endothelial cells (Boshoff et al., 1995), and 
dendritic cells (Rettig et al., 1997). Apart from KS, infection with KSHV leads to the 
development of two other tumour diseases: primary effusion lymphoma (PEL), and a subset 
of multicentric Castleman’s disease (MCD) (Cesarman et al., 1995; Soulier et al., 1995). While 
PEL and MCD are primary disorders of the B-cell lineage, KS originates from endothelium-
derived cells. KS is classified into four different epidemiological forms: classic KS, iatrogenic 
KS, African endemic KS, and AIDS-associated epidemic KS. All forms have the same 
histological features, but reveal different progression rates and risk factors, and evolve in 
different populations (Friedman-Kien & Saltzman, 1990).  
The classic KS primarily affects elderly men of Eastern European or Mediterranean origin 
and usually proceeds very slowly. Patients receiving immunosuppressive therapy (e.g. 
after solid-organ transplantation) are at increased risk for iatrogenic KS. This rare form of 
KS is more aggressive than classic KS (Stickler & Friedman-Kien, 1991). The interruption 
or modulation of the immunosuppressive therapy is usually sufficient for the regression 
of iatrogenic KS (Stallone et al., 2005; Wijnveen et al., 1987). The African endemic KS is 
much more aggressive and affects adults as well as children, predominantly in Sub-
Saharan Africa (Stickler & Friedman-Kien, 1991). In the endemic regions, KS accounts for 
up to 13% of all malignancies (Parkin et al., 2008). The most clinically aggressive form of 
KS is the AIDS-associated epidemic KS (AKS). This entity is the most common cancer in 
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
194 
patients infected with the human immunodeficiency virus type-1 (HIV-1). HIV-1-positive 
homosexual men are predominantly affected (J.N. Martin et al., 1998). The fact that co-
infection with HIV-1 acts as co-factor for AKS development is specifically supported by 
the significant decline of AKS incidence after the introduction of highly active anti-
retroviral therapy (HAART) for treatment of HIV-1 infection (J. Gill et al., 2002; 
Ledergerber et al., 1999). Nevertheless, KS is still among the most commonly observed 
tumours in certain regions of central Africa, and is a clinical threat for organ transplant 
recipients (Parkin et al., 2008; Trattner et al., 1993). 
In 1996, the complete genome sequence of KSHV was made available, indicating that KSHV 
encodes more than 86 genes (Neipel et al., 1997; Russo et al., 1996). The large KSHV genome 
provides innumerable possibilities to interfere with cellular signalling cascades in the course 
of the viral life cycle and thereby induce tumorigenesis. It is still an unsolved question how 
KSHV may initiate and/or perpetuate KS development. Research on KS tumorigenesis was 
hampered for long time by the fact that an efficient in vitro culture system for KSHV 
infection and replication in endothelial derived cells was lacking. Moreover, an appropriate 
animal model system in which KSHV transmission causes KS is missing. Sporadic 
observations of KS development in common marmosets (New World primates) require still 
further confirmation (H. Chang et al., 2009). In this chapter, we will review the 
histopathology of KS and the oncogenic potential of KSHV.  
2. KS histogenesis and the biology of the KS spindle cells 
KS was first described by Moritz Kaposi in 1872 as an idiopathic multiple pigment sarcoma 
of the skin (Kaposi, 1872). KS is a multifocal, highly vascularised tumour of endothelial 
origin with a complex histology. Apart from KSHV-positivity, KS lesions contain three 
further hallmarks — (1) a pronounced inflammatory infiltrate composed of monocytes, 
macrophages, T-cells and dendritic cells, (2) neovascular spaces, which are incomplete or 
dilated vessel-like structures, often associated with extravasated erythrocytes and oedema, 
and (3) predominantly in later stages of tumour development, bundles of spindle shaped 
cells, which are called the KS spindle cells and are considered to be the tumour cells of KS 
(Gottlieb & Ackerman, 1988; Grayson & Pantanowitz, 2008; Stickler & Friedman-Kien, 1991). 
The tumour occurs at onset predominantly in the skin, visceral organs, and lymph nodes, 
while in progressed late stages, all organs can be affected (Pantanowitz & Dezube, 2008). KS 
evolves over time from the early patch stage to the intermediate plaque stage and manifests 
later on into a nodular stage. The patch stage is characterized by pinpoint macules on the 
skin with proliferating endothelial cells, which form the slit-like neovascular structures. 
These neovascular channels are only partially lined with KSHV-positive cells (Dupin et al., 
1999), lack coating by pericytes or smooth muscle cells, and are prone to leakage and 
rupture (McNutt et al., 1983). Early-stage lesions are further characterized by the presence of 
infiltrating inflammatory cells such as macrophages, monocytes, dendritic cells, and B- and 
T-cells (Gottlieb & Ackerman, 1988). Productive KSHV infection of B-cells, monocytes, and 
macrophages within KS lesions has been described (Ascherl et al., 1999a; Blasig et al., 1997; 
Stürzl et al., 2001), indicating that these cells may represent the viral replication reservoirs. 
In the plaque stage, flat macules and patches start to enlarge vertically to slightly elevated 
lesions termed papules or plaques. In this stage, the typical KS spindle cells appear. In the 
nodular stage, the KS spindle cells become the predominant cell type. Up to 80% of these 
cells are infected by KSHV, wherein the virus resides mainly in the latent stage of the viral 
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life cycle (Staskus et al., 1997; Stürzl et al., 1997). These cells were initially considered as the 
main proliferating element of KS.  
The nature of the KS spindle cells has been debated for many years. Nowadays, it is 
commonly accepted that the spindle cells are of endothelial origin, as most of them express 
markers of both lymphatic and blood vessel derived endothelial cells (Boshoff et al., 1995; 
Stürzl et al., 1992a). However, whether these cells originate from lymph or blood vessel 
endothelial cells (LECs and BECs respectively) is still not unequivocally proven. Initial in 
vivo studies of AIDS- and classic KS showed that the KS spindle cells are of endothelial 
origin (CD31-positive), and related to, or even derived from, LECs. The KS spindle cells 
stained positive for the typical lymph endothelial markers vascular endothelial growth 
factor receptor (VEGFR)-3 and podoplanin (Dupin et al., 1999; Skobe et al., 1999; Weninger 
et al., 1999), but were negative for BEC marker (Beckstead et al., 1985; Roth et al., 1992), 
excluding their origin from blood vessel or hematopoietic cells.  
However, several further studies showed that KSHV does not only infect LECs, but also 
BECs (Carroll et al., 2004; Moses et al., 1999; Poole et al., 2002). Microarray analyses revealed 
that infection with KSHV seems to induce a cellular reprogramming of each cell type 
towards the gene expression profile of the other, driving these cells away from their 
terminally differentiated state towards the opposing lineage (Hong et al., 2004; Petrova et 
al., 2002; H.W. Wang et al., 2004). This was supported by observations that KSHV-infection 
of BECs led to increased expression of LEC markers such as VEGFR-3, podoplanin, LYVE-1, 
PROX1, VEGF-A and VEGF-C (Carroll et al., 2004; Sivakumar et al., 2008), while in parallel, 
KSHV infection of LECs led to increased expression of BEC markers (H.W. Wang et al., 
2004). Thus, the resulting infected LECs or BECs are more similar to one another than their 
uninfected counterparts. This is in agreement with the observation that KS spindle cells do 
not represent the typical transcriptional profile of LECs nor of BECs, but instead are poorly 
differentiated, expressing markers of both lymphatic and blood vessel endothelium 
(Cornelissen et al., 2003; Lagos et al., 2007; Pyakurel et al., 2006b; H.W. Wang et al., 2004). 
Currently, two hypotheses describe the origin of the KS spindle cells: the first hypothesis 
suggests that KSHV infects both BECs and LECs, and induces a transcriptional 
dedifferentiation towards the gene expression profile of an endothelial precursor cell (EPC) (R. 
Liu et al., 2010). This hypothesis is supported by the studies of Chang et al., where a high-
throughput approach was employed to study the genome-wide alternative splicing events in 
LECs and CD34+ EPCs (T.Y. Chang et al., 2011). The authors found a significant difference in 
the exon usage between LECs and CD34+ EPCs, and observed that KSHV infection of LECs 
resulted in a LEC-to-precursor dedifferentiation-like reprogramming. Moreover, it seems that 
KSHV prefers LECs, as (1) mature endothelial cells surrounding normal vascular blood vessels 
within a KS lesion are only very rarely infected with KSHV (Dupin et al., 1999; Lorenz, 2007) 
and (2) LECs exhibit an increased number of viral genome copies per cell compared to BECs, 
indicating that the virus replicates more efficiently in LECs than in BECs (H.W. Wang et al., 
2004). The second hypothesis suggests that KSHV productively infects and replicates in CD34+ 
EPCs, which might serve as the KSHV reservoir (Della Bella et al., 2008; Henry et al., 1999; 
Pellet et al., 2006; Wu et al., 2006). This is in accordance with the observation that CD34+ 
circulating endothelial cells are increased in classic KS patients (Taddeo et al., 2008) and that 
KSHV-infected CD34+ hematopoietic progenitor cells are transmitted through the graft during 
transplantation (Barozzi et al., 2003). KSHV infection of circulating EPCs might drive their 
gene expression profile towards a more lymphatic genotype. This would explain the 
simultaneous expression of marker proteins for lymphatic endothelial cells, blood vessel 
endothelial cells, and pericytes, which originate all from CD34+ EPCs. 
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patients infected with the human immunodeficiency virus type-1 (HIV-1). HIV-1-positive 
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(Gottlieb & Ackerman, 1988; Grayson & Pantanowitz, 2008; Stickler & Friedman-Kien, 1991). 
The tumour occurs at onset predominantly in the skin, visceral organs, and lymph nodes, 
while in progressed late stages, all organs can be affected (Pantanowitz & Dezube, 2008). KS 
evolves over time from the early patch stage to the intermediate plaque stage and manifests 
later on into a nodular stage. The patch stage is characterized by pinpoint macules on the 
skin with proliferating endothelial cells, which form the slit-like neovascular structures. 
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life cycle (Staskus et al., 1997; Stürzl et al., 1997). These cells were initially considered as the 
main proliferating element of KS.  
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KSHV prefers LECs, as (1) mature endothelial cells surrounding normal vascular blood vessels 
within a KS lesion are only very rarely infected with KSHV (Dupin et al., 1999; Lorenz, 2007) 
and (2) LECs exhibit an increased number of viral genome copies per cell compared to BECs, 
indicating that the virus replicates more efficiently in LECs than in BECs (H.W. Wang et al., 
2004). The second hypothesis suggests that KSHV productively infects and replicates in CD34+ 
EPCs, which might serve as the KSHV reservoir (Della Bella et al., 2008; Henry et al., 1999; 
Pellet et al., 2006; Wu et al., 2006). This is in accordance with the observation that CD34+ 
circulating endothelial cells are increased in classic KS patients (Taddeo et al., 2008) and that 
KSHV-infected CD34+ hematopoietic progenitor cells are transmitted through the graft during 
transplantation (Barozzi et al., 2003). KSHV infection of circulating EPCs might drive their 
gene expression profile towards a more lymphatic genotype. This would explain the 
simultaneous expression of marker proteins for lymphatic endothelial cells, blood vessel 
endothelial cells, and pericytes, which originate all from CD34+ EPCs. 
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3. KS tumorigenesis  
As detailed above, KS lesions display a remarkable diversity of cell types, dominated by 
endothelial-derived KS spindle cells (Regezi et al., 1993; Stürzl et al., 1992a). While the 
infiltrating inflammatory cells appear already during the early patch stage, the KS spindle 
cells start to appear in the intermediate plaque stage and are present in increased numbers 
in late nodular stages. In the late stages of KS, nearly all spindle cells are infected (Dupin et 
al., 1999; Katano et al., 2000; Staskus et al., 1997; Stürzl et al., 1997), indicating that the 
spindle cells constitute the main tumour mass of KS. The abundance of spindle cells in late 
stage lesions is thought to derive from the growth and/or survival advantages of infected 
over uninfected cells due to oncoviral transformation by KSHV.   
3.1 KS: Reactive hyperplasia rather than true malignancy? 
Among the oncoviruses, especially throughout the herpesviruses, virus-induced 
transformation of cells occurs mostly due to the continuous expression of viral proteins in 
the host cell. For example, among the closest relatives of KSHV, the herpesvirus saimiri 
(HVS) transforms T-cells by expressing the saimiri transformation-associated protein (Stp) 
and in the HVS subgroup C additionally the tyrosine kinase-interacting protein (Tip) 
(Biesinger et al., 1995; Duboise et al., 1998; Murthy et al., 1989), while the Epstein-Barr virus 
(the only other known member of the human pathogenic gamma-herpesviruses) transforms 
resting primary human B-cells by continuously expressing the latent membrane protein-1 
(LMP-1) (D. Wang et al., 1985). In contrast, it is still unclear whether KSHV-infection results 
in full tumorigenic cell transformation, and the underlying mechanisms of KS tumorigenesis 
are unknown. Several studies have tried to address these questions, but the mechanisms of 
cell alteration used by KSHV differ from that of other oncogenic viruses.  
One crucial question is whether KS represents a hyperplastic proliferation or a clonal 
neoplastic growth. Several features indicate a neoplastic transformation of the KS spindle cells, 
such as anchorage independent growth and prolonged survival due to increased telomerase 
activity (Chen et al., 2001; Flore et al., 1998; Moses et al., 1999), protection from apoptosis (Mori 
et al., 1996; Morris et al., 1996; Stürzl et al., 1999; Thurau et al., 2009), increased angiogenesis, 
inflammation, invasion and metastasis (Gottlieb & Ackerman, 1988), genomic instability 
(Cuomo et al., 2008; Pan et al., 2004; Pyakurel et al., 2006a; Si & Robertson, 2006), and immune 
evasion strategies (Means et al., 2002), as well as the ability to reprogram the cellular 
metabolism (Karki et al., 2011; Montaner, 2007). Moreover, two studies indicated monoclonal 
expansion of KS. In the first study, KS clonality has been assessed by determining the 
methylation pattern of the X-linked androgen receptor gene (HUMARA) (Rabkin et al., 1997). 
The authors proved concordance among the methylation pattern of the HUMARA alleles in 
several different KS tumours from a given patient (in total, 8 female patients), indicating that 
multiple KS lesions in the same patient arise from a single clone of cells (Rabkin et al., 1997). 
The second study examined the clonal loss of the Y-chromosome in 20 of 23 male KS biopsies, 
as analysed by comparative genomic hybridisation (CGH) analysis (Pyakurel et al., 2006a). 
However, this study did not clarify if KSHV preferentially infects endothelial precursor cells 
that have sporadically lost their Y-chromosome or whether KSHV infection triggers the loss of 
the Y chromosome. 
In contrast, a considerable amount of evidence is supporting a hyperplastic process of 
tumour development. First, KS spindle cells seem to be incompletely immortalised. This is 
indicated by the fact that (1) explanted KS cells are strongly dependent on external cytokines 
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and growth factors for the growth in vitro (Ensoli et al., 1989; Roth et al., 1989) and for the 
induction of tumours in immunodeficient mice (Salahuddin et al., 1988) and (2) KS spindle 
cells loose their ability to proliferate ad infinitum after explantation (Gao et al., 2003; 
Grossmann et al., 2006; Roth et al., 1989).  
Second, KSHV-infected spindle cells do not exhibit enhanced proliferation in KS lesions, but 
on the contrary, show significantly reduced proliferation rates as compared to uninfected 
cells (Kaaya et al., 2000; Kaaya et al., 1995; Köster et al., 1996). In this context, Pyakurel and 
colleagues showed that only a small fraction (up to 5%) of all latency-associated nuclear 
antigen (LANA)-1-positive KS spindle cells proliferate in KS lesions (Pyakurel et al., 2004). 
Our data confirmed these findings (Lorenz, 2007). KS lesions were stained for LANA-1 as a 
marker for infected cells (Fig. 1C, brown staining) and for Ki67 as a marker for proliferating 
cells (Fig. 1C, blue staining). Using double staining procedure of KS lesions, we could 
demonstrate that KSHV-infected cells were only rarely proliferating, while the main 
proliferating population was composed of uninfected cells (Fig. 1C). By contrast, in body 
cavity based lymphoma cells, most of the infected cells (Fig. 1A, LANA-1, brown staining) 
are also proliferating (Fig. 1B, Ki67, brown staining). Thus, in KS lesions, the KSHV-infected 
cells do not represent the major proliferative element.  
 
 
Fig. 1. KSHV infection and cell proliferation in body cavity-based lymphomas (A, B) and KS 
(C). Immunohistochemical detection of KSHV-LANA-1 (A) and of the proliferation-
associated antigen Ki67 (B) in body cavity-based lymphoma cells shows that almost every 
infected cell is proliferating. Immunohistochemical double staining procedure of KSHV-
LANA-1 (C, brown staining) and of the proliferation-associated antigen Ki67 (C, blue 
staining) in KS tissue shows that KSHV-infected cells are only rarely proliferating and that 
the major proliferative activity is observed in non-infected cells. Examples of positively 
stained cells are indicated by arrows. 
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and growth factors for the growth in vitro (Ensoli et al., 1989; Roth et al., 1989) and for the 
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demonstrate that KSHV-infected cells were only rarely proliferating, while the main 
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Fig. 1. KSHV infection and cell proliferation in body cavity-based lymphomas (A, B) and KS 
(C). Immunohistochemical detection of KSHV-LANA-1 (A) and of the proliferation-
associated antigen Ki67 (B) in body cavity-based lymphoma cells shows that almost every 
infected cell is proliferating. Immunohistochemical double staining procedure of KSHV-
LANA-1 (C, brown staining) and of the proliferation-associated antigen Ki67 (C, blue 
staining) in KS tissue shows that KSHV-infected cells are only rarely proliferating and that 
the major proliferative activity is observed in non-infected cells. Examples of positively 
stained cells are indicated by arrows. 
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Third, several studies provided evidence that KS expansion is polyclonal. The largest study 
was performed in 2007 on 62 biopsies. In order to investigate the cellular clonality of KS 
lesions, the authors determined the size heterogeneity of the KSHV-fused terminal repeat 
region (Duprez et al., 2007). The authors revealed in 59 cases a clonal pattern. Of those, 11 
KS lesions were monoclonal, while 48 were oligoclonal expansions. Other studies sustain 
these findings, although performed with a smaller number of biopsies (Delabesse et al., 
1997; P.S. Gill et al., 1998; Judde et al., 2000).  
Fourth, KS lesions show a substantial rate of spontaneous remission, observed after the 
introduction of HAART (J. Gill et al., 2002; Ledergerber et al., 1999), cessation of 
immunosuppression (Kondo et al., 2000; Nagy et al., 2000), or treatment with ganciclovir or 
foscarnet, which selectively inhibits lytic KSHV replication (Glesby et al., 1996; Mocroft et 
al., 1996). Together, these features imply that KS is not a true malignancy, but rather a 
polyclonal reactive hyperplasia.  
3.2 Contribution of latency and lytic replication to KS tumorigenesis 
As typical for herpesviruses, KSHV establishes a latent state of infection after entering the 
cell. During latency, only a few viral genes are expressed, among them are the LANA-1, 
viral cyclin, viral FLICE-inhibitory protein (vFLIP), Kaposin, and the viral-encoded 
microRNAs. All of the latently expressed proteins have been shown to have individual 
transforming potential by driving cell proliferation and preventing apoptosis (Friborg et al., 
1999; Muralidhar et al., 1998; Radkov et al., 2000; Stürzl et al., 1999; Stürzl et al., 2001; Sun et 
al., 2003; Verschuren et al., 2002). Therefore, it was long assumed that latently expressed 
proteins are involved in KS tumorigenesis and that latently infected cells contribute 
significantly to the development of KS. The fact that most of the KS spindle cells are latently 
infected is in line with the herpesviral persuasion that the latency program drives 
tumorigenesis.  
Nevertheless, several lines of evidence suggest that latent replication is not sufficient to 
induce KS. First, KS is typically observed in patients with higher circulating KSHV loads, 
indicating that lytic expression is necessary for the recruitment and de novo infection of cells 
(Campbell et al., 2000; Whitby et al., 1995). Second, ganciclovir and foscarnet have been 
shown to mediate the long-term remission of KS (Glesby et al., 1996; Mocroft et al., 1996), 
again indicating that ongoing lytic replication is necessary for lesion formation. Third, 
immunosuppression favours KS development, and this is connected with KSHV 
reactivation and lytic replication (Bourboulia et al., 2004; D.F. Martin et al., 1999). Fourth, 
cells expressing only latent genes are unable to induce tumour formation in nude mice, 
unless cells expressing viral G protein-coupled receptor (vGPCR), a lytic cycle protein, are 
co-injected (Montaner et al., 2006). A contribution of lytic replication to the development of 
KS is further sustained by the fact that a minority of cells within KS lesions do express lytic 
viral proteins and produce virions (Orenstein et al., 1997; Staskus et al., 1997). 
By now, the crucial question arises concerning the way lytically infected cells might 
contribute to KS tumour development, albeit (1) only up to 2% of the infected cells within 
KS lesions replicate lytically and (2) all lytically infected cells die after virus release. The 
common hypothesis is based on the fact that KSHV encodes many viral lytic genes whose 
products are secreted factors homologous to cellular chemokines, cytokines, and growth 
factors, such as the viral interleukin (IL)-6 and the three viral chemokines (vCCL-1, -2, and -
3, or alternatively named viral macrophage inflammatory protein, vMIP-I, -II, and III) 
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(Nicholas, 2003). The vIL-6 is produced and released by infected cells during lytic infection 
and activates cell proliferation (Meads & Medveczky, 2004) and local angiogenesis (Aoki et 
al., 1999), while the viral MIPs are agonists for cellular chemokine receptors and exhibit 
angiogenic properties (Boshoff et al., 1997; Endres et al., 1999; C. Liu et al., 2001; Stine et al., 
2000). The vMIP-I was shown to induce the migration of endothelial cells, which suggests 
that uninfected endothelial cells are recruited to the KS lesion as a target for infection 
(Haque et al., 2001) and vMIP-II was demonstrated to be a selective chemoattractant for Th2 
cells and monocytes (Sozzani et al., 1998). Furthermore, two KSHV transmembrane proteins 
– K1, an immunoreceptor tyrosine-based activation motif (ITAM) containing receptor, and 
vOX2, a glycosylated cell surface protein belonging to the immunoglobulin superfamily 
homologous to the cellular OX2 protein – are suggested to be important for secretion of 
cellular inflammatory cytokines and growth factors. K1 induces the expression of VEGF and 
matrix metalloproteinase-9 (MMP-9) in endothelial cells (L. Wang et al., 2004), indicating its 
role in proliferation and migration of these cells. Solubilised vOX2 stimulates monocytes, 
macrophages, and dendritic cells to produce the inflammatory cytokines IL-1β, IL-6, 
monocyte chemoattractant protein 1 (MCP-1), and tumour necrosis factor α (TNF-α) (Chung 
et al., 2002). Thus, lytically infected cells are thought to produce or activate signalling 
molecules which promote inflammation and angiogenesis in the KS lesions in a paracrine 
manner.  
In addition, KSHV encodes a vGPCR, a homologue of the cellular IL-8 receptor CXCR2, 
which has a mutation within the highly conserved DRY sequence, rendering the receptor 
constitutively active. Therefore, the vGPCR was long thought to play a key role in the 
initiation of KS. This was further enforced in 2003, when Montaner and colleagues 
succeeded in engineering a novel transgenic mouse that allowed endothelial cell-specific 
retroviral transduction. With that technique, they expressed several single KSHV genes that 
were assumed to have oncogenic properties in mouse endothelial cells. The authors showed 
that the vGPCR was the only gene that was able and sufficient to induce angioproliferative 
tumours that resembled human KS (Montaner et al., 2003). Thus, lytically expressed vGPCR 
may contribute to KS pathogenesis. As vGPCR is a protein produced only during the lytic 
replication of KSHV, its expression should correlate with the rate of lytically replicating cells 
in KS lesions. Concordantly, in all KS mouse models, expression of vGPCR is restricted to a 
small subset of cells within the lesions, which is similar to the part of lytically replicating 
cells in human KS. This supports the hypothesis that vGPCR influences tumour growth by 
paracrine mechanisms promoted by the cytokines, chemokines, and growth factors secreted 
by vGPCR-expressing cells (Jham & Montaner, 2010). However, it remains to be proven if 
the vGPCR alone (together with latently infected cells) is sufficient to trigger KS 
tumorigenesis or additional factors are necessary. 
3.3 Interplay between inflammatory cytokines and angiogenic factors in KS 
tumorigenesis  
KS tumorigenesis is characterized by the interplay between three processes: proliferation, 
inflammation and angiogenesis. These processes are connected by paracrine signalling 
pathways driven by the interplay between viral gene products, inflammatory cytokines, and 
growth factors released not only by infected cells, but also by chemoattracted infiltrating 
inflammatory cells. KSHV-infected cells secrete factors, such as MCP-1 or granulocyte-
macrophage-colony-stimulating factor (GM-CSF), to recruit and activate inflammatory cells 
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products are secreted factors homologous to cellular chemokines, cytokines, and growth 
factors, such as the viral interleukin (IL)-6 and the three viral chemokines (vCCL-1, -2, and -
3, or alternatively named viral macrophage inflammatory protein, vMIP-I, -II, and III) 
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(Nicholas, 2003). The vIL-6 is produced and released by infected cells during lytic infection 
and activates cell proliferation (Meads & Medveczky, 2004) and local angiogenesis (Aoki et 
al., 1999), while the viral MIPs are agonists for cellular chemokine receptors and exhibit 
angiogenic properties (Boshoff et al., 1997; Endres et al., 1999; C. Liu et al., 2001; Stine et al., 
2000). The vMIP-I was shown to induce the migration of endothelial cells, which suggests 
that uninfected endothelial cells are recruited to the KS lesion as a target for infection 
(Haque et al., 2001) and vMIP-II was demonstrated to be a selective chemoattractant for Th2 
cells and monocytes (Sozzani et al., 1998). Furthermore, two KSHV transmembrane proteins 
– K1, an immunoreceptor tyrosine-based activation motif (ITAM) containing receptor, and 
vOX2, a glycosylated cell surface protein belonging to the immunoglobulin superfamily 
homologous to the cellular OX2 protein – are suggested to be important for secretion of 
cellular inflammatory cytokines and growth factors. K1 induces the expression of VEGF and 
matrix metalloproteinase-9 (MMP-9) in endothelial cells (L. Wang et al., 2004), indicating its 
role in proliferation and migration of these cells. Solubilised vOX2 stimulates monocytes, 
macrophages, and dendritic cells to produce the inflammatory cytokines IL-1β, IL-6, 
monocyte chemoattractant protein 1 (MCP-1), and tumour necrosis factor α (TNF-α) (Chung 
et al., 2002). Thus, lytically infected cells are thought to produce or activate signalling 
molecules which promote inflammation and angiogenesis in the KS lesions in a paracrine 
manner.  
In addition, KSHV encodes a vGPCR, a homologue of the cellular IL-8 receptor CXCR2, 
which has a mutation within the highly conserved DRY sequence, rendering the receptor 
constitutively active. Therefore, the vGPCR was long thought to play a key role in the 
initiation of KS. This was further enforced in 2003, when Montaner and colleagues 
succeeded in engineering a novel transgenic mouse that allowed endothelial cell-specific 
retroviral transduction. With that technique, they expressed several single KSHV genes that 
were assumed to have oncogenic properties in mouse endothelial cells. The authors showed 
that the vGPCR was the only gene that was able and sufficient to induce angioproliferative 
tumours that resembled human KS (Montaner et al., 2003). Thus, lytically expressed vGPCR 
may contribute to KS pathogenesis. As vGPCR is a protein produced only during the lytic 
replication of KSHV, its expression should correlate with the rate of lytically replicating cells 
in KS lesions. Concordantly, in all KS mouse models, expression of vGPCR is restricted to a 
small subset of cells within the lesions, which is similar to the part of lytically replicating 
cells in human KS. This supports the hypothesis that vGPCR influences tumour growth by 
paracrine mechanisms promoted by the cytokines, chemokines, and growth factors secreted 
by vGPCR-expressing cells (Jham & Montaner, 2010). However, it remains to be proven if 
the vGPCR alone (together with latently infected cells) is sufficient to trigger KS 
tumorigenesis or additional factors are necessary. 
3.3 Interplay between inflammatory cytokines and angiogenic factors in KS 
tumorigenesis  
KS tumorigenesis is characterized by the interplay between three processes: proliferation, 
inflammation and angiogenesis. These processes are connected by paracrine signalling 
pathways driven by the interplay between viral gene products, inflammatory cytokines, and 
growth factors released not only by infected cells, but also by chemoattracted infiltrating 
inflammatory cells. KSHV-infected cells secrete factors, such as MCP-1 or granulocyte-
macrophage-colony-stimulating factor (GM-CSF), to recruit and activate inflammatory cells 
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(especially CD8+-T-cells, plasma cells, monocytes and macrophages) to the site of infection 
(Barillari et al., 1992; Ensoli & Stürzl, 1998; Sciacca et al., 1994). To further enhance the 
infiltration and binding of immune cells within the lesions, KS spindle cells express 
additionally high levels of adhesion molecules, such as intercellular adhesion molecule 1 
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin (Fiorelli et al., 1995; 
Galea et al., 1998). The recruited and activated infiltrating inflammatory cells in turn release 
inflammatory cytokines (IC), such as IFN-γ, IL-1β, TNF-α, and IL-6, which are essential for 
the activation and proliferation of cells comprised in the KS lesions. Interestingly, these 
cytokines can induce uninfected endothelial cells to acquire the phenotypic and functional 
features of KS spindle cells (Fiorelli et al., 1998; Monini et al., 1999; Qin et al., 2010; 
Samaniego et al., 1995; Sirianni et al., 1998; Stürzl et al., 1995). In accordance, these cytokines 
are also detected in vivo at increased concentrations in the serum of patients with all forms 
of KS and of individuals at high risk for KS (Emilie et al., 1990; Ensoli et al., 1992; Fuchs et 
al., 1989; Hober et al., 1989). 
The presence of an inflammatory milieu is further supported by several studies that have 
been performed to analyse the impact of KSHV infection on the transcriptome or proteome 
of endothelial cells. KSHV-infection is associated with a strong IFN-related cell response. 
Up-regulation of several interferon-inducible proteins, interferon-induced transmembrane 
protein 1 (IFI9-27), myxovirus resistance protein 1 (MxA), CXCL11, and members of the 
guanylate binding protein (GBP) family were observed (Chandriani & Ganem, 2007; Lagos 
et al., 2007; Moses et al., 2002; Naranatt et al., 2004; Poole et al., 2002; Stürzl et al., 2009). Of 
these factors, especially  GBP-1 has been shown to have antiangiogenic effects in endothelial 
cells in vitro and in vivo (Guenzi et al., 2001; Guenzi et al., 2003; Hammon et al., 2011; 
Lubeseder-Martellato et al., 2002; Naschberger et al., 2008), which might explain the 
observed reduced proliferation rate in infected spindle cells within KS lesions.  
Additionally to the IC, the infiltrating inflammatory cells release the angiogenic growth 
factors basic fibroblast growth factor (bFGF) and VEGF, which are known to induce 
angiogenesis, vascular permeability, and oedema, the typical histological features of KS 
(Barillari et al., 1992; Barillari et al., 1999; Samaniego et al., 1998). These angiogenic growth 
factors were detected at increased concentrations in the serum of HIV-1 infected patients, 
supporting their important role in KS pathogenesis (Ascherl et al., 1999b). Furthermore, 
another growth factor, namely PDGF-B, was shown to be an important paracrine mitogen in 
KS lesions. In vitro, PDGF-B activates the proliferation and migration of KS spindle cells. In 
vivo gene expression analysis revealed that PDGF-B, as well as the PDGF-receptor, is present 
in KS lesions (Köster et al., 1996; Stürzl et al., 1995; Stürzl et al., 1992b). Accordingly, 
treatment of AIDS-related KS patients with imatinib, an inhibitor of the PDGF-receptor, 
induced clinical regression of KS in five out of ten patients within four weeks of therapy. 
Imatinib is also active against c-kit, another receptor tyrosine kinase that has been 
implicated in KS formation. Thus, further molecular studies and clinical trials are necessary 
to better elucidate the significance of PDGF-receptor and c-kit expression in KS and the 
therapeutic role of imatinib (Koon et al., 2005; Rossi et al., 2009).  
The angiogenic environment in the KS lesions is further promoted by numerous paracrine 
or juxtacrine active proteins expressed by KSHV-infected cells. For example, increased 
expression of Angiopoeitin-2 (Ang-2), angiopoietin-related protein 4, angiopoietin-like 
polypeptide, ephrins A1 and B2, endothelin convertase, serpin B2 (plasminogen activator 
inhibitor 2), VEGF-A and -C, thrombomodulin, members of the matrix metalloproteinases 
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(MMP-1 and -9), urokinase-type plasminogen activator receptor, CXCR7, and MCP-1 has 
been observed upon KSHV infection (Chandriani & Ganem, 2007; Cornali et al., 1996; Moses 
et al., 2002; Naranatt et al., 2004; Poole et al., 2002; Thewes et al., 2000; Vart et al., 2007). Of 
those, Ang-2 is thought to destabilise endothelial cells interaction and to prime endothelial 
cells to respond to angiogenic stimuli, such as VEGF (Gale et al., 2002). It also plays an 
important function in lymphangiogenesis (Gale et al., 2002) and regulates the expression of 
inflammatory proteins in endothelial cells (Fiedler et al., 2006).  
Moreover, lytically replicating KSHV-infected cells express a vGPCR, which has the ability 
to up-regulate the activity of numerous transcription factors, such as hypoxia inducible 
factor-1α (HIF-1α), nuclear factor-kappaB (NF-κB), activator protein-1 (AP-1), cAMP 
response element-binding protein (CREB) and nuclear factor of activated T cells (NFAT), 
and thereby mediates the secretion of paracrine factors promoting endothelial cell survival, 
proliferation and angiogenesis. Among the paracrine-acting factors are angiogenic growth 
factors such as VEGF, bFGF, and VEGFR-2, pro-inflammatory chemokines and cytokines 
such as IL-1β, IL-2, IL-4, IL-6, IL-8, MIP-1, and TNF-α, and adhesion molecules such as 
ICAM-1, VCAM-1, and E-selectin (Arvanitakis et al., 1997; Bais et al., 1998; Grisotto et al., 
2006; D. Martin et al., 2008; Montaner et al., 2004; Schwarz & Murphy, 2001; Sodhi et al., 
2000; Yang et al., 2000). 
In summary, viral proteins and virus-induced cellular proteins are secreted by infected cells 
and act in autocrine and paracrine loops to recruit inflammatory cells into the lesions, which 
in turn secrete inflammatory cytokines, chemokines, and angiogenic growth factors. The fact 
that KSHV-infection leads to up-regulation of angiogenesis-related and interferon-inducible 
genes in endothelial cells highlights the importance of an inflammatory-angiogenic milieu 
during KS tumorigenesis. This is further sustained by the observation that these genes are 
strongly transcribed, although KSHV encodes a DNA exonuclease SOX/orf37, which 
mediates the shut-off of host transcription during the lytic cycle of KSHV (Chandriani & 
Ganem, 2007). All these secreted proteins appear to cooperate in the activation of 
endothelial cells and are important for tumour neovascularisation and KS development 
(Ensoli et al., 1992; Ensoli et al., 1989; Ganem, 1995; Safai et al., 1985). 
3.4 Paracrine model of KS tumorigenesis 
The presence of paracrine-acting factors in KS lesions and the transcriptome analyses of 
infected endothelial cells (see above) argue for a paracrine stimulation of proliferation in the 
KS lesions. The current theory is that the paracrine-driven cell proliferation is promoted by 
the concerted action of latent and lytic gene products inducing a specific “tumorigenic” 
environment of growth factors and cytokines. In this scenario, KSHV-infected cells may 
stimulate the proliferation of uninfected endothelial cells in the vicinity and/or recruit 
endothelial cells in a paracrine manner, and thereby increase the number of target cells for 
de novo infection with virus particles released from lytic replicating cells. Accordingly, 
proliferation might be driven by latently, and a few lytically, infected cells, and the initial 
tumour mass might be predominantly formed by uninfected endothelial cells (in early 
lesions). The abnormal cell proliferation of uninfected endothelial cells may contribute to the 
increased formation of dilated vessels with abnormal structure and the formation of spindle 
cells observed in the course of KS development. Subsequent KSHV infection of these cells 
may predominantly result in a survival advantage of these cells with reduced proliferation 
rate, overall resulting in the stabilisation of KS lesions. This is supported by several data. 
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(MMP-1 and -9), urokinase-type plasminogen activator receptor, CXCR7, and MCP-1 has 
been observed upon KSHV infection (Chandriani & Ganem, 2007; Cornali et al., 1996; Moses 
et al., 2002; Naranatt et al., 2004; Poole et al., 2002; Thewes et al., 2000; Vart et al., 2007). Of 
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In summary, viral proteins and virus-induced cellular proteins are secreted by infected cells 
and act in autocrine and paracrine loops to recruit inflammatory cells into the lesions, which 
in turn secrete inflammatory cytokines, chemokines, and angiogenic growth factors. The fact 
that KSHV-infection leads to up-regulation of angiogenesis-related and interferon-inducible 
genes in endothelial cells highlights the importance of an inflammatory-angiogenic milieu 
during KS tumorigenesis. This is further sustained by the observation that these genes are 
strongly transcribed, although KSHV encodes a DNA exonuclease SOX/orf37, which 
mediates the shut-off of host transcription during the lytic cycle of KSHV (Chandriani & 
Ganem, 2007). All these secreted proteins appear to cooperate in the activation of 
endothelial cells and are important for tumour neovascularisation and KS development 
(Ensoli et al., 1992; Ensoli et al., 1989; Ganem, 1995; Safai et al., 1985). 
3.4 Paracrine model of KS tumorigenesis 
The presence of paracrine-acting factors in KS lesions and the transcriptome analyses of 
infected endothelial cells (see above) argue for a paracrine stimulation of proliferation in the 
KS lesions. The current theory is that the paracrine-driven cell proliferation is promoted by 
the concerted action of latent and lytic gene products inducing a specific “tumorigenic” 
environment of growth factors and cytokines. In this scenario, KSHV-infected cells may 
stimulate the proliferation of uninfected endothelial cells in the vicinity and/or recruit 
endothelial cells in a paracrine manner, and thereby increase the number of target cells for 
de novo infection with virus particles released from lytic replicating cells. Accordingly, 
proliferation might be driven by latently, and a few lytically, infected cells, and the initial 
tumour mass might be predominantly formed by uninfected endothelial cells (in early 
lesions). The abnormal cell proliferation of uninfected endothelial cells may contribute to the 
increased formation of dilated vessels with abnormal structure and the formation of spindle 
cells observed in the course of KS development. Subsequent KSHV infection of these cells 
may predominantly result in a survival advantage of these cells with reduced proliferation 
rate, overall resulting in the stabilisation of KS lesions. This is supported by several data. 
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First, KS spindle cells exhibit up-regulation of the VEGFR and increased response to growth 
factors (Brown et al., 1996; Flore et al., 1998; Sivakumar et al., 2008). Second, KS spindle cells 
show increased protection against apoptosis, mainly through activation of the NF-κB signal 
transduction pathway (Keller et al., 2000; Konrad et al., 2009; Stürzl et al., 1999; Thurau et 
al., 2009). Third, in KS spindle cells, the prosurvival phosphatidylinositol 3-kinase/Akt 
signal transduction pathway is activated (Montaner et al., 2001; L. Wang & Damania, 2008). 
Finally, infection of endothelial cells with KSHV increases telomerase activity (Flore et al., 
1998), causing prolonged growth and survival of the infected cells beyond their natural 
lifespan. Thus, during the progression of KS, more and more endothelial cells might be 
attracted to the lesions and become infected with KSHV, thereby resulting in the histological 
presentation observed above (Fig. 1): a high number of latently infected spindle cells with a 
low proliferation rate. 
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al., 2009). Third, in KS spindle cells, the prosurvival phosphatidylinositol 3-kinase/Akt 
signal transduction pathway is activated (Montaner et al., 2001; L. Wang & Damania, 2008). 
Finally, infection of endothelial cells with KSHV increases telomerase activity (Flore et al., 
1998), causing prolonged growth and survival of the infected cells beyond their natural 
lifespan. Thus, during the progression of KS, more and more endothelial cells might be 
attracted to the lesions and become infected with KSHV, thereby resulting in the histological 
presentation observed above (Fig. 1): a high number of latently infected spindle cells with a 
low proliferation rate. 
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1. Introduction 
Herpesviruses are large and complex DNA viruses which infect a wide range of vertebrates 
and invertebrates, including humans and domestic animals (Davison et al., 2005a). Severe 
infections are usually only observed in foetuses and very young or immunocompromised 
individuals, but economic consequences for livestock can be significant. Certain 
herpesviruses may also cause serious disease in non-reservoir host species - for example, 
Bovine malignant catharral fever. Prevention and treatment are complicated due to the 
ability of herpesviruses to persist as a latent infection. 
In general, the occurrence of herpesviruses is host-specific (Davison, 2002). Most 
herpesviruses have evolved with their hosts over long periods of time and are well adapted 
to them. This view is supported by molecular phylogenetic data, and consistent with the 
generally modest pathogenicity of these viruses. In order to understand the evolutionary 
origin and consequences of herpesviruses infecting higher vertebrates, a profound 
understanding of the taxonomy of lower vertebrate and invertebrate herpesviruses is 
needed. 
In many of the major aquaculture species, such as carp, salmon, catfish, eel, sturgeon and 
oyster, herpesviruses have been identified (Table 1). These herpesviruses merely represent 
the focus of current fish disease research, and it is expected that many other herpesviruses of 
lower vertebrates exist. The herpesviruses infecting fish, amphibians, and invertebrates 
make up two families, which are only distantly related to the well-known family of 
herpesviruses of mammals, birds, and reptiles (Davison et al., 2009).  
In the last decades several mass mortality outbreaks in fish and oysters were found to be 
associated with herpesvirus infections. Management strategies are taken at fish farms to 
reduce the production losses due to these viruses. Several less-pathogenic fish herpesviruses 
are known to induce skin tumours and tumour-like proliferations (Anders & Yoshimizu, 
1994), and one amphibian herpesvirus causes renal adenocarcinoma (McKinnell & Carlson, 
1997). Experimental studies on these spontaneously-occurring viral tumours may serve as a 
model for viral carcinogenesis in humans. Interestingly, the course of infection of both the 
high pathogenic and tumour-inducing alloherpesviruses seems to be dependent on host age 
and ambient water temperature. 
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Genus Virus name Common name Natural host(s) Key reference for taxonomy 
Batrachovirus Ranid herpesvirus 1 Lucké tumour herpesvirus Leopard frog (R. pipiens) 
(Davison et al., 
2006) 
 Ranid herpesvirus 2 Frog virus 4 Leopard frog (R. pipiens) (Davison et al., 2006) 
Cyprinivirus Cyprinid herpesvirus 1 Carp pox Common carp (C. carpio) (Waltzek et al., 2005) 
 Cyprinid herpesvirus 2 Goldfish hematopoietic necrosis virus Goldfish (C. auratus) 
(Waltzek et al., 
2005) 
 Cyprinid herpesvirus 3 Koi herpesvirus Common carp (C. carpio carpio) & Koi (C. carpio koi) 
(Waltzek et al., 
2005) 
Ictalurivirus Acipenserid herpesvirus 2 White sturgeon herpesvirus 2 
White sturgeon (A. 
ransmontatus) 
(Kurobe et al., 
2008) 
 Ictalurid herpesvirus 1 Channel catfish virus Channel catfish (I. punctatus) (Davison, 1992) 
 Ictalurid herpesvirus 2 Ictalurus melas herpesvirus 
Black bullhead (A. melas) & 
Channel catfish (I. punctatus)
(Doszpoly et al., 
2008) 
Salmonivirus Salmonid herpesvirus 1 Herpesvirus salmonis Rainbow trout (O. mykiss) (Waltzek et al., 2009) 
 Salmonid herpesvirus 2 Coho salmon herpesvirus 
Salmon spp. (Oncorhynchus 
spp.) 
(Waltzek et al., 
2009) 
 Salmonid herpesvirus 3 Epizootic epitheliotrophic disease virus Lake trout (S. namaycush) 
(Waltzek et al., 
2009) 
Unclassified 
alloherpesviruses Acipenserid herpesvirus 1 
White sturgeon 
herpesvirus 1 
Sturgeon spp. (Acipenser 
spp.) 
(Kurobe et al., 
2008) 
 Anguillid herpesvirus 1 Eel herpesvirus European eel (A. anguilla) & Japanese eel (A. japonica) 
(van Beurden et 
al., 2010) 
 - Pilchard herpesvirus Pacific sardine (S. sagax) (Doszpoly et al., 2011a) 
Uncharacterized 
alloherpesviruses Esocid herpesvirus 1 Blue spot disease virus 
Northern pike (E. Lucius) & 
muskellunge (E. masquinongy) - 
 Percid herpesvirus 1 Herpesvirus vitreum Walleye (S. vitreum) - 
 Pleuronectid herpesvirus 1 
Herpesvirus 
scopthalami Turbot (S. maximua) - 
  Atlantic salmon papillomatosis virus Atlantic salmon (S. salar) - 
  Herpesvirus of osmerus eperlanus 1 
European smelt (O. eperlanus) & 
rainbow smelt (O. mordax) - 
  Tilapia larvae encephalitis virus Tilapia (Oreochromis spp.) - 
  Viral epidermal hyperplasia/necrosis Japanese flounder (P. esus) - 
  - Angelfish (P. altum) - 
  - Golden ide (L. ide) - 
  - Red striped rockfish (S. proriger) - 
  - Smooth dogfish (M. canis) - 
Ostreavirus Ostreid herpesvirus 1 Oyster herpesvirus 
Japanese oyster (C. gigas) & 
other bivalves 
(Davison et al., 
2005b) 
Unclassified 
malacoherpesvirus Abalone herpesvirus 1 Abalone herpesvirus 
Abalone 
(H. diversicolor supertexta) 
(Savin et al., 
2010) 
Table 1. Classified, characterized and uncharacterized fish and amphibian herpesviruses of 
the family Alloherpesviridae, and invertebrate herpesviruses of the family Malacoherpesviridae 
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Herpesviruses of fish, amphibians and invertebrates form an important and potentially 
large group of many yet-undiscovered pathogens. Although the fundamental characteristics 
of herpesviruses of humans and several other mammals have been thoroughly studied, 
there is still little knowledge of the herpesviruses of lower vertebrates and invertebrates. 
This lack of knowledge hampers the development of therapeutic and preventive strategies. 
This book chapter describes the fundamentals of herpesviruses infecting fish, amphibians 
and invertebrates, including their biology, classification and taxonomy, capsid structure and 
structural proteins, and genome organization and gene conservation. Where possible, a 
comparison with herpesviruses infecting higher vertebrates is made. An overview of the 
current knowledge on gene expression, latency and virulence factors of alloherpesviruses, as 
well as the characterization of specific genes and the development of vaccines, is given at the 
end of this chapter. 
2. Biology of fish, amphibian and invertebrate herpesviruses 
2.1 Frog herpesviruses 
The North American leopard frog (Rana pipiens) is occasionally affected with a renal 
adenocarcinoma known as the Lucké tumour. A viral aetiology was proposed based on the 
presence of acidophilic inclusions in tumour cell nuclei, and transmission experiments 
(Lucké, 1934; 1938). Viral particles were observed by electron microscopy (EM) about 20 
years later (Fawcett, 1956). Yet another decade later, the virus was characterized as a herpes-
type virus (Lunger, 1964), later designated Ranid herpesvirus 1 (RaHV-1). Tumour formation 
could be induced by injection with purified RaHV-1 (Mizell et al., 1969), and Koch-Henle’s 
postulates were fulfilled (Naegele et al., 1974). Virus replication is promoted by low 
temperature (Granoff, 1999), whereas induction of metastasis is promoted by high 
temperature (Lucké & Schlumberger, 1949; McKinnell & Tarin, 1984). Although RaHV-1 
cannot be cultured in cell lines, it was the first amphibian herpesvirus subjected to extensive 
genomic studies (Davison et al., 1999). 
During an attempt to isolate the causative agent of the Lucké tumour from pooled urine of 
tumour-bearing frogs, another virus – designated frog virus 4 – was isolated using a frog 
embryo cell line (Rafferty, 1965). The virus was shown to possess the morphological 
characteristics of a herpesvirus (Gravell et al., 1968), but appeared to be clearly distinctive 
from the Lucké tumour herpesvirus with regard to the possibility of in vitro propagation and 
genomic properties (Gravell, 1971). In addition, frog virus 4 has no oncogenic potential, 
although it infects leopard frog embryos and larvae effectively (Granoff, 1999). Frog virus 4 
was later designated Ranid herpesvirus 2 (RaHV-2). 
2.2 Catfish herpesviruses 
In the United States, during the rapid expansion of the pond-cultured channel catfish 
(Ictalurus punctatus) industry in the late 1960s, high mortalities were reported in fingerlings 
and fry shortly after transfer from the hatchery to the fry ponds (Wolf, 1988). Moribund fish 
showed behavioural changes (swimming in spirals and hanging vertically with the head at 
the water surface), exophthalmus, pale or haemorrhagic gills, external and internal 
haemorrhages, and distension of abdomen (ascites and oedema) and stomach (Fijan et al., 
1971). In 1968 a virus was isolated from various fish farms, designated channel catfish virus. 
A year later the virus was shown to be a herpesvirus which replicated best at 25-33 °C (Wolf 
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Genus Virus name Common name Natural host(s) Key reference for taxonomy 
Batrachovirus Ranid herpesvirus 1 Lucké tumour herpesvirus Leopard frog (R. pipiens) 
(Davison et al., 
2006) 
 Ranid herpesvirus 2 Frog virus 4 Leopard frog (R. pipiens) (Davison et al., 2006) 
Cyprinivirus Cyprinid herpesvirus 1 Carp pox Common carp (C. carpio) (Waltzek et al., 2005) 
 Cyprinid herpesvirus 2 Goldfish hematopoietic necrosis virus Goldfish (C. auratus) 
(Waltzek et al., 
2005) 
 Cyprinid herpesvirus 3 Koi herpesvirus Common carp (C. carpio carpio) & Koi (C. carpio koi) 
(Waltzek et al., 
2005) 
Ictalurivirus Acipenserid herpesvirus 2 White sturgeon herpesvirus 2 
White sturgeon (A. 
ransmontatus) 
(Kurobe et al., 
2008) 
 Ictalurid herpesvirus 1 Channel catfish virus Channel catfish (I. punctatus) (Davison, 1992) 
 Ictalurid herpesvirus 2 Ictalurus melas herpesvirus 
Black bullhead (A. melas) & 
Channel catfish (I. punctatus)
(Doszpoly et al., 
2008) 
Salmonivirus Salmonid herpesvirus 1 Herpesvirus salmonis Rainbow trout (O. mykiss) (Waltzek et al., 2009) 
 Salmonid herpesvirus 2 Coho salmon herpesvirus 
Salmon spp. (Oncorhynchus 
spp.) 
(Waltzek et al., 
2009) 
 Salmonid herpesvirus 3 Epizootic epitheliotrophic disease virus Lake trout (S. namaycush) 
(Waltzek et al., 
2009) 
Unclassified 
alloherpesviruses Acipenserid herpesvirus 1 
White sturgeon 
herpesvirus 1 
Sturgeon spp. (Acipenser 
spp.) 
(Kurobe et al., 
2008) 
 Anguillid herpesvirus 1 Eel herpesvirus European eel (A. anguilla) & Japanese eel (A. japonica) 
(van Beurden et 
al., 2010) 
 - Pilchard herpesvirus Pacific sardine (S. sagax) (Doszpoly et al., 2011a) 
Uncharacterized 
alloherpesviruses Esocid herpesvirus 1 Blue spot disease virus 
Northern pike (E. Lucius) & 
muskellunge (E. masquinongy) - 
 Percid herpesvirus 1 Herpesvirus vitreum Walleye (S. vitreum) - 
 Pleuronectid herpesvirus 1 
Herpesvirus 
scopthalami Turbot (S. maximua) - 
  Atlantic salmon papillomatosis virus Atlantic salmon (S. salar) - 
  Herpesvirus of osmerus eperlanus 1 
European smelt (O. eperlanus) & 
rainbow smelt (O. mordax) - 
  Tilapia larvae encephalitis virus Tilapia (Oreochromis spp.) - 
  Viral epidermal hyperplasia/necrosis Japanese flounder (P. esus) - 
  - Angelfish (P. altum) - 
  - Golden ide (L. ide) - 
  - Red striped rockfish (S. proriger) - 
  - Smooth dogfish (M. canis) - 
Ostreavirus Ostreid herpesvirus 1 Oyster herpesvirus 
Japanese oyster (C. gigas) & 
other bivalves 
(Davison et al., 
2005b) 
Unclassified 
malacoherpesvirus Abalone herpesvirus 1 Abalone herpesvirus 
Abalone 
(H. diversicolor supertexta) 
(Savin et al., 
2010) 
Table 1. Classified, characterized and uncharacterized fish and amphibian herpesviruses of 
the family Alloherpesviridae, and invertebrate herpesviruses of the family Malacoherpesviridae 
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Herpesviruses of fish, amphibians and invertebrates form an important and potentially 
large group of many yet-undiscovered pathogens. Although the fundamental characteristics 
of herpesviruses of humans and several other mammals have been thoroughly studied, 
there is still little knowledge of the herpesviruses of lower vertebrates and invertebrates. 
This lack of knowledge hampers the development of therapeutic and preventive strategies. 
This book chapter describes the fundamentals of herpesviruses infecting fish, amphibians 
and invertebrates, including their biology, classification and taxonomy, capsid structure and 
structural proteins, and genome organization and gene conservation. Where possible, a 
comparison with herpesviruses infecting higher vertebrates is made. An overview of the 
current knowledge on gene expression, latency and virulence factors of alloherpesviruses, as 
well as the characterization of specific genes and the development of vaccines, is given at the 
end of this chapter. 
2. Biology of fish, amphibian and invertebrate herpesviruses 
2.1 Frog herpesviruses 
The North American leopard frog (Rana pipiens) is occasionally affected with a renal 
adenocarcinoma known as the Lucké tumour. A viral aetiology was proposed based on the 
presence of acidophilic inclusions in tumour cell nuclei, and transmission experiments 
(Lucké, 1934; 1938). Viral particles were observed by electron microscopy (EM) about 20 
years later (Fawcett, 1956). Yet another decade later, the virus was characterized as a herpes-
type virus (Lunger, 1964), later designated Ranid herpesvirus 1 (RaHV-1). Tumour formation 
could be induced by injection with purified RaHV-1 (Mizell et al., 1969), and Koch-Henle’s 
postulates were fulfilled (Naegele et al., 1974). Virus replication is promoted by low 
temperature (Granoff, 1999), whereas induction of metastasis is promoted by high 
temperature (Lucké & Schlumberger, 1949; McKinnell & Tarin, 1984). Although RaHV-1 
cannot be cultured in cell lines, it was the first amphibian herpesvirus subjected to extensive 
genomic studies (Davison et al., 1999). 
During an attempt to isolate the causative agent of the Lucké tumour from pooled urine of 
tumour-bearing frogs, another virus – designated frog virus 4 – was isolated using a frog 
embryo cell line (Rafferty, 1965). The virus was shown to possess the morphological 
characteristics of a herpesvirus (Gravell et al., 1968), but appeared to be clearly distinctive 
from the Lucké tumour herpesvirus with regard to the possibility of in vitro propagation and 
genomic properties (Gravell, 1971). In addition, frog virus 4 has no oncogenic potential, 
although it infects leopard frog embryos and larvae effectively (Granoff, 1999). Frog virus 4 
was later designated Ranid herpesvirus 2 (RaHV-2). 
2.2 Catfish herpesviruses 
In the United States, during the rapid expansion of the pond-cultured channel catfish 
(Ictalurus punctatus) industry in the late 1960s, high mortalities were reported in fingerlings 
and fry shortly after transfer from the hatchery to the fry ponds (Wolf, 1988). Moribund fish 
showed behavioural changes (swimming in spirals and hanging vertically with the head at 
the water surface), exophthalmus, pale or haemorrhagic gills, external and internal 
haemorrhages, and distension of abdomen (ascites and oedema) and stomach (Fijan et al., 
1971). In 1968 a virus was isolated from various fish farms, designated channel catfish virus. 
A year later the virus was shown to be a herpesvirus which replicated best at 25-33 °C (Wolf 
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& Darlington, 1971), later designated Ictalurid herpesvirus 1 (IcHV-1). Although mortality 
among young channel catfish may be very high, the effects of the disease can be minimized 
through management practices (Wolf, 1988). IcHV-1 has been studied extensively ever since 
(Kucuktas & Brady, 1999), starting with the biological properties (including pathogenicity 
and diagnostic possibilities), followed by molecular and structural studies, as well as 
vaccine development. IcHV-1 was the first fish herpesvirus for which the genome sequence 
became available (Davison, 1992), which had a significant impact on herpesvirus taxonomy. 
In the summer of 1994 another catfish herpesvirus was isolated from adult black bullhead 
(Ameiurus melas) from two different farms in Italy (Alborali et al., 1996). Morbidity and 
mortality were very high (80-90%), with clinical signs being unexpected spiral movements, 
swimming in a vertical position and death. Internal findings included haemorrhages on 
skin, spleen and liver. This catfish herpesvirus was shown to be different from IcHV-1, but 
appeared to be highly virulent for channel catfish fry and juveniles (Hedrick et al., 2003). 
Hence, the virus was later designated Ictalurid herpesvirus 2 (Waltzek et al., 2009). 
2.3 Carp herpesviruses 
Pox disease of carp was described as early as 1563 by Conrad Gessner. Four hundred years 
later,  herpesvirus-like particles were found to be associated with the pox-like lesions in carp 
(Schubert, 1966). The agent was eventually isolated in Japan, and designated Cyprinid 
herpesvirus 1 (CyHV-1) (Sano et al., 1985a; Sano et al., 1985b). Infection trials showed that the 
virus was highly pathogenic for carp-fry, but not for older carp (Sano et al., 1990b; Sano et 
al., 1991). The majority of surviving carp-fry and a number of older carp developed 
papillomas several months after infection. Mortality and regression of the papillomas 
appeared to be temperature dependent (Sano et al., 1993). 
The causative agent of herpesviral haematopoietic necrosis of goldfish was first identified in 
the early 1990s in Japan (Jung & Miyazaki, 1995), and later designated Cyprinid herpesvirus 2 
(CyHV-2). This virus may cause severe mortality especially among juvenile goldfish (Chang 
et al., 1999; Groff et al., 1998; Jeffery et al., 2007; Jung & Miyazaki, 1995), at water 
temperatures between 15 and 25 °C (Jeffery et al., 2007). Clinical signs include lethargy, 
anorexia and inappetence. Gross pathology includes pale gills, and swollen spleen and 
kidney (Jeffery et al., 2007). The disease has been reported in the USA (Goodwin et al., 2006; 
Goodwin et al., 2009; Groff et al., 1998), Taiwan (Chang et al., 1999), Australia (Stephens et 
al., 2004), UK (Jeffery et al., 2007), and Hungary (Doszpoly et al., 2011b). CyHV-2 seems to 
be widespread on commercial goldfish farms, with outbreaks occurring when fish are 
subjected to stress during permissive temperatures (Goodwin et al., 2009). 
In the late 1990s, mass mortalities associated with gill and skin disease occurred in the koi 
and common carp (Cyprinus carpio spp.) industries worldwide (Haenen et al., 2004). Affected 
fish were lethargic, anorexic and showed increased respiratory movements (Bretzinger et al., 
1999; Walster, 1999). The disease is characterized by epidermal lesions, extensive gill 
necrosis, and an enlarged anterior kidney showing moderate damage histologically. The 
course is acute or peracute in most cases, with high morbidity and mortality, depending on 
the water temperature (15-28 °C). EM analyses revealed the presence of herpesvirus-like 
particles in respiratory epithelial cells of gills of affected koi carp (Bretzinger et al., 1999), 
and River’s postulates were fulfilled subsequently (Hedrick et al., 2000). The etiological 
agent koi herpesvirus was shown to differ from CyHV-1 (Gilad et al., 2002), and later 
designated Cyprinid herpesvirus 3 (CyHV-3) (Waltzek et al., 2005). Common and koi carp are 
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among the most economically important aquaculture species worldwide, with CyHV-3 still 
being one of the most significant threats (Michel et al., 2010). CyHV-3 has therefore been the 
subject of advanced fundamental and applied research in the past decade. 
2.4 Salmon herpesviruses 
During the early 1970s a herpesvirus was isolated from a rainbow trout (Oncorhynchus 
mykiss) hatchery in the USA, which had increased post spawning mortalities (30-50%) for 
several years (Wolf, 1976). The virus could only be propagated in cell cultures of salmonid 
origin at low temperatures (10°C) (Wolf et al., 1978). General characteristics of a herpesvirus 
were demonstrated by EM. Rainbow trout fry could be infected with this virus, with 
mortality ranging from 50-100%, but related salmonid species could not (Wolf, 1976). 
Symptoms observed included inappetence, lethargy, dark pigmentation, pale gills, and 
sometimes haemorrhagic exophthalmia (Wolf & Smith, 1981). Visceral organs and the heart 
showed major pathological changes, with the liver and kidneys being prime targets for the 
virus. The disease failed to spread by cohabitation. The etiological agent was later 
designated Salmonid herpesvirus 1 (SalHV-1). 
In the same period a number of herpesviruses was isolated in Japan from different salmonid 
species, such as kokanee salmon (Oncorhynchus nerka) (Sano, 1976), masu salmon 
(Oncorhynchus masou) (Hayashi et al., 1986; Kimura et al., 1981b), yamame (Oncorhynchus 
masou) (Sano et al., 1983), coho salmon (Oncorhynchus kisutch) (Kumagai et al., 1994), and 
rainbow trout (Yoshimizu et al., 1995). The viruses appeared to be highly pathogenic 
particularly for young fry of different salmonid species (Kimura et al., 1983; Yoshimizu et 
al., 1995). The liver and kidney were the primary target organs, characterized by necrosis 
(Tanaka et al., 1984). Interestingly, surviving fish developed epithelial tumours around the 
mouth (Kimura et al., 1981a; Sano et al., 1983; Yoshimizu et al., 1987). Subsequent serological 
and DNA restriction endonuclease cleavage analysis demonstrated that all isolates could be 
considered as a single virus species, designated Salmonid herpesvirus 2 (SalHV-2) (Hayashi et 
al., 1986; Hayashi et al., 1989; Hedrick et al., 1987; Yoshimizu et al., 1995). 
A third salmonid herpesvirus caused high mortalities among hatchery-reared juvenile lake 
trout (Salvelinus namaycush) in the Great Lakes Region of the USA for several subsequent 
springs and falls (6-15°C) during the mid-1980s (Kurobe et al., 2009). Epidemics were 
characterized by the rapid onset of mortality, followed by a number of nonspecific clinical 
signs, including corkscrew swimming, lethargy, and periods of hyperexcitability (Bradley et 
al., 1989). External symptoms included haemorrhages in the eyes, fin and skin degeneration, 
and secondary fungus infections (Bradley et al., 1989; McAllister & Herman, 1989). Mortality 
could be as much as 100%, with fry being more susceptible than fingerlings. In the late 1980s 
herpesvirus-like particles were associated with the disease. Transmission experiments 
demonstrated that Salmonid herpesvirus 3 (SalHV-3) was the etiologic agent of the epizootic 
epitheliotrophic disease restricted to lake trout. Propagation of the virus in cell culture is still 
impossible, which hampered detection until very recently (Kurobe et al., 2009). 
A fourth salmonid herpesvirus has been described, but not yet characterized. In the late 
1970s benign proliferative epidermal papillomatous lesions of cultured Atlantic salmon 
(Salmo salar) in Scandinavia and the UK were investigated (Bylund et al., 1980; Carlisle & 
Roberts, 1977). Papillomas developed in July and August, after which they sloughed, and in 
December nearly all were gone. The papillomas appeared as white plaques which raised 
several millimetres and were up to several centimetres in diameter. They were frequently 
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& Darlington, 1971), later designated Ictalurid herpesvirus 1 (IcHV-1). Although mortality 
among young channel catfish may be very high, the effects of the disease can be minimized 
through management practices (Wolf, 1988). IcHV-1 has been studied extensively ever since 
(Kucuktas & Brady, 1999), starting with the biological properties (including pathogenicity 
and diagnostic possibilities), followed by molecular and structural studies, as well as 
vaccine development. IcHV-1 was the first fish herpesvirus for which the genome sequence 
became available (Davison, 1992), which had a significant impact on herpesvirus taxonomy. 
In the summer of 1994 another catfish herpesvirus was isolated from adult black bullhead 
(Ameiurus melas) from two different farms in Italy (Alborali et al., 1996). Morbidity and 
mortality were very high (80-90%), with clinical signs being unexpected spiral movements, 
swimming in a vertical position and death. Internal findings included haemorrhages on 
skin, spleen and liver. This catfish herpesvirus was shown to be different from IcHV-1, but 
appeared to be highly virulent for channel catfish fry and juveniles (Hedrick et al., 2003). 
Hence, the virus was later designated Ictalurid herpesvirus 2 (Waltzek et al., 2009). 
2.3 Carp herpesviruses 
Pox disease of carp was described as early as 1563 by Conrad Gessner. Four hundred years 
later,  herpesvirus-like particles were found to be associated with the pox-like lesions in carp 
(Schubert, 1966). The agent was eventually isolated in Japan, and designated Cyprinid 
herpesvirus 1 (CyHV-1) (Sano et al., 1985a; Sano et al., 1985b). Infection trials showed that the 
virus was highly pathogenic for carp-fry, but not for older carp (Sano et al., 1990b; Sano et 
al., 1991). The majority of surviving carp-fry and a number of older carp developed 
papillomas several months after infection. Mortality and regression of the papillomas 
appeared to be temperature dependent (Sano et al., 1993). 
The causative agent of herpesviral haematopoietic necrosis of goldfish was first identified in 
the early 1990s in Japan (Jung & Miyazaki, 1995), and later designated Cyprinid herpesvirus 2 
(CyHV-2). This virus may cause severe mortality especially among juvenile goldfish (Chang 
et al., 1999; Groff et al., 1998; Jeffery et al., 2007; Jung & Miyazaki, 1995), at water 
temperatures between 15 and 25 °C (Jeffery et al., 2007). Clinical signs include lethargy, 
anorexia and inappetence. Gross pathology includes pale gills, and swollen spleen and 
kidney (Jeffery et al., 2007). The disease has been reported in the USA (Goodwin et al., 2006; 
Goodwin et al., 2009; Groff et al., 1998), Taiwan (Chang et al., 1999), Australia (Stephens et 
al., 2004), UK (Jeffery et al., 2007), and Hungary (Doszpoly et al., 2011b). CyHV-2 seems to 
be widespread on commercial goldfish farms, with outbreaks occurring when fish are 
subjected to stress during permissive temperatures (Goodwin et al., 2009). 
In the late 1990s, mass mortalities associated with gill and skin disease occurred in the koi 
and common carp (Cyprinus carpio spp.) industries worldwide (Haenen et al., 2004). Affected 
fish were lethargic, anorexic and showed increased respiratory movements (Bretzinger et al., 
1999; Walster, 1999). The disease is characterized by epidermal lesions, extensive gill 
necrosis, and an enlarged anterior kidney showing moderate damage histologically. The 
course is acute or peracute in most cases, with high morbidity and mortality, depending on 
the water temperature (15-28 °C). EM analyses revealed the presence of herpesvirus-like 
particles in respiratory epithelial cells of gills of affected koi carp (Bretzinger et al., 1999), 
and River’s postulates were fulfilled subsequently (Hedrick et al., 2000). The etiological 
agent koi herpesvirus was shown to differ from CyHV-1 (Gilad et al., 2002), and later 
designated Cyprinid herpesvirus 3 (CyHV-3) (Waltzek et al., 2005). Common and koi carp are 
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among the most economically important aquaculture species worldwide, with CyHV-3 still 
being one of the most significant threats (Michel et al., 2010). CyHV-3 has therefore been the 
subject of advanced fundamental and applied research in the past decade. 
2.4 Salmon herpesviruses 
During the early 1970s a herpesvirus was isolated from a rainbow trout (Oncorhynchus 
mykiss) hatchery in the USA, which had increased post spawning mortalities (30-50%) for 
several years (Wolf, 1976). The virus could only be propagated in cell cultures of salmonid 
origin at low temperatures (10°C) (Wolf et al., 1978). General characteristics of a herpesvirus 
were demonstrated by EM. Rainbow trout fry could be infected with this virus, with 
mortality ranging from 50-100%, but related salmonid species could not (Wolf, 1976). 
Symptoms observed included inappetence, lethargy, dark pigmentation, pale gills, and 
sometimes haemorrhagic exophthalmia (Wolf & Smith, 1981). Visceral organs and the heart 
showed major pathological changes, with the liver and kidneys being prime targets for the 
virus. The disease failed to spread by cohabitation. The etiological agent was later 
designated Salmonid herpesvirus 1 (SalHV-1). 
In the same period a number of herpesviruses was isolated in Japan from different salmonid 
species, such as kokanee salmon (Oncorhynchus nerka) (Sano, 1976), masu salmon 
(Oncorhynchus masou) (Hayashi et al., 1986; Kimura et al., 1981b), yamame (Oncorhynchus 
masou) (Sano et al., 1983), coho salmon (Oncorhynchus kisutch) (Kumagai et al., 1994), and 
rainbow trout (Yoshimizu et al., 1995). The viruses appeared to be highly pathogenic 
particularly for young fry of different salmonid species (Kimura et al., 1983; Yoshimizu et 
al., 1995). The liver and kidney were the primary target organs, characterized by necrosis 
(Tanaka et al., 1984). Interestingly, surviving fish developed epithelial tumours around the 
mouth (Kimura et al., 1981a; Sano et al., 1983; Yoshimizu et al., 1987). Subsequent serological 
and DNA restriction endonuclease cleavage analysis demonstrated that all isolates could be 
considered as a single virus species, designated Salmonid herpesvirus 2 (SalHV-2) (Hayashi et 
al., 1986; Hayashi et al., 1989; Hedrick et al., 1987; Yoshimizu et al., 1995). 
A third salmonid herpesvirus caused high mortalities among hatchery-reared juvenile lake 
trout (Salvelinus namaycush) in the Great Lakes Region of the USA for several subsequent 
springs and falls (6-15°C) during the mid-1980s (Kurobe et al., 2009). Epidemics were 
characterized by the rapid onset of mortality, followed by a number of nonspecific clinical 
signs, including corkscrew swimming, lethargy, and periods of hyperexcitability (Bradley et 
al., 1989). External symptoms included haemorrhages in the eyes, fin and skin degeneration, 
and secondary fungus infections (Bradley et al., 1989; McAllister & Herman, 1989). Mortality 
could be as much as 100%, with fry being more susceptible than fingerlings. In the late 1980s 
herpesvirus-like particles were associated with the disease. Transmission experiments 
demonstrated that Salmonid herpesvirus 3 (SalHV-3) was the etiologic agent of the epizootic 
epitheliotrophic disease restricted to lake trout. Propagation of the virus in cell culture is still 
impossible, which hampered detection until very recently (Kurobe et al., 2009). 
A fourth salmonid herpesvirus has been described, but not yet characterized. In the late 
1970s benign proliferative epidermal papillomatous lesions of cultured Atlantic salmon 
(Salmo salar) in Scandinavia and the UK were investigated (Bylund et al., 1980; Carlisle & 
Roberts, 1977). Papillomas developed in July and August, after which they sloughed, and in 
December nearly all were gone. The papillomas appeared as white plaques which raised 
several millimetres and were up to several centimetres in diameter. They were frequently 
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multiple and found anywhere on the skin and fins posterior to the head. Morbidity and 
mortality were generally low. Virus-like particles were observed using EM in samples from 
papillomatous tissue (Carlisle, 1977), later characterized as a herpesvirus in Atlantic salmon 
from Russia (Shchelkunov et al., 1992). Attempts to isolate the observed virus in cell culture 
failed (Carlisle, 1977; Shchelkunov et al., 1992). 
2.5 Sturgeon herpesviruses 
In 1991 a herpesvirus was isolated from juvenile white sturgeon (Acipenser transmontanus) 
from a commercial farm in California, USA (Hedrick et al., 1991). The white sturgeon 
herpesvirus 1, later designated Acipenserid herpesvirus 1 (AciHV-1), was associated with 
infections of the tegument and oropharyngeal mucosa, and mortality among the juvenile 
white sturgeons. Experimentally induced infections also resulted in mortality. AciHV-1 was 
later isolated from other farmed white sturgeons in California and Italy (Kelley et al., 2005; 
Kurobe et al., 2008). 
Few years later another herpesvirus called white sturgeon herpesvirus 2, or Acipenserid 
herpesvirus 2 (AciHV-2), was isolated from dermal lesions of subadult white sturgeon and 
ovarian fluids of a mature white sturgeon (Watson et al., 1995). Mortality among 
experimentally infected juvenile white sturgeons reached a cumulative total of 80%. AciHV-
2 has since been isolated from wild white sturgeon in Idaho and Oregon (USA), from 
farmed shortnose sturgeon (Acipenser brevirostrum) from Canada, and from Siberian 
sturgeon (Acipenser baeri) in Russia (Doszpoly & Shchelkunov, 2010; Kelley et al., 2005; 
Kurobe et al., 2008; Shchelkunov et al., 2009). 
2.6 Eel herpesvirus 
Herpesvirus-like particles in wild European eels (Anguilla anguilla) were described for the 
first time in 1986 (Békési et al., 1986). A herpesvirus was later isolated from cultured 
European eels and Japanese eels (A. japonica) in Japan (Sano et al., 1990a). Serological, 
molecular, and sequence data indicated that Asian and European eel herpesvirus isolates 
can be considered as a single virus species (Chang et al., 2002; Lee et al., 1999; Rijsewijk et 
al., 2005; Sano et al., 1990a; Ueno et al., 1992; Ueno et al., 1996; Waltzek et al., 2009), 
designated Anguillid herpesvirus 1 (AngHV-1). Clinical and pathological findings of the 
infection varied among and within outbreaks, and were predominantly apathy, 
haemorrhages and ulcerative lesions in skin and fins, haemorrhagic or pale and congested 
gills, a pale spleen, a pale and haemorrhagic liver, a distended gall bladder, and ascites 
(Chang et al., 2002; Davidse et al., 1999; Haenen et al., 2002; Lee et al., 1999; Sano et al., 
1990a). AngHV-1 infection in cultured eels resulted in decreased growth rates and an 
increased mortality (Haenen et al., 2002). The virus is also frequently observed in wild 
European eels (Haenen et al., 2010; Jørgensen et al., 1994; van Ginneken et al., 2004). 
2.7 Pilchard herpesvirus 
In 1995, a massive epizootic occurred in adult Australasian pilchards (Sardinops sagax 
neopilchardus) in south Australia (O'Neill, 1995). In several months it spread thousands of 
kilometres bidirectionally along the Australian coastline, and then to New Zealand 
(Whittington et al., 1997). A similar event occurred a few years later in 1998/1999 (Murray et 
al., 2003). Affected pilchards showed progressive gill inflammation followed by epithelial 
hypertrophy and hyperplasia (Whittington et al., 1997). Consequent clinical symptoms 
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included hypoxaemia and hypercapnea, resulting in an estimated mortality of at least 10%. 
Involvement of an infectious agent was suggested, and PCR analysis revealed the putative 
involvement of a herpesvirus (Tham & Moon, 1996), which was soon confirmed by EM 
(Hyatt et al., 1997). Diagnostic tools for detection of the pilchard herpesvirus have been 
developed (Crockford et al., 2005; Crockford et al., 2008), revealing that the virus is now 
endemic in Australian pilchard populations (Whittington et al., 2008). Although the pilchard 
herpesvirus has not yet been isolated in cell culture, hampering further studies, limited 
phylogenetic analysis showed its relation to other fish and frog herpesviruses  (Doszpoly et 
al., 2011a). 
2.8 Other fish herpesviruses 
Several other herpesvirus-like particles have been observed and found to be associated with 
disease in other fish species. Many of these viruses have not been isolated yet, however, and 
limited sequence availability hampers official classification. 
In the late 1970s a herpes-type viral infection of the epithelia of the skin and gills of turbot 
(Scophthalmus maximus) was found, presumably associated with heavy mortalities among 
farmed turbot (Buchanan & Madeley, 1978; Buchanan et al., 1978). Although the virus could 
not be isolated in cell culture, EM observations clearly demonstrated herpesvirus 
characteristics. The virus was tentatively named herpesvirus scophthalmi, later referred to 
as pleuronectid herpesvirus 1 (PlHV-1). 
Few years later a herpesvirus was isolated from hyperplastic epidermal tissue from a 
walleye (Stiozostedion vitreum vitreum) taken in Saskatchewan, Canada (Kelly et al., 1983). 
The virus was isolated in a walleye ovarian cell line and identified as a herpesvirus based on 
size, morphology, and apparent pattern of replication. The virus was initially called 
herpesvirus vitreum, but later designated percid herpesvirus 1 (PeHV-1). 
A year later the same research group observed typical herpesvirus particles in epidermal 
hyperplasia or blue spot disease of northern pike (Esox lucius) in several waters of central 
Canada (Yamamoto et al., 1984). The virus, tentatively designated esocid herpesvirus 1 
(EsHV-1), could not be isolated in cell culture, however. EsHV-1 was later also observed in 
northern pike and muskellunge (Esox masquinongy) in the USA, with clinical signs present 
only for a short period when water temperatures were between 2 and 13 °C (Margenau et 
al., 1995), and in northern pike in Ireland (Graham et al., 2004).  
In the early 1980s, in a quarantined population of golden ide (Leuciscus idus) imported from 
Germany to the USA, 5% of the fish developed carp pox-like lesions (McAllister et al., 1985). 
EM analysis showed herpesvirus-like particles associated with the lesions, but the virus 
could not be isolated in cell culture. 
In 1985 herpesvirus-like particles were observed in so-called spawning papillomas on the 
skin and fins of smelt (Osmerus eperlanus) in Germany (Anders & Möller, 1985). Herpesvirus-
like particles were also observed in similar epidermal tumours of rainbow smelt (O. mordax) 
during spawning-time in Canada and the USA (Herman et al., 1997; Morrison et al., 1996). 
Isolation and genomic analysis of the herpesvirus of smelt have failed so far (Jakob et al., 
2010). 
In the same year a viral dermatitis was observed in a small percentage of wild and captive 
smooth dogfish (Mustelus canis) (Leibovitz & Lebouitz, 1985). Most skin eruptions were 
found on the tail and fins, often exceeding 1 cm in diameter, and histologically characterized 
by epidermal cell degeneration. EM revealed the progressive development of cellular 
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multiple and found anywhere on the skin and fins posterior to the head. Morbidity and 
mortality were generally low. Virus-like particles were observed using EM in samples from 
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sturgeon (Acipenser baeri) in Russia (Doszpoly & Shchelkunov, 2010; Kelley et al., 2005; 
Kurobe et al., 2008; Shchelkunov et al., 2009). 
2.6 Eel herpesvirus 
Herpesvirus-like particles in wild European eels (Anguilla anguilla) were described for the 
first time in 1986 (Békési et al., 1986). A herpesvirus was later isolated from cultured 
European eels and Japanese eels (A. japonica) in Japan (Sano et al., 1990a). Serological, 
molecular, and sequence data indicated that Asian and European eel herpesvirus isolates 
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pathology associated with a specific epidermal viral infection, and viral particles showed the 
characteristics of a herpesvirus. 
In the mid-1980s a new disease characterized by skin and fin opacity, and associated with 
high mortality occurred in larvae and juveniles of Japanese flounder (Paralichthys olivaceus) 
hatcheries in Japan (Iida et al., 1989; Miyazaki et al., 1989). Microscopically, epidermal cells 
at the surface were rounded, and histopathologically the epidermis appeared to be 
hyperplastic and necrotic (Iida et al., 1991; Miyazaki, 2005). Although the causative agent 
could not be isolated, herpesvirus-like particles were observed by EM. Infection trials 
showed that especially larvae <10 mm were susceptible, at water temperatures around 20 °C 
(Masumura et al., 1989). 
After a stress-trigger, all three angelfish (Pterophyllum altum) in a fish tank showed loss of 
equilibrium and hung apathetic at the water surface (Mellergaard & Bloch, 1988). The fish 
had skin haemorrhages, pale gills and distended liver and spleen. Histopathological 
findings of the spleen were all suggestive of severe haemolytic anaemia. Herpesvirus-like 
particles were observed by EM in the nuclei of spleen macrophages and monocytes. 
A wild redstriped rockfish (Sebastes proriger) demonstrated hepatic lesions, which were 
histologically suggestive of a herpesvirus-type infection (Kent & Myers, 2000). EM analysis 
of suboptimally preserved liver tissue revealed the presence of intranuclear particles, 
consistent in size and shape with herpesvirus capsids. 
Recently, an outbreak of a novel disease characterized by a whirling syndrome and high 
mortality rates occurred in laboratory-reared tilapia larvae (Oreochromis spp.) (Shlapobersky 
et al., 2010). The disease was designated viral encephalitis of tilapia larvae. The 
morphological characteristics of virus particles found in the brains of diseased larvae as 
observed by EM were comparable to those of a herpesvirus.  
2.9 Oyster herpesvirus 
The first description of a herpesvirus-like virus in oysters originates from the United 
States (Farley et al., 1972). As for the fish and amphibian herpesviruses, it was only the 
virus morphology that identified this oyster virus as a herpesvirus. The principle 
susceptible species is the Japanese oyster (Crassostrea gigas), and the virus was designated 
Ostreid herpesvirus 1 (OsHV-1). In Europe, where the virus was found for the first time in 
the early 1990s, OsHV-1 has been associated with high mortalities in oyster seedlings 
(Garcia et al., 2011). Herpesvirus-like particles – later confirmed to be OsHV-1 by 
molecular analyses – have also been observed in various other bivalve species, associated 
with mortalities (Arzul et al., 2001; Burge et al., 2011). Recently, an OsHV-1 variant, 
designated OsHV-1 μvar, was identified as the causative agent of high mortalities in 
juvenile oysters (Segarra et al., 2010).  
2.10 Abalone herpesvirus 
A second herpesvirus with an invertebrate host has been identified by EM in cultured 
abalone (Haliotis diversicolor supertexta) in Taiwan in early 2003 and in Australia in late 2005 
(Chang et al., 2005; Tan et al., 2008). Abalones of all ages suffered from the disease, which 
was characterized by mantle recession and muscle stiffness, followed by high mortality 
within a few days. Histologically the nerve system appeared to be the primary target tissue, 
characterized by tissue necrosis with infiltration of haemocytes. The virus has been 
designated Abalone herpesvirus 1 (AbHV-1). 
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3. Classification and taxonomy of the order Herpesvirales 
Herpesviruses are large and complex DNA viruses with a distinctive virion morphology, 
which consists of four distinct structures: the core, capsid, tegument, and envelope 
(Davison et al., 2005a). The order Herpesvirales is subdivided into three families (Davison 
et al., 2009), which separated about 500 million years ago (McGeoch et al., 2006). The 
family Herpesviridae comprises the herpesviruses with mammalian, avian and reptilian 
hosts, and is further subdivided into the subfamilies Alpha-, Beta- and Gammaherpesvirinae, 
which fall into genera. 
The family Alloherpesviridae comprises the piscine and amphibian herpesviruses (Waltzek et 
al., 2009). The criteria for the establishment of genera within the family Alloherpesviridae have 
not been defined yet, nor have rules been formulated for deciding whether species should 
belong to a particular genus. Currently, genera and their respective species are assigned 
largely based on available phylogenetic analyses, with phylogenetically closely related 
species assigned to the same genus. To date, four genera in the family Alloherpesviridae have 
been established: Batrachovirus, Cyprinivirus, Ictalurivirus and Salmonivirus, comprising a 
total of 11 different species (Table 1, Fig. 1). In the majority of the cases the classification 
follows the grouping of alloherpesviruses infecting the same host. At least another 14 
herpesviruses infecting fish have been described, but not yet characterized sufficiently to 
allow classification. 
The oyster herpesvirus OsHV-1 has been assigned to the genus Ostreavirus of the third 
herpesvirus family Malacoherpesviridae, which comprises the invertebrate herpesviruses 
(Davison et al., 2009; Davison et al., 2005b). The other invertebrate herpesvirus infecting 
abalone AbHV-1 has been shown to be related to OsHV-1 (Savin et al., 2010). Despite the 
similarities in capsid structure between the herpesviruses of mammals, birds and reptiles, 
fish and amphibians, and invertebrates, the three families are highly divergent. Only a 
single gene, encoding a DNA packaging enzyme complex distantly related to the ATPase 
subunit of bacteriophage T4 terminase, is convincingly conserved among all herpesviruses 
(Davison, 1992; 2002). 
4. Conservation of herpesvirus capsid architecture & structural proteins 
4.1 Capsid architecture of herpesviruses 
Despite their diversity by genes, host range, and genome size, herpesvirus structure is 
conserved throughout the entire order Herpesvirales. Herpesvirus virions invariably consist 
of a large (diameter >100 nm) thick-walled icosahedral nucleocapsid (T=16), surrounded by 
a host-derived envelope with a diameter of about 200 nm, with an intervening proteinaceous 
layer called the tegument (Booy et al., 1996). This appearance is distinctively different from 
that of any other animal virus. Key to this morphological conservatism is the icosahedral 
nucleocapsid made up of hollow capsomers. The functionality of the genes involved in 
capsid assembly is largely conserved.  
The capsid structures of alloherpesvirus IcHV-1 and malacoherpesvirus OsHV-1 have been 
studied by cryoelectron microscopy and three-dimensional image reconstruction (Booy et 
al., 1996; Davison et al., 2005b). Both viruses have capsids with diameters of approximately 
116 nm, which is slightly smaller than the capsids of the human model herpesvirus, Herpes 
simplex virus type 1 (HSV-1, diameter 125 nm). The capsids of IcHV-1 and OsHV-1 are 
roughly hexagonal in outline and reconstruction revealed an icosahedral structure with a 
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triangulation number of T=16. The icosahedral facets of IcHV-1 appeared to be flatter, and 
the shell is about 20% thinner (12.4 nm vs. 15 nm) than that of HSV-1, consistent with the 
smaller size of its major capsid protein. The hexons and pentons showed protrusions with 
an axial channel through each capsomer. The outer surface is composed of heterotrimeric 
complexes or triplexes at the sites of local threefold symmetry, and the inner surface has a 
relatively flat and featureless appearance. IcHV-1 and OsHV-1 capsids are therefore similar 
in overall appearance to those of all other herpesviruses studied to date. 
 
 
Fig. 1. Phylogenetic tree depicting the relationships (topology only) among viruses in the 
order Herpesvirales, based on partially deduced amino acid sequence of the terminase gene 
(107 residues, including gaps), analysed with the maximum likelihood method, using the 
JTT matrix (1,000 replicates), and rooted with bacteriophage T4 
4.2 Structural proteins of Alloherpesviridae 
Complete herpesvirus virions are made up of about 40 viral proteins. Recent mass 
spectrometry (MS) analyses showed that HSV-1 virions comprise at least 8 viral capsid 
proteins, 13 viral glycoproteins, 23 potential viral teguments, and 49 host proteins (Loret et 
al., 2008). When in 1995 the structural proteins of IcHV-1 were identified by MS (Davison & 
Davison, 1995), a total of 11 genes encoding 15 virion proteins was identified. Based on 
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analyses of capsid, capsid-tegument, and envelope fractions, the proteins could be assigned 
to the different compartments of the virion.  
More recent studies on the structural proteins of CyHV-3 and AngHV-1 used liquid 
chromatography tandem MS-based proteomic approaches. For CyHV-3 a total of 40 
structural proteins was identified, which were classified based on homology and 
bioinformatic analyses as capsid (3), envelope (13), tegument (2) and unclassified (22) 
structural proteins (Michel et al., 2010). For AngHV-1, by analysing separately prepared 
fractions of capsid, tegument, and envelope, the identified proteins could also be 
functionally characterized. A total of 40 structural proteins was identified, of which  7 could 
be assigned to the capsid, 11 to the envelope, and 22 to the tegument (van Beurden et al., 
2011). 
The protein composition of fish herpesvirus capsids generally mirrors that of mammalian 
herpesvirus capsids. MS analyses of purified alloherpesvirus capsids demonstrated the 
presence of the major capsid protein, the capsid triplex protein 2, and, presumably, the 
capsid triplex protein 1 (Davison & Davison, 1995; van Beurden et al., 2011). The protease-
and-scaffolding protein is only abundantly present in premature capsids, and later replaced 
by viral DNA during maturation. The small protein which forms the hexon tips in 
mammalian herpesviruses has not been found in alloherpesvirus capsids.  
Conservation of tegument and envelope proteins among fish herpesviruses is rather limited 
(van Beurden et al., 2011). A large tegument protein was found to be partially conserved, 
and two envelope proteins might be conserved. The higher conservation of structural 
proteins between members of the family Herpesviridae resembles the greater evolutionary 
distance of the family Alloherpesviridae. 
5. Genome organization and gene conservation 
5.1 Genome properties 
The single linear double stranded DNA genomes of herpesviruses vary greatly in size, 
ranging from 124 kbp for Simian varicella virus, to more than 250 kbp. This enormous 
variation is also present within the family Alloherpesviridae, in which IcHV-1 has the smallest 
genome of 134 kbp, and AngHV-1 and CyHV-3 represent the largest herpesvirus genomes 
known of 249 and 295 kbp, respectively (Table 2). G+C content varies from 32 to 75% within 
the family Herpesviridae (McGeoch et al., 2006), but seems to be more restricted among 
members of the family Alloherpesviridae (52.8 to 59.2%), and is rather low for OsHV-1 
(38.7%). 
5.2 Genome organization 
Herpesvirus genomes characteristically contain one or two regions of unique sequence 
flanked by direct or inverted repeats (McGeoch et al., 2006). To date, six different classes of 
genome organization have been identified (Davison, 2007). The genome organization of six 
alloherpesviruses has been determined. The genomes of AngHV-1, CyHV-3, IcHV-1, RaHV-
1 and RaHV-2 all consist of one long unique region (U) flanked by two short direct repeat 
regions (TR) at the termini (Fig. 2).This genome structure (A) is also represented among the 
Betaherpesvirinae (Davison, 2007). Interestingly, the terminal repeats of the ranid 
herpesviruses are considerably shorter (<1-kbp) than those of the fish herpesviruses (>10-
kbp). Genome organization A does not seem to be a general feature of the Alloherpesviridae, 
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triangulation number of T=16. The icosahedral facets of IcHV-1 appeared to be flatter, and 
the shell is about 20% thinner (12.4 nm vs. 15 nm) than that of HSV-1, consistent with the 
smaller size of its major capsid protein. The hexons and pentons showed protrusions with 
an axial channel through each capsomer. The outer surface is composed of heterotrimeric 
complexes or triplexes at the sites of local threefold symmetry, and the inner surface has a 
relatively flat and featureless appearance. IcHV-1 and OsHV-1 capsids are therefore similar 
in overall appearance to those of all other herpesviruses studied to date. 
 
 
Fig. 1. Phylogenetic tree depicting the relationships (topology only) among viruses in the 
order Herpesvirales, based on partially deduced amino acid sequence of the terminase gene 
(107 residues, including gaps), analysed with the maximum likelihood method, using the 
JTT matrix (1,000 replicates), and rooted with bacteriophage T4 
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Davison, 1995), a total of 11 genes encoding 15 virion proteins was identified. Based on 
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analyses of capsid, capsid-tegument, and envelope fractions, the proteins could be assigned 
to the different compartments of the virion.  
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1 and RaHV-2 all consist of one long unique region (U) flanked by two short direct repeat 
regions (TR) at the termini (Fig. 2).This genome structure (A) is also represented among the 
Betaherpesvirinae (Davison, 2007). Interestingly, the terminal repeats of the ranid 
herpesviruses are considerably shorter (<1-kbp) than those of the fish herpesviruses (>10-
kbp). Genome organization A does not seem to be a general feature of the Alloherpesviridae, 
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since SalHV-1 is known to have a long unique region (UL) linked to a short unique region 
(US) flanked by an inverted repeat (IRS and TRS) (Davison, 1998). This genome structure (D) 
is characteristic of Alphaherpesvirinae in the Varicellovirus genus (Davison, 2007). 
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Table 2. Genome characteristics of completely sequenced members of the families 
Alloherpesviridae and Malacoherpesviridae 
Genome structure E is the most complex genome structure and characteristic of 
Alphaherpesvirinae in the Simplexvirus genus, and certain members of the genus 
Cytomegalovirus of the Betaherpesvirinae (Davison, 2007). The gross genome organization of 
OsHV-1 is a combination of class D and E genomes, consisting of two invertible unique 
regions (UL & US), each flanked by inverted repeats (TRL & IRL and IRS & TRS), with an 
additional short unique sequence (X) between the inverted repeats (Davison et al., 2005b). 
 
 
Fig. 2. Schematic representation of the genome organization of selected members of the 
families Alloherpesviridae and Malacoherpesviridae 
5.3 Gene conservation 
Herpesvirus genomes show a wide range in number of genes, ranging from about 70 
(Varicella zoster virus) to more than 200 (Human cytomegalovirus) genes (Davison, 2007; 
McGeoch et al., 2006). Herpesvirus genes are divided into core genes and non-core genes. 
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The core genes are inherited from a common ancestor and fundamental to replication, 
being involved in capsid assembly and structure, DNA replication machinery, processing 
and packaging of DNA, egress of capsids from the nucleus, and control and modulation. 
The non-core genes represent accessory systems that developed more recently and fit a 
virus to a particular biological niche. These genes are involved in cellular tropisms, 
control of cellular processes, manipulation or evasion from the host immune system, and 
latency. Among the Herpesviridae, there is a subset of 43 core genes (McGeoch & Davison, 
1999).  
Only 13 genes are convincingly conserved among all members of the family Alloherpesviridae 
(Aoki et al., 2007). These genes encode proteins putatively involved in capsid 
morphogenesis, DNA replication and DNA packaging (Table 3). Five of the identified 
conserved genes encode proteins with unknown functions. With only 13 genes conserved 
among all family members, the family Alloherpesviridae appears to be considerably more 
divergent than the family Herpesviridae, reflecting the greater divergence of its host species. 
 
Function AngHV-1 CyHV-3 IcHV-1 RaHV-1 RaHV-2 
ATPase subunit of terminase ORF10 ORF33 ORF62 ORF42 ORF68 
Primase ORF21 ORF46 ORF63 ORF87 ORF121 
Unknown ORF22 ORF47 ORF64 ORF88 ORF122 
Capsid triplex protein 2 ORF36 ORF72 ORF27 ORF95 ORF131 
DNA helicase ORF37 ORF71 ORF25 ORF93 ORF129 
Unknown ORF52 ORF80 ORF60 ORF84 ORF118 
DNA polymerase ORF55 ORF79 ORF57 ORF72 ORF110 
Capsid protease and 
scaffolding protein ORF57 ORF78 ORF28 ORF63 ORF88 
Large envelope glycoprotein ORF67 ORF99 ORF46 ORF46 ORF72 
Unknown ORF82 ORF61 ORF54 ORF75 ORF113 
Unknown ORF98 ORF107 ORF56 ORF73 ORF111 
Unknown ORF100 ORF90 ORF37 ORF52 ORF78 
Major capsid protein ORF104 ORF92 ORF39 ORF54 ORF80 
Table 3. Conserved genes of the family Alloherpesviridae 
The arrangement of homologous genes in AngHV-1 and CyHV-3 appears to be conserved in 
clusters (van Beurden et al., 2010). Several conserved gene blocks can be identified, either in 
the same or in inverse orientation. At the Alloherpesviridae family level, the 13 conserved 
genes seem to be conserved within the same clusters, which was previously shown also for 
IcHV-1 and SalHV-1 (Davison, 1998), and appears to apply for all completely sequenced 
Alloherpesviridae (Fig. 3). This resembles the seven blocks of core genes that are typically 
arranged throughout the family Herpesviridae (McGeoch et al., 2006). 
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since SalHV-1 is known to have a long unique region (UL) linked to a short unique region 
(US) flanked by an inverted repeat (IRS and TRS) (Davison, 1998). This genome structure (D) 
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latency. Among the Herpesviridae, there is a subset of 43 core genes (McGeoch & Davison, 
1999).  
Only 13 genes are convincingly conserved among all members of the family Alloherpesviridae 
(Aoki et al., 2007). These genes encode proteins putatively involved in capsid 
morphogenesis, DNA replication and DNA packaging (Table 3). Five of the identified 
conserved genes encode proteins with unknown functions. With only 13 genes conserved 
among all family members, the family Alloherpesviridae appears to be considerably more 
divergent than the family Herpesviridae, reflecting the greater divergence of its host species. 
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the same or in inverse orientation. At the Alloherpesviridae family level, the 13 conserved 
genes seem to be conserved within the same clusters, which was previously shown also for 
IcHV-1 and SalHV-1 (Davison, 1998), and appears to apply for all completely sequenced 
Alloherpesviridae (Fig. 3). This resembles the seven blocks of core genes that are typically 
arranged throughout the family Herpesviridae (McGeoch et al., 2006). 
  




Fig. 3. Geneblock conservation throughout the family Alloherpesviridae: conserved genes are 
coloured red and connected through the genomes by coloured bars; red bars indicate similar 
and reading frame direction, blue bars indicate reversed reading frame direction; percentage 
sequence identity at amino acid level is indicated by bar colour intensity 
6. Extended characterization of Alloherpesviridae 
6.1 Gene expression 
Gene expression of herpesviruses is regulated in a temporal fashion, with genes being 
classified on the basis of their expression kinetics as immediate early, early, and late genes 
(McGeoch et al., 2006). Temporal gene expression has been suggested for IcHV-1 based on 
polypeptide analyses of in vitro infection experiments (Dixon & Farber, 1980). Transcription 
studies of selected ORFs, especially of the terminal repeat region of IcHV-1, confirmed the 
temporal expression of these genes (Huang & Hanson, 1998; Silverstein et al., 1995; 
Silverstein et al., 1998; Stingley & Gray, 2000). Expression of certain ORFs of CyHV-3 at 
lower and higher temperatures in vitro has been studied using RT-PCR (Dishon et al., 2007). 
Initial experiments to determine the complete transcription profile of AngHV-1 by 
quantitative RT-PCR showed similar temporal expression kinetics as have been determined 
for members of the family Herpesviridae (van Beurden et al., unpublished results). 
6.2 Latency 
The ability to establish a latent infection is one of the hallmarks of herpesviruses. Latent 
infections are characterized by the absence of infectious virus particles and regular viral 
transcription and replication, but the presence of intact viral genomic DNA and 
transcription of latency associated transcripts. Accordingly, the presence of viral DNA (and 
not infectious virus) has been demonstrated in fish surviving infections with IcHV-1 and 
CyHV-3 (Eide et al., 2011a; Gray et al., 1999), whereas viral replication was absent in such 
 
Herpesviruses of Fish, Amphibians and Invertebrates 
 
231 
fish (Eide et al., 2011b; Stingley et al., 2003). It has been shown in vitro that CyHV-3 is able to 
persist in cultured cells at a nonpermissive temperature, with viral propagation and viral 
gene transcription being turned off, and reactivated upon return to the permissive 
temperature (Dishon et al., 2007). Reactivation of fish herpesviruses in vivo has been 
demonstrated for AngHV-1 following dexamethasone treatment (van Nieuwstadt et al., 
2001), and for CyHV-3 following temperature stress (Eide et al., 2011b; St-Hilaire et al., 
2005). 
6.3 Gene characterization 
Identification and characterization of most alloherpesvirus ORFs is based on sequence 
homology and bioinformatics. Recent probabilistic mapping of IcHV-1 (Kunec et al., 2009), 
and complete transcriptome analysis of AngHV-1 (van Beurden et al., unpublished results), 
show, however, that there might still be a large discrepancy between the predicted and 
actual numbers of ORFs. 
MS analysis of purified capsids resulted in the identification of the structural proteins of 
IcHV-1, CyHV-3 and AngHV-1 (Davison & Davison, 1995; Michel et al., 2010; van Beurden 
et al., 2011). Based on the localization of the structural proteins in the different virion 
compartments, several of these proteins could be functionally characterized. Two 
alloherpesvirus proteins have been characterized in more detail: IcHV-1 ORF50 has been 
shown to encode a secreted mucin-like glycoprotein (Vanderheijden et al., 1999), and CyHV-
3 ORF81 has been identified as an envelope protein (Rosenkranz et al., 2008).  
6.4 Virulence factors and vaccine development 
In many herpesviruses the homologues of cellular enzymes are nonessential for virus 
replication in vitro, but relevant for virulence in vivo. Attenuated IcHV-1 and CyHV-3 strains 
with specific gene deletions have been developed and tested for virulence. Thymidine 
kinase-negative mutants of IcHV-1 resembled wild type IcHV-1 in vitro, but appeared to be 
much less pathogenic in vivo (Zhang & Hanson, 1995). Similarly, CyHV-3 recombinants 
possessing deletions within the viral ribonucleotide reductase, thymidine kinase and 
dUTPase genes were developed and tested for attenuation (Fuchs et al., 2011). The use of the 
attenuated strains as modern live vaccines in challenges with wild-type virus showed 
promising results. 
Several other attempts of vaccine development have been undertaken for IcHV-1 and 
CyHV-3. For CyHV-3, immunization with wild type and attenuated virus has been tested in 
relation to different water temperatures (Ronen et al., 2003). For IcHV-1, experimental 
subunit and attenuated vaccines were developed and tested (Dixon, 1997). Also, DNA 
vaccination with several different ORFs has been tested for IcHV-1 (Nusbaum et al., 2002). 
Later, an overlapping and a full BAC have been developed for IcHV-1 (Kunec et al., 2008) 
and CyHV-3 (Costes et al., 2008), respectively. The latter was used to test attenuation after 
disruption of the thymidine kinase locus and deletion of ORF16. To date no satisfying 
vaccine has been developed nor registered for any of the fish herpesviruses. 
7. Conclusions 
In conclusion, herpesviruses of fish, amphibians and invertebrates form a potentially large 
group of important pathogens. Understanding the origins of the distantly related families 
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Alloherpesviridae and Malacoherpesviridae provides insights into the evolution of the family 
Herpesviridae. The association of many fish herpesviruses with severe diseases in important 
aquaculture species has stimulated fundamental and applied research. For a selected 
number of alloherpesviruses, complete genome sequences and structural analyses of the 
virus particles are now available and have revealed similarity to the basic composition of 
higher vertebrate herpesviruses. Extended characterization of gene expression, latency, the 
function of specific genes and virulence factors as well as vaccine development is currently 
ongoing. These studies will add to the control and prevention of fish herpesvirus associated 
diseases, and might serve as models for research on human and domestic animal 
herpesviruses. 
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Alloherpesviridae and Malacoherpesviridae provides insights into the evolution of the family 
Herpesviridae. The association of many fish herpesviruses with severe diseases in important 
aquaculture species has stimulated fundamental and applied research. For a selected 
number of alloherpesviruses, complete genome sequences and structural analyses of the 
virus particles are now available and have revealed similarity to the basic composition of 
higher vertebrate herpesviruses. Extended characterization of gene expression, latency, the 
function of specific genes and virulence factors as well as vaccine development is currently 
ongoing. These studies will add to the control and prevention of fish herpesvirus associated 
diseases, and might serve as models for research on human and domestic animal 
herpesviruses. 
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Sciences of the Czech Republic, 
Czech Republic 
1. Introduction  
Viral infections have accompanied humankind from time immemorial. Herpesvirus 
infections, especially those caused by HSV-1 and HSV-2, are among the most common viral 
infections at all. The control and treatment of the virus has changed through history, starting 
with cauterization with hot iron, recommended in ancient Rome, through the most diverse 
herbal treatments and naturopathic remedies including miracle diets. Fundamental change 
in the approach to the whole issue occurred in the second half of the twentieth century with 
discoveries in the field of nucleic acid chemistry. Explanation of nucleic acid structure 
initiated not only enormous interest and the subsequent boom of molecular biology and 
genetics but also the formation of a new field of organic chemistry – chemistry of nucleic 
acid components: nucleosides, nucleotides and oligonucleotides. 
2. Chemically modified nucleosides: First generation of antimetabolites of 
nucleic acids 
It was shown that chemically modified nucleosides or nucleobases can work as 
antimetabolites in the process of nucleic acid metabolism. The word “antimetabolite” 
means, generally, a chemically modified molecule of a natural metabolite able to influence 
some enzyme reactions. Antimetabolites can influence processes in cells (neoplasia) as well 
as processes in cell parasites, e.g. viruses, parasites, and fungi. The first generation of 
antimetabolites is distinguished by a maximum structural resemblance to natural 
metabolites. Many nucleoside or nucleobase analogues from this group were found to be 
effective cytostatics: cytosine arabinoside (Cytarabine, Ara-C), an antileukemic agent used 
for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, 6-
mercaptopurine (Purinethol®, 6-MP) used for the acute lymphoblastic leukemia, 5-
fluorouracil (Efudex® , 5-FU), a thymidylate synthase inhibitor used for the treatment of 
colon, rectal, stomach, skin, breast and pancreatic cancer, and finally, antileukemic agents 5-
azacytidine (Vidaza®) and 2´-deoxy-5-azacytidine (decitabine, Dacogene®), so far the most 
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successful agents approved for therapy of myelodysplastic syndrom. Discoveries of these 
great molecules came in the sixtieth decade of the last century, a period of the beginning of 
great development of nucleoside chemistry. This chemistry was substantially supported by 
the pharmaceutical industry with the intent to finally find an effective medicine against the 
terror of mankind known as cancer. In these times, viral infections were not in the forefront.  
3. Acyclic analogues of nucleosides: The second generation of 
antimetabolites 
The situation had changed by the end of the 1960s and at the beginning of the 1970s. The 
turning point was a large “epidemy” of genital herpes (HSV-2) in the USA, especially 
widespread due to the promiscuous lifestyle of the time. This sexually transmitted disease 
became a common problem for the whole society, and a fast solution got priority. The great 
success came with the synthesis and clinical development of acyclovir (Zovirax) by 
Burroughs-Wellcome. So far this drug is one of the most frequently used drugs against 
HSV-1 and HSV-2 infections. Among others, development of acyclovir resulted in the first 
Nobel Prize targeted to the pharmaceutical industry: in 1988 the Nobel Prize winners for 
medicine were Gertrude B. Elion and Georg Hitchings from the above mentioned company.  
Acyclovir, 9-(2-hydroxyethoxymethyl)guanine, similar to the many other antiherpetic 
agents (penciclovir, ganciclovir and their prodrug forms), belongs to the group of acyclic 
nucleoside analogues, compounds having the sugar furanose ring substituted with a 
polyhydroxylic carbon chain (Fig. 1). These compounds represent the so-called second 
generation of antimetabolites where the structural resemblance to a natural metabolite is 
only present in some basic aspects and the necessary steric arrangement can be formed by 
its subsequent contact with a target metabolic enzyme. 
 
 
Fig. 1. Structures of the most commonly-used antiherpetic drugs from the family of acyclic 
nucleoside analogues 
Fundamental developments in this field were also made in Prague at the Institute of 
Organic Chemistry and Biochemistry in the laboratory of Antonin Holy. His synthetic effort 
and close collaboration with the Belgian virologist Erik De Clercq resulted in many new 
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acyclic nucleoside analogues whose activity against herpes viruses was confirmed. The most 
potent agents were found to be N9-alkyl derivatives of adenine with hydroxyl group(s) on 
the alkyl chain (RS)-3-(adenin-9-yl)-2-hydroxypropanoic acid (AHPA, especially in the form 
of alkyl esters), D-eritadenine and the broad-spectrum antiviral agent (S)-(2,3-
dihydroxypropyl)adenine (DHPA) (De Clercq et al. 1978, De Clercq & Holý 1985, Holý et al. 
1982). Antiviral potency of these adenosine analogues concerns their inhibition of SAM-
dependent methylation reactions via inhibition of S-adenosylhomocysteine (SAH) 
hydrolase. SAH is the product of S-adenosylmethionine (SAM) mediated transmethylation 
reactions and it is itself a feedback inhibitor of these reactions. If SAH hydrolase is inhibited, 
SAH accumulates and thereby all biological processes that require intensive methylations 
are suppressed. One such situation is the maturation of viral mRNA, i.e., 5'-cap formation 
and subsequent blocking virus replication. The most effective inhibitor of SAH hydrolase, 
DHPA became an approved drug for the topical treatment of herpes labialis (HSV-1) in the 
former Czechoslovakia, marketed under the name Duvira® gel (Fig. 2). 
 
 
Fig. 2. Aliphatic analogues of adenosine as inhibitors of SAH hydrolase: DHPA (“Duvira 
gel”), D-eritadenine and AHPA esters 
4. Acyclic nucleoside phosphonates 
The necessary condition for any antimetabolite to be of use in enzyme reactions is its 
phosphorylation. Unfortunately, the direct medical application of phosphates of the 
antimetabolites has no advantage due to their instability. To overcome this problem, in the 
mid-1980s, our Prague team lead by Antonin Holy came up with the revolutionary idea of 
preparation of phosphonomethyl derivatives: compounds stabilized by the introduction of a 
methylene bridge between a phosphonic acid residue and the rest of the molecule. During 
the short time, acyclic nucleoside phosphonates (ANPs) were revealed as compounds with 
an extraordinary broad spectrum of biological activities: antiviral, cytostatic, antiparasitic or 
immunomodulatory. Some of them are commercially available pharmaceuticals effective 
against serious viral infections (cidofovir, adefovir and tenofovir) (Holý, 2003; De Clercq & 
Holý, 2005). Several comprehensive reviews on ANPs as antiviral agents have been 
published recently (Holý & De Clercq, 2010; De Clercq, 2011). 
The mentioned compounds represent three different types of ANPs: HPMP derivatives, i.e. 
(S)-[3-hydroxy-2-(phosphonomethoxy)propyl] derivatives (e.g. HPMPC, cidofovir), PME 
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derivatives, i.e. 2-(phosphonomethoxy)ethyl derivatives (e.g. PMEA, adefovir) and PMP 
derivatives, i.e. (R)-2-(phosphonomethoxy)propyl derivatives (e.g. PMPA, tenofovir).  
4.1 (S)-[3-Hydroxy-2-(phosphonomethoxy)propyl] derivatives (HPMP derivatives) –
Synthesis and activity of HPMPA and its aza/deaza analogues  
HPMP derivatives are active against DNA viruses; the activity is bound always to S 
enantiomers. The first described ANP was 9-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]adenine (HPMPA), a compound derived from above 
mentioned DHPA by the introduction of a phosphonomethyl group (De Clercq et al., 1986; 
Holý & Rosenberg, 1987). 
Synthesis of (S)-HPMP derivatives mostly utilizes basically catalyzed nucleophilic opening 
of the oxirane ring in (2S)-2-[(trityloxy]methyl]oxirane or (R)-glycidol butyrate with an 
appropriate nucleobase, e.g. N4-benzoylcytosine, N6-benzoyladenine or 2,6-
bis(benzoylamino)purine (Webb et al., 1988; Brodfuehrer et al., 1994). This reaction proceeds 
regioselectively to N9 position of the purine or N1 position of the pyrimidine base. The 
intermediary formed 2,3-dihydroxypropyl derivatives are subsequently etherified with 
dialkyl (diethyl or diisopropyl) ester of tosyloxymethanephosphonate in the presence of 
sodium hydride. After removal of benzoyl groups and trityl, phosphonic ester groups are 




Fig. 3. Synthetic scheme for the preparation of (S)-[3-hydroxy-2-
(phosphonomethoxy)propyl] derivatives of adenine and cytosine (HPMPC and HPMPA) 
from appropriate oxiranes 
Preparation of diisopropyl tosyloxymethanephosphonate consists of the treatment of 
diisopropyl phosphite with paraformaldehyde and triethyl amine followed by tosylation 
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(Holý, 1993). Another possibility for the introduction of a phosphonomethyl ether group 
based on use of diisopropyl bromomethylphosphonate (Göbel et al., 1992) is also 
recommended (Holý, 2005; Oh & Hong, 2008). Most recently, a novel, very efficient and 
environmentally friendly synthesis of diisopropyl bromomethylphosphonate (and other 
dialkylhaloalkylphosphonates in general), has been developed in our Institute using a 
microwave-assisted Michaelis–Arbuzov reaction of dihaloalkanes. Diisopropyl 
bromomethylphosphonate thus can be prepared by reaction of dibromomethane with 
triisopropyl phosphite (Jansa et al., 2011). Syntheses of both agents are depicted in Fig. 4. 
 
 
Fig. 4. Syntheses of reagents for an introduction of a phosphonomethyl residue to the 
molecule of acyclic nucleoside analogues: synthesis of the “Holy´s tosylate”, diisopropyl 
tosyloxymethanephosphonate and the microwave assisted approach to diisopropyl 
bromomethylphosphonate by Jansa  
(S)-HPMPA is a compound with a broad spectrum of anti DNA-virus activities, so far not 
clinically developed. It efficiently inhibits herpesviruses (Andrei et al., 1992) including 
clinical isolates of varicella zoster virus (Andrei et al., 1995), HHV-6 (Reymen et al., 1995) 
and HHV-8 (Neyts & De Clercq, 1997). HHV-6 is one of the recently discovered members of 
the betaherpesviridae family. It is involved in pathogenesis of several diseases including the 
childhood disease exanthema subitum (roseola) (Yamanishi et al. 1988) and 
lymphoproliferative disorders, and it probably takes part in the progression of chronic 
fatigue syndrome (Komaroff, 2006). HHV-6 has also been proposed to be a cofactor in the 
progression of AIDS; high levels of HHV-6 have been found in many AIDS patients. The 
comparative study of effectiveness of diverse kinds of ANP towards HHV-6 revealed, 
besides HPMPA, also several other active (S)-HPMP derivatives: (S)-HPMPC, (S)-cHPMPC, 
(S)-3-deaza-HPMPA, (S)-3-deaza-cHPMPA, (S)-HPMPG, (S)-cHPMPG and (R)-HPMPG, 
their EC50 values ranging from 1 to 11 /µM and their selectivity index ranging from 6 to 30 
(Reymen et al., 1995).  
A special attention is now paid to the investigation of HPMPA prodrugs to improve the 
pharmacokinetic profile of this ANP, especially the development of alkoxyalkyl esters 
(Beadle et al., 2006). It is based on etherification of the appropriate hydroxy derivate with 
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alkoxyalkyl tosyloxymethanephosphonate, a phosphonomethyl residue containing an agent 
having the lipophilic group already preattached. This compound can be prepared in three 
steps from diethyl tosyloxymethanephosphonate: deprotection of ethyl ester groups with 
bromotrimethylsilane, transformation to chloridate by the action of oxalyl chloride, and 
reaction with alkoxyalkanols under basic conditions. The starting material for syntheses of 
HPMPA esters is (S)-9-(3-trityloxy-2-hydroxypropyl)-N6-trityladenine, an intermediate in 
preparation of HPMPA according to Webb’s method (Webb, 1989). 
The whole process is outlined in Figure 5. 
 
 
Fig. 5. Synthesis of alkoxyalkyl ester prodrugs of HPMPA.  
Excellent anti-DNA virus effects were also found at other HPMP derivatives, e.g. 2,6-
diaminopurine counterpart of HPMPA, (S)-HPMPDAP. Recently, a detailed 
investigation of this compound and its ester prodrugs has been performed (Krečmerová 
et al., 2010a). This research, originally targeted to antipoxvirus agents, also selected, 
among others, several candidates with excellent antiherpetic effects. Remarkable broad-
spectrum antiherpetic effects were found at some base modified ANPs (aza/deaza 
analogs). Anti-DNA-viral activity was found especially at (S)-8-aza-HPMPA and (S)-3-
deaza-HPMPA.  
Syntheses of deazapurines, i.e. purines lacking one nitrogen atom in position 1, 3 or 7 and 
their nucleosides and ANPs, were developed by Holý and Dvořáková (Dvořáková et al., 
1993; Dvořáková & Holý, 1993). Activity of (S)-3-deazaHPMPA against herpesviruses is 
comparable to that of the parent compound (S)-HPMPA, especially in case of VZV and 
CMV (Dvořáková et al., 1990). (S)-3-deaza-HPMPA, and its cyclic form, (S)-3-deaza-
cHPMPA are also highly active against HHV-6 infections (Naesens and De Clercq, 2006). 
Evaluation of a series of diverse ANPs for activity against HHV-6 in HSB-2 cells showed 3-
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deaza-HPMPA as a compound with the highest selectivity index (Reymen et al., 1995). In 
spite of all the progress in this topic, there is so far no approved drug for the treatment of 
HHV-6 infections (De Bolle et al., 2005). Moreover there is also another difficulty: no animal 
model for HHV-6 testing. These facts substantiate further intensive exploration of ANPs, 
especially 3-deaza-HPMPA and HPMPA, as potential drug candidates for the treatment of 
HHV-6 infections. 
The synthesis of acyclic nucleotide analogues derived from 8-azapurine was first reported in 
1996 (Holý et al., 1996). In the HPMP series, only (S)-HPMP-8-azaadenine exhibits 
remarkable inhibitory potency to all DNA viruses tested. The best data were found for HSV-
1, TK− HSV, HSV-2, VZV, TK− VZV and vaccinia virus. In particular, exquisitely inhibitory 
effects were found for VZV with MIC 0.2-2 µg/mL. In general, the antiviral potency of 
HPMP-8-azaA is mostly comparable to (S)-HPMPA. Its 2,6-diaminopurine counterpart, (S)-
HPMP-8-aza-DAP is approximately two orders of magnitude less potent of an inhibitor of 
these viruses than HPMP-8-azaA. Other structural types of 8-azapurine ANPs (PMP and (S)-
FPMP derivatives) are not markedly inhibitory to any of the DNA viruses tested. In a series 
of PME derivatives, only PME-8-azaguanine was inhibitory to HSV-1, the thymidine kinase 
(TK-) deficient HSV-1 strains, HSV-2, CMV, both TK+ and TK- VZV strains and vaccinia 
virus (Holý et al., 1996). Structures of the most important anti-DNA viral HPMP derivatives 
are depicted in Fig. 6. 
 
 
Fig. 6. HPMP derivatives: acyclic nucleoside phosphonates with a broad spectrum of 
activities against herpes- and other DNA virus infections 
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Fig. 6. HPMP derivatives: acyclic nucleoside phosphonates with a broad spectrum of 
activities against herpes- and other DNA virus infections 
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4.2 Cidofovir (HPMPC) 
Cidofovir, 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine, is a broad spectrum 
anti DNA virus agent whose spectrum of activities covers all types of human herpesviruses 
[HSV-1, HSV-2, varicella-zoster virus (VZV), Epstein–Barr virus, CMV, HHV-6, HHV-7 and 
HHV-8 — and also thymidine kinase-deficient (TK–) HSV and VZV, and protein kinase-
deficient (PK–) CMV variants], and polyoma-, papilloma-, adeno- and poxviruses. The large 
scale of cidofovir activities has already been a topic of many reviews, e.g. (Hitchcock et al., 
1996; Naesens & De Clercq, 1997; De Clercq, 1998; Naesens et al., 1997). 
Cidofovir was the first acyclic nucleoside phosphonate utilized in clinical practice: in 1996 
this drug was approved by the FDA for the treatment of cytomegalovirus retinitis in AIDS 
patients. The drug is marketed by Gilead Sciences, Inc. under the commercial name 
VistideTM and it is applied to patients in the form of intravenous injections (Fig. 7). CMV 
retinitis is a systemic infection commonly seen in patients suffering from AIDS. It is most 
easily characterized by the cloudiness which can appear in the patient’s retina. If untreated, 
the virus will attack retina cells and develop into lesions. These lesions can eventually lead 
to vision impairment or permanent blindness. Cidofovir suppresses CMV replication by the 
selective inhibition of viral DNA polymerase and therefore prevention of viral replication 
and transcription (Wachsman et al., 1996; Lalezari et al., 1997). A serious side-effect of 
cidofovir (and all other ANPs) is its dose-dependent nephrotoxicity. To surmount this 
problem, cidofovir must be administered in conjunction with probenecid (Bagnis et al., 1999; 
Lacy et al., 1998).  
 
 
Fig. 7. VistideTM - cidofovir injections. The first approved acyclic nucleoside phosphonate in 
clinical practice 
At the present time, cidofovir is also important (off label) particularly for the treatment of 
severe cases of (malignizing) papillomatoses (anogenital, laryngeal)(Calista, 2000; 
Bielamovicz et al., 2002), progressive multifocal leukoencephalopathy caused by JC virus 
(Gasnault et al., 2001), adenovirus infections (Legrand et al., 2001) and some rather obscure 
severe infections caused by poxviruses (vaccinia, orf, molluscum contagiosum) (Bray 
&Wright, 2003). The attractiveness of cidofovir is dramatically enhanced by its supreme 
activity against smallpox virus and related monkey pox virus; both of these highly 
infectious viruses can be easily cultivated and purposely used in a bioterrorist attack. For 
this purpose, the cidofovir prodrug, hexadecyloxypropyl ester CMX001, is currently 
clinically investigated (Chimerix, Inc., California). Moreover, CMX001 is also being 
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developed to treat cytomegalovirus (CMV) and BK virus – potentially deadly diseases for 
immunocompromised patients (www.chimerix-inc.com). 
4.3 5-Azacytosine analogue of cidofovir (HPMP-5-azaC): Higher potency with a lower 
toxicity 
Great success in our search for antiviral compounds came with the discovery of ANPs 
bearing a triazine ring, especially 5-azacytosine as a base component (Krečmerová et al., 
2007a). The 5-azacytosine analogue of cidofovir, i.e. 1-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC), shows antiviral activities 
similar - or in some cases higher - compared to cidofovir, better selectivity, and lower 
toxicity. 
Synthesis of (S)-HPMP-5-azaC can be performed in two different manners. The first 
approach is based on nucleophilic opening of an oxirane ring in (2S)-2-
[(trityloxy]methyl]oxirane with 5-azacytosine under basic conditions, e.g. in a presence of 
sodium hydroxide. The reaction gives regiospecifically the only N-1 substituted product, 1-
[(2S)-2-hydroxy-3-(triphenylmethoxy)propyl]-5-azacytosine), in excellent yield. Its further 
treatment with diisopropyl tosyloxymethylphosphonate in the presence of excess sodium 
hydride in N,N-dimethylformamide gave fully protected phosphonate ester, which was 
subsequently treated with bromotrimethylsilane followed by hydrolysis. This process leads 
simultaneously to a removal of trityl group and phosphonate protecting diisopropyl ester 
groups under formation of the final HPMP-5-azaC (Fig. 8). 
 
 
Fig. 8. Synthesis of (S)-HPMP-5-azaC from (2S)-2-[(trityloxy)methyl]oxirane. The stepwise 
approach 
The second approach is based on alkylation of 5-azacytosine with an appropriate chiral 
synthon, i.e. the whole aliphatic part activated with a suitable leaving group, usually tosyl 
or halogen (Fig. 9). Preparation of “(S)-HPMP synthon”, i.e. diisopropyl ester of (1S)-[2-
hydroxy-1-tosyloxymethyl)ethoxy]methylphosphonate followed the protocol originally 
developed for its racemic form (Hocek et al., 1996). Also in this case, (2S)-2-
[(trityloxy]methyl]oxirane was selected as a starting material. The oxirane ring was first 
opened by nucleophilic reaction with sodium benzylate to give (2S)-1-benzyloxy-3-
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trityloxypropan-2-ol. The next steps are introduction of a phosphonomethyl residue using 
diisopropyl bromomethanephosphonate, removal of the trityl group with acetic acid, 
tosylation, and the final deprotection of benzyl group by catalytic hydrogenation. Removal 
of benzyl group just in this step, i.e. still in a stage of the synthon is necessary. Its removal in 
some of the following steps would not be possible due to a sensitivity of 5-azacytosine 
towards catalytic hydrogenation leading to 5,6-dihydro-5-azacytosine derivatives. 
Diisopropyl (1S)-[2-hydroxy-1-tosyloxymethyl)ethoxy]methylphosphonate (HPMP-
synthon) was used for the final condensation with a sodium salt of 5-azacytosine. This 
condensation proceeds exclusively to form the desired N-1 isomer, i.e. diisopropyl ester of 
HPMP-5-azaC, accompanied by N-3 and O-isomers in a small amount only. This reaction 
was revealed as an advantageous approach to HPMP-5-azaC, especially for its larger-scale 
syntheses (Krečmerová et al., 2010b). The final deprotection of ester groups was performed 
by the standard procedure with bromotrimethylsilane, followed by hydrolysis. 
 
 
Fig. 9. Synthesis of (S)-HPMP-5-azaC by the synthon approach 
HPMP-5-azaC showed potent and selective activity against several DNA viruses, including 
different herpesviruses (HSV-1, HSV-2, VZV, HCMV and HHV-6), adenovirus (Ad2) and 
poxvirus (vaccinia virus) with 50% effective concentration (EC50) values of 0.71µg/mL for 
Ad2, 2.56 µg/mL for vaccinia virus and 0.02-0.6 µg/mL for herpesviruses. The antiviral 
activity of HPMP-5-azaC was comparable to cidofovir against HSV-1, HSV-2 and vaccinia 
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virus, or 2 to 7 times more active against VZV, HCMV, HHV-6 and Ad2. HPMP-5-azaC 
proved to be 2 times less cytotoxic for HEL cells than (S)-HPMPC but 2-fold more toxic for 
human T-lymphoblast HSB-2 cells. For all these DNA viruses, HPMP-5-azaC showed a 2- to 
16-times higher antiviral selectivity index (ratio of CC50 to EC50) than (S)-HPMPC (cidofovir) 
(Krečmerová et al., 2007a). 
In contrast to cidofovir, HPMP-5-azaC has more complicated metabolic profile, and, similar 
to other N-1 substituted 5-azacytosine derivatives (riboside, 2´-deoxyriboside, arabinoside), 
it decomposes in alkaline conditions (Dračínský et al., 2008). The first step is a reversible 
ring opening of the sym-triazine to the N-formylguanidine derivative which can close back 
to the cyclic structure. This hydrolytic reaction is slow and reaches equilibrium within 
several days. However, the reversible ring-opening hydrolysis is accompanied by 
irreversible deformylation reaction of the intermediary formyl derivative that gives rise to 
antivirally inactive 2-{[(2S)-3-hydroxy-2-(phosphonomethoxy)propyl]carbamoylguanidine. 
Among these decomposition products (Fig. 10), the N-formylguanidine derivative, which 
can close back to the cyclic structure, showed activity with equivalent EC50 values to those 
obtained for the original compound HPMP-5-azaC (VZVand HCMV) or at 3- to 25-fold 
higher EC50’s for HSV-1, HSV-2, HHV-6, Ad2 and vaccinia virus. In contrast, the final 
decomposition product, the carbamoylguanidine derivative, is antivirally inactive 
(Krečmerová et al., 2007a). 
 
 
Fig. 10. The course of decomposition of (S)-HPMP-5-azaC in alkaline conditions 
Investigation of the intracellular metabolism of HPMP-5-azaC revealed its phosphorylation 
to mono- and diphosphate (60 fold higher then cidofovir) and deaminated uracil product 
(HPMP-5-azaU) as a minor component (6%). HPMP-5-azaC also showed about 45-fold 
higher incorporation into cellular DNA than cidofovir. In general, HPMP-5-azaC has a 
favorable metabolic profile that is characterized by low sensitivity to catabolic deamination 
and high efficiency for phosphorylation and DNA incorporation (Naesens et al., 2008).  
Discovery of the unique antiviral activity of HPMP-5-azaC resulted in the necessity to also 
prepare some kinds of prodrugs: the cyclic form of 1-(S)-[3-hydroxy-2-
(phosphonomethoxy)propyl]-5-azacytosine (cHPMP-5-azaC) and its esters. Transformation 
of HPMP-5-azaC to its cyclic form was realized by the action of dicyclohexylcarbodiimidide 
(DCC) and N,N,-dicyclohexyl-4-morpholinocarboxamidine. To assess the role of ester 
structure in antiviral activity, four diverse ester types were synthesized: alkyl (octadecyl), 
alkenyl (erucyl, i.e. (Z)-docos-13-enyl), pivaloyloxymethyl (POM) and alkoxyalkyl (2-
(hexadecyloxy)ethyl, HDE). The most successful esterification method was the reaction of 
tetrabutylammonium salt of cHPMP-5-azaC with alkyl bromides or with chloromethyl 
pivalate, respectively (Fig. 11) (Krečmerová et al., 2007b).  
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Fig. 11. Synthesis of ester prodrugs derived from the cyclic (S)-HPMP-5-azaC 
cHPMP-5-azaC was able to inhibit the replication of poxviruses (vaccinia virus), and 
different herpesviruses, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), 
thymidine kinase-deficient HSV-1 [acyclovir resistant (ACVr)], varicella-zoster virus (VZV), 
human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6) with EC50 values in 
the range of 0.06 to 3.1 µg/ml. cHPMP-5-azaC did not affect cell morphology or cell growth 
(measured on HEL cells). This resulted in selectivity indices (ratio of CC50 to EC50) varying 
from >47 (vaccinia virus) to >1500 (HCMV). The potency of the new triazine analogues 
HPMP-5-azaC and cHPMP-5-azaC was comparable to that of HPMPC and cHPMPC; 
however, HPMP-5-azaC and cHPMP-5-azaC proved to be approximately 2 times less 
cytostatic for HEL cells than HPMPC and cHPMPC, resulting in a superior selectivity.  
When the different ester prodrugs, i.e. octadecyl, (erucyl), alkoxyalkyl (HDE) and 
pivaloyloxymethyl (POM), were evaluated, the HDE emerged as the most active one, with 
EC50 values in the range of 0.003 to 0.008 µg/mL for HSV, ≤0.0008 to ≤.0014 µg/mL for VZV, 
≤0.00014 to ≤0.00038 µg/mL (HCMV), 0.008 to 0.037 µg/mL for HHV-6 and 0.037 µg/mL for 
vaccinia virus. This resulted in 58- (vaccinia virus), 100- (mean for HSV strains), 123- (mean 
for VZV strains) to 250-fold (mean for HCMV strain) increase in antiviral activity when 
compared to cHPMP-5-azaC. Not only an improvement in the antiviral activity, but also an 
increase in selectivity, was observed for HDE-cHPMP-5-azaC. Thus, selectivity indices for 
HDE-cHPMP-5-azaC were found 43 (HHV-6A), 70 (HHV-6B), 173 (vaccinia virus), 1160 
(HSV), ≥5800 (VZV) and ≥24600 (HCMV), as compared to 74 (HHV-6A), 11 (HHV-6B), >47 
(vaccinia virus), >180 (HSV), >740 (VZV) and >1540 (HCMV) for the free cHPMP-5-azaC.  
Although a marked increase in antiviral potency was noted for the octadecyl ester compared 
to free cHPMP-5-azaC against HCMV (EC50 = 0.0014-0.0037 µg/mL), only a slight increase 
in activity against VZV or a decrease in potency against HSV was observed. Despite the fact 
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that the octadecyl ester did not affect cell growth up to a concentration of 100 µg/mL, it 
produced an alteration of cell morphology at a concentration ≥20 µg/mL.  
The esterification of cHPMP-5-azaC to the erucyl prodrug resulted in a loss of activity 
against vaccinia virus and no improvement or slight decrease in activity against HSV and 
VZV. The pivaloyloxymethyl ester has a good potency against HCMV (EC50 <0.032 µg/mL), 
but generally, its EC50 values are equivalent to those of the free cHPMP-5-azaC.  
Progress in the investigation of HPMP-5-azaC and its derivatives is currently still under 
way. The compound finished its preclinical stage of investigation; its eventual clinical 
development can be supported by the very promising results in in vivo models of poxvirus 
and herpesvirus infections, as well as by our recent progress on the development of new 
types of ester prodrugs. These results can substantially improve oral bioavailability of the 
compound and pharmacological properties in general. HPMP-5-azaC also has a potent 
activity and selectivity against polyomaviruses: murine polyoma virus, primate simian virus 
40 strains and BK virus in human primary renal cells. These findings highlight HPMP-5-
azaC and its derivatives as potential drug candidates against polyomavirus associated 
nephropathies in kidney transplant patients, a diagnosis so far with no FDA approved 
treatment (Topalis et al., 2011). 
4.4 (S)-HPMPDAP and its prodrugs – Synthesis of ester prodrugs in HPMP series 
In our recent collaborative project with the Rega Institute in Belgium, we have performed a very 
detailed study of the antiviral efficacy of (S)-HPMPDAP against various DNA viruses, 
including poxviruses [i.e. vaccinia virus (VACV)] and herpesviruses [i.e. herpes simplex virus 
type 1 (HSV-1)] and type 2 (HSV-2), thymidine kinase-deficient HSV-1 (acyclovir-resistant, 
ACVr), varicella-zoster virus (VZV), human cytomegalovirus (HCMV), and human herpesvirus 
6 (HHV-6)]. In the case of HSV-1, HSV-1 ACVr, HSV-2, and VZV, EC50 values for (S)-
HPMPDAP and its cyclic form and (S)-HPMPC were similar. In contrast, (S)-HPMPC was more 
inhibitory towards HCMV than (S)-HPMPDAP or its cyclic form (Krečmerová et al., 2010a).  
(S)-HPMPDAP, similar to other acyclic nucleoside phosphonates, represents a compound 
with a low bioavailability caused by the high polarity of a phosphonic group; its utilization 
in a prodrug form is thus highly desirable (Fig. 12). 
ANPs lacking a free hydroxyl group in a side chain (PME and PMP derivatives) are mostly 
developed in a form of neutral bis(esters) or bis(amidates). In contrast to them, no prodrugs 
are commercially available in the case of HPMP derivatives, compounds having a free 
hydroxyl group in a side chain. Synthesis of their diesters is problematic due to a formation 
of corresponding cyclic phosphonates. So far, the most promising prodrugs seem to be 
alkoxyalkyl monoesters (Kern et al., 2002). One representative of this group, 
hexadecyloxypropyl ester of cidofovir (CMX001) is currently developed as antipox virus 
agent in clinical Phase II (www.chimerix-inc.com). 
The alkoxyalkyl ester prodrugs of (S)-HPMPDAP, i.e. hexadecyloxypropyl, 
octadecyloxyethyl and hexadecyloxyethyl derivatives, emerged as the most potent and 
selective compounds against VACV with EC50 values consistently in the range of 0.00074-
0.0012 µM. Although the alkoxyalkyl ester prodrugs proved more toxic than the parent 
compound (S)-HPMPDAP, either for HEL cell morphology or HEL cell growth, they were 
more selective than (S)-HPMPDAP, with selectivity indices [ratio = CC50 / EC50] higher than 
10,000 compared to >625 for (S)-HPMPDAP. The alkoxyalkyl ester prodrugs of the cyclic 
form of (S)-HPMPDAP (both cis and trans isomers) inhibited VACV replication with EC50 
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that the octadecyl ester did not affect cell growth up to a concentration of 100 µg/mL, it 
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values that were 10-fold (ODE ester, trans), 48-fold (HDP ester), 100-fold (ODE ester cis) and 
100- to 200-fold (HDE, cis and trans) lower than that of cyclic(S)-HPMPDAP. The EC50 values 
obtained for the alkoxyalkyl ester prodrugs of cyclic(S)-HPMPDAP were about 3- to 70-fold 
higher against vaccinia virus than the corresponding monoester prodrugs of (S)-HPMPDAP, 
and they had selectivity indices of 1,200 to 8,000.  
The alkoxyalkyl ester prodrugs of (S)-HPMPDAP and its cyclic form also proved 
remarkably potent and selective against HSV-1, HSV-2, HSV-1 ACVr, VZV, and HCMV, 
with EC50 values in the range of 0.007-0.0008 µM. Lower activities of the alkoxyalkyl ester 
prodrugs of cyclic(S)-HPMPDAP than of the corresponding alkoxyalkyl ester prodrugs of 
(S)-HPMPDAP were also observed against HSV and VZV. The alkoxyalkyl ester prodrugs 
also showed potent activity against HCMV, with EC50 values at least 225-fold lower than 
those for the corresponding parent compound. The alkoxyalkyl ester prodrugs proved 
rather toxic against the lymphoblast HSB-2 cells; and the only compounds, the HDP 
derivatives of (S)-HPMPDAP and cyclic(S)-HPMPDAP, respectively, showed selective 
activity against HHV-6 at non-toxic concentrations.  
Although the POM esters (both monoester and cis and trans isomers of the cyclic form), 
2,2,2-(trifluoro)ethyl esters, the butylsalicylyl derivatives, and prodrugs based on 
peptidomimetics proved less active than the alkoxyalkyl ester prodrugs, they appeared to be 
less cytotoxic and cytostatic. The POM derivate of cyclic(S)-HPMPDAP, either the 
diastereoisomeric mixture or the trans isomer, was able to inhibit VACV replication with 
EC50 values similar to those observed with the parent compounds, while 2,2,2-
(trifluoro)ethyl esters, the butylsalicylyl derivatives, and peptidomimetic esters showed EC50 
values 4- to 16-fold higher than the parent compounds. The POM, 2,2,2-(trifluoro)ethyl, 
butylsalicylyl derivatives, and prodrugs based on peptidomimetics also proved active 
against HSV, VZV, and HCMV, with EC50’s similar or 10-fold higher than those of the 
parent drugs. Both types of POM esters (cyclic and monoester) also displayed potent and 
selective activity against HHV-6. The EC50 values and the selectivity indices for these 
compounds against HHV-6 were equivalent to those observed for (S)-HPMPDAP. 
As mentioned above, despite the great experience in development of phosphonate and 
phosphate prodrugs, preparation of prodrugs in HPMP series remained long problematic 
(Hecker & Erion, 2008). In our recent work on HPMPDAP prodrugs, we managed to work 
out conditions for the selective transformation of a free HPMP derivative to the 
corresponding POM monoester in one reaction step. Reaction can be achieved by the action 
of chloromethyl pivalate in DMF in the presence of N,N,-dicyclohexyl-4-
morpholinecarboxamidine; the reaction conditions were optimized so that no cyclization or 
formation of decomposition products occurred (Krečmerová et al., 2010a). This procedure 
was also found generally useful for preparation of other POM HPMP monoesters (e.g. 
HPMPC, HPMP-5-azaC, HPMPA). Preparation of cyclic HPMP POM esters can be 
performed by the action of chloromethyl pivalate and a tetrabutyl ammonium salt of an 
appropriate cyclic phosphonate (Fig. 13). 
Besides procedures based on alkylation of tetrabutylammonium salt of the cyclic 
phosphonate, we focused on development of new approaches based on activation of a 
phosphonic acid residue with hexafluorophosphate coupling agents - PyBOP, PyBroP or 
HATU. Such reagents are currently used as coupling agents, especially in peptide chemistry 
(Han & Kim, 2004). This approach proved successful, e.g. in preparation of 2,2,2-
(trifluoro)ethyl esters, so far known only in PME series (Sekyia et al., 2002; Kamiya et al., 
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2002). Also in this case, the desired 2,2,2-(trifluoroethyl) monoester could be prepared from 
a free phosphonic acid (HPMPDAP) in one reaction step without any protection (Fig. 14).  
 
 
Fig. 12. Structurally diverse types of (S)-HPMPDAP prodrugs prepared for investigation of 
their anti-poxvirus and anti-herpesvirus activities 
 
 
Fig. 13. Synthesis of POM esters of (S)-HPMPDAP. The reactions were successfully applied 
also for HPMPC, HPMP-5-azaC and HPMPA.  
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Fig. 14. Structures of some hexafluorophosphate coupling agents and their utilization in 
synthesis of 2,2,2-(trifluoro)ethyl ester prodrugs of (S)-HPMPDAP 
Also, synthesis of other types of HPMP prodrugs can be simplified using the above-
mentioned coupling agents, e.g. synthesis of salicylyl esters or peptidomimetic prodrugs 
((Krečmerová et al., 2010a; Peterson et al., 2011).  
4.5 PME derivatives, open-ring analogues and other structures 
In a (phosphonomethoxy)ethyl (PME) series, special attention should be paid to the adenine 
derivative 9-(2-phosphonomethoxyethyl)adenine (PMEA), 2,6-diaminopurine derivative 
(PMEDAP) and its N6-substituted analogues. The activity of PME-derivatives against DNA 
viruses is generally lower compared to their counterparts in the HPMP-series (Holý, 2003). 
The most active compound is 9-(2-phosphonomethoxyethyl)-2,6-diaminopurine (PMEDAP). 
PME-derivatives of adenine and 2,6-diaminopurine reveal remarkable activity against HHV-
6 in vitro (Reymen et al., 1995; Manichanh et al., 2000). PMEDAP is also highly effective 
against HCMV; it inhibits the expression of HCMV late antigens.  
N6-substitutution on the 6-amino group of PMEDAP by one or two alkyl, aryl or cycloalkyl 
group lead to the compounds with pronounced activities against herpesviruses, especially 
cytomegalovirus, VZV and EBV (Snoeck et al., 1997; Meerbach et al., 1998). Despite its 
excellent antiviral parameters, PMEDAP has never been systematically investigated as an 
antiviral agent. Its main clinical potential lies in its cytostatic effects. 
During the past decade, we have also systematically investigated a novel group of base 
modified ANP, the “open-ring” analogues (Fig. 15). They are characterized by an aliphatic 
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chain (PME-, PMP and/or HPMP-group) linked to the position 6 of 2,4-diaminopyrimidine 
(DAPy) via the oxygen atom. These compounds can be thought of as mimics of the 
appropriate 2,6-diaminopurine derivatives with an open imidazole ring. Their antiviral 
activity is essentially identical to that of the parent compounds, including their enantiomeric 
specificity (De Clercq et al., 2005). The 6-[2-(phosphonomethoxy)ethoxy]-2,4-
diaminopyrimidine (PMEO-DAPy) and its 5-substituted derivatives offer antiviral potential 
similar to adefovir, mostly against retroviruses and HBV. (R)-HPMPO-DAPy has antiviral 




Fig. 15. Structures of selected (phosphonomethoxy)ethyl (PME) derivatives and “open-ring” 
analogues 
5. Animal herpesviruses  
The last chapter should be devoted to a special part of virology – animal viruses (Giguère et 
al., 2006). Their study is important from a veterinary viewpoint in general but many of them 
can cause diseases which are economically devastating. There is a wide variety of different 
herpesviruses with different biological characteristics. In animals the most important 
herpesviruses belong to the Alphaherpesviridae.  
Pseudorabies virus causing Aujeszky's disease in pigs is now extensively studied as a model 
for basic processes during lytic herpesvirus infection and for unravelling molecular 
mechanisms of herpesvirus neurotropism. The disease is caused by porcine herpesvirus 1, 
also called pseudorabies virus (PRV) or suid herpesvirus-1 (SHV-1). PRV is considered to be 
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the most economically important viral disease of swine in areas where hog cholera has been 
eradicated (“Hog cholera” is an alternative name of classical swine fewer (CSF), an 
infectious disease caused by a pestivirus CSFV from the family Flaviviridae) (Fenner et al., 
1993). Pseudorabies is endemic in most parts of the world. Pigs are the only natural host for 
the Aujeszky's virus. Clinical signs in pigs vary depending on the age of the pigs involved. 
In neonatal pigs, the incubation period is 2-4 days, and signs of central nervous system 
disease (shivering, inco-ordination and hind leg weakness) are seen. In weaned pigs, 
respiratory disease is the predominant problem. Sneezing, coughing and laboured breathing 
is accompanied by fever and weight loss. Mortality rates tend to decrease as the age of the 
affected pigs rises. Clinical signs can be present for 6-10 days. In uncomplicated cases, the 
animals often recover. (Lee & Wilson, 1979). Other domestic and wild mammals, such as 
cattle, sheep, goats, cats, dogs and raccoons (Thawley & Wright, 1982), are also susceptible 
to this virus. For these hosts, the disease is usually fatal and no effective treatment is 
available. The main symptoms in dogs include intense itching, jaw and pharyngeal 
paralysis, howling, and death. In cats, the disease is so rapidly fatal that there are usually no 
symptoms. Death usually occurs within 48 hours. Vaccines are available only for swine. 
Bovine herpesvirus 1 causes several diseases in cattle: infectious bovine rhinotracheitis 
(IBR), infectious pustular vulvovaginitis (IPV), balanoposthitis, conjunctivitis, abortion, 
encephalomyelitis, and mastitis. The respiratory form is most common. The viral infection 
itself is not life-threatening but predisposes to secondary bacterial pneumonia, which may 
result in death. (Jones & Chowdhury, 2007, 2010). Immunization with modified live or 
inactivated virus vaccine generally provides adequate protection against clinical disease. 
The avian herpesvirus 1 (also called Gallid herpesvirus 1, GaHV-1) is phylogenetically 
different from both abovementioned viruses and serves to underline similarity and diversity 
within the Alphaherpesviridae. The virus is a causative agent of laryngotracheitis in poultry. 
(Hidalgo, 2003). A vaccine is available but it does not prevent latent infections. 
Herpesvirus infections are one of the main reasons of animal abortions (Chénier et al., 2004; 
Smith, 1997). Abortion or neonatal diseases may follow infection with not only alpha-
herpesviruses but also beta and gamma-herpesviruses. The alpha-herpesvirus, equine 
herpesvirus-1 (EHV-1), causes single or epizootic abortions or neonatal deaths in horses, and 
the closely related virus EHV-4 causes sporadic equine abortions. In cattle, the alpha-
herpesviruses, bovine herpesvirus-1 (infectious bovine rhinotracheitis virus) and bovine 
herpesvirus-5 (bovine encephalitis virus), and a gamma-herpesvirus, bovine herpesvirus-4, 
have all been implicated as causes of abortion. In pigs, suid herpesvirus-1 (SHV-1: 
pseudorabies virus), an alpha-herpesvirus, and SHV-2 (porcine cytomegalovirus), a beta-
herpesvirus, each cause abortion or neonatal piglet losses. Caprine herpesvirus-1, canine 
herpesvirus and feline herpesvirus-1, all alpha-herpesviruses, cause abortions or neonatal 
deaths in goats, dogs and cats, respectively.  
5.1 Investigation of antiviral activity of acyclic nucleoside phosphonates against 
animal herpesviruses 
Many years of lasting research on acyclic nucleoside phosphonates (ANPs) as exceptional 
drugs and/or drug candidates against human viral infections gave an impetus for their 
study as antivirals in veterinary medicine. The well- researched candidate is cidofovir, 
active against equine herpes virus type 1, bovine herpesvirus type 1, feline herpesvirus type 
1 and caprine herpesvirus type 1. Remarkable effects against animal herpesviruses were also 
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observed at HPMPA and finally at PMEDAP, 9-(phosphonomethoxypropyl)-2,6-
diaminopurine, a compound mostly investigated for its cytostatic effects. 
Recently, several extensive studies have been paid to the treatment of caprine herpesvirus 1 
(CpHV-1) infections by cidofovir.  
Caprine herpesvirus 1 (CpHV-1) is responsible for recidivous genital disease in adult goats, 
characterized by confluent vesicles evolving to ulcers and crusts on the vulvar rima and 
vaginal mucosa (Tempesta et al., 1999). Several biological similarities exist between CpHV-1 
and the human genital herpesvirus type 2, such as the preferential tropism for the genital 
tract, the vesicular ulcerative nature of the topical lesions, and the tendency to become latent 
in the sacral ganglia (Lafferty et al., 1987; Tempesta et al., 1999). This makes the genital 
CpHV-1 infection of goats a reliable animal model for comparative studies. In described 
experiments, goats were infected experimentally by the vaginal route with CpHV-1 and 
then treated topically at different time intervalas after infection. The administration of 1% 
cidofovir cream onto vaginal mucosa was able to prevent the onset of genital lesions and to 
decrease significantly the titers of the virus shed by the infected animals, notably in the 
groups treated shortly after infection (24 and 48 h). The efficacy of cidofovir against caprine 
herpesvirus infection was higher when the treatment was started shortly after infection than 
when lesions were already present and advanced (Tempesta et al., 2007, 2008). Concerning 
other drugs effective against CpHV-1, the attention of researchers has been focused in recent 
years also on the study of acyclovir and ganciclovir. 
In horses, two herpesvirus infections mostly occur: equine herpesviruses 1 (EHV-1) and 4 
(EHV-4) (Patel & Heldens, 2005). Although both viruses may cause febrile 
rhinopneumonitis, EHV-1 is the main cause of abortions, paresis and neonatal foal deaths. 
The lesion central to these three conditions is necrotising vasculitis and thrombosis resulting 
from lytic infection of endothelial cells lining blood capillaries. The initiation of infection in 
these lesions is likely to be by reactivated EHV-1 from latently infected leukocytes. 
However, host factors responsible for reactivation remain poorly understood. Although 
vaccines are available, they are not fully protective and outbreaks of disease may occur in 
vaccinated herds. Therefore, there is an urgent need for effective antiviral treatment. 
It was found that ganciclovir is the most potent compound and therefore a valuable 
candidate for the treatment.  
Ganciclovir displays the best overall activity against EHV-1infection in vitro, without 
affecting cell viability. However, due to the high cost price, there is no direct clinical 
application possible. Therefore, acyclovir seems to be a more valuable candidate for 
antiviral therapy against EHV-1. As acyclovir has been patented since 1997 and generic 
alternatives are available, it seems attractive to use this drug for the treatment of horses 
during an outbreak (Wilkins et al., 2005). However, the bioavailability of orally 
administered acyclovir is a serious restriction (Bentz al., 2006). Bioavailability of only 2.8%, 
resulting in low plasma concentrations, is inadequate to expect any clinically relevant 
antiviral efficacy. The oral prodrug of acyclovir, valacyclovir seems to be more effective due 
to its higher bioavailability (Ormrod & Goa, 2000). Recently, a large study comparing the 
effect of several antiviral drugs - acyclovir, ganciclovir, cidofovir, adefovir, 9-(2-
phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and foscarnet against three 
abortigenic (94P247, 97P70 and 99P96) and three neuropathogenic isolates (97P82, 99P136 
and 03P37) of EHV-1 was performed (Garré, B. et al., 2007). Ganciclovir was most potent in 
reducing plaque number, followed by PMEDAP and acyclovir. Adefovir and cidofovir were 
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the most economically important viral disease of swine in areas where hog cholera has been 
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(Hidalgo, 2003). A vaccine is available but it does not prevent latent infections. 
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herpesvirus and feline herpesvirus-1, all alpha-herpesviruses, cause abortions or neonatal 
deaths in goats, dogs and cats, respectively.  
5.1 Investigation of antiviral activity of acyclic nucleoside phosphonates against 
animal herpesviruses 
Many years of lasting research on acyclic nucleoside phosphonates (ANPs) as exceptional 
drugs and/or drug candidates against human viral infections gave an impetus for their 
study as antivirals in veterinary medicine. The well- researched candidate is cidofovir, 
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observed at HPMPA and finally at PMEDAP, 9-(phosphonomethoxypropyl)-2,6-
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Caprine herpesvirus 1 (CpHV-1) is responsible for recidivous genital disease in adult goats, 
characterized by confluent vesicles evolving to ulcers and crusts on the vulvar rima and 
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years also on the study of acyclovir and ganciclovir. 
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The lesion central to these three conditions is necrotising vasculitis and thrombosis resulting 
from lytic infection of endothelial cells lining blood capillaries. The initiation of infection in 
these lesions is likely to be by reactivated EHV-1 from latently infected leukocytes. 
However, host factors responsible for reactivation remain poorly understood. Although 
vaccines are available, they are not fully protective and outbreaks of disease may occur in 
vaccinated herds. Therefore, there is an urgent need for effective antiviral treatment. 
It was found that ganciclovir is the most potent compound and therefore a valuable 
candidate for the treatment.  
Ganciclovir displays the best overall activity against EHV-1infection in vitro, without 
affecting cell viability. However, due to the high cost price, there is no direct clinical 
application possible. Therefore, acyclovir seems to be a more valuable candidate for 
antiviral therapy against EHV-1. As acyclovir has been patented since 1997 and generic 
alternatives are available, it seems attractive to use this drug for the treatment of horses 
during an outbreak (Wilkins et al., 2005). However, the bioavailability of orally 
administered acyclovir is a serious restriction (Bentz al., 2006). Bioavailability of only 2.8%, 
resulting in low plasma concentrations, is inadequate to expect any clinically relevant 
antiviral efficacy. The oral prodrug of acyclovir, valacyclovir seems to be more effective due 
to its higher bioavailability (Ormrod & Goa, 2000). Recently, a large study comparing the 
effect of several antiviral drugs - acyclovir, ganciclovir, cidofovir, adefovir, 9-(2-
phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and foscarnet against three 
abortigenic (94P247, 97P70 and 99P96) and three neuropathogenic isolates (97P82, 99P136 
and 03P37) of EHV-1 was performed (Garré, B. et al., 2007). Ganciclovir was most potent in 
reducing plaque number, followed by PMEDAP and acyclovir. Adefovir and cidofovir were 
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less effective and foscarnet was the least effective compound. There were no differences 
detected for acyclovir, ganciclovir, adefovir and PMEDAP between the abortigenic and 
neuropathogenic isolates. Although cidofovir is not highly efficient in reducing plaque 
number, it is able to significantly reduce plaque size at very low concentrations. Cidofovir 
was 40-fold more effective in reducing plaque size than in reducing plaque number (Garré, 
B. et al., 2007). 
A similar comparative study was also performed for feline herpesvirus. Feline herpesvirus 1 
(FHV-1) is a common cause of respiratory and ocular disease in cats. Especially in young 
kittens that have not yet reached the age of vaccination, but have already lost maternal 
immunity, severe disease may occur. In the study, the efficacy of six antiviral drugs - 
acyclovir, ganciclovir, cidofovir, foscarnet, adefovir and 9-(2-phosphonylmethoxyethyl)-2, 6-
diaminopurine (PMEDAP), against FHV-1 was compared in Crandell-Rees feline kidney 
(CRFK) cells using reduction in plaque number and plaque size as parameters. The capacity 
to reduce the number of plaques was most pronounced for ganciclovir, PMEDAP and 
cidofovir. All antiviral drugs were able to significantly reduce plaque size when compared 
with the untreated control. As observed for the reduction in plaque number, ganciclovir, 
PMEDAP and cidofovir were most potent in reducing plaque size. Adefovir and foscarnet 
were intermediately potent. The most remarkable effect was observed for cidofovir and 
ganciclovir. None of the products were toxic for CRFK cells at antiviral concentrations (van 
der Meulen, K. et al., 2006). 
6. Conclusion 
For a long time, viral infections remained a major medical problem worldwide due to a lack 
of therapy, prevention, or vaccination strategy, and also due to the rapid development of 
resistance. Four decades of intensive research in the field of nucleic acid component 
chemistry brought the fundamental changes in the treatment of most viral infections. 
Discovery of acyclic nucleoside phosphonates and their systematic investigation resulted in 
marketed drugs effective so far against fatal infections (AIDS, HBV, CMV infections in 
immunocompromised patients, etc.). The fundamental research in the field resulted in many 
excellent active structures so far waiting for clinical investigation, e.g. “open-ring” 
analogues, HPMP-5-azaC, HPMPDAP, and many other structures described in the text. 
Investigation of these compounds still remains a significant challenge for the 
pharmaceutical industry.  
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1. Introduction 
Postherpetic neuralgia (PHN) is the most common and feared complication of herpes zoster 
(HZ); it is mainly reported among the elderly and is described as painful and refractory. It is 
a complication rather than a continuation of acute HZ, and is defined as persistent pain in 
HZ-involved areas that continues for > 3 months after disappearance of the vesicles 
(Rowbotham & Fields, 1989). It is considered one of the most important neuropathic pains 
for the reasons set out in table 1. 
 
1. There is an elevated incidence of PHN among the elderly. PHN occurs in 10.20% of all HZ patients 
but in >50% of elderly HZ patients. 
2. Neurosensory lesions frequently have a pain component (Rowbotham &Petersen 2001)  
- Sensitive: dysesthesia, paresthesia, allodynia… 
- Motor: paresis, paralysis… 
3. There is a high associated comorbidity in previously healthy individuals: loss of nocturnal sleep, loss 
of appetite, marked functional limitation, and major emotional component, which all impair the long-
term quality of life of patients (Jensen et al, 2007) 
4. The pain is highly intense and often disproportionate to the initial injury. 
5. It is characterized by a high chronicity, although only around 50% of patients developing PHN are 
moderately symptomatic at 1 year after onset. 
6. Diverse pathophysiological mechanisms are involved in the different spontaneous and evoked 
symptoms in PHN, resulting in: 
- A very heterogeneous symptomatology that varies between one patient and another. 
- Symptoms that change over time 
- Highly complex and difficult treatment, with the need to test and combine different therapies to 
obtain a satisfactory outcome. 
- Only partial pain relief  
7. These patients consume large amounts of healthcare resources, making PHN an important 
institutional and public health problem (Gauthier et al, 2009).  
8. PHN and diabetic neuropathy (DPN) are the models preferentially selected and required by the 
FDA and EMA in controlled trials for any drug or technique seeking approval against peripheral 
neuropathic pain.  
Table 1. Clinical relevance of postherpetic neuralgia (Watson & Evans, 1986; Robotham& 
Fields, 1989; Helgason et al, 2000; Dubinsky et al, 2004; Scholz & Woolf 2007). 
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Mixed inflammatory and neuropathic pain is experienced in acute HZ, whereas neuropathic 
pain is highly predominant in PHN and the symptoms persist over time (Rowbotham et al, 
2001). The clinical symptoms presented by these patients are very heterogeneous, and some 
are spontaneous while others are evoked. Spontaneous symptoms frequently include a 
constant deep and burning pain and an intermittent intense and lancing pain throughout 
the painful area, leaving it hypersensitive and painful for some minutes. Other disagreeable 
symptoms are pruritus and painless, but nevertheless disabling, sensations of coldness or 
numbness (Anne et al, 2005; Treede et al, 2008).  
 
SPONTANEOUS PAIN (due to spontaneous firing of axons or dorsal horn neurons):  
- Burning, constant pain 
- Cramping and dysesthesia 
- Lancing and paroxysmal pain 
EVOKED PAIN (due to damage in peripheral and central sensory neurons): 
- Hyperalgesia (mechanical and thermal) 
- Allodynia (mechanical and thermal)  
OTHER CLASSIC SYMPTOMS: 
- Positive: hyperhidrosis, pruritus, tic  
- Negative: hypoesthesia, paresis, paralysis 
Table 2. Classic PHN symptomatology  
The characteristics of PHN often lead to two well-known situations: 
a. Desperation of the affected patients and their relatives. 
b. Frustration of the professionals treating it. 
As a result, patients complaining of PHN are often referred by primary care centers and 
emergency departments to the Pain Unit or Neurology and Dermatology specialists in an 
attempt to seek a definitive solution that cannot, unfortunately, be completely achieved.  
Treatments are either partially or totally ineffective for many people with PHN. The 
development of PHN may be prevented by the antiviral agents used to treat the rash. Once 
PHN is established, various well-known selection drugs and techniques may alleviate the 
pain (Dubinsky et al, 2004). The recent appearance of specific evidence-based analgesic 
guidelines and algorithms for neuropathic pain, including PHN, offers an excellent 
opportunity to improve pain management in these patients.  
2. Background and objectives 
Despite the social and public health importance of PHN, there is a wide variability in its 
routine clinical management by different healthcare professionals. The objective of this 
chapter was to review and update the different treatments available for PHN in light of the 
analgesic drugs and techniques that have appeared in this field (especially pharmacological 
therapy), from the time of its detection and diagnosis in primary care to its treatment in the 
Pain Unit if not controlled. We also describe current approaches to PHN in the most recent 
clinical guidelines, according to the available evidence, and offer a practical view of 
analgesia for the different professionals involved in PHN. No attempt is made to review the 
available evidence, given the existence of excellent guidelines published in different 
specialist journals. 
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3. Analgesic strategy 
As with other neuropathic pains, the approach to PHN is complex but always in the 
pursuit of clear and, when possible, viable objectives (see Table 3), usually shared by the 
specialist and primary healthcare professional (Dubinsky et al, 2004; Galvez, 2009; 
Dworking et al, 2010). The majority of PHN patients are initially and sometimes 
exclusively attended at the level of primary care, which is the entry gate into the health 
system in many countries and therefore plays a key role in the prevention of PHN. In the 
case of children, it is the pediatrician who has the possibility to educate parents to 
vaccinate their children against chickenpox and thereby reduce its incidence, explaining 
that when this infection reactivates, e.g., in an immunodepressed state, it can produce re-
infection by HZ virus, which is the virus that produces chickenpox in children, 
emphasizing that the severest complication of this re-infection is HZ and subsequently 
PHN. Since 2008, HZ vaccines have been recommended that can be administered to over-
70-year-olds, the age group most susceptible to complications (Anne & Mounsey, 2005; 
Redondo et al, 2007). 
 
1. To relieve the pain by drugs/techniques with reduced adverse effects that are 
acceptable to the patient. 
2. To recover nocturnal sleep. 
3. To reduce symptoms related to hypersensitivity and allodynia by at least 3 points on 
the 11-point Likert scale. 
4. To improve the ability of the patient to deal with the pain. 
5. To stabilize the patient’s emotional state. 
Table 3. Analgesic objectives in PHN 
The analgesic strategy is based on the application of the drugs with the strongest scientific 
evidence on their effectiveness in PHN, but with reduced and tolerable adverse effects. 
Table 4 contains a summary of this global strategy. 
 
1. Immediate initiation of treatment (PHN worsens with passage of time) 
2. Communication of correct information and realistic expectations to the patient  
3. Analgesia using drugs with the best evidence on their usefulness in PHN 
4. Evidence-based pharmacological therapy as the main approach 
5. Active rehabilitation program  
6. Educational resources for patients with neuropathic pain  
7. Some invasive techniques in certain cases  
Table 4. Key points of PHN treatment strategy (Turk &Stieg, 1987; Dubinsky et al, 2004; 
Argoff et al, 2004; Baron et al, 2010) 
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Antidepressants ( tricyclic antidepressants, …) 
Antiepileptics (gabapentinoids, carbamazepine…) 
Tramadol and opioids (morphine, oxycodone, methadone...) 
Other drugs acting on modifications generated in the synapses of injured neurons  
(N-methyl-D-aspartate receptor antagonists, etc.) 
Topical agents (5% lidocaine patch, capsaicin cream or patch...) 
Other drugs (baclofen, mexiletine, clonidine…) 
Some techniques: nerve blocks, transcutaneous electrical nerve stimulation, spinal cord 
stimulation, intrathecal infusion …  
Table 5. Main drugs used in PHN 
However, despite the ever-expanding therapeutic arsenal of drugs and techniques against 
PHN (table 5), there is little scientific evidence on the majority of analgesic treatments and 
they are rarely compared in head-to-head trials (Dubinsky et al, 2004). In fact, analgesic 
responses are frequently highly disparate, even among patients in similar situations of PHN 
and treated with identical analgesic regimens, explaining the need to individualize PHN 
therapy (Papagallo & Haldey, 2003) 
Classically, the symptoms and signs of pain in PHN have been treated globally, regardless 
of the specific clinical symptoms. However, a new approach has been developed over the 
past decade, which proposes the selective analgesic treatment of the different spontaneous 
or evoked symptoms that arise (Jensen & Baron 2003; Hanson, 2003). A recent article 
described six clinical subtypes of neuropathic pain according to the predominant symptoms, 
each with a different profile and obtained from a sample of 2100 patients with diabetic 
neuropathy (DPN) or PHN (Arning & Baron, 2009; Baron et al, 2009; Wasner & Baron, 2009; 
Baron et al, 2010). Treatment may vary as a function of the clinical subtype of neuropathic 
pain and the symptoms detected. However, considerable research remains to be done before 
protocols can be established for the treatment of distinct subtypes and symptoms in daily 
clinical practice. 
4. Analgesic pharmacology 
Analgesic pharmacotherapy is considered the basis of PHN treatment, and there has been 
a major strategic change with the proposal of a series of specific drugs for this type of 
pain. It is recognized by the scientific community that the classic Analgesic Ladder of the 
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(McCleane, 2004; Dubinsky, 2004; Backonja et al, 2006; Jensen et al, 2009; Martinez-Salio et 
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The first step of the new ladder for neuropathic pain calls for certain antiepileptic drugs 
(AEDs), such as gabapentinoids (gabapentin or pregabalin), and some antidepressants, such 
as tricyclic antidepressants (TCAs) or serotonin and norepinephrine reuptake inhibitors 
(SNRIs), e.g., venlafaxine and duloxetine. Some topical treatments, such as lidocaine or 
capsaicin patches, can be considered. Opioids like oxycodone or tramadol have 
demonstrated effectiveness in neuropathic pain but are on the second or third step of the 
ladder due to their adverse effects. If the pain is not alleviated, the second step is the 
combination of first-step drugs with tramadol. On the third step, the first-step drugs are 
maintained and combined with potent opiates (morphine, oxycodone, methadone, fentanyl 
transdermal, or buprenorphine transdermal) (Gilron et al, 2005). Nerve blocks or 
transcutaneous electrical nerve stimulation (TENS) can be useful at any point. If these drugs 
and techniques fail, patients must be referred to more specialized departments, e.g., the Pain 
Unit or Neurosurgery, for more invasive techniques such as Dorsal Root Entry Zone 
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Fig. 2. Neuropathic Pain Analgesic Ladder 
5. Antidepressants 
For more than 30 years, antidepressants have played an important role in the treatment of 
chronic pain. The most widely known and used drugs have been TCAs (amitriptyline, 
imipramine, chlorimipramine, and desipramine) (Mc Quay et al, 1996). TCAs have a proven 
analgesic effect in neuropathic pain that is independent of their effect on the state of mind, 
with reports that the analgesic effect appears before the antidepressant effect and that a 
lower dose is required for analgesia than for the treatment of depression (Mc Quay et al, 
1996; Saarto & Wifen 2005). TCAs have different action mechanisms with primarily 
analgesic effects. The main mechanism is the modulation of neurotransmitters by inhibiting 
the reuptake of serotonin (5HT) and noradrenaline (NA) at presynaptic level, increasing 
their bioavailability. NA and 5HT are involved in modulating pathways mediated by 
endorphins at both central nervous system (CNS) and spinal cord level. There is also 
evidence that they antagonize N-methyl-D-aspartate (NMDA) receptors and block 
muscarinic, cholinergic, histamine H1, and alpha-adrenergic receptors, which may 
participate in the modulation of the nociceptive response. TCAs also act on sodium channels 
in neuronal tissue, thereby stabilizing peripheral nerves and modulating the 
hyperexcitability of neurons at CNS level.  
As already noted, PHN is a major cause of chronic pain among the elderly, in whom TCAs 
have also been traditionally used. Meta-analysis of TCA trials for this indication found that 
they are able to significantly relieve pain in PHN (Watson et al, 1982; Mc Quay et al, 1996; 
Saarto & Wifen 2005; Sindrup et al, 2005). Amitriptyline has proven effective as an analgesic 
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and is the most widely used drug with the best outcomes. In a recent controlled trial, 
nortriptyline showed practically the same efficacy as opioids in PHN (Raja et al, 2002). 
The adverse effects of TCAs are largely related to their anticholinergic action: dryness of the 
mouth, constipation, urinary retention, and tachycardia. The blocking of alpha-1 adrenergic 
receptors can produce orthostatic hypotension, and the blocking of histamine receptors is 
associated with sedation and weight gain. All of these adverse effects can be minimized by slow 
titrations. The adverse effect that causes greatest concern is the alteration of cardiac conduction 
(through inhibition of noradrenalin reuptake). The response is dose-dependent, and it is 
recommended to start treatment at low doses (10 mg in over 65-year-olds and 25 mg in others) 
before bedtime and to titrate the dose very slowly according to the clinical response, without 
exceeding 75 mg/day. TCAs have a lower NNT (number needed to treat) value in comparison 
to other analgesic drugs in neuropathic pain and are attributed with the best evidence in clinical 
guidelines. Amitriptyline has an NNT of 2.2 for PHN, but its adverse effects, lack of 
recommendation in the elderly, and the small sample size of studies have relegated it behind 
antiepileptics for certain PHN cases (Saarto & Wifen 2005; Dworking et al, 2007). Nortriptyline, 
maprotiline, and desipramine have also proven effective, but less so than amitriptyline.  
The SNRIs duloxetine and venlafaxine are efficacious in painful polyneuropathy but have 
not been studied in PHN. Selective serotonin reuptake inhibitors (SSRIs) have shown little 
effectiveness in neuropathic pain and practically none in PHN (McQuay et al, 1996; Saarto & 
Wifen 2005).  
5.1 Conclusions 
TCAs have shown lower NNT values in comparison to other drugs against PHN. 
Amitriptyline has demonstrated the strongest evidence on effectiveness. Other non-tricyclic 
antidepressants have shown no evidence of efficacy in PHN. 
6. Anticonvulsant drugs (AEDs) 
AEDs or anticonvulsants have been used in pain management since the 1960s and represent 
a very important therapeutic option in chronic neuropathic pain, especially when this is 
lancing or burning. Since the initial use of carbamazepine, a new generation of antiepileptic 
drugs have been incorporated into clinical practice (>40 controlled trials) with characteristics 
that distinguish them from the classical drugs, including greater tolerability, fewer 
pharmacological interactions, and novel action mechanisms (Robotham et al, 1998; Rice et al 
2001; Dworking et al, 2003; Sabatowsky et al, 2004; Van Seventer et al, 2006). A Cochrane 
meta-analysis (Wifen et al, 2005) yielded significant evidence to support the efficacy of 
AEDs in the treatment of PHN, especially calcium channel α2-δ ligands (gabapentin and 
pregabalin) (Wifen et al, 2005; Gilron et al, 2011). The results evidenced their effectiveness, 
highlighting the use of pregabalin and later gabapentin in PHN treatment. There have only 
been small observational studies on carbamazepine in PHN, with no controlled trials.  
AEDs took their place as analgesics in neuropathic pain, which is accompanied by 
hyperexcitability and lancing pains suggestive of a somatosensory lesion. Although the action 
mechanism differs among AEDs and is not fully understood, it is known that they can alter 
pathophysiological mechanisms implicated in the genesis and/or maintenance of neuropathic 
pain, primarily by stabilizing the neuronal membrane and reducing the number of repetitive 
discharges in nerves lesioned by different mechanisms (Tremont-Lukats et al, 2000).  
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Structurally, gabapentin is analogous to gamma-aminobutyric acid (GABA) but does not 
interact with its receptors. Its action mechanism has not been fully elucidated but appears to 
be related to specific alpha-2-delta subunits of calcium channels. Pregabalin, which 
appeared after gabapentin, is a GABA analog but does not bind to the receptor or develop 
GABAergic activity, and its action mechanism, although not completely understood, is also 
based on its capacity to bind to the alpha-2-delta protein subunit of voltage-dependent 
calcium channels. In PHN, effective doses range between 1200 and 2400 mg/day for 
gabapentin but between only 220 and 600 mg/day for pregabalin. Their adverse effects are 
observed in more than 30% of patients and are related to the CNS, notably somnolence, 
vertigo and the loss of concentration, which are closely linked to the speed of dose titration 
and sensitivity of the patient. As a result, around 15-30% of patients cannot tolerate these 
drugs and abandon treatment (Dworking et al, 2007; Jensen et al, 2009).  
6.1 Conclusions 
There is good-quality evidence that gabapentinoids are the most effective antiepileptic 
drugs in PHN. Pregabalin is somewhat more effective than gabapentin. A slow titration is 
necessary to reduce adverse effects.  
7. Opioids 
Since the editorial by Dubner in Pain at the beginning of the 1990s (Dubner, 1991), evidence 
has begun to emerge on the use of opioids to treat neuropathic pain. The first systematic 
Cochrane review appeared in 1999 (Dellemin et al, 1999), followed by a meta-analysis in 
2006 that included 23 clinical trials and clearly evidenced the efficacy of opioids in 
neuropathic pain (Eisenberg et al, 2006).  
Opioid analgesics are agonists of presynaptic and postsynaptic opioid receptors. Their 
efficacy has been reported in several randomized controlled trials in different peripheral 
neuropathic pain disorders. Their effectiveness is probably lower for certain symptoms, 
such as thermal hyperalgesia and allodynia, due to the involvement of fibers with no opioid 
receptors. The same may be true for static mechanical allodynia and hyperalgesia 
(Dickenson AH et al, 2005; Trescot AM et al, 2008; Besson M et al, 2008).  
In more recent reviews, morphine, oxycodone, and methadone have demonstrated a similar 
effectiveness to that of TCAs in PHN, but opioids are relegated to the second analgesic line 
due to their possible adverse effects (Watson et al, 1998; Przewlocki et al, 2005). The most 
recent studies have been on oxycodone in PHN and DPN, showing an acceptable 
effectiveness. Combined gabapentin and morphine was very useful in neuropathic cancer 
pain (Keskinbora et al, 2007). 
Tramadol exerts a weak opiate effect on mu receptors in comparison to opioids and a weak 
monoaminergic effect in comparison to TCAs and AEDs. However, the adverse effect profile 
of tramadol is more acceptable than that of TCAs and AEDs, and tolerance and dependence 
complications are uncommon. Tramadol has demonstrated effectiveness but in studies 
offering low-quality evidence (Boureau et al, 2003). Its administration starts with an oral 
dose of 12.5-25 mg every 6 or 8 hours, with rescue doses of the same amount remaining 
available until the pain is controlled and then passing to sustained formulations up to a 
maximum recommended dose of 400 mg/day (Hollingshead et al,2006; Eisemberg et al, 
2006). 
 




These drugs have an effect on neuropathic pain but are not considered first-line drugs due 
to issues around dependence, cognitive impairment, tolerance, and possible hormonal 
problems. 
8. Topical drugs 
The ease and effectiveness of topical applications have led to the increasing introduction of 
topical drugs with local analgesic effects. However, despite the thinness of skin, only drugs 
with certain characteristics are able to pass through it, limiting the use of this administration 
route. Topical drugs can be in cream, ointment, lotion, spray, or patch form. Topical 
analgesics provide pain relief with minimal risk of systemic toxicity or drug-drug 
interactions, because they are formulated to produce a local effect while avoiding high 
plasma concentrations and adverse systemic events. Among patients with PHN, especially 
those with peripheral symptoms, various topical agents have proven effective and represent 
a viable treatment option. Topical treatment also offers a therapeutic approach to patients in 
whom systemic treatment is contraindicated.  
9. Lidocaine 
The analgesic effectiveness of topical local anesthetics has long been known, based on the 
direct binding of the local anesthesia with anomalous sodium channels of skin nerve 
endings (which participate in the maintenance of both spontaneous and evoked neuropathic 
pain), blocking them and thereby stabilizing the neuronal membrane and the production of 
ectopic discharges (Robotham, 1995). The first drug to be used was EMLA cream, a mixture 
of lidocaine and prilocaine, which had already shown some effectiveness in some PHN 
patients (Wheeler JG 1991; Stow, 1989). Subsequently, after a report on the usefulness of 5% 
lidocaine-medicated plaster (LMP) in PHN (Robotham, 1996; Galer et al, 1999) as a new 
topical treatment and its FDA approval for PHN pain in 1999, multiple studies evaluated 
this therapy. In 2007, the Cochrane Library produced a review (Khalick, 2007) of three 
articles on lidocaine treatment of PHN, although two of these were on lidocaine gel and 
only one used 5% LMP. The authors of the review concluded that there was inadequate 
evidence to recommend 5% LMP as a first-line analgesic against PHN.  
A new exhaustive review of articles on 5% LMP (up to May 2010) was recently published, 
comparing its effects in PHN with those of other therapies or placebo (Wolff, 2011). Out of 
2417 references, it included 32 articles reporting on 20 studies on 5% LMP. Patches (10 x 14 
cm) containing 700 mg lidocaine each were daily placed for a maximum of 12 hours and 
then removed, generally using 3 or sometimes 4 patches simultaneously to cover the painful 
area. The 5% LMP patch showed effectiveness versus placebo, especially for allodynia, one of 
the most important and disagreeable symptoms in PHN. Pain relief was achieved, and there 
were no cases of anesthesia or loss of cutaneous sensitivity Comparison between 5% LMP 
and pregabalin showed them to have the same efficacy for pain relief, while 5% LMP had a 
greater positive effect on almost all quality of life dimensions (in the SF-36 survey), with 
much lower adverse effects, and received a higher overall rating by patients. In the meta-
analysis, only gabapentin and 5% LMP produced a reduction in baseline pain (on VAS scale) 
in comparison to placebo, and this reduction was larger with 5% LMP. Pain relief was 
greater with gabapentin or 5% LMP than with capsaicin or pregabalin. Topical lidocaine in 
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greater with gabapentin or 5% LMP than with capsaicin or pregabalin. Topical lidocaine in 
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patients with various localized peripheral neuropathic pain syndromes had a good NNT, 
leading to the recommendation of lidocaine plaster for PHN patients (Woolf 2011). 
All articles reported the good tolerability and low (< 3%) systemic absorption of lidocaine 
(Davies, 2004), with the consequent scarcity of adverse systemic reactions. Patients receiving 
pregabalin reported dizziness, somnolence, and tiredness whereas the only effect in those 
treated with 5% LMP was local irritation and mild erythema (in 6-28% of cases). The dropout 
from treatment was also more frequent among pregabalin-treated patients. The review by 
Woolf noted various major limitations in studies, primarily the small sample sizes in most 
reports and the short treatment duration, which was usually 4 weeks. A further limitation was 
the scarcity of studies directly comparing 5% LMP with other drugs, so that comparisons had 
to be indirect (Liedgens et al, 2008). There was only one head-to-head study, comparing 5% 
LMP and pregabalin (Baron 2009; Rehm 2010). Comparative economic analysis of six-month 
courses of 5% LMP, gabapentin, and pregabalin found 5% LMP to be the most cost-effective 
treatment (Dakin et al, 2007); moreover, these authors concluded that the good tolerability and 
efficacy of 5% LMP places it as first-line topical analgesic treatment in PHN. In this sense, 
another economic study has ended favourable toward 5% LMP (Ritchie et al, 2010). 
9.1 Conclusions 
Lidocaine has demonstrated high analgesic effectiveness in PNH, especially in the form of 
5% patches, and is indicated as first-line drug for the treatment of localized pain.  
10. Capsaicin 
Capsaicin is an alkaloid substance of natural origin and is the main chemical compound 
(70%) in capsaicinoids, which include more than 90 varieties of chili. Capsaicin is a selective 
agonist of transient receptor potential vanilloid type 1 (TRPV1), preferentially bound to 
small-diameter amyelinic nociceptive nerve fibers such as C fibers, capable of synthesizing 
and releasing primarily substance P and other excitatory neurotransmitters (Green 1988; 
Bjerring 1989). The topical application of capsaicin initially activates C-fiber nociceptors by 
depolarization of the neuronal membrane and alteration of calcium and sodium ions, 
producing an initial erythematous sensation and skin reddening. However, if this contact 
with capsaicin is maintained, it leads to a transient and reversible desensitization and 
degradation of TRPV1-expressing cutaneous nerve endings, without altering other 
sensations (Nolano 1999; Szolcsany 2004).  
The cream started to be applied at low capsaicin concentrations (0.025% and 0.075%) several 
times a day, obtaining pain relief, although; h moderate and short-lived, as well as producing 
local discomfort, occasionally refractory, which sometimes led to the suspension of the 
treatment (Berstein et al, 1989; Peikert et al, 1991; Watson et al, 1993). A high-concentration 
(8%) capsaicin dermal patch (179 mg capsaicin; 280 cm2) was recently introduced, which is 
applied for 60 minutes in the peripheral pain area after its treatment with topical local 
anesthesia to avoid the initial burning pain. The relief obtained persists for around 12 weeks. 
One week after exposure to the 8% capsaicin patch there was also an 80% reduction in the 
density of the majority of epidermal nerve fibers (ENFs) in treated areas compared to 
untreated areas of healthy volunteers. It has been demonstrated that reinnervation practically 
returns to normality at 224 weeks after patch application (Kennedy 2010). These data support 
its topical utilization for different symptoms related to peripheral neuropathic pain.  
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In 2009, a Cochrane review was conducted of randomized, double blind placebo-controlled 
studies of at least six weeks duration in which topical capsaicin was used to treat 
neuropathic pain (Derry et al, 2009). Six studies (389 participants in total) compared the 
regular application of low-dose (0.075%) capsaicin cream with placebo cream, reporting a 
very good NNT for any pain relief. Two initial studies (709 participants in total) compared a 
single application of 8% capsaicin patch with placebo patch, finding a good NNT for < 30% 
pain relief over 12 weeks. The authors concluded that capsaicin may provide a degree of 
pain relief to some patients with painful neuropathic conditions, either through the repeated 
application of a low-dose (0.075%) cream or the single application of a high-dose (8%) patch. 
Earlier studies with repeated applications of low-dose capsaicin have not convincingly 
demonstrated good efficacy, while the single application of an 8% capsaicin patch has 
emerged as a new strategy.  
Jones et al in 2011 reviewed the evidence on the 8% capsaicin patch in PHN pain, finding 
that its topical application decreased pain linked to TPRV1 receptors and transiently 
reduced the number of nociceptive nerve endings at the application site. Their review was 
based on two pivotal studies in which the 8% patch was compared with 0.04% capsaicin. 
The primary endpoint of both trials was the reduction in numerical pain rating scale (NPRS) 
score. The 8% capsaicin patch reduced the pain from baseline to weeks 2-8 (by 29.6% and 
32%), a significantly greater reduction (P ≤ 0.01) than found in 0.04% capsaicin-treated 
controls to weeks 2-8 (19.9% and 24.4%). At the end of week 12, the reduction in pain was 
more pronounced (P ≤ 0.03) in the 8% capsaicin group (by 29.9% and 32.3%) than in the 
controls (by 20.4% and 25%). Around 40% of all treated patients were responders, 
considered an acceptable proportion in controlled trials of other analgesics in neuropathic 
pain. Applications of 8% patch can be repeated a maximum of once every 3 months, as 
needed. In conclusion, the author concluded that one 8% capsaicin patch every 3 months 
offers acceptable efficacy in comparison to other PHN treatments requiring daily doses. 
With regard to safety, the systemic absorption is low, and drug interactions are not 
expected, with virtually no systemic repercussions. All remains of capsaicin metabolites 
have practically disappeared at 6 hours after removing the capsaicin patch (Babbar et al, 
2010; Irving et al, 2010). The only adverse effect is a mild increase in blood pressure in 
some patients during application of the 8% patch. There have also been reports of eye and 
airway irritation due to aerosolization of capsaicin during patch removal or inhalation of 
the dried cream (Rains et al, 1995). The most common adverse drug reactions with 
capsaicin are at the application site, with burning reported by 60% of patients using 
0.075% capsaicin cream (Dubinsky 2004) and mild or moderate erythema (63%) and 
burning pain (42%) described by 63% and 42% of patients, respectively, at the 8% 
capsaicin patch site. It is often necessary to administer analgesics or local cold during the 
first 24-72 hours after patch application.  
Withdrawals due to adverse events were nearly all due to skin reactions. In two single-dose 
studies, 37 patients (15%) withdrew out of 242 patients receiving 0.075% capsaicin cream, 
whereas only three patients (0.7%) had to cease treatment out of 430 patients receiving 8% 
capsaicin patches. Withdrawals were more frequent with repeated low-dose capsaicin 
applications than with a single high-dose patch application (Derry et al, 2009).  
A 48-week study was conducted to test the long-term efficacy and tolerability of the 8% 
capsaicin patch (Backjonja et al, 2010), finding virtually no changes in analgesic efficacy over 
the passage of time and no increase in treatment dropout or topical adverse effects.  
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Another recent study indirectly compared the cost-effectiveness of 8% capsaicin patch with 
that of other PNH treatments (Angstrom et al, 2011), evaluating the analgesic improvement, 
adverse effects, and cost per quality-adjusted life-year (QALY) of the treatments. It reported 
that the 8% capsaicin patch and topical lidocaine patch were significantly more effective in 
comparison to oral agents used to treat PHN. The cost-effectiveness and cost per QALY of 
the 8% capsaicin patch were similar to those of the lidocaine patch and superior to those of 
the oral products.  
10.1 Conclusions 
The 8% capsaicin patch is effective to reduce PHN pain, and its usefulness is supported by 
stronger evidence in comparison to other topical agents. Studies have demonstrated some 
benefit from the use of 0.075% capsaicin cream in PHN. 
11. Other topical drugs  
Other trials of topical drugs in PHN have not yielded noteworthy results. A crossover trial 
of single doses of indomethacin, aspirin, and diclofenac in solutions with diethyl-ether 
against placebo (Beneditti, 1996) found that solutions prepared with aspirin and 
indomethacin were effective in PHN, but not those with diclofenac. However, the data were 
inadequate for conclusions to be reached.  
A double-blind multiple-dose cross-over study comparing 3% benzydamine cream with 
placebo in PHN treatment (Mc Quay et al, 1990) found no significant differences, which the 
authors attributed to the short treatment periods studied. 
12. Other modalities for PHN 
Interventional treatment is indicated when the pharmacological treatment is not effective or 
cannot be tolerated by the patient. It can also be considered in patients who need continued 
high-dose treatment to control the pain and may prefer an invasive or surgical approach. 
In a randomized, controlled, single-blind study, four weekly injections of 60 mg of 
preservative-free methylprednisolone were administered intrathecally or into the epidural 
space in PHN patients. There was a substantial benefit for the intrathecal group at 1 and 24 
weeks after completion of the treatment, with a good NNT, but no improvement was 
observed in the epidural group. In a double-blind, randomized, controlled clinical trial, 277 
patients with PHN were randomized for the intrathecal administration of 60 mg of 
preservative-free methylprednisolone in 3 ml of 3% lidocaine, or 3 mL of 3% lidocaine alone, 
or no lumbar puncture. In the methylprednisolone group, 90% of the patients reported good 
to excellent pain relief at the end of the treatment, which continued during 2 years of follow-
up. No adverse events were reported during the 2-year follow-up period (Kikuchi et al, 
1999; Kotani et al, 2000). 
The aim of neuromodulation treatments of pain is to use minimally invasive and reversible 
techniques that can be modified as a function of changes in patient symptoms. Implantable 
systems with opioids or ziconotide are used in patients with refractory pain (Cruccu et al, 
2007; Deer et al, 2007), but there is scant evidence on their use in PHN patients.  
Electricity has been used to relieve pain for thousands of years. TENS, defined by the 
American Physical Therapy Association as the application of electrical stimulation to the 
skin for pain control, is non-invasive, inexpensive, safe, and easy to use. TENS has multiple 
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indications and has demonstrated some efficacy in PHN (Nonahan &Kumbang 2008; Cruccu 
et al, 2007). However, the scientific evidence on its use in PHN is limited and does not allow 
definitive recommendations to be made (McQuay H, et al, 1998). For its part, the usefulness 
of spinal cord stimulation has not been supported by a randomized controlled trial ( Benzon 
et al, 2009) 
13. Clinical guidelines for PHN treatment  
Over the past decade, numerous European and American guidelines on neuropathic pain 
have emerged. Most of them are specific to peripheral neuropathic pain (e.g., PHN) but their 
preparation has been difficult because almost all of the studies only offer comparisons with 
placebo and were conducted in small samples of patients for short time periods, despite the 
chronicity of the disease (Feder et al, 99). There is also a shortage of data on long-term 
outcomes and on the usefulness of combining different drugs. Methodological limitations 
include the retrospective calculation of data from studies with different experimental 
designs and results. Taking this into account, most of the proposals for the treatment of 
neuropathic pain are based on cost-effectiveness estimations using indirect indicators such 
as the NNT (number needed to treat to obtain 50% pain relief in one patient) and NNH 
(number of patients needed for harm, i.e., for withdrawal of one patient from the study due 
to adverse effects), positively rating treatments with a low NNT and high NNH. Table 6 
provides a global summary of the analgesic evidence. 
a. Finnerup established an algorithm for peripheral neuropathic pain (including PHN) in 
2005 (Finnerup et al, 2005) and published a revised version in 2007 (Finnerup et al, 
2007), based on the available evidence and with many limitations. However, it served as 
a guide for analgesic treatment in neuropathic pain. They reviewed 105 randomized 
clinical trials against placebo that were considered to offer high-quality evidence, 
gathered by a search of Medline, EMBASE and the Cochrane Database, taking the NNT 
and NNH as reference. Studies of oncologic neuropathic pain and those with a sample 
of < 10 patients were excluded.  
b. Recommendations: 
- Based on the results of these studies, the authors recommend that localized pain in 
PHN be treated by the topical administration of the 5% lidocaine patch. When the pain 
is more widespread, they recommend initiating monotherapy with TCAs or 
gabapentinoids (oral gabapentin oral or pregabalin) as first-line analgesics. 
- Second-line drugs are the new SNRIs, such as venlafaxine and especially duloxetine, 
although the studies have been in peripheral neuropathic pain. 
- Opioids, including tramadol, can be considered as third-line options because they have 
an effect on neuropathic pain, but they are associated with dependency, tolerance, 
cognitive impairment, and even long-term hormonal disorders. 
c. In 2006 (Attal et al, 2006), a group of experts in neuropathic pain from the EFNS 
published guidelines on the pharmacological management of neuropathic pain 
according to the quality of evidence in studies available in Medline or the Cochrane 
Database. They only analyzed controlled trials (from 1966 to 2006) considered class I or 
II trials according to the EFNS classification, using the NNT value as reference. They 
mainly took account of the drugs’ analgesic efficacy to reduce the signs and symptoms 
of neuropathic pain and of their adverse effects, but they also considered the 
repercussions on the quality of life and state of mind of the patient.  
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d. Recommendations in PHN: 
- First-line analgesics: TCAs, pregabalin, and gabapentin, with grade A evidence.  
- Second-line: SNRIs (e.g., duloxetine and venlafaxine), although their effectiveness and 
lesser adverse effects in comparison to TCAs mean that the new SNRI antidepressants 
are often prioritized.  
- Lower-quality evidence is available for opioids (tramadol and oxycodone) and 
lamotrigine. 
- When the pain relief is inadequate, they proposed using combinations of first-line drugs 
that do not interact and have complementary action mechanisms, despite the scant 
scientific evidence on this approach, and as a last resort, combinations with opioids. 
e.  In 2007 (Moulin et al, 2007), the Canadian Pain Society published evidence-based 
guidelines on the clinical management of neuropathic pain, directed at Canadian 
healthcare professionals. The main treatment lines and a concise management 
algorithm were included. They only considered well-designed controlled clinical trials 
against a placebo or effective substance with a minimum of 10 patients, gathered from 
Medline and the Cochrane Database. Recommendations were based on four criteria: 
analgesic efficacy with at least grade 1B evidence, tolerability, ease of management, and 
cost-effectiveness.  
f. Recommendations for PHN: 
- First-line analgesics: TCAs (amitriptyline and imipramine) or antiepileptics (gabapentin 
and pregabalin). If the drug fails or cannot be tolerated, it is recommended to try 
another from the same group. 
- Second-line: SNRIs (e.g., venlafaxine and duloxetine) due to the weaker evidence and 
their higher cost. Lidocaine patches. 
- Third-line: opioids such as tramadol and oxycodone for moderate or intense pain. 
- Fourth-line: cannabinoids, methadone, SSRIs and other AEDs. 
- Non-pharmacological procedures, such as physiotherapy, moderate exercise and 
psychological support are recommended alongside the different drugs. 
g. A group of neuropathic pain experts from the IASP (Dworking et al, 2007) provided an 
evidence-based update on recommendations for neuropathic pain management. They 
reviewed articles (from 1966 to 2007) in Medline and the Cochrane Database on 
controlled clinical trials (grade 1b evidence or higher) as well as relevant book chapters 
and other publications. They highlighted the lack of head-to-head studies of the drugs, 
making it difficult to clearly establish their relative efficacy or safety. The main criteria 
applied for establishing recommendations were: degree of efficacy of the drug in 
neuropathic pain, its safety and tolerability, drug-drug interactions, ease of 
management, impact on patient quality of life, improvement in comorbidities 
associated with neuropathic pain (sleep, anxiety, etc.), costs associated with the therapy, 
the potential risk of abuse and addiction, and the risk of overdose.  
Recommendations: 
- First-line: TCAs, SNRIs (duloxetine and venlafaxine), calcium channel alpha2delta 
ligands (pregabalin and gabapentin), and topical lidocaine.  
- Second-line: opioids (morphine, oxycodone, methadone) and tramadol, based on trials 
with grade A evidence, the clinical experience of the experts, and guidelines on the 
management of opioids in non-oncologic pain, although it can be considered as first-line 
treatment in certain circumstances (more intense pain or during titration of other drugs). 
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- Third-line: capsaicin, mexiletine, or NMDA receptor antagonists, based on controlled 
trials with grade B evidence alongside the clinical experience of the experts, although 
these drugs can be used as first-line treatment in certain specific situations.  
- For non-responding patients, they recommended trying combinations among first-line 
drugs with different action methods or even with a third-line drug, although there is 
scant evidence on these strategies.  
h. In 2009 (Attal et al,2009), the group of experts in neuropathic pain of the EFNS again 
published an update, using Medline and the Cochrane Database and classifying trials 
according to the etiology. All class I and II randomized controlled trials were 
considered.  
Recommendations 
- First-line: TCAs (amitriptyline or imipramine 25-150mg/day), pregabalin (150-600 
mg/day), and gabapentin (1200-3600 mg/day), supported by the strongest evidence. As 
topical analgesics, 5% lidocaine patch (maximum of 3 patches at a time, with special 
indication in the elderly) and 8% capsaicin patch.  
- Second- or third-line: 0.075% capsaicin cream and valproate, with weaker supporting 
evidence. Opioids such as morphine, oxycodone, or methadone and tramadol (200-
400 mg/day), with good evidence in PHN but in 2nd or 3rd line due to their adverse 
effects. 
- When first-line treatments fail, combinations are recommended, despite the little 
evidence available. The association of morphine with gabapentin has shown some 
effectiveness in PHN.  
 
DRUG N N T 
1. TCAs (tricyclic antidepressants) 2.8 (2.2-3.8) Amitriptyline (better evidence) 
2. SNRIs N D  
3. Gabapentin 3.8 (3.1-5.1), 
4. Pregabalin  3.7 (3.2-4.4), 
5. Opioids 2.6 (1.9-4.1) Oxycodone (better evidence) 
6. Tramadol 4.8 (2.6-27) 
7. NMDA antagonists  N E 
8. 5% Lidocaine patch UK 
9. 8% Capsaicin patch UK 
10. Capsaicin cream 3.2 (2.2-5.9) 
ND: No data available; NE: No efficacy in PHN; UK: Unknown 
Table 6. NNT of pharmacological therapies in PHN (Dubinsky et al, 2004; Argoff et al, 2004; 
Finnerup et al, 2007; Attal et al, 2010; Baron et al, 2010) 
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14. Conclusions (Hemperstal 2005; Baron, 2010; Dubinsky et al, 2004; 
O´Connor et al, 2009) 
1. A multidisciplinary approach is needed, using pharmacological and non-
pharmacological treatments. 
2. The optimum individual pharmacological regimen in PHN should balance analgesia 
with harm in terms of side-effects, comorbidities, and drug interactions. 
3. Drugs providing the greatest pain relief with fewest side-effects should be 
identified. 
4. Drugs with strongest evidence as first-line analgesics should be used. TCAs 
(amitriptyline, imipramine), calcium channel α2-δ ligands (gabapentin, pregabalin), 
topical 5% lidocaine patch, and topical 8% capsaicin patch have shown consistent 
efficacy in randomized controlled clinical trials and meta-analyses in PHN (Table 6). 
Figure 1. 
5. Some opioid analgesics and tramadol may be indicated if there is no response to other 
drugs. Despite the evidence on their efficacy, they are relegated to the second-line due 
to the possible adverse effects. They can only be considered as first-line treatment in 
certain circumstances (severe pain or poor tolerability of first-line drugs). 
6. Topical agents may be first-line in PHN patients who are elderly or with the presence of 
multiple diseases, despite weak evidence. 
7. There is no evidence-based treatment of PHN with NSAIDs. 
8. In clinical practice, a combination of two or more drugs is often needed to achieve 
satisfactory pain relief, although there have been few trials to support this clinical 
observation. Regular assessment is mandatory. 
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1. Introduction 
1.1 Marek’s disease virus (MDV) 
Marek’s disease virus (MDV) belongs to the alphaherpesvirus family, like Herpes simplex 
viruses 1 and 2 (HSV-1 and HSV-2) and varicella zoster virus (VZV). Marek’s Disease Virus 
(MDV) is the etiologic agent of Marek’s Disease (MD), a highly contagious malignant 
lymphoma of chickens. (Morimura, et al. 1998).  
Marek’s Disease (MD) was first described by József Marek in 1907 as fowl paralysis caused 
by mononuclear infiltration into the sciatic nerve plexi (Marek, 1907). Marek’s Disease (MD) 
is a lymphoproliferative and neuropatic disease of domestic chickens and, less commonly, 
turkeys and quails (Payne & Venugopal, 2000). 
Generally, four different clinical forms of the disease are recognized in flocks infected with 
MDV: A) Classical or neuronal form; B) Acute form; C) Transient paralysis and D) Acute 
mortality syndrome. 
1.2 MDV life cycle 
The infection occurs by inhalation of infected dust (Beasley, et al. 1970) in the poultry house 
environment contaminated with the viruses shed from the feather follicle epithelium of 
infected birds. According to the current model of MDV pathogenesis, it is thought that the 
virus is transported by macrophages from the lungs to the lymphoid tissues of the spleen, 
thymus and the bursa of Fabricius, where virus targets the lymphocyte subsets, the major 
cells of the host immune system (Fig. 1). These cells could transport MDV to the lymphoid 
tissues via the lymph or blood, where it can be detected as early as 18 h post-infection 
(Adldinger & Calnek, 1973) 
Calnek and coworkers (Calnek, 1985; Calnek, 1986; Schat, 1987) developed a model for the 
pathogenesis of MD in the early 1980s which remains valid (Fig. 2). MDV is first detected in 
the spleen 3 days post-exposure after exposure by inhalation. The virus causes an early 
cytolytic infection in B cells, which are presumed to be the primary target for viral 
replication (Schat et al., 1980; Calnek et al., 1982; Shek et al., 1983). Resting T cells are 
refractory to infection; successively, T cells become activated and susceptible to MDV 
infection (Calnek et al,. 1984 a, b).  
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Fig. 1. Pathogenesis of MD. Feather follicle epithelium (FFE); B-cells (B); T-cells (T); 
macrophages (M) (Modified from: Nair, 2005). 
 




Fig. 2. Sequential events in lymphocyte infections with MDV (Modified from: Calnek, 
1985) 
It was hypothesized (Schat & Xing,  2000; Schat, 2001) that, during the lytic infection, the 
MDV transfer from B to T cells may be facilitated by the production of vIL-8. This is a CXC 
chemokine and it was described as a homologue of IL-8 (vIL-8) (Parcells et al., 2001); vIL-8 is 
the first reported CXC chemokine encoded by an alphaherpesvirus (Liu et al., 1999). The 
majority of these T cells are CD4+TCR1+, but a small percentage of infected cells are 
CD8+TCR2+ (Sugano et al., 1987; Martins-Green, 2001). Moreover, MDV-driven tumors are 
dominated by a highly restricted number of CD4+ clones. Further, the responding CD8+ T 
cell infiltrate is oligoclonal, indicating recognition of a limited number of MDV antigens 
(Mwangi et al., 2011). 
These early cytolytic events result in atrophic changes in the bursa of Fabricius and 
thymus, leading to severe debilitation of the immune system and marked 
immunosuppression. One week post-infection, when virus levels peak, MDV switches 
from early cytolytic to latent infection, probably due to cell-mediated immune responses 
(Buscaglia et al., 1988; Schat & Xing, 2000). During latency, clinical signs of the infection 
diminish, productive viral antigen cannot be detected in the bursa, thymus and spleen, 
and within 2 weeks the lymphocyte populations in the bursal follicles and thymic cortex 
return to normal. 
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1.3 Defence  mechanisms against MDV infection 
1.3.1 Nonspecific immune responses 
Against MDV infections, the organisms establish both nonspecific and specific immune 
responses. The cells involved in these responses are NK cells and macrophages.  It has 
been hypothesized that avian NK cells are able to recognize target cells as mammalian 
NK cells do (Kaufman, 1996; Kaufman & Salomonsen, 1997; Kaufman & Venugopal, 
1998). Macrophages play an important role in resistance to MDV infection both in vitro 
and in vivo; their depletion leads to a lower immunity versus MD and reduces protective 
efficacy of vaccination (Gupta et al., 1989). They are thought to be critical during the 
early stages after MDV infection, but are also important during the later stages of 
pathogenesis (Calnek, 2001); they limit MDV replication or have a detrimental role (Lee. 
et al., 1978 a,b).  
Macrophages are involved in virus phagocytosis, but no replication, or antigenic changes at 
the cell surface have been observed (Haffer & Sevoian, 1979; Haffer et al., 1979). MDV 
antigen expression was not evident after co-culturing of either bone marrow-derived 
macrophages or macrophage cell lines with MDV-infected lymphocytes, suggesting the 
requirement for in vivo conditions. These data indicate that macrophages could be a primary 
target for cytolytic infection in vivo, in addition to facilitating transportation of the virus, as 
proposed by Calnek (Calnek, 2001). Macrophages from MDV-infected chickens are also able 
to inhibit the DNA synthesis of MD lymphoblastoid cell lines (Lee et al., 1978 b) and 
suppress the mitogen response of T lymphocytes (Lee et al., 1978 a,b); these effects have also 
been found in macrophages isolated from uninfected chickens (Sharma, 1980; Von Bulow & 
Klasen, 1983).  
Macrophages are also able to produce large quantities of Nitric Oxide (NO) (Hussain & 
Qureshi, 1997); depletion of these cells causes the suppression of NO production and so 
the increase of viral load in the blood, tumour incidence and tumour load (Rivas  et al., 
2003). Moreover, in addition the high levels of IL-1, IL-6, IL-12, iNOS, and type 1 and 2 
IFNs, the relative expression levels of IL-4, IL-10, and IL-13 were significantly 
upregulated in the infected chickens during the lytic phase of infection compared to 
uninfected controls. This observation suggests that an immune response with a Th-2 
characteristic is induced by a very virulent plus MDV strain during the lytic phase of 
infection, and there is no significant MDV-specific immune response in the latent phase 
of infection (Heidari et al., 2008) 
1.3.2 Specific immune responses 
Specific immune responses are antigen-dependent and require lymphocyte activation to 
produce specific antibodies and antigen-specific CD4+ and CD8+ T cells.  Cell-mediated 
immune responses (CMI) and virus neutralizing antibodies are important in herpesvirus 
infections in general (Mester & Rouse, 1991) and have been described after natural infection 
with oncogenic MDV and after inoculation with vaccine strains. It was suggested that CTL 
(Cytotoxic T Limphocytes) responses are also important for the elimination of MDV-infected 
cells (Ross, 1977; Kodama et al., 1979). Although immune defences against infected cells are 
predominantly mediated by CTL, humoral immune responses also play an important role in 
herpesvirus infections (Medveczky et al., 1998). Antibodies to the virus envelope neutralise 
viral infectivity, kill lytically infected cells by antibody-dependent cell cytotoxicity (ADCC), 
and protect against reinfections with EBV (Chubb & Churchill, 1969).  
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1.3.3 Induction of apoptosis 
Apoptosis of virus-infected cells can be beneficial to the host if cells are eliminated before 
virus assembly. It is therefore not surprising that certain viruses code for proteins inhibiting 
apoptosis during the early phase of replication but facilitate the process during the later 
stages of replication. Apoptosis occurs during MDV infection in CD4+CD8+ thymus tissues 
in the first week after infection (Morimura et al., 1996), during the second week in CD4+ T 
cells in peripheral blood (Morimura et al., 1995) and spleen cells from chickens 7 days post 
infection with the JM-16 strain of MDV (Schat & Xing, 2000). However, it is likely that the 
Meq protein is responsible for the prevention of apoptosis. This protein is expressed in most, 
if not all, MD tumour cell lines and overexpression of meq in the rodent cell line Rat-2 
caused transformation of these cells. The transformed cells became highly resistant to the 
induction of apoptosis (Liu  et al., 1998). It is of interest to note that meq is transcribed during 
the lytic infection without an apparent effect on apoptosis. However, the regulation of meq 
transcription is very complex and alternate splicing has been described (Peng & Shirazi, 
1996). Recently was described that the Meq oncoprotein interacts directly with p53 and 
inhibits p53-mediated transcriptional activity and apoptosis, providing a valuable insight 
into the molecular basis for the function of meq in MDV oncogenesis (Deng et al., 2010) 
Moreover, expression of pp38 in tumour cells may be correlated with the induction of 
apoptosis (Schat & Xing, 2000). This hypothesis is interesting in view of the finding that 
pp38 expression in MD tumour cell lines is generally low and is apparently inversely related 
to the expression of meq and a small RNA antisense to ICP4 (Ross et al., 1997). Expression of 
pp38 in tumour cell lines can be upregulated by transfection with ICP4 (Pratt et al., 1994). 
There are very recent data that involve microRNAs (highly conserved among different field 
strains of MDV1), and they are expressed in lytic and latent infections and in MDV1-derived 
tumors. This evidence suggests that these small molecules are very important to the virus, 
and that they play some roles in immune evasion, anti-apoptosis, or proliferation (Burnside 
& Morgan, 2011). All these data suggest that the fate of tumour cells depends on an intricate 
balance between the expression and phosphorylation of Meq (Liu et al., 1999), pp38, ICP4 
and the small antisense RNA to ICP4 (Gimeno & Cortes, 2010).  
1.3.4 MD vaccination 
It is thought that the economic impact of MD on the global poultry industry accounts for at 
least US $1 bn yearly (Nair, 2005).  The first MDV vaccine was obtained with an oncogenic 
strain repeatedly passaged in vitro; it was able to prevent MD tumors in chickens challenged 
with oncogenic MDV (Churchill & Chubb, 1969) but not to prevent the infection with field 
viruses. The first attenuated vaccine was used in the UK in 1970 but was quickly replaced by 
an HVT vaccine (Turkey Herpes Virus) (Witter et al., 1970). Introduction of HVT as a live 
vaccine resulted in significant reduction of MD incidence and was extensively used because 
of its efficacy and economical production in tissue culture (Okazaki et al., 1970; Purchase & 
Okazaki, 1971). However, within 10 years, new outbreaks of clinical MD occurred in 
vaccinated flocks (Eidson et al., 1978; Witter et al., 1980) and vvMDV isolated from these 
birds had a greater pathogenic effect than field viruses present before vaccine introduction 
(Witter, 1983). It was probably due to imperfect vaccination practices and, in some countries, 
wrong hygienic conditions that led to reservoirs of viruses in poultry houses (Bourne, 1996). 
In response to the increasing number of MD outbreaks in vaccinated flocks, in the 1980s, 
new vaccines based on the non-oncogenic serotype-2 MDV were introduced in bivalent 
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and in vivo; their depletion leads to a lower immunity versus MD and reduces protective 
efficacy of vaccination (Gupta et al., 1989). They are thought to be critical during the 
early stages after MDV infection, but are also important during the later stages of 
pathogenesis (Calnek, 2001); they limit MDV replication or have a detrimental role (Lee. 
et al., 1978 a,b).  
Macrophages are involved in virus phagocytosis, but no replication, or antigenic changes at 
the cell surface have been observed (Haffer & Sevoian, 1979; Haffer et al., 1979). MDV 
antigen expression was not evident after co-culturing of either bone marrow-derived 
macrophages or macrophage cell lines with MDV-infected lymphocytes, suggesting the 
requirement for in vivo conditions. These data indicate that macrophages could be a primary 
target for cytolytic infection in vivo, in addition to facilitating transportation of the virus, as 
proposed by Calnek (Calnek, 2001). Macrophages from MDV-infected chickens are also able 
to inhibit the DNA synthesis of MD lymphoblastoid cell lines (Lee et al., 1978 b) and 
suppress the mitogen response of T lymphocytes (Lee et al., 1978 a,b); these effects have also 
been found in macrophages isolated from uninfected chickens (Sharma, 1980; Von Bulow & 
Klasen, 1983).  
Macrophages are also able to produce large quantities of Nitric Oxide (NO) (Hussain & 
Qureshi, 1997); depletion of these cells causes the suppression of NO production and so 
the increase of viral load in the blood, tumour incidence and tumour load (Rivas  et al., 
2003). Moreover, in addition the high levels of IL-1, IL-6, IL-12, iNOS, and type 1 and 2 
IFNs, the relative expression levels of IL-4, IL-10, and IL-13 were significantly 
upregulated in the infected chickens during the lytic phase of infection compared to 
uninfected controls. This observation suggests that an immune response with a Th-2 
characteristic is induced by a very virulent plus MDV strain during the lytic phase of 
infection, and there is no significant MDV-specific immune response in the latent phase 
of infection (Heidari et al., 2008) 
1.3.2 Specific immune responses 
Specific immune responses are antigen-dependent and require lymphocyte activation to 
produce specific antibodies and antigen-specific CD4+ and CD8+ T cells.  Cell-mediated 
immune responses (CMI) and virus neutralizing antibodies are important in herpesvirus 
infections in general (Mester & Rouse, 1991) and have been described after natural infection 
with oncogenic MDV and after inoculation with vaccine strains. It was suggested that CTL 
(Cytotoxic T Limphocytes) responses are also important for the elimination of MDV-infected 
cells (Ross, 1977; Kodama et al., 1979). Although immune defences against infected cells are 
predominantly mediated by CTL, humoral immune responses also play an important role in 
herpesvirus infections (Medveczky et al., 1998). Antibodies to the virus envelope neutralise 
viral infectivity, kill lytically infected cells by antibody-dependent cell cytotoxicity (ADCC), 
and protect against reinfections with EBV (Chubb & Churchill, 1969).  
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1.3.3 Induction of apoptosis 
Apoptosis of virus-infected cells can be beneficial to the host if cells are eliminated before 
virus assembly. It is therefore not surprising that certain viruses code for proteins inhibiting 
apoptosis during the early phase of replication but facilitate the process during the later 
stages of replication. Apoptosis occurs during MDV infection in CD4+CD8+ thymus tissues 
in the first week after infection (Morimura et al., 1996), during the second week in CD4+ T 
cells in peripheral blood (Morimura et al., 1995) and spleen cells from chickens 7 days post 
infection with the JM-16 strain of MDV (Schat & Xing, 2000). However, it is likely that the 
Meq protein is responsible for the prevention of apoptosis. This protein is expressed in most, 
if not all, MD tumour cell lines and overexpression of meq in the rodent cell line Rat-2 
caused transformation of these cells. The transformed cells became highly resistant to the 
induction of apoptosis (Liu  et al., 1998). It is of interest to note that meq is transcribed during 
the lytic infection without an apparent effect on apoptosis. However, the regulation of meq 
transcription is very complex and alternate splicing has been described (Peng & Shirazi, 
1996). Recently was described that the Meq oncoprotein interacts directly with p53 and 
inhibits p53-mediated transcriptional activity and apoptosis, providing a valuable insight 
into the molecular basis for the function of meq in MDV oncogenesis (Deng et al., 2010) 
Moreover, expression of pp38 in tumour cells may be correlated with the induction of 
apoptosis (Schat & Xing, 2000). This hypothesis is interesting in view of the finding that 
pp38 expression in MD tumour cell lines is generally low and is apparently inversely related 
to the expression of meq and a small RNA antisense to ICP4 (Ross et al., 1997). Expression of 
pp38 in tumour cell lines can be upregulated by transfection with ICP4 (Pratt et al., 1994). 
There are very recent data that involve microRNAs (highly conserved among different field 
strains of MDV1), and they are expressed in lytic and latent infections and in MDV1-derived 
tumors. This evidence suggests that these small molecules are very important to the virus, 
and that they play some roles in immune evasion, anti-apoptosis, or proliferation (Burnside 
& Morgan, 2011). All these data suggest that the fate of tumour cells depends on an intricate 
balance between the expression and phosphorylation of Meq (Liu et al., 1999), pp38, ICP4 
and the small antisense RNA to ICP4 (Gimeno & Cortes, 2010).  
1.3.4 MD vaccination 
It is thought that the economic impact of MD on the global poultry industry accounts for at 
least US $1 bn yearly (Nair, 2005).  The first MDV vaccine was obtained with an oncogenic 
strain repeatedly passaged in vitro; it was able to prevent MD tumors in chickens challenged 
with oncogenic MDV (Churchill & Chubb, 1969) but not to prevent the infection with field 
viruses. The first attenuated vaccine was used in the UK in 1970 but was quickly replaced by 
an HVT vaccine (Turkey Herpes Virus) (Witter et al., 1970). Introduction of HVT as a live 
vaccine resulted in significant reduction of MD incidence and was extensively used because 
of its efficacy and economical production in tissue culture (Okazaki et al., 1970; Purchase & 
Okazaki, 1971). However, within 10 years, new outbreaks of clinical MD occurred in 
vaccinated flocks (Eidson et al., 1978; Witter et al., 1980) and vvMDV isolated from these 
birds had a greater pathogenic effect than field viruses present before vaccine introduction 
(Witter, 1983). It was probably due to imperfect vaccination practices and, in some countries, 
wrong hygienic conditions that led to reservoirs of viruses in poultry houses (Bourne, 1996). 
In response to the increasing number of MD outbreaks in vaccinated flocks, in the 1980s, 
new vaccines based on the non-oncogenic serotype-2 MDV were introduced in bivalent 
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combination with HVT (Calnek et al., 1983; Witter et al., 1984). The use of polyvalent vaccine 
provided a better protection against MDV challenge (Witter, 1992). This strategy was 
initially effective, but in the 1990s new and more virulent MDV pathotypes (vv + MDV) 
were isolated from flocks vaccinated with bivalent vaccines. In Europe, the problems have 
been less severe and in the Netherlands a very effective MDV vaccine, based on a weakly 
oncogenic serotype-1 MDV (CVI988), has been available (Rispens et al.,1972; Geerligs et al., 
1999;  Witter, 2001, Baigent et al., 2006; Schat & Baranowski, 2007). All these vaccination 
strategies are unfortunately due to the rapid variability of virus; vaccines are poorly 
effective in preventing infection in time (Gimeno, 2008). 
1.3.5 Mechanisms of Herpesviruses infection 
Attachment of HSV to cells occurs upon binding of gC to GAGs that decorate heparan 
sulphate or chondroitin sulphate (Spear et al., 1992). This step enhances HSV infectivity, but 
is not an absolute requirement, as cells defective in heparin sulphate and chondroitin 
sulphate exhibit a 100-fold reduced susceptibility to infection, yet can be infected 
(Gruenheid et al., 1993). A large variety of viruses use heparan sulphate proteoglycans as 
receptors; their broad expression argues that they cannot be responsible for any specific 
viral tropism. Herpes simplex virus type 1 (HSV-1) infects a wide range of cells and causes 
disease in a variety of different tissues.  
Electron microscopy studies suggested that this virus enters host cells by means of either 
endocytosis or fusion between the membranes of the virus and the cell (Hodnichak et al., 
1984). The envelope of the HSV-1 virion contains at least ten different viral glycoproteins, 
several of which project as distinct spikes from the membrane surface and are likely to 
interact sequentially or simultaneously with different binding sites on the cell surface (Fuller 
& Lee, 1992; Herold et al., 1994). The initial attachment of virions to cells is shown to be 
mediated independently by interactions of either glycoprotein C (gC) or glycoprotein B (gB) 
with heparan sulphate moieties of cell surface proteoglycans (Campadelli-Fiume et al., 1990; 
Spear et al., 1992; Shieh et al., 1992; Gruenheid et al., 1993; Herold et al., 1994; Trybala et al., 
1994).  
Heparin, an anionic related glycosaminoglycan, has been demonstrated to block HSV-1 
adsorption to cells (WuDunn & Spear, 1989). There is also evidence that glycoprotein D (gD) 
may interact with its own cell receptor (Johnson et al., 1990), and oligomers of glycoprotein 
H (gH) and glycoprotein L (gL) are also known to be required for HSV-1 penetration (Fuller 
& Lee, 1992; Forrester et al., 1992; Roop et al., 1993). Moreover, it has been suggested that the 
low-density lipoprotein receptor present in coated pits may interact with domains in gB, gC 
or gD allowing the virions to penetrate by an endocytosis process (Becker et al., 1994).  
Heparan sulphate, the primary cell surface receptor for HSV-1, is a ubiquitous and 
multifunctional constituent of most mammalian cell plasma membranes and of extracellular 
matrices, and has been also identified as a binding site for human and bovine lactoferrin (Ji 
& Mahley, 1994; Mann et al., 1994; Wu et al., 1995).  The evidence that heparan sulphate 
proteoglycans and the low density lipoprotein receptor-related protein are capable of 
binding to lactoferrin, and acting as receptors for initial cell-HSV-1 interactions, suggested 
the idea that lactoferrin could interfere with early events of viral infection.  
In previous studies the efficacy of Lactoferrin and Ovotransferrin to prevent the in vitro 
infection of chicken cell lines with MDV was demonstrated (Giansanti et al., 2002, 2005). The 
efficacy of Lactoferrin and its derivative peptides against a variety of viruses as rotavirus 
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and HSV was also demonstrated (Gruenheid et al., 1993; Siciliano et al., 1999; Spear et al., 
2000; Superti et al., 2001)  
2. Lactoferrin 
Lactoferrin (Lf) is a non-haem iron-binding protein that is part of the transferrin protein 
family, along with serum transferrin (sTf), ovotransferrin (Otrf), melanotransferrin and the 
inhibitor of carbonic anhydrase. Lf is produced by mucosal epithelial cells in various 
mammalian species, including humans, cows, goats, horses, dogs, and several rodents 
(González-Chávez et al., 2009). This glycoprotein has protective functions and it is found in 
mucosal secretions, including tears, saliva, vaginal fluids, semen (van der Strate et al., 2001), 
nasal and bronchial secretions, bile, gastrointestinal fluids, urine (Öztas & Özgünes, 2005) 
and, most highly, in milk and colostrum (up to 7 g/L) (Rodriguez et al., 2005) making it the 
second most abundant protein in milk after caseins (Connely, 2001). It can also be found in 
bodily fluids such as blood plasma and amniotic fluid, and in considerable amounts in 
secondary neutrophil granules (15 μg/106 neutrophils) (Bennett & Kokocinski, 1987; 
González-Chávez et al., 2009), where it plays a significant physiological role. Lf possesses a 
great iron-binding affinity with the ability to retain the metal over a wide pH range (Aisen & 
Leibman, 1972) including extremely acidic pH. It also exhibits a great resistance to 
proteolysis. In addition to these differences, Lf net positive charge and its distribution in 
various tissues make it a multifunctional protein (Valenti & Antonini 2005; Baker & Baker, 
2009).  
2.1 Lactoferrin structure 
Lf is an 80 kDa glycosylated protein of ca. 700 aminoacids (711 aa for hLf and 689 aa bLf) 
with high homology among species. It is a simple polypeptide chain folded into two 
symmetrical lobes (N and C lobes) which are highly homologous with one another (33–41% 
homology) (Anderson et al., 1987, 1989; Baker, 1994; Moore et al., 1997; Sharma et al., 1998; 
Baker & Baker, 2009).  These two lobes are connected by a hinge region containing parts of 
an α-helix between residues 333 and 343 in human Lf (hLF), which provides additional 
flexibility to the molecule. The polypeptide chain includes amino acids 1–332 for the N lobe 
and 344–703 for the C lobe, and is made up of α-helix and β-pleated sheet structures that 
create two domains for each lobe (domains I and II) (Moore et al., 1997). Each lobe can be 
further divided into two subdomains (N1 and N2 in the N-lobe and C1 and C2 in the C-
lobe) that form a cleft inside of which the iron is bound. The subdomain N1 contains 
residues 1-90 and 251-333, while N2 contains the residues 91-250) (Baker et al., 1998; Moore 
et al., 1997; Baker & Baker, 2009). Each lobe can bind a metal atom in synergy with the 
carbonate ion (CO32−). Lf notably binds Fe2+ and Fe3+ ions, but also Cu2+, Zn2+ and Mn2+ ions 
(Aisen & Harris, 1989; Baker et al., 1994, 2005; Baker & Baker, 2009). 
2.2 Antinfective activities of Lf 
Lf is involved in several physiological functions, including: regulation of iron absorption in 
the bowel; immune response; and antioxidant, anticarcinogenic and anti-inflammatory 
properties. Protection against microbial infection is the most widely studied function to date 
(Sanchez et al., 1992; Brock, 1995; Lonnerdal & Iyer; 1995; Vorland, 1999; Brock, 2002; Valenti 
& Antonini, 2005; Baker & Baker, 2009; Leboffe et al., 2009). The antimicrobial activity of LF 
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combination with HVT (Calnek et al., 1983; Witter et al., 1984). The use of polyvalent vaccine 
provided a better protection against MDV challenge (Witter, 1992). This strategy was 
initially effective, but in the 1990s new and more virulent MDV pathotypes (vv + MDV) 
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been less severe and in the Netherlands a very effective MDV vaccine, based on a weakly 
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Attachment of HSV to cells occurs upon binding of gC to GAGs that decorate heparan 
sulphate or chondroitin sulphate (Spear et al., 1992). This step enhances HSV infectivity, but 
is not an absolute requirement, as cells defective in heparin sulphate and chondroitin 
sulphate exhibit a 100-fold reduced susceptibility to infection, yet can be infected 
(Gruenheid et al., 1993). A large variety of viruses use heparan sulphate proteoglycans as 
receptors; their broad expression argues that they cannot be responsible for any specific 
viral tropism. Herpes simplex virus type 1 (HSV-1) infects a wide range of cells and causes 
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Electron microscopy studies suggested that this virus enters host cells by means of either 
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several of which project as distinct spikes from the membrane surface and are likely to 
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Heparin, an anionic related glycosaminoglycan, has been demonstrated to block HSV-1 
adsorption to cells (WuDunn & Spear, 1989). There is also evidence that glycoprotein D (gD) 
may interact with its own cell receptor (Johnson et al., 1990), and oligomers of glycoprotein 
H (gH) and glycoprotein L (gL) are also known to be required for HSV-1 penetration (Fuller 
& Lee, 1992; Forrester et al., 1992; Roop et al., 1993). Moreover, it has been suggested that the 
low-density lipoprotein receptor present in coated pits may interact with domains in gB, gC 
or gD allowing the virions to penetrate by an endocytosis process (Becker et al., 1994).  
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matrices, and has been also identified as a binding site for human and bovine lactoferrin (Ji 
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proteoglycans and the low density lipoprotein receptor-related protein are capable of 
binding to lactoferrin, and acting as receptors for initial cell-HSV-1 interactions, suggested 
the idea that lactoferrin could interfere with early events of viral infection.  
In previous studies the efficacy of Lactoferrin and Ovotransferrin to prevent the in vitro 
infection of chicken cell lines with MDV was demonstrated (Giansanti et al., 2002, 2005). The 
efficacy of Lactoferrin and its derivative peptides against a variety of viruses as rotavirus 
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and HSV was also demonstrated (Gruenheid et al., 1993; Siciliano et al., 1999; Spear et al., 
2000; Superti et al., 2001)  
2. Lactoferrin 
Lactoferrin (Lf) is a non-haem iron-binding protein that is part of the transferrin protein 
family, along with serum transferrin (sTf), ovotransferrin (Otrf), melanotransferrin and the 
inhibitor of carbonic anhydrase. Lf is produced by mucosal epithelial cells in various 
mammalian species, including humans, cows, goats, horses, dogs, and several rodents 
(González-Chávez et al., 2009). This glycoprotein has protective functions and it is found in 
mucosal secretions, including tears, saliva, vaginal fluids, semen (van der Strate et al., 2001), 
nasal and bronchial secretions, bile, gastrointestinal fluids, urine (Öztas & Özgünes, 2005) 
and, most highly, in milk and colostrum (up to 7 g/L) (Rodriguez et al., 2005) making it the 
second most abundant protein in milk after caseins (Connely, 2001). It can also be found in 
bodily fluids such as blood plasma and amniotic fluid, and in considerable amounts in 
secondary neutrophil granules (15 μg/106 neutrophils) (Bennett & Kokocinski, 1987; 
González-Chávez et al., 2009), where it plays a significant physiological role. Lf possesses a 
great iron-binding affinity with the ability to retain the metal over a wide pH range (Aisen & 
Leibman, 1972) including extremely acidic pH. It also exhibits a great resistance to 
proteolysis. In addition to these differences, Lf net positive charge and its distribution in 
various tissues make it a multifunctional protein (Valenti & Antonini 2005; Baker & Baker, 
2009).  
2.1 Lactoferrin structure 
Lf is an 80 kDa glycosylated protein of ca. 700 aminoacids (711 aa for hLf and 689 aa bLf) 
with high homology among species. It is a simple polypeptide chain folded into two 
symmetrical lobes (N and C lobes) which are highly homologous with one another (33–41% 
homology) (Anderson et al., 1987, 1989; Baker, 1994; Moore et al., 1997; Sharma et al., 1998; 
Baker & Baker, 2009).  These two lobes are connected by a hinge region containing parts of 
an α-helix between residues 333 and 343 in human Lf (hLF), which provides additional 
flexibility to the molecule. The polypeptide chain includes amino acids 1–332 for the N lobe 
and 344–703 for the C lobe, and is made up of α-helix and β-pleated sheet structures that 
create two domains for each lobe (domains I and II) (Moore et al., 1997). Each lobe can be 
further divided into two subdomains (N1 and N2 in the N-lobe and C1 and C2 in the C-
lobe) that form a cleft inside of which the iron is bound. The subdomain N1 contains 
residues 1-90 and 251-333, while N2 contains the residues 91-250) (Baker et al., 1998; Moore 
et al., 1997; Baker & Baker, 2009). Each lobe can bind a metal atom in synergy with the 
carbonate ion (CO32−). Lf notably binds Fe2+ and Fe3+ ions, but also Cu2+, Zn2+ and Mn2+ ions 
(Aisen & Harris, 1989; Baker et al., 1994, 2005; Baker & Baker, 2009). 
2.2 Antinfective activities of Lf 
Lf is involved in several physiological functions, including: regulation of iron absorption in 
the bowel; immune response; and antioxidant, anticarcinogenic and anti-inflammatory 
properties. Protection against microbial infection is the most widely studied function to date 
(Sanchez et al., 1992; Brock, 1995; Lonnerdal & Iyer; 1995; Vorland, 1999; Brock, 2002; Valenti 
& Antonini, 2005; Baker & Baker, 2009; Leboffe et al., 2009). The antimicrobial activity of LF 
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is mostly due to two different mechanisms: the first one is iron sequestration in sites of 
infection, which deprives the microorganism of this metal, thus creating a bacteriostatic 
effect. The other mechanism is the direct interaction of LF with the infectious agents. 
Positively charged amino acids of LF can interact with anionic molecules on some bacterial, 
viral, fungal and parasite surfaces, causing cell lysis (Bullen, 1981; Braun & Braun, 2002; 
Valenti & Antonini, 2005). Considering the physiological capabilities of Lf in host defence, in 
addition to current pharmaceutical and nutritional needs, Lf is considered to be a 
nutraceutical, and for several decades investigators have searched for the most convenient 
way to produce it (González-Chávez et al., 2009).  
Molecular mechanims of Lf antiparasitic activity are more complex. Antiparasitic activities 
of Lf often appear to involve interference with iron acquisition by some parasites, e.g. 
Pneumocystis carinii, while Lf appears to act as a specific iron donor in other parasites such as 
Trichomonas foetus; in the latter case, Lf could be expected to enhance infection. 
Preincubation of Toxoplasma gondii and Eimeria stiedai sporozoites with an Lf-derived 
peptide, lactoferricin, reduces their infectivity in animal models. Lf antiparasitic activity is 
also sometimes mediated by interaction with host cells. Thus, iron-saturated Lf enhances 
intramacrophage killing of T. cruzi amastigotes and decreases intra-erythrocytic growth of 
Plasmodium falciparum. Lf is able to inhibit the invasion of cultured cells by Plasmodium spp. 
sporozoites through specific binding to HS. In the case of Plasmodium berghei, Lf reduces 
invasion by inhibiting the binding of the plasmodial CS protein, with or without HS, 
suggesting the possibility that Lf can also bind to the same site on LDL receptor-related 
protein (LRP) as the CS protein (see Leboffe et al., 2009). 
The antiviral activity of hLf was firstly demonstrated in mice infected with the polycythemia-
inducing strain of the Friend virus complex (FVC-P) (Lu et al., 1987). Since 1995, potent 
antiviral activity of hLf and bLf has been demonstrated against both enveloped and naked 
viruses, like Cytomegalovirus (CMV) (Harmsen et al., 1995; Andersen et al., 2001), Herpes simplex 
virus (HSV) (Marchetti et al., 1996, 1998; Siciliano et al., 1999; Valenti & Antonini, 2005), Human 
immunodeficiency virus (HIV) (Swart et al., 1996; Puddu et al., 1998), as well as Human hepatitis C 
(HCV) and human hepatitis B (HBV) viruses (Ikeda et al., 1998; Hara et al., 2002). 
3. Ovotransferrin 
Ovotransferrin is the iron-binding glycoprotein belonging to the family of transferrin iron-
binding glycoproteins, found in avian egg white and in avian serum. Contrary to the 
mammalian genome, the avian genome contains only one transferrin gene which is 
expressed both in liver and oviduct, being present in most bodily fluids, including serum 
and egg albumen where its concentration reaches values as high as 12 g/L (Stevens, 1991). 
The expression of this avian transferrin gene is modulated by iron level in liver and by 
steroid hormones in oviduct.  The liver and  oviduct products are known as avian serum 
transferrin and ovotransferrin, respectively (Dierich et al., 1987). Avian serum transferrin is 
devoted to iron transport and delivery, while ovotransferrin displays protective functions, 
similarly to mammalian lactoferrin. 
3.1 Ovotransferrin structure 
Strong similarities could be observed between mammalian serum transferrin, lactoferrin 
and ovotransferrin; despite few differences in aminoacids sequences, the overall 3D 
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structure is strictly conserved. The polypeptide chain is folded into two lobes, each 
containing a single iron-binding site. The two lobes have very similar structures, as expected 
from the sequence identity of 37.4% with mammalian lactoferrin (Jeltsch & Chambon, 1982; 
Williams et al., 1982). The polypeptide chain includes amino acids 1-329 for the N lobe and 
330-686 for the C lobe (Thakurta et al., 2003). Interestingly, the two half molecules of 
ovotransferrin corresponding to the N-terminal and C-terminal lobes, obtained by a limited 
proteolysis procedure, have the ability to re-associate non-covalently in solution (Oe et al., 
1988). Most of the secondary structural elements are comparable between the two lobes. The 
main differences between the two lobes are in the loop regions, as expected by sequence 
insertions and deletions in the primary structure. Each lobe is comprised of two distinct, 
similar-sized α/β sub-domains (N-terminal lobe with N1 and N2 subdomains; C-terminal 
lobe with C1 and C2 subdomains). The two sub-domains are linked by two antiparallel β-
strands that allow them to adopt either open or closed conformations. Iron (III) ions bound 
to Otrf are hexacoordinated, and the two iron-binding sites are located in the inter-sub-
domain cleft of each lobe (Kurokawa et al., 1995; Kurokawa et al., 1999; Mizutani et al., 1999, 
2000; Lindley et al., 1993; Kuser et al., 2002; Thakurta et al., 2003) being very similar each 
other and to those reported for human lactoferrin and for human serum transferrin 
(Anderson et al., 1989).  
3.2 Antinfective activities of ovotransferrin 
Ovotransferrin antibacterial activity partially depends on its ability to bind and sequester 
iron, essential for bacterial growth (Alderton et al., 1946, Bullen et al,. 1978). This activity is 
bacteriostatic, and the effect can be reversed by addition of exogenous iron ions. Other 
studies suggested that the antibacterial activity of Otrf is not simply due to the removal of 
iron from the medium, but probably involves further, more complex mechanisms (Ibrahim 
et al., 2000). Ovotransferrin, as well as serum transferrin and lactoferrin, were also shown to 
permeate the E. coli outer membrane and to access the inner membrane, where they caused 
permeation of ions in a selective manner (Aguilera et al., 2003). The importance of the 
presence of cationic sequences on the surface of Otrf in exploiting the antibacterial activity 
has been clearly pointed out by Ibrahim (Ibrahim et al., 1998) using a peptide called OTAP-
92 obtained by limited proteolysis, consisting of 92 amino acid residues located within the 
109–200 sequence at the lip of the N2 domain of the N lobe  
In relation to the antifungal activity of Otrf, a direct interaction of iron-loaded protein with 
Candida cells has been reported (Valenti et al., 1985), like bovine and human lactoferrin 
(Leboffe et al., 2009). The inhibiting activity of Otrf was tested against one hundred strains of 
Candida spp; the anti-mycotic effect was not coupled to iron sequestration, but rather 
related to Otrf binding on the Candida cell surface (Valenti et al., 1985; Valenti et al., 1986; 
Superti et al., 2007 a, b). 
Ovotransferrin’s antibacterial activity was established many years ago while the antiviral 
activity of Otrf was demonstrated only recently towards the Marek’s disease virus (MDV), 
an avian herpesvirus (Giansanti et al., 2002). In addition, it was found that following 
infection with MDV on Chichen Embryo Fibroblasts (CEF), a variety of host genes were 
transcribed, including ovotransferrin (Morgan et al., 2001). Moreover, in vitro viral infection 
of chicken embryo fibroblasts caused a slight increase of ovotransferrin release, whereas 
viral re-infection of lymphoblastoid cells in vitro caused a remarkable ovotransferrin release 
in a virus concentration-dependent manner (Giansanti et al., 2007). Finally, the production of 
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effect. The other mechanism is the direct interaction of LF with the infectious agents. 
Positively charged amino acids of LF can interact with anionic molecules on some bacterial, 
viral, fungal and parasite surfaces, causing cell lysis (Bullen, 1981; Braun & Braun, 2002; 
Valenti & Antonini, 2005). Considering the physiological capabilities of Lf in host defence, in 
addition to current pharmaceutical and nutritional needs, Lf is considered to be a 
nutraceutical, and for several decades investigators have searched for the most convenient 
way to produce it (González-Chávez et al., 2009).  
Molecular mechanims of Lf antiparasitic activity are more complex. Antiparasitic activities 
of Lf often appear to involve interference with iron acquisition by some parasites, e.g. 
Pneumocystis carinii, while Lf appears to act as a specific iron donor in other parasites such as 
Trichomonas foetus; in the latter case, Lf could be expected to enhance infection. 
Preincubation of Toxoplasma gondii and Eimeria stiedai sporozoites with an Lf-derived 
peptide, lactoferricin, reduces their infectivity in animal models. Lf antiparasitic activity is 
also sometimes mediated by interaction with host cells. Thus, iron-saturated Lf enhances 
intramacrophage killing of T. cruzi amastigotes and decreases intra-erythrocytic growth of 
Plasmodium falciparum. Lf is able to inhibit the invasion of cultured cells by Plasmodium spp. 
sporozoites through specific binding to HS. In the case of Plasmodium berghei, Lf reduces 
invasion by inhibiting the binding of the plasmodial CS protein, with or without HS, 
suggesting the possibility that Lf can also bind to the same site on LDL receptor-related 
protein (LRP) as the CS protein (see Leboffe et al., 2009). 
The antiviral activity of hLf was firstly demonstrated in mice infected with the polycythemia-
inducing strain of the Friend virus complex (FVC-P) (Lu et al., 1987). Since 1995, potent 
antiviral activity of hLf and bLf has been demonstrated against both enveloped and naked 
viruses, like Cytomegalovirus (CMV) (Harmsen et al., 1995; Andersen et al., 2001), Herpes simplex 
virus (HSV) (Marchetti et al., 1996, 1998; Siciliano et al., 1999; Valenti & Antonini, 2005), Human 
immunodeficiency virus (HIV) (Swart et al., 1996; Puddu et al., 1998), as well as Human hepatitis C 
(HCV) and human hepatitis B (HBV) viruses (Ikeda et al., 1998; Hara et al., 2002). 
3. Ovotransferrin 
Ovotransferrin is the iron-binding glycoprotein belonging to the family of transferrin iron-
binding glycoproteins, found in avian egg white and in avian serum. Contrary to the 
mammalian genome, the avian genome contains only one transferrin gene which is 
expressed both in liver and oviduct, being present in most bodily fluids, including serum 
and egg albumen where its concentration reaches values as high as 12 g/L (Stevens, 1991). 
The expression of this avian transferrin gene is modulated by iron level in liver and by 
steroid hormones in oviduct.  The liver and  oviduct products are known as avian serum 
transferrin and ovotransferrin, respectively (Dierich et al., 1987). Avian serum transferrin is 
devoted to iron transport and delivery, while ovotransferrin displays protective functions, 
similarly to mammalian lactoferrin. 
3.1 Ovotransferrin structure 
Strong similarities could be observed between mammalian serum transferrin, lactoferrin 
and ovotransferrin; despite few differences in aminoacids sequences, the overall 3D 
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structure is strictly conserved. The polypeptide chain is folded into two lobes, each 
containing a single iron-binding site. The two lobes have very similar structures, as expected 
from the sequence identity of 37.4% with mammalian lactoferrin (Jeltsch & Chambon, 1982; 
Williams et al., 1982). The polypeptide chain includes amino acids 1-329 for the N lobe and 
330-686 for the C lobe (Thakurta et al., 2003). Interestingly, the two half molecules of 
ovotransferrin corresponding to the N-terminal and C-terminal lobes, obtained by a limited 
proteolysis procedure, have the ability to re-associate non-covalently in solution (Oe et al., 
1988). Most of the secondary structural elements are comparable between the two lobes. The 
main differences between the two lobes are in the loop regions, as expected by sequence 
insertions and deletions in the primary structure. Each lobe is comprised of two distinct, 
similar-sized α/β sub-domains (N-terminal lobe with N1 and N2 subdomains; C-terminal 
lobe with C1 and C2 subdomains). The two sub-domains are linked by two antiparallel β-
strands that allow them to adopt either open or closed conformations. Iron (III) ions bound 
to Otrf are hexacoordinated, and the two iron-binding sites are located in the inter-sub-
domain cleft of each lobe (Kurokawa et al., 1995; Kurokawa et al., 1999; Mizutani et al., 1999, 
2000; Lindley et al., 1993; Kuser et al., 2002; Thakurta et al., 2003) being very similar each 
other and to those reported for human lactoferrin and for human serum transferrin 
(Anderson et al., 1989).  
3.2 Antinfective activities of ovotransferrin 
Ovotransferrin antibacterial activity partially depends on its ability to bind and sequester 
iron, essential for bacterial growth (Alderton et al., 1946, Bullen et al,. 1978). This activity is 
bacteriostatic, and the effect can be reversed by addition of exogenous iron ions. Other 
studies suggested that the antibacterial activity of Otrf is not simply due to the removal of 
iron from the medium, but probably involves further, more complex mechanisms (Ibrahim 
et al., 2000). Ovotransferrin, as well as serum transferrin and lactoferrin, were also shown to 
permeate the E. coli outer membrane and to access the inner membrane, where they caused 
permeation of ions in a selective manner (Aguilera et al., 2003). The importance of the 
presence of cationic sequences on the surface of Otrf in exploiting the antibacterial activity 
has been clearly pointed out by Ibrahim (Ibrahim et al., 1998) using a peptide called OTAP-
92 obtained by limited proteolysis, consisting of 92 amino acid residues located within the 
109–200 sequence at the lip of the N2 domain of the N lobe  
In relation to the antifungal activity of Otrf, a direct interaction of iron-loaded protein with 
Candida cells has been reported (Valenti et al., 1985), like bovine and human lactoferrin 
(Leboffe et al., 2009). The inhibiting activity of Otrf was tested against one hundred strains of 
Candida spp; the anti-mycotic effect was not coupled to iron sequestration, but rather 
related to Otrf binding on the Candida cell surface (Valenti et al., 1985; Valenti et al., 1986; 
Superti et al., 2007 a, b). 
Ovotransferrin’s antibacterial activity was established many years ago while the antiviral 
activity of Otrf was demonstrated only recently towards the Marek’s disease virus (MDV), 
an avian herpesvirus (Giansanti et al., 2002). In addition, it was found that following 
infection with MDV on Chichen Embryo Fibroblasts (CEF), a variety of host genes were 
transcribed, including ovotransferrin (Morgan et al., 2001). Moreover, in vitro viral infection 
of chicken embryo fibroblasts caused a slight increase of ovotransferrin release, whereas 
viral re-infection of lymphoblastoid cells in vitro caused a remarkable ovotransferrin release 
in a virus concentration-dependent manner (Giansanti et al., 2007). Finally, the production of 
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nitric oxide (NO), a molecule naturally exerting an antiviral activity, was observed in 
MDCC-MSB1 (Chicken hematopoietic lymphoblastic cell line) following reinfection and/or 
Otrf and lactoferrin (Lf) or following treatment with the cytokines IL-8 and IFN-), thus 
suggesting a possible role as a complementary or alternative strategy against MDV infection 
spread (Giardi et al.,  2009). 
4. Antiviral activity of intact lactoferrin 
The antiviral effect of lactoferrin was first believed to be linked to its iron-binding property, 
similarly to other iron-chelating substances known as inhibitors of herpesvirus ribonucleotide 
reductases (Spector et al., 1989, 1991). In contrast, lactoferrin effect towards HSV-1 infection 
does not appear related to iron-withholding since no significant differences in the HSV-1 
inhibition were found between lactoferrins in apo- and iron-saturated form. The infection 
inhibition occurs during the very early phases of the viral multiplication cycle, since the 
highest inhibitory effect took place when lactoferrin was added during the attachment step. In 
fact, the binding of [35S]methionine-labelled HSV-1 virions to Vero cells was strongly inhibited 
when bLf was added. bLf interacts with both Vero cell surfaces and HSV-1 particles, 
suggesting that the hindrance of cellular receptors and/or of viral attachment proteins may be 
involved in its antiviral mechanism (Marchetti et al., 1996). The antiviral effect of lactoferrin 
correlates well with its affinity for the virus receptor binding sites. In fact, polyanionic 
glycosaminoglycan chains of heparan sulphate and apo-lipoprotein-E receptor have been 
shown to interact with highly cationic lactoferrin (Pierce et al., 1991).  
Consequently, it can be assumed that the capability of lactoferrin to inhibit HSV-1 infection 
at the level of viral attachment may rely to a large extent on its competitive interaction with 
cell receptors for HSV-1 which can hinder the binding of the virus attachment proteins. bLf 
is a better inhibitor than hLf, with a selectivity index being over 10-fold higher. This effect of 
bLf on HSV-1 infection probably involves more than a simple mechanism of interference at 
the level of cell receptors. A direct interaction of bovine lactoferrin with virus particles has 
been demonstrated by the findings that virus binds efficiently to bLf immobilized on a solid-
phase surface, as revealed by an ELISA method, and causes the rapid agglutination of bLf 
coated latex beads. It can be put forward that the lower activity of hLf against HSV-1 (or the 
absence of antiviral activity anti HSV-1 of the hen’s Ovotransferrin), as compared with that 
of bLf, is linked to differences in the molecular structure. Bovine lactoferrin is 69% identical 
to human lactoferrin (49% to Ovotransferrin), but, in spite of this high degree of similarity, 
their comparison shows that the glycan chains of the molecules and the number of 
disulphide bridges vary (Metz-Boutigue et al., 1984; Pierce et al., 1991). These variations are 
likely to contribute to the differences in the functional domains responsible for the binding 
properties of the lactoferrins to host cells and viral particles (Marchetti et al., 1996). 
4.1 Antiviral activity of lactoferrin peptides 
Antimicrobial peptides are produced by a wide variety of organisms as their first line of 
defense, the so-called innate immune strategy (Hancock, 2001).  Hundreds of such peptides 
have been isolated (Hancock  & Chapple, 1999), suggesting their importance in the innate 
immune system (Hancock & Diamond, 2000). Antimicrobial peptides are typically relatively 
short (12 to 100 amino acids), positively charged, amphiphilic and have been isolated from 
single-celled microorganisms, amphibians, birds, fish plants and mammals, including man 
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(Wang & Wang, 2004; Ganz, 2005). Several antimicrobial peptides have been shown to also 
inhibit viral infection. The spectrum of viruses that are affected primarily comprises the 
enveloped RNA and DNA viruses. In most cases it has been concluded that antiviral activity is 
exerted at a very early stage in the viral multiplication cycle, either by direct action of the 
peptides on the virus itself (Aboudy  et al., 1994; Robinson  et al., 1998) or at the virus-cell 
interface (Belaid et al., 2002). It has also been demonstrated that antimicrobial peptides regulate 
multiple cellular genes (Scott et al., 2002), findings which support peptide stimulation of the 
cellular immune response (Andersen et al., 2004). A reasonable hypothesis is that the products 
of a subset of these peptide-upregulated genes are able to suppress endotoxic responses that 
lead to production of pro-inflammatory cytokines while upregulating other genes assisting in 
resolving infections (Bowdish et al., 2005 a, b; Bowdish & Hancock, 2005;  Jenssen, 2005). 
bLf derived peptide lactoferricin B (bovine lactoferrin fragment bLf17–41), generated from 
pepsin digestion of such protein, besides activities reported against bacteria, fungi, 
protozoa, and tumors (Bellamy et al., 1992; Yoo  et al.,   1998; Omata  et al., 2001), exerts a 
small, although significant, antiviral activity towards herpes simplex virus (Andersen  et al., 
2004), human cytomegalovirus (Andersen  et al., 2001), and adenovirus (Di Biase et al., 2003). 
In solution, lactoferricin B adopts a twisted beta-sheet structure that becomes markedly 
amphipathic with the hydrophobic groups lining up on one face of the peptide, while the 
opposite face contains most of the basic residues (Vogel  et al., 2002; Zhou  et al.,2004) 
possibly interacting with glycosaminoglycan viral receptors. The N-terminus of lactoferrin 
binds to surface glycosaminoglycans (Mann et al., 1994; Wu et al., 1995), which are initial 
binding sites for HASV-1 virus (WuDunn & Spear, 1989; Roderiquez et al., 1995) and a direct 
lactoferrin interaction with viral particles has been hypothetized (Marchetti et al., 1996; 
Swart et al., 1996; Yi et al., 1997). In an attempt to identify other lactoferrin amino acid 
sequences contributing to the antiviral activity, the antiviral activity of a library of peptide 
fragments, derived from the tryptic digestion of bLf, was analysed towards HSV1, a 
susceptible enveloped virus. The pool of fragments deriving from tryptic digestion of bLf 
showed antiviral activity toward HSV-1, suggesting that the inhibition of viral infection 
could not be exclusively linked to native, undigested bLf (Siciliano et al., 1999).  
Moreover, the protective effect towards HSV-1 infection possessed by low and high molecular 
weight peptides, deriving from tryptic digestion of bLf, was analyzed. Among high molecular 
weight peptides, the fraction with amino acid sequence 1–280, belonging to the N-lobe, was 
ten-fold more effective towards HSV-1 infection than the fraction representing the whole C-
lobe. On the other hand, the fraction 1-280 was still six-fold less active than native bLf, which 
exerted the maximal antiviral activity. The different antiviral activity of the C-lobe and N-lobe 
toward HSV-1 cannot be explained on the basis of their different glycosylation sites (three 
glycosylation sites present in C-lobe while only one in N-lobe) since their removal from 
undigested bLf did not affect anti HSV-1 activity (Sicilano et al., 1999). The absence of antiviral 
activity of the large fraction with amino acid sequence 86–258, which corresponds to the N2 
domain, has been correlated to the lack of amino acid sequences 1–85 and/or 259–280, present 
in the effective fraction 1–280 which contains the N2 domain together with part of the N1 
domain. Furthermore, it was observed that, among the low molecular weight fragments, only 
the association of two small peptides (ADRDQYELL (bLf222–230) and EDLIWK (bLf264–269) 
was effective. Considering their molecular mass, these peptides showed a much lower 
antiviral activity than that displayed by undigested bLf and by the fraction 1-280. Interestingly, 
these small peptides did not display any antiviral activity when they were separately tested.  
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nitric oxide (NO), a molecule naturally exerting an antiviral activity, was observed in 
MDCC-MSB1 (Chicken hematopoietic lymphoblastic cell line) following reinfection and/or 
Otrf and lactoferrin (Lf) or following treatment with the cytokines IL-8 and IFN-), thus 
suggesting a possible role as a complementary or alternative strategy against MDV infection 
spread (Giardi et al.,  2009). 
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The antiviral effect of lactoferrin was first believed to be linked to its iron-binding property, 
similarly to other iron-chelating substances known as inhibitors of herpesvirus ribonucleotide 
reductases (Spector et al., 1989, 1991). In contrast, lactoferrin effect towards HSV-1 infection 
does not appear related to iron-withholding since no significant differences in the HSV-1 
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highest inhibitory effect took place when lactoferrin was added during the attachment step. In 
fact, the binding of [35S]methionine-labelled HSV-1 virions to Vero cells was strongly inhibited 
when bLf was added. bLf interacts with both Vero cell surfaces and HSV-1 particles, 
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correlates well with its affinity for the virus receptor binding sites. In fact, polyanionic 
glycosaminoglycan chains of heparan sulphate and apo-lipoprotein-E receptor have been 
shown to interact with highly cationic lactoferrin (Pierce et al., 1991).  
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at the level of viral attachment may rely to a large extent on its competitive interaction with 
cell receptors for HSV-1 which can hinder the binding of the virus attachment proteins. bLf 
is a better inhibitor than hLf, with a selectivity index being over 10-fold higher. This effect of 
bLf on HSV-1 infection probably involves more than a simple mechanism of interference at 
the level of cell receptors. A direct interaction of bovine lactoferrin with virus particles has 
been demonstrated by the findings that virus binds efficiently to bLf immobilized on a solid-
phase surface, as revealed by an ELISA method, and causes the rapid agglutination of bLf 
coated latex beads. It can be put forward that the lower activity of hLf against HSV-1 (or the 
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of bLf, is linked to differences in the molecular structure. Bovine lactoferrin is 69% identical 
to human lactoferrin (49% to Ovotransferrin), but, in spite of this high degree of similarity, 
their comparison shows that the glycan chains of the molecules and the number of 
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Antimicrobial peptides are produced by a wide variety of organisms as their first line of 
defense, the so-called innate immune strategy (Hancock, 2001).  Hundreds of such peptides 
have been isolated (Hancock  & Chapple, 1999), suggesting their importance in the innate 
immune system (Hancock & Diamond, 2000). Antimicrobial peptides are typically relatively 
short (12 to 100 amino acids), positively charged, amphiphilic and have been isolated from 
single-celled microorganisms, amphibians, birds, fish plants and mammals, including man 
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(Wang & Wang, 2004; Ganz, 2005). Several antimicrobial peptides have been shown to also 
inhibit viral infection. The spectrum of viruses that are affected primarily comprises the 
enveloped RNA and DNA viruses. In most cases it has been concluded that antiviral activity is 
exerted at a very early stage in the viral multiplication cycle, either by direct action of the 
peptides on the virus itself (Aboudy  et al., 1994; Robinson  et al., 1998) or at the virus-cell 
interface (Belaid et al., 2002). It has also been demonstrated that antimicrobial peptides regulate 
multiple cellular genes (Scott et al., 2002), findings which support peptide stimulation of the 
cellular immune response (Andersen et al., 2004). A reasonable hypothesis is that the products 
of a subset of these peptide-upregulated genes are able to suppress endotoxic responses that 
lead to production of pro-inflammatory cytokines while upregulating other genes assisting in 
resolving infections (Bowdish et al., 2005 a, b; Bowdish & Hancock, 2005;  Jenssen, 2005). 
bLf derived peptide lactoferricin B (bovine lactoferrin fragment bLf17–41), generated from 
pepsin digestion of such protein, besides activities reported against bacteria, fungi, 
protozoa, and tumors (Bellamy et al., 1992; Yoo  et al.,   1998; Omata  et al., 2001), exerts a 
small, although significant, antiviral activity towards herpes simplex virus (Andersen  et al., 
2004), human cytomegalovirus (Andersen  et al., 2001), and adenovirus (Di Biase et al., 2003). 
In solution, lactoferricin B adopts a twisted beta-sheet structure that becomes markedly 
amphipathic with the hydrophobic groups lining up on one face of the peptide, while the 
opposite face contains most of the basic residues (Vogel  et al., 2002; Zhou  et al.,2004) 
possibly interacting with glycosaminoglycan viral receptors. The N-terminus of lactoferrin 
binds to surface glycosaminoglycans (Mann et al., 1994; Wu et al., 1995), which are initial 
binding sites for HASV-1 virus (WuDunn & Spear, 1989; Roderiquez et al., 1995) and a direct 
lactoferrin interaction with viral particles has been hypothetized (Marchetti et al., 1996; 
Swart et al., 1996; Yi et al., 1997). In an attempt to identify other lactoferrin amino acid 
sequences contributing to the antiviral activity, the antiviral activity of a library of peptide 
fragments, derived from the tryptic digestion of bLf, was analysed towards HSV1, a 
susceptible enveloped virus. The pool of fragments deriving from tryptic digestion of bLf 
showed antiviral activity toward HSV-1, suggesting that the inhibition of viral infection 
could not be exclusively linked to native, undigested bLf (Siciliano et al., 1999).  
Moreover, the protective effect towards HSV-1 infection possessed by low and high molecular 
weight peptides, deriving from tryptic digestion of bLf, was analyzed. Among high molecular 
weight peptides, the fraction with amino acid sequence 1–280, belonging to the N-lobe, was 
ten-fold more effective towards HSV-1 infection than the fraction representing the whole C-
lobe. On the other hand, the fraction 1-280 was still six-fold less active than native bLf, which 
exerted the maximal antiviral activity. The different antiviral activity of the C-lobe and N-lobe 
toward HSV-1 cannot be explained on the basis of their different glycosylation sites (three 
glycosylation sites present in C-lobe while only one in N-lobe) since their removal from 
undigested bLf did not affect anti HSV-1 activity (Sicilano et al., 1999). The absence of antiviral 
activity of the large fraction with amino acid sequence 86–258, which corresponds to the N2 
domain, has been correlated to the lack of amino acid sequences 1–85 and/or 259–280, present 
in the effective fraction 1–280 which contains the N2 domain together with part of the N1 
domain. Furthermore, it was observed that, among the low molecular weight fragments, only 
the association of two small peptides (ADRDQYELL (bLf222–230) and EDLIWK (bLf264–269) 
was effective. Considering their molecular mass, these peptides showed a much lower 
antiviral activity than that displayed by undigested bLf and by the fraction 1-280. Interestingly, 
these small peptides did not display any antiviral activity when they were separately tested.  
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It is important to note that effective fraction 1–280 contains both amino acid sequences of the 
two small co-purified peptides (amino acid sequences 222– 230 and 264–269), while 
ineffective fraction 86–258 does not contain the amino acid sequence 264–269 (Siciliano et al., 
1999). In the three-dimensional structure of iron-saturated bLf, these two small peptides are 
exposed to the solvent at the bLf surface and are located at opposite sites of the N-lobe 
(belonging to N2 and N1 domains respectively) (Moore et al., 1997). The markedly reduced 
antiviral activity displayed by the two associated peptides (amino acid sequences 222–230 
and 264–269) could therefore be correlated with the lack of the correct folding when they are 
separated from the protein.  
All together, these results suggest that in bovine lactoferrin, both amino acid sequences and 
their conformations are involved in protection form HSV-1 infection (Siciliano et al., 1999). 
Therefore it was concluded that the cluster of positive charges present in bLf has to be 
considered to be crucial for anti-herpesvirus activity. Interestigly, it should be noted that the 
anti HSV-1 active fragments belonging to the N-lobe of bLf do not have anti-rotavirus 
activity, while other peptides, belonging to the C-lobe, possess anti-rotavirus activity. The 
antiviral activity of lactoferrin towards viruses belonging to different families appears, 
therefore to be due to specific, although different, mechanisms, depending on the inhibited 
virus (Superti et al., 2001) 
5. Antiviral activity of intact ovotransferrin 
Contrary to the antiviral activity of lactoferrin, the antiviral activity of ovotransferrin was 
not demonstrated until a model of chicken embryo fibroblasts infected with Marek’s Disease 
Virus (MDV) was used (Giansanti et al., 2002).  
MDV belongs to the Herpesviridae family, and is currently grouped within the 
Alphaherpersvirinae subfamily, together with the herpesvirus of turkey (HVT) (Calnek, 2001). 
It possesses a 166–184 kb, double-stranded DNA genome. Like many herpesviruses (Izumiya et 
al., 2001), MDV is highly cell-associated. MDV infection of susceptible cells is generally 
cytocidal, but latency can also be established. The virus-induced pathological changes, known 
as the cytopathic effect (CPE), take place in both the cytoplasm and the nucleus when the lytic 
cycle is ongoing. MDV has been shown to induce the synthesis of ovotransferrin in infected 
chicken embryo fibroblasts (Morgan et al., 2001).  In chicken embryo fibroblast primary cultures, 
Otrf is effective in inhibiting infection by the herpesvirus of Marek disease. In this experimental 
avian herpes virus system, Otrf was more active than bLf or hLf. As already shown in human 
HSV model (Marchetti et al., 1996), iron saturation of the proteins did not influence the 
inhibiting activity of the iron-binding proteins, even though it could be expected that conditions 
increasing iron availability may facilitate virus infection since this metal ion is essential for 
nucleic acids and protein synthesis. These similarities suggested that Otrf inhibits MDV 
replication in a way similar to that utilized by hLf and bLf in inhibiting HSV-1 replication.  
5.1 Antiviral activity of ovotransferrin peptides 
Like lactoferrin, Otrf displays antiviral activity, though only when tested in homologous cell 
systems using primary cultures of chicken embryo fibroblasts infected with Marek’s disease 
virus. Lactoferricin B (bovine lactoferrin fragment bLf17–41) and two peptides, derived from the 
tryptic digestion of bLf, fragments ADRDQYELL (bLf222–230) and EDLIWK (bLf264–269), have 
been found to display antiviral activity towards herpes simplex virus (Siciliano  et al.,   1999), 
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although, the antiviral activity of lactoferricin B and of these two other peptides was much 
lower than that of the intact protein, and this was tentatively attributed to the lack of correct 
folding of such fragments when they are separated from the protein. Therefore, fragments in 
hOtrf having sequence and/or structural homologies with the fragments with antiviral activity 
found in bLf were identified and tested for their antiviral activity with the aim of evaluating 
their possible involvement in the antiviral activity of the intact ovotransferrin.  No fragment 
was identified in hOtrf having sequence homology with bLf fragment lactoferricin B (bLf17–41). 
On the contrary, two fragments having sequence homology with bLf fragments ADRDQYELL 
(bLf222–230) and EDLIWK (bLf264–269) were identified in hOtrf. The first one was the 
fragment DQKDEYELL (hOtrf219-227), while the second one was the fragment KDLLFK. 
Interestingly, the latter fragment KDLLFK is repeated twice in hOtrf, both in N-lobe (hOtrf269–
361) and in C-lobe (hOtrf633–638). Moreover, hOtrf fragments DQKDEYELL and KDLLFK are 
located at the surface of the protein. As concerning structural homologies in the intact proteins, 
the hOtrf fragment KDLLFK possesses into the intact hOtrf a conformation similar to that 
possessed by the fragment EDLIWK in intact bLf (see figure 3). Similarly, the fragment 
LQMDDFELL (hOtrf561–569) displays the greatest structural homology in intact hOtrf with the 
fragments ADRDQYELL into intact bLf (see figure 3).  
 
 
PANEL A: Fragment ADRDQYELL (bLf222–230),  
PANEL B: Fragment DQKDEYELL (hOtrf219-227)  
PANEL C: Fragment EDLIWK (bLf264–269)  
PANEL D: Fragment KDLLFK (hOtrf269–361 and hOtrf633–638). 
The fragments are shown with the conformation they have in the intact proteins: bovine lactoferrin 
(bLf) and hen’s ovotransferrin (hOTrf). The ribbons indicate the presence of alpha-elices. In Panel A, the 
arrow indicates a.a. sequence direction. The colors indicate aminoacid properties: Green: hydrophobic; 
Blue: negatively charged; Red: positively charged; White: polar. 
Molecular graphics images were produced using the UCSF chimera package (Pettersen et al., 2004) 
Fig. 3. Lactoferrin and ovotransferrin fragments with anti-herpesvirus activity 
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It is important to note that effective fraction 1–280 contains both amino acid sequences of the 
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and 264–269) could therefore be correlated with the lack of the correct folding when they are 
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Therefore it was concluded that the cluster of positive charges present in bLf has to be 
considered to be crucial for anti-herpesvirus activity. Interestigly, it should be noted that the 
anti HSV-1 active fragments belonging to the N-lobe of bLf do not have anti-rotavirus 
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systems using primary cultures of chicken embryo fibroblasts infected with Marek’s disease 
virus. Lactoferricin B (bovine lactoferrin fragment bLf17–41) and two peptides, derived from the 
tryptic digestion of bLf, fragments ADRDQYELL (bLf222–230) and EDLIWK (bLf264–269), have 
been found to display antiviral activity towards herpes simplex virus (Siciliano  et al.,   1999), 
 
Antiviral Activity of Lactoferrin and Ovotransferrin Derived Peptides Towards Herpesviridae 
 
307 
although, the antiviral activity of lactoferricin B and of these two other peptides was much 
lower than that of the intact protein, and this was tentatively attributed to the lack of correct 
folding of such fragments when they are separated from the protein. Therefore, fragments in 
hOtrf having sequence and/or structural homologies with the fragments with antiviral activity 
found in bLf were identified and tested for their antiviral activity with the aim of evaluating 
their possible involvement in the antiviral activity of the intact ovotransferrin.  No fragment 
was identified in hOtrf having sequence homology with bLf fragment lactoferricin B (bLf17–41). 
On the contrary, two fragments having sequence homology with bLf fragments ADRDQYELL 
(bLf222–230) and EDLIWK (bLf264–269) were identified in hOtrf. The first one was the 
fragment DQKDEYELL (hOtrf219-227), while the second one was the fragment KDLLFK. 
Interestingly, the latter fragment KDLLFK is repeated twice in hOtrf, both in N-lobe (hOtrf269–
361) and in C-lobe (hOtrf633–638). Moreover, hOtrf fragments DQKDEYELL and KDLLFK are 
located at the surface of the protein. As concerning structural homologies in the intact proteins, 
the hOtrf fragment KDLLFK possesses into the intact hOtrf a conformation similar to that 
possessed by the fragment EDLIWK in intact bLf (see figure 3). Similarly, the fragment 
LQMDDFELL (hOtrf561–569) displays the greatest structural homology in intact hOtrf with the 
fragments ADRDQYELL into intact bLf (see figure 3).  
 
 
PANEL A: Fragment ADRDQYELL (bLf222–230),  
PANEL B: Fragment DQKDEYELL (hOtrf219-227)  
PANEL C: Fragment EDLIWK (bLf264–269)  
PANEL D: Fragment KDLLFK (hOtrf269–361 and hOtrf633–638). 
The fragments are shown with the conformation they have in the intact proteins: bovine lactoferrin 
(bLf) and hen’s ovotransferrin (hOTrf). The ribbons indicate the presence of alpha-elices. In Panel A, the 
arrow indicates a.a. sequence direction. The colors indicate aminoacid properties: Green: hydrophobic; 
Blue: negatively charged; Red: positively charged; White: polar. 
Molecular graphics images were produced using the UCSF chimera package (Pettersen et al., 2004) 
Fig. 3. Lactoferrin and ovotransferrin fragments with anti-herpesvirus activity 
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However, NMR spectroscopy indicated that, as expected, all these peptides do not have a 
favourite conformation in solution, as they are too short to have any secondary structure. 
All the fragments were then chemically synthesized and the corresponding peptides were 
tested on CEF/ MDV system for their cytotoxic and antiviral activities, hOtrf and bLf being 
used as positive control proteins. The peptide LNNSRA, with no sequence or structural 
homologies, was used as negative control. The maximal antiviral activities were shown by 
the positive control intact proteins (hOtrf and bLf) and no antiviral activity was shown by 
the negative control peptide LNNSRA. The peptides LQMDDFELL (hOtrf561–569) and 
KDCIIK (hOtrf378–383), which have little or no sequence homologies with the 
corresponding bLf fragment despite structural homologies in the intact proteins, showed 
little or no antiviral activity. On the contrary, the peptides in hOtrf having greatest sequence 
homology, DQKDEYELL (hOtrf219–227) and KDLLFK (hOtrf269–361 and hOtrf633–638), 
with the bLf peptides with antiviral activity ADRDQYELL (bLf222–230) and EDLIWK 







Control Blf fragment with antiviral 
activity ≥ 50 
DQKDEYELL (Otrf219-227) 
hOtrf fragment with sequence homology 
with bLf222-230 
≥ 125 * 
EDLIWK (bLf264-269) 
Control Blf fragment with antiviral 
activity ≥ 20 
KDLLFK (Otrf269-361) and 
(Otrf633-638) 
hOtrf fragment with sequence homology 
with bLf264-269 
≥ 40 * 
LNNSRA negative control 1 
Hen Ovotransferrin positive control ≥ 1600 
Bovine lactoferrin positive control ≥ 1000 
Selectivity index (SI) is expressed as the ratio between the effective dose required to inhibit fluorescence 
by 50% and the effective dose required for 50 % cytotoxicity. Statistically significant differences (P < 
0.05) of the hOtrf fragment selectivity index as compared with that of the corresponding bLf fragment. 
Table 1. Bovine lactoferrin and hen ovotransferrin fragments: Characteristics and Selectivity 
Index (SI) towards Marek Disease Virus (modified from Giansanti et al., 2002). 
The antiviral activities of these two hOtrf peptides were about the double of those shown by 
the corresponding bLf derived peptides with sequence homologies. It is worth noting that 
these two hOtrf fragments possess significant antiviral activity such as the corresponding 
homologous fragments in bLf, suggesting that these fragments could indeed have a role in 
the exploitation of antiviral activity towards herpes viruses of those proteins when they are 
in native conformation. However, the presence of hydrophobic and positively charged 
residues is possibly a condition needed but not sufficient for the antiviral activity of bLf and 
hOtrf derived peptides, since the conformations they assume in the intact proteins may also 
be required (Giansanti et al., 2005) 
 




The results reported here suggest that clusters of positive charges present in the N-lobe of 
both bovine lactoferrin and hen’s ovotransferrin are the most responsible for the anti-
herpesvirus activity. The antiviral activity of these proteins is exerted at a very early stage in 
the viral multiplication cycle, possibly by interference at the virus-cell interface by binding 
to cell surface glycosaminoglycans. Few protein short peptides display anti-herpesviridae 
activity, although hundreds-fold less than the intact proteins, indicating that, for the 
exploitation of the maximal antiviral activity, the correct folding of aminoacids containing 
these clusters of positive charges is also required.  
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In order to fully understand the nature of viruses, it is important to look at them from 
both, their basic science and clinical, standpoints. Our goal with this book was to 
dissect Herpesviridae into its biological properties and clinical significance in order 
to provide a logical, as well as practical, approach to understanding and treating the 
various conditions caused by this unique family of viruses. In addition to their up-to-
date and extensive text, each chapter is laced with a variety of diagrams, tables, charts, 
and images, aimed at helping us achieve our goal. We hope that this book will serve as 
a reference tool for clinicians of various specialties worldwide.




 Look Into Th
is U
nique Fam
ily of V
iruses
6863 8
